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Abstract 
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease which predominantly 
affects the synovial joints. Local gene therapy represents an approach to produce therapeutic 
molecules (i.e. soluble TNF receptor (sTNFR)-Fc and interleukin-1 receptor antagonist (IL-
1Ra)) directly in arthritic joints. Gene therapy could be designed to link the level of therapeutic 
gene expression directly to disease activity, through the use of transcriptional and post-
transcriptional regulatory elements. The experiments in this thesis describe the construction 
of multi-responsive, composite synthetic promoters, comprised of the binding sites for an array 
of transcription factors activated in arthritic joints. Optimal spatial arrangements of binding 
sites in relation to each other and to the TATA box were determined by Assembly PCR cloning 
and the functionality of the resulting synthetic promoters revealed additive or synergistic 
induction of luciferase reporter gene expression in response to combined stimulation. 
Candidate synthetic promoters were cloned into a lentiviral vector between insulator elements 
and displayed significantly enhanced induction, in excess of 1,500 fold in response to 
combined stimulation. Inflammation-specific activation of lentiviral synthetic promoters was 
confirmed in a carrageenan-induced paw inflammation mouse model, which demonstrated the 
strong correlation between local luciferase gene expression and paw inflammation.  
Post-transcriptional gene regulation was also investigated by exploiting the differential 
expression of endogenous miR-23b during inflammation. Insertion of miR-23b target sites into 
the 3’UTR of the luciferase gene subjected luciferase mRNA to regulation by miR-23b. 
Experiments demonstrated that high basal gene expression driven by constitutive and 
inducible promoters was significantly downregulated by miR-23b without significantly 
impairing high gene expression upon stimulation. Overall, the experiments in this thesis have 
confirmed the induction of inflammation-specific gene expression, regulated by inflammation-
responsive endogenous transcriptional and post-transcriptional elements.  
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FLS    Fibroblast-like synoviocyte  
GM-CSF   Granulocyte-macrophage colony stimulating factor 
gRNA   Genomic RNA  
HEK    Human embryonic kidney 
HGF    Hepatocyte growth factor  
HIF-1α   Hypoxia inducible factor-1α  
Hi-FBS  Heat-inactivated foetal bovine serum 
hIL-17A  Human IL-17A  
HIV-1   Human immunodeficiency virus-1  
HLA    Human leukocyte antigen 
HOMECs  Human omental microvascular endothelial cells 
HRE   Hypoxia-responsive element 
hsa   Homo sapien 
HSCs    Haematopoietic stem cells  
HSP70   Heat-shock protein 70 
HSV    Herpes simplex virus  
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HUVECs  Human umbilical vein endothelial cells  
HVJ   Hemagglutinating virus of Japan 
i.a.   Intra-articular  
i.m    Intramuscular  
ICAM-1  Intercellular adhesion molecule-1 
IFU   Infectious units 
Ig   Immunoglobulin 
iGEM   International genetically engineered machine 
IKKα   IκB-kinase α 
IL   Interleukin 
IL-1Ra   Interleukin-1 receptor antagonist 
IN   Integrase  
IRAK1   IL-1 receptor-associated kinase 1  
IκB   Inhibitor of κB  
JDP    Jun dimerisation partners  
LAP    Liver-enriched transcriptional activating protein  
LB    Luria bertani  
LFA-1   Leukocyte function-associated antigen-1 
Lin-4   Lineage-4  
LIP    Liver-enriched transcriptional inhibitory protein 
LNA    Locked nucleic acid 
LP   Lentiviral particle 
LTR   Long terminal repeat 
Luc+   Luciferase gene 
LV   Lentiviral vector 
MAPK   Mitogen-activated protein kinase  
MAR   Matrix attachment region 
mCMV   Minimal CMV  
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MCP-1   Monocyte chemotactic protein-1 
M-CSF   Macrophage colony stimulating factor 
MHC    Major histocompatibility complex  
mIL-17A   Mouse IL-17A 
miRNA   MicroRNA 
MMP   Matrix metalloproteinase 
mRNA   Messenger RNA 
MTX   Methotrexate 
NAB   NGFI-A binding protein  
NEB   New England Biolab 
Nef   Negative regulatory factor 
NEMO   NFκB essential modulator  
NFAT    Nuclear factor of activated T cells  
NF-IL6   Nuclear factor for IL-6 expression 
NGF    Neuronal growth factor 
NICE   National Institute for Health and Care Excellence  
NIK   NFκB inducing kinase 
NPC    Nuclear pore complex  
NSAID   Non-steroidal anti-inflammatory drugs  
ODD   Oxygen-dependent degradation domain 
ODN    Oligodeoxynucleotide 
Ori   Origin of replication  
PAMP   Pathogen-associated molecular pattern  
PAS    Per/ARNT/Sim 
Pasha    Partner of Drosha  
PBMC   Peripheral blood mononuclear cell 
PBS   Primer binding site  
PCA   Polymerase chain assembly  
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P-CAF   p300/CREB-binding protein-associated factor  
PCR   Polymerase chain reaction 
PGE2   Prostaglandin E2  
PHD   Prolyl hydroxylase enzyme 
PIC   Preinitiation complex  
PIC   Preintegration complex  
piRNA   Piwi-interacting RNA 
PMA    Phorbol-12-myristate-13-acetate 
PPT    Polypurine track  
PR    Protease  
pre-miRNA   Precursor miRNA  
pri-miRNA  Primary miRNA  
pVHL   Von hippel-lindau protein  
RA    Rheumatoid arthritis  
RANKL   Receptor activator of nuclear factor B ligand 
RASF   RA synovial fibroblast 
RER    Rough endoplasmic reticulum  
Rev   Regulator of virion protein expression 
RF    Rheumatoid factor  
RHD    Rel homology domain 
RISC    RNA-induced silencing complex 
RLU   Relative light unit 
RNAi   RNA interference 
ROI   Regions of interest  
RT   Reverse transcriptase  
RTC    Reverse transcription complex 
rtTA    Reverse Tet-repressor 
Saa3   Serum amyloid A3  
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SAPK    Stress-activated protein kinase 
SCW   Streptococcal cell wall  
SEM   Standard error of the mean 
SFFV   Spleen focus forming virus 
shRNA   Short hairpin RNA 
SIN   Self-inactivating 
siRNA   Small interfering RNA 
SLE   Systemic lupus erythematosus 
SNP   Single nucleotide polymorphism 
sTNFR   Soluble TNF receptor  
stRNA   Short temporal RNA 
TAB   TAK1-binding protein  
TAD   Transactivation domain 
TAF   TBP-associated factor 
TAR   Transactivation-responsive region 
Tat   Transactivator of transcription 
TBP   TATA-binding protein 
TCR   T-cell receptor 
Tet    Tetracycline  
TetO   Tet operator 
TetR    Tet repressor protein  
TetR-KRAB   Tetracycline repressor-kruppel associated box 
TF   Transcription factor 
TFBS   Transcription factor binding site 
TIMP   Tissue inhibitors of metalloproteinase 
TK   Thymidine kinase  
TLR    Toll-like receptor 
TNF   Tumour necrosis factor 
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TPA   12-O-tetradecanoylphorbol-13-acetate 
TRAF6   TNF receptor-associated factor 6  
TRBP   Transactivating response RNA-binding protein  
TSS    Transcriptional start site 
tTA   Tetracycline-controlled transactivator 
TU   Transducing units 
u-Pa   Urokinase-type plasminogen activator 
v/v    Volume per volume 
VCAM-1  Vascular adhesion molecule  
VEGF   Vascular endothelial growth factor 
Vif   Virion infectivity factor 
Vpr   Viral protein R 
Vpu   Viral protein U 
VSV-G   Vesicular stomatitis virus glycoprotein  
w/v    Weight per volume 
w/w    Weight per weight 
WPRE   Woodchuck post-transcriptional regulatory element 
WT    Wild type  
YFP   Yellow fluorescence protein 
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1.1. Rheumatoid Arthritis 
Rheumatoid arthritis (RA) is a multifactorial, autoimmune and systemic disease characterised 
by chronic and progressive inflammation. The characteristic features of RA include 
inflammatory cell infiltration into the joint and hyperplasia of the synovial membrane, resulting 
in structural damage to the bone, cartilage and ligaments within the synovial joints (Iwamoto 
et al., 2008). 
 
1.1.1. Epidemiology 
Over the past two decades, population-based studies conducted in various geographically and 
ethnically diverse populations have consistently estimated the prevalence of RA in the adult 
population to be approximately 1% worldwide (Gabriel and Michaud, 2009). Using the 1987 
American College of Rheumatology (ACR) classification criteria for RA, which predominantly 
identifies patients with active RA (Arnett et al., 1988), Symmons and colleagues estimated a 
0.8% prevalence of RA in a Norfolk population study, equating to approximately 400,000 
people in the UK suffering from the disease (Symmons et al., 2002, Rheumatoid Arthritis; 
National Clinical Guideline for Management and Treatment in Adults, UK, 2009). 
Epidemiological studies have generally demonstrated the RA incidence to be low, but 
importantly these studies highlight another feature of RA, which is the striking imbalance 
between the sexes, as women are typically three times more likely to develop RA than men. 
The reasons for this overrepresentation of women are not clear however, hormonal and X-
linked genetic factors are likely to be involved (van VollenHoven, 2009).  
 
In 2006, Alamanos and colleagues conducted a systematic review of incidence and 
prevalence studies of RA from January 1988 to December 2005 across northern American 
countries, north and south European and developing countries. Although there were 
substantial variations in the incidence and prevalence across the various studies and time 
periods (potentially due to methodological limitations), the considerable decline in RA 
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incidence, with a prominent shift toward an elderly age of onset, was a consistent observation 
(Alamanos et al., 2006). Similarly, the peak age of incidence in the UK for both genders is ~70 
years, although all ages can develop RA. Despite extensive research, the aetiology of RA 
remains obscure, however, the contributions of genetic and environmental risk factors in the 
development of RA have been highlighted by epidemiological studies. 
 
1.1.1.2. Genetic factors 
Although the prevalence of RA has consistently been estimated at 1% worldwide, the variation 
in the prevalence of RA among different ethnic groups has supported a genetic role in disease 
risk. Genetic and epidemiological data have implicated the major histocompatibility complex 
(MHC) class II molecules in the pathogenesis of numerous autoimmune diseases. The human 
leukocyte antigen (HLA), located on the short arm of chromosome 6, is a gene-rich area 
encoding for MHC where a large number of these genes are related to immune functions in 
humans. Namely, the MHC class II molecules, located on the surface of antigen-presenting 
cells, are central to the adaptive immune system as these molecules display various peptides 
for recognition by the T-cell receptors of CD4+ T helper cells (Jones et al., 2006). The 
association of certain MHC class II HLA-DRB1 alleles with RA has long been established 
(Gregersen et al., 1987) which has since been consistently identified as a RA susceptibility 
gene in many populations around the world (The Wellcome Trust Case Control Consortium, 
2007). The HLA-DRB1 alleles code a five amino acid sequence motif (QKRAA) on the HLA-
DRβ chain, termed the ‘shared epitope’, which is carried by most patients with RA and is 
thought to affect the antigen presentation of specific peptides to T-cell receptors. Therefore, 
the presentation of arthritis-related peptides by disease-associated HLA-DRB1 alleles may 
result in the expansion of autoantigen-specific T-cells in the joints and lymph nodes of RA 
patients (Choy, 2012).  
 
Data from twin studies have reported that only ~60% of the genetic contribution to RA can be 
implicated by genetic factors (MacGregor et al., 2000), which encouraged the search for non-
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MHC genes and highlighted the potential influence of non-genetic factors. Genome-wide 
association studies using single nucleotide polymorphisms (SNPs) have also indicated that in 
addition to genes in the HLA region, numerous other non-MHC genes may be involved in 
disease susceptibility, particularly those encoding immune regulatory factors. For example, 
the PTPN22 gene encodes a protein tyrosine phosphatase which is involved in the negative 
regulation of T and B-cell activation via the T cell receptors and B cell antigen receptors, and 
has been reproducibly associated with RA. Other putative RA susceptibility genes have been 
associated with cytokine signalling such as the IL-2 gene, which plays an important role for T-
cell homeostasis and survival and also the TNFAIP3 gene, which is a negative regulator of 
NFκB and inhibitor of the effects of TNF-receptor mediated signalling (Ruyssen-Witrand et al., 
2012). Although major advances have been made in identifying RA susceptibility genes both 
within and outside of the MHC, epidemiological data suggests an important role of non-genetic 
factors in RA aetiology. 
 
1.1.1.3. Non-genetic factors 
Population studies conducted within a country have been useful in separating the contribution 
of genetic and non-genetic factors in patients. For example, the high prevalence of disease in 
population subgroups typically suggests genetic associations whereas higher rates of disease 
in specific geographical areas are indicative of environmental influences. These observations 
were supported by epidemiological data reporting very high RA prevalence in Native American 
Pima Indians (5.3%) and in the Chippewa Indians (6.8%) which suggested that although a 
predominant genetic association can be assumed, the influence of social habits, living 
conditions and other environmental factors may also play a role in RA development (Silman 
and Pearson, 2002). Increased urbanisation has also been associated with increased RA 
prevalence in populations. For example, the Xhosa tribe of South Africa living in urban rather 
than rural environments demonstrated a higher prevalence of RA (Solomon et al., 1975). 
Similar observations were also described in populations in urban, suburban and rural areas of 
Taiwan (Chou et al., 1994).   
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Circulating RA associated autoantibodies such as rheumatoid factor (RF) and anticyclic 
citrullinated peptide (anti-CCP) have been detected more than 10 years before the onset of 
clinical disease (Nielen et al., 2004) and there is increasing evidence suggesting that early 
environmental factors may influence the onset of RA before clinical disease and symptoms 
become apparent. Conversely, much indirect evidence has implicated exposure to infectious 
agents in the development of RA in adult life, including Epstein-Barr virus, Parvovirus and 
bacteria such as Proteus and Mycoplasma, however, no agent has been conclusively shown 
to be causative (Silman and Pearson, 2002). 
 
Incidence cohorts have consistently demonstrated a high prevalence of RA in women 
compared to men which strongly suggests that sex hormonal factors are likely to modulate the 
susceptibility and course of RA (van VollenHoven, 2009). Further evidence includes the 
reduced risk of developing RA in women who regularly take the oral contraceptive pill 
(Brennan et al., 1997) and the clinical fluctuations in RA symptoms during the menstrual cycle 
and pregnancy (Cutolo and Lahita, 2005). Interestingly, gene-environment studies have 
established compelling links between cigarette smoking, the shared epitope  and anti-
citrullinated protein antibody (ACPA) production, with an increased risk of RA (Silman and 
Pearson, 2002).  
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1.1.2. Clinical features 
RA can affect any synovial joint but characteristically affects the small synovial joints of the 
hands (Fig 1.1) and feet (metacarpophalangeal, proximal interphalangeal and 
metatarsophalangeal joints) and usually progresses to the larger joints such as the knee, hip, 
elbow and shoulder, in a symmetrical fashion (Suresh, 2004).    
 
 
Figure 1.1. A hand affected by rheumatoid arthritis. RA patient with joint swelling in the 
hands. Photograph courtesy of James Heilman, MD, via Wikimedia Commons. (This 
photograph is licensed under the Creative Commons Attribution-Share Alike 3.0 Unported 
licence, which grants permission to copy this document under the terms of the GNU Free 
Documentation License, Version 1.2).    
 
 
The classical manifestations of RA include pain (due to stretching of pain receptors in the 
tissues surrounding the joint), heat and sometimes redness (due to increased blood flow and 
inflammation of the joint), swelling (due to proliferation of the synovial membrane and 
increased synovial fluid) and joint stiffness (due to loss of muscle and increased pain and 
swelling which often results in loss of function). The degree of progressive damage is related 
to the intensity and duration of inflammation therefore, chronic inflammation consequently 
results in deformity, disability and multiple co-morbidities (Rheumatoid Arthritis; National 
Clinical Guideline for Management and Treatment in Adults, UK, 2009).  
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RA is a systemic disease and in addition to joint symptoms, the progression of RA from a self-
limiting phase to a chronic phase can result in extra-articular or systemic manifestations or 
both (Hochberg et al., 2008). Extra-articular manifestations include rheumatoid nodules, 
vasculitis, pericarditis, keratoconjunctivitis sicca, uveitis, subcutaneous and pulmonary nodule 
formation, while systemic manifestations include the production of acute-phase proteins, 
haematological abnormalities, cardiovascular disease, osteoporosis, fatigue and depression 
and subsequently a poorer quality of life (Choy, 2012). These extra-articular and systemic 
complications associated with chronic RA can lower the life expectancy of patients by 3-10 
years (Amaya-Amaya et al., 2013) as well as increasing the mortality rate, which is twice as 
high as the general population and appears to be increasing (McInnes and Schett, 2011; 
Gonzalez et al., 2007).  
 
The clinical diagnosis of RA is often initiated by a consultation regarding a history of joint 
swelling, early morning stiffness lasting more than 30 minutes and systemic symptoms such 
as tiredness, malaise fever, weight loss which is followed by examinations of the joints 
(Suresh, 2004). Although no blood test can conclusively diagnose RA, routine blood tests 
include the erythrocyte sedimentation rate (ESR) test which is based on the observation that 
red blood cells of patients with inflammatory conditions sink at a faster rate than normal red 
blood cells, the C-reactive protein (CRP) test which can indicate the presence of inflammation 
in the body based on raised CRP levels in the blood and also, serological tests which primarily 
detect the amount of the rheumatoid factor (RF) antibody present in the blood. The RF 
antibody is present in eight out of ten people with RA, however, this antibody has also been 
detected in one in twenty people who do not have RA, which can lead to false positive results. 
Early changes in the joint may precede the symptomatic onset of RA by many years, therefore, 
the combination of radiological scans, blood tests, consultations and examination of joints 
have enabled clinicians to efficiently diagnose RA in patients. However, diagnoses of early RA 
are not without challenges and common limitations include the lack of specific diagnostic tests, 
poor sensitivity in laboratory tests, ‘normal’ test results in patients with definite RA and general 
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inability to recognise early synovitis which often does not progress to RA (Rheumatoid 
Arthritis; National Clinical Guideline for Management and Treatment in Adults, UK, 2009).   
 
Also, the morbidity and long-term disability associated with RA has imposed a considerable 
economic burden on both RA patients and the health services. The total UK costs including 
NHS expense, carer fees, nursing homes, private expenditure, sick leave and work-related 
disability are estimated to be approximately £3.8 - £4.75 billion per year (Rheumatoid Arthritis; 
National Clinical Guideline for Management and Treatment in Adults, UK, 2009). Therefore, 
early diagnosis of RA and administration of effective treatments are imperative in improving 
the quality of life of the patient and reducing the economic burden imposed on RA patients 
and the health services.  
 
1.1.3. Pathogenesis of RA 
The complex interaction between immune cells, cytokines, effector molecules and signalling 
pathways are fundamental to the development of the inflammatory process in the synovium, 
which is the primary site of pathology.  
 
1.1.3.1. Anatomy of a healthy joint 
Normal synovial joints are composed of two opposing bone surfaces covered in articular 
cartilage which is responsible for weight-bearing, shock absorbing and reducing friction. The 
articular surfaces are separated by a narrow joint cavity containing synovial fluid, an albumin 
and hyaluronic acid-rich fluid responsible for lubricating, nourishing and removing the waste 
from the articular cartilage. The joint capsule encloses the joint cavity and retains the synovial 
fluid and is comprised of the outer fibrous capsule, which is adjoined to the periosteum of the 
bones, and the inner synovial membrane. The synovial membrane is composed of an intimal 
lining, comprising one to three layers of cells loosely attached to the basement membrane, 
and the synovial sublining that is composed mainly of extracellular matrix, blood and lymphatic 
vessels, adipocytes and fibroblasts (Haywood and Walsh, 2001; Knedla et al., 2007). The 
37 
 
synovial intimal lining consists of two mesenchymal-like cells; fibroblast-like type B 
synoviocytes (synovial fibroblasts), which produce matrix molecules and hyaluronan to 
increase the viscosity of the synovial fluid, and macrophage-like type A synoviocytes, which 
clear apoptotic neutrophils and other cells from the joint cavity (Shiozawa et al., 2011).  
 
1.1.3.2. Pre-articular phase of RA  
As previously described, genetic predisposition and environmental (non-genetic) factors are 
believed to initiate the onset of RA by promoting the dysregulation of the immune system and 
breakdown of immune tolerance leading to autoimmunity, as indicated by the presence of 
autoantibodies against self-antigens (Song and Kang, 2010). The activation of the innate 
immune system is the earliest event in the pathogenesis of RA and occurs prior to the 
development of the clinical signs (Nielen et al., 2004). This process initially involves the 
activation and maturation of dendritic cells in response to exposure to numerous triggers 
including bacterial and viral products, immune complexes, cytokines, multiple endogenous 
ligands and disruption of cell-cell contact (Hitchon and El-Gabalawy, 2011). The RA synovium 
contains abundant myeloid and immature plasmacytoid dendritic cells which are primarily 
located in the sublining tissue near T-cell-B-cell aggregates and in perivascular lymphocytic 
areas. These dendritic cells express cytokines (IL-12, -15, -18 and 23), HLA class II molecules, 
chemokine receptors and costimulatory molecules required for T-cell activation and antigen 
presentation (McInnes and Schett, 2011).  
 
There is substantial evidence suggesting that invading T-cells, particularly CD4+ helper cells 
are vital in the early immunological response. Antigen-presenting cells, including dendritic 
cells, macrophages and activated B-cells, present arthritis-associated antigens to T-cells 
leading to stimulation and expansion of autoantigen-specific T-cells in the joints and lymph 
nodes (Buch and Emery, 2002). In addition to antigen-presentation, B-cells which are primarily 
located in T-cell-B-cell aggregates, become activated by the autoantigen-specific   T-cells to 
produce autoantibodies e.g. RF and anti-CCP autoantibodies. These autoantibodies can form 
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larger immune complexes resulting in complement fixation, neutrophil activation, and the 
production of pro-inflammatory cytokines which perpetuates inflammation (Hitchon and El-
Gabalawy, 2011). Consequently, T-and B-cell activation results in increased production of pro-
inflammatory cytokines and chemokines resulting in additional T-cell, macrophage and B-cell 
interactions. Specifically, the interaction between synovial macrophages and T-cells drives 
TNFα and IL-1β production and activated fibroblasts secrete IL-6, IL-8 and prostaglandin E2 
(PGE2). Furthermore, T-cells differentiate into Th17-cells which produce high levels of pro-
inflammatory IL-17 cytokine in the synovium resulting in the perpetuation of inflammation and 
progression to the onset of clinical disease (Choy, 2012).  
 
1.1.3.3. Articular phase of RA  
The transition from the pre-articular to the articular phase of RA is a multi-step complex 
process. The key role of activated RA synovial fibroblasts (RASFs) in the pathogenesis of RA 
has become increasingly evident, as these cells significantly contribute to the destructive 
processes in RA (Ospelt et al., 2004). During the pre-clinical phase, RASFs may become 
activated by infectious and non-infectious agents and their respective degradation products. 
Microbial fragments or endogenous ligands, such as RNA from necrotic cells within the 
synovium, can stimulate RASFs via Toll-like receptors (TLR-2, -3 and 4), found on the cell 
surface of RASFs (Seibl et al., 2003). TLR signalling in RASFs results in upregulated 
expression of pro-inflammatory cytokines and chemokines leading to the attraction and 
accumulation of immune cells to the synovium and through a positive feedback loop, RASFs 
can initiate and perpetuate the disease process.   
 
The characteristics of activated RASFs include changes to the normal spindle-shaped 
cytoskeleton, dense rough endoplasmic reticulum (RER) and large nucleus with prominent 
nucleoli indicating both active RNA metabolism and protein production (Huber et al., 2006). 
These activated RASFs produce matrix metalloproteinases (MMPs) and various pro-
inflammatory cytokines (IL-1β, IL-6, IL-7, IL-15, IL-16, LTβ, GM-CSF) and chemokines (MIP-
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1α, MCP-1 and RANTES) that promote the recruitment and activation of other immune cells 
to the synovium (McInnes and Schett, 2007). The substantial influx and local activation of 
immune cells including T-cells, B-cells, plasma cells, dendritic cells, macrophages, mast cells 
and neutrophils into the synovium resulting in synovitis (Choy, 2012) and further infiltration of 
immune cells and the progression of synovitis is perpetuated by angiogenesis, which provides 
oxygen and nutrients to the expanding tissue (Paleolog, 2002). Additionally, the expanded 
endothelial cells contribute to local cytokine production and leukocyte recruitment, further 
exacerbating the prolonged inflammatory environment in the joint and persistence of the 
disease process (Szekanecz and Koch, 2000). 
 
The first step of synovial invasion involves the attachment of RASFs to the articular cartilage, 
a process mediated by the upregulation of adhesion molecules on the surface of RASFs. 
Adhesion molecules, specifically integrins of the β1 subfamily, mediate the attachment of 
RASFs to fibronectin-rich sites of the articular cartilage, cartilage oligomeric matrix protein 
(COMP) and to collagens, namely collagen type II. Following adhesion of RASFs, integrins 
and other adhesion molecules such as vascular adhesion molecule (VCAM-1) activate 
signalling pathways within the cell involved in the regulation of the early cell cycle genes, such 
as c-Fos/AP-1 and c-myc, and activate the expression of MMPs, thereby promoting 
hyperplasia of the synovium and ultimately, cartilage degradation (Shiozawa and Tsumiyama, 
2009). Synovial hyperplasia is a characteristic feature of RA resulting from the combined effect 
of RASF hyperproliferation and impaired apoptosis. The upregulated transcription factor c-
Fos/AP-1 activates Wee1 kinase, which inhibits mitotic cell division by phosphorylating cdc2, 
resulting in arrested mitotic cell division and cellular proliferation (Kawasaki et al., 2003). 
RASFs also display altered characteristics in cell death pathways and a low rate of apoptosis. 
The resistance to apoptosis potentially results from increased expression of anti-apoptotic 
proteins such as FLIP and Bcl-2 and survival proteins such as heat-shock protein 70 (HSP70), 
sentrin-1 (also known as SUMO-1) and sumoylated proteins which prolong survival of RASFs 
(Huber et al., 2006). Consequently, the hyperplastic synovium develops into the characteristic 
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synovial overgrowth, commonly known as ‘pannus’. This ‘tumour-like’ granulation tissue 
exhibits features of tumours such as hyperproliferation, evasion of apoptosis, anchorage-
independence and loss of contact inhibition, all of which contribute to the overgrowth of the 
pannus and its gradual invasion into the adjacent articular cartilage and the underlying bone, 
resulting in cartilage degradation and bone erosion (Shiozawa et al., 2011).  
 
Articular cartilage is composed of a non-mineralised surface layer and a mineralised layer 
adjacent to the bone and both layers contain chondrocytes which are involved in cartilage 
metabolism (McInnes and Schett, 2007). The destruction of articular cartilage is a multi-step 
process mediated by the release of matrix-degrading enzymes such as aggrecanases 1 and 
2 (also known as A Disintegrin and Metalloproteinase with Thrombospondin Motifs (ADAMTS-
)-4 and 5) and MMPs. In healthy joints, MMP activity is balanced by endogenously produced 
tissue inhibitors of metalloproteinases (TIMPs) which inhibit MMPs by non-covalently binding 
to its enzymatic active site with a 1:1 stoichiometry. However in RA, pro-inflammatory 
cytokines such as TNFα and IL-1β, growth factors and matrix molecules induce the expression 
of MMPs via transcriptional activation from RASFs resulting in the amount of MMPs exceeding 
approximately x44 that of TIMPs (Shiozawa et al., 2011). Further cartilage degradation is 
promoted by IL-1β and IL-17 which induce a switch in chondrocytes from an anabolic matrix-
synthesising state to a catabolic state, characterised by the formation of ADAMTSs and 
MMPs. Chondrocytes also synthesise and respond to pro-inflammatory cytokines to 
accelerate the switch from an anabolic to a catabolic state (Otero and Goldring, 2007). Other 
proteinases, including urokinase-type plasminogen activator and the cathepsins B, L and D 
which contribute to cartilage destruction by degrading various cartilage matrix components 
and cathepsin K, are expressed by synovial fibroblasts, synovial macrophages, articular 
cartilage chondrocytes, osteoclasts and osteoblasts (Muller-Ladner et al., 2007).  
 
The primary mediators of bone destruction are osteoclasts, which are found at the interface 
between the pannus and the adjacent subchondral bone. The presence of M-CSF 
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(macrophage colony stimulating factor) and RANKL (receptor activator of nuclear factor B 
ligand) which are also expressed at the site of pannus invasion, enable the differentiation of 
osteoclasts from their precursors (McInnes and Schett, 2011). The osteoclastic activity of 
osteoclasts is initiated by the binding of RANKL, produced from activated lymphocytes and 
osteoblasts, to the cognate RANK receptor on their cell surface, and the activated osteoclasts 
along with cathepsin K, promote the local activation of bone resorption with destruction of the 
mineralised bone matrix, resulting in bone erosion (Gravallese, 2002).  
 
Pro-inflammatory cytokines are involved in each phase of the pathogenesis of RA, from 
promoting autoimmunity (including during the pre-articular phase), to maintaining chronic 
inflammatory synovitis and also during the destruction of adjacent joint tissue (McInnes and 
Schett, 2007). The main cytokines involved in integrating the immune-regulatory and tissue 
destruction events in RA are summarised in Figure 1.2. 
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Figure 1.2. Schematic diagram depicting the events occurring in the RA joint. Cell 
surface adhesion molecules such as the intercellular adhesion molecule-1 (ICAM-1), present 
on endothelial cells, facilitate the trafficking of cells i.e. leukocytes, expressing leukocyte 
function-associated antigen-1 (LFA-1) between the blood and the synovial tissue. In the 
synovial tissue, pro-inflammatory cytokines such as IL-12 and IL-23 are produced by antigen-
presenting cells (APC) that also possess co-stimulatory molecules (CD80/86) and the major 
histocompatibility complex (MHC) class II molecule which interact with CD28 and T-cell 
receptor (TCR), respectively, on the cell surface of T cells. Activated T cells secrete IFN-γ, IL-
17, GM-CSF and IL-4. B-cells produce autoantibodies such as Rheumatoid Factor (RF). 
Macrophages secrete IL-15 and IL-18 and also produce TNFα and IL-1, which activate 
synovial fibroblasts and chondrocytes to secrete matrix metalloproteinases (MMPs) that 
contribute to cartilage degradation and activate osteoclasts involved in bone destruction. 
Figure redrawn, with modifications, from the image by Smolen and Steiner (2003). 
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1.1.4. Animal models of RA 
Animal models of RA have proven to be very useful research tools for the study of the 
pathogenic pathways involved in the disease and also, for the development and preclinical 
evaluation of anti-arthritic therapies (Bevaart et al., 2010).  
Numerous mouse models of RA and/or paw inflammation have been established including 
collagen-induced arthritis (CIA) (Courtenay et al., 1980), antigen-induced arthritis (AIA) 
(Brackertz et al., 1977), carrageenan-induced paw oedema (Levy, 1969), as well as transgenic 
spontaneous models of arthritis such as the K/BxN (Kouskoff et al., 1996) and TNFα mouse 
models (Butler et al., 1997). Although no animal model perfectly duplicates the pathogenic 
features of human RA, most have some pathological similarities to the human disease. 
However, animal models often have greater bone resorption and bone formation in response 
to joint inflammation, as well as a more rapid disease progression than observed in human 
RA (Bendele, 2001).  
In addition to the selection of an animal model which has similar pathology to that of human 
disease, other important selection criteria include the predictability of the disease process, 
reproducibility of data, appropriate duration of disease and the relative ease of performing the 
model. The aforementioned rodent models of ‘induced’ arthritis and/or paw inflammation have 
been extensively used to develop a greater understanding of the pathogenesis of the disease 
process, to identify new therapeutic targets and to investigate the therapeutic efficacy of new 
drugs (Kannan et al., 2005). 
 
1.1.4.1. Collagen-induced arthritis (CIA) 
The CIA mouse model is an extensively used model of RA which shares both immunological 
and pathological features of human RA. Arthritis is elicited in genetically susceptible strains of 
mice such as DBA/1, B10.Q, and B10.RIII, following immunisation with heterologous type II 
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collagen emulsified in complete Freund’s adjuvant (intra-dermal injection) which results in the 
breakdown of immune tolerance and the induction of an autoimmune-mediated attack on the 
joints (Kollias et al., 2011).  
The immunopathogenesis of CIA is predominantly mediated by T-cell and B-cell specific 
responses to type II collagen, resulting in the production of collagen-specific T-cells and anti-
collagen type II antibodies by activated B-cells. During the early stages of disease, collagen-
specific antibodies bind to the collagen type II in the joint, resulting in immune-complex 
formation, complement activation, induction of a local inflammatory response, recruitment of 
monocytes and T-cells to the joint and the production of proinflammatory cytokines and 
mediators (Bevaart et al., 2010). 
Chronic polyarthritis typically occurs 21-28 days after immunisation and peaks at 
approximately day 35 and gradually declines over the following weeks. Mouse CIA is 
characterised by cartilage degradation associated with immune complex deposition on 
articular surfaces, synovial hyperplasia, mononuclear cell infiltration, bone resorption, 
periosteal bone proliferation and inflammation, similar to human RA. However, there is little or 
no sex bias in CIA and importantly, these mice develop antibodies directed against collagen, 
which is not a consistent feature in patients with RA (Brand et al., 2007). Nevertheless, this 
model has been extremely useful in evaluating the therapeutic efficacy of biological agents 
such as soluble TNF receptor (Bevaart et al., 2010). 
The CIA mouse model is quite reproducible and a disease incidence of 80% can be achieved 
for most susceptible strains. However, the kinetics of arthritis development for each mouse in 
the same experimental group can vary widely (Brand et al., 2007), which can impact on the 
timing/setup of experiments. Also, disease can occur in any combination of paws or joints, 
therefore, other mouse models with more predictable arthritis and/or inflammation, may be 
better suited for early evaluation studies of the therapeutic efficacy of drugs, on single and 
defined inflamed joints.  
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1.1.4.2. Antigen-induced arthritis (AIA) 
AIA in most strains of mice, rats and rabbits can be elicited by immunisation with an antigen 
(e.g. methylated BSA in complete Freund’s adjuvant, administered subcutaneously or 
intradermally) followed by a subsequent intraarticular challenge with the same antigen at least 
14 days later, in one joint and a control joint can be treated with vehicle alone. Methylated 
BSA binds to the cartilage and induces an immune-complex-mediated inflammatory process, 
complement activation and T-cell-mediated responses on the articular cartilage surface, 
resulting in the onset of acute inflammation, secretion of pro-inflammatory mediators, immune 
cell infiltration and cartilage destruction, 3-4 weeks after AIA (Asquith et al., 2009).  
Mouse, rat and rabbit AIA models are commonly used to investigate the role of specific 
cytokines in various pathogenic processes the arthritis (e.g. van de Loo et al., 1995). Also, the 
ability to repeatedly induce inflammation by re-challenging mice with methylated BSA offers 
the prospect of monitoring the therapeutic efficacy of biological agents e.g. IL-1 receptor 
antagonist, since IL-1 plays a major role in AIA (Di Domizio et al., 2013).  
 
1.1.4.3. Carrageenan-induced paw oedema  
Carrageenans are sulphated polygalactans derived from a number of red seaweeds, of the 
class Rhodophyceae, and are of three major types; lambda (λ), kappa (κ) and iota (ι). The 
induction of paw inflammation by an intraplantar injection of λ-carrageenan in rat paws was 
first demonstrated by Winter et al., (1962), where the inflammatory process was described as 
acute, non-immune and highly reproducible. A similar observation in mice was reported by 
Levy (1969) and later research by Henriques et al., (1987) revealed that λ-carrageenan 
injected into the mouse paw elicits biphasic oedema where the first phase peaks at ~5 hours 
post-carrageenan injection and is characterised by low-intensity oedema while the second 
phase develops after 24 hours and peaks at 72 hours in a dose-dependent manner and 
decreases thereafter. 
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The injection of λ-carrageenan into mice paws provokes an acute local inflammatory reaction 
which is characterised by the production of pro-inflammatory mediators such as histamine, 
serotonin, bradykinin, complement and prostaglandins which results in an increase in vascular 
permeability and cellular infiltration leading to oedema formation (Necas and Bartosikova, 
2013). The infiltration and activation of leukocytes, mainly neutrophils, contribute to the 
inflammatory reaction by producing reactive oxygen and nitrogen species and hydroxyl 
radicals, which can also be produced at the injured site (Posadas et al., 2004).  
In the literature, there are over 400 papers reporting the use of mouse paw oedema and the 
carrageenan-induced paw oedema model has been increasingly used to study different 
mechanisms of the inflammatory process and to study the therapeutic effects of anti-
inflammatory drugs e.g. NSAIDs, where it has become a popular model for localised 
inflammation (Posadas et al., 2004).  
All animal models of human diseases have inherent limitations and the choice of the most 
suitable model is influenced by the selection criteria of the specific experiment. Overall, the 
research on animal models of RA and paw inflammation has positively contributed to the 
growing understanding of the disease mechanisms and has been instrumental in facilitating 
the development and preclinical evaluation of novel therapeutics for the treatment of the 
disease.  
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1.1.5. Treatment of RA 
Although the aetiology of RA is unclear, the pathogenesis of RA is better understood and 
therefore, has facilitated the innovative developments of effective RA therapies. The general 
aims of drug management in RA are to alleviate the symptoms of the disease, and to modify 
the pathological process to prevent or stop further disease progression in order to ultimately 
achieve RA remission i.e. having scores below certain levels on disease activity indices (e.g. 
Disease Activity Score in 28 joints (DAS28) <2.6) (Rheumatoid Arthritis; National Clinical 
Guideline for Management and Treatment in Adults, UK, 2009). The current therapies used to 
treat RA can be divided into three groups; non-steroidal anti-inflammatory drugs (NSAIDs), 
disease modifying anti-rheumatic drugs (DMARDs) and biological therapies. 
 
1.1.5.1. NSAIDs 
NSAIDs are effective anti-inflammatory and analgesic drugs, which inhibit the biosynthesis of 
prostaglandins to provide symptomatic relief. NSAIDs exert their actions by binding to the 
active site and inhibiting cyclooxygenase (COX) enzymes, which are key enzymes responsible 
for the formation of eicosanoids from arachidonic acid. Eicosanoids can be subdivided into 
prostanoids, comprising prostaglandins, prostacyclin and thromboxane A2, all of which play 
important roles in inflammation (Crofford, 2013).  
COX exists in two isoforms; the constitutively expressed COX-1, which is present in most 
tissues including vascular endothelium, stomach mucosa and kidneys, and the inducible COX-
2, which is induced in a number of cells by pro-inflammatory stimuli and is therefore the main 
target for the treatment of inflammatory diseases (Mitchell and Warner, 1999). The prostanoids 
produced by COX-1 are important in gastric protection, therefore, the broad inhibition of COX 
enzymes have detrimental effects on gastric function e.g. non-selective NSAIDs (COX-1 and 
COX-2 inhibitors) such as indomethacin, naproxen and diclofenac inhibit prostaglandin 
production which increases gastric motility and provokes severe gastric lesions. This 
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consequently led to the development of selective COX-2 inhibitors (COXIBs) which 
significantly reduced gastric side effects (Jackson et al., 2000). However, COXIBs have been 
linked to increased risk of cardiovascular events and increased reports of deaths associated 
with COXIBs, particularly rofecoxib (Moodley, 2008). Also, COXIBs decrease the release of 
prostacyclins, which are inhibitors of platelet aggregation and are potent vasodilators, 
therefore, COXIBs may also promote increased prothrombotic activity and cardiovascular 
complications (Mukherjee et al., 2001).  
 
1.1.5.2. DMARDs  
Conventional DMARDs, including methotrexate (MTX), sulphasalazine, hydroxychloroquine, 
leflunomide and gold injections, act to modify the progression of RA by reducing pain, 
inflammation and joint damage (Upchurch and Kay, 2012). MTX is the most frequent drug of 
choice for the early stage of RA and exerts anti-proliferative effects by competitively inhibiting 
folate-dependent enzymes such as dihydrofolate reductase to prevent de novo purine and 
pyrimidine synthesis, which is essential for DNA and RNA synthesis. Also, the anti-
inflammatory effects of MTX are due to increased extracellular levels of                          5-
aminoimidazole-4-carboxamide ribonucleotide, that leads to inhibition of adenosine and AMP-
deaminase and accumulation of extracellular adenosine and AMP that bind to the adenosine-
A2 receptor to increase the production of anti-inflammatory IL-10 cytokine and inhibit NFκB 
activity. Consequently, treatment with MTX can result in decreased cell proliferation, increased 
cell apoptosis of immune cells and decreased pro-inflammatory cytokine production (Meier et 
al., 2013). Disease activity is evaluated periodically and it has been observed that the 
effectiveness of DMARDs often decreases as the disease progresses or when patients 
experience adverse effects and therefore, DMARD therapy often fails to stop the progressive 
destruction of articular cartilage and bone. The decision to initiate biological drug treatment in 
these DMARD-inadequate responders is recommended to patients who have persistently 
elevated DAS28 >5.1 indicating severe RA and who have failed to respond to two DMARDS 
(including MTX, unless contraindicated) taken over a minimum of 6 months each. In such 
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cases, biological TNFα antagonists i.e. infliximab, are the first ‘biologic’ option (Kiely et al., 
2012).  
 
1.1.5.3. Biological drugs 
The substantial evidence of the integral role of pro-inflammatory cytokines and immune cells 
in RA pathology has led to the development of targeted biological drugs which modify the 
disease process by inhibiting specific pro-inflammatory cytokines or inflammatory cells 
implicated in inflammatory pathways (Table 1.1). These biological proteins have revolutionised 
the treatment of RA and improved the quality of life of millions of RA sufferers. However, these 
drugs are not without adverse effects which therefore limit their long-term use. 
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Agent Structure Method of action Dosage and administration Reported side effects 
Etanercept 
 
Fusion protein consisting 
of the extracellular domain 
of the p75-TNF receptor 
fused with human IgG1 
Binds to circulating TNF and lymphotoxin 
and membrane bound TNF, thereby blocking 
the interaction of TNF with TNF-receptors. 
May have effects that are mediated through 
neuro-endocrine pathways as wells 
25 mg twice weekly for 3 
months or 50mg once 
weekly, subcutaneously 
 
-Injection site reactions 
(pain, swelling, erythema) 
 
 
-Upper respiratory tract 
infections (reactivation of 
latent diseases) 
 
 
-Oncogenic potential 
(particularly lymphoma) 
 
-Infusion-related reactions 
(fever, chills, chest pain, 
shortness of breath) 
 
-Serious infections e.g. 
pneumonia, cellulitis  
Infliximab 
Chimeric (human/mouse) 
humanised monoclonal 
antibody against TNFα 
Binds to soluble and membrane-bound 
forms of TNFα, thereby blocking the 
interaction of TNFα with TNF-receptors. 
Infliximab causes apoptosis of cells with cell 
surface TNF 
3-10 mg/kg over the 
course of 2-3 hours, 
intravenously. 
Administered every 4-8 
weeks. Initial dosing may 
be at 0, 2, and 6 weeks  
Adalimumab 
‘Fully’ human recombinant 
IgG1 monoclonal antibody 
with specificity for TNFα 
Binds to soluble and membrane bound TNFα 
leading to a blockade of activity of TNFα 
causing apoptosis of cells with membrane-
bound TNF 
40 mg every other week, 
subcutaneously 
Abatacept  
Fusion protein consisting 
of the extracellular protein 
of human CTLA4  with a 
fragment of the Fc portion 
of human IgG1 
Binds to CD80/86 on the cell surface of 
antigen-presenting  cells to prevent                  
co-stimulatory binding of CD28 on the 
surface of T-cells, thereby inhibiting T-cell 
activation 
 
 
 
 
The dose of abatacept 
depends on body weight 
(500mg-1000mg range). 
Intravenous infusions at 
week 0, 2, 4 and then 
every 4 weeks thereafter 
 
 
 
-Infections including sepsis 
and pneumonia 
-Contraindicated in patients 
with severe, uncontrolled 
and/or opportunistic 
infections 
Rituximab 
 
Chimeric monoclonal 
antibody against CD20 
antigen 
 
 
 
Binds to CD20 on the cell surface of mature 
B cells, causing apoptosis. Targets and 
selectively depletes CD20+ B-cells without 
targeting stem cells or existing plasma cells. 
Cell lysis via either complement-dependent 
cytotoxicity  and/or antibody-dependent cell-
mediated cytotoxicity 
Two 1000 mg  
intravenous infusions, 
given 2 weeks apart  
 
 
-Contraindicated in patients 
allergic to the drug or its 
components, hepatitis B 
carriers, patients with 
cardiac arrhythmia, angina 
pectoris or active infections 
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Table 1.1. Biological Agents: Their structure, method of action, doses, administration and side effects. Information in 
table modified from Callen, (2007) and National Institute for Health and Care Excellence (NICE) Technology Appraisal Guidance 
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Although >30% of patients receive biologics as a monotherapy, the combination of biologics 
with DMARDs such as MTX (unless contraindicated) dramatically increases the efficiency of 
the treatment. Generally, the targeted suppression of key inflammatory pathways involved in 
joint inflammation and destruction using biologics reduces the signs and symptoms of RA, 
inhibits the progression of structural damage and improves the physical function in patients 
with moderate to severe RA (Doan et al., 2006). However, the treatment with biologics is 
based on continuous immunosuppresion irrespective of the patient’s inflammatory status and 
their continued use raises many concerns and challenges, particularly the serious side effects 
such as the increase in the risk of infections and reactivation of latent diseases. As well as 
being very expensive, many patients develop inadequate responses to biological treatments 
(Kiely et al., 2012). Also, the relatively short half-life of these proteins (few days) require 
frequent systemic injections at high doses in order to maintain efficacious levels of the 
therapeutic protein in the joint. Consequently, non-target organs are exposed to high 
concentrations of anti-inflammatory agents which can increase the risk of 
immunosuppression. 
Due to the localised nature of the RA joint, the intra-articular delivery of therapeutic agents 
provides a safer and more cost-effective alternative to systemically administered drugs. 
However, the intra-articular delivery of therapeutic proteins is a challenge due to the rapid 
clearance of small molecules (via the synovial capillaries) and macromolecules (via the 
lymphatic system) and repeated intra-articular injections is not a feasible option for the 
treatment of RA (Evans et al., 2013). An attractive alternative to protein therapy is to 
genetically modify the cells to synthesise and express the encoded therapeutic proteins within 
the joint, using gene therapy.   
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1.2. Gene therapy 
Somatic gene therapy can be broadly defined as an experimental technique involving the 
transfer of genetic material into living cells (excluding germ cells) to cure, treat or prevent 
diseases (Chernajovsky et al., 2004). The success of gene therapy approaches is primarily 
dependent on efficient gene transfer and expression of therapeutic genes, which has been 
achieved in various experimental systems and has brought gene therapy to the forefront of 
molecular medicine. Safer methods have been developed and extensively optimised to 
provide efficient gene delivery to RA joints, using in vivo and ex vivo strategies in conjunction 
with a variety of viral and non-viral vectors. 
 
1.2.1. Mode of gene transfer 
Systemic and local delivery of therapeutic genes can be achieved by either direct in vivo or 
indirect ex vivo gene delivery. The general concept of the ex vivo strategy involves the genetic 
modification of cells in vitro with the therapeutic DNA, followed by transplantation of the 
genetically modified cells either locally or systemically. Ex vivo gene delivery offers the 
advantage of characterising and then selecting and expanding the desired transduced cells 
for delivery. However, this strategy is limited by the accessibility and isolation of the cells and 
their ability to survive in culture for long periods of time without significantly changing their 
phenotype as well as the complexity and high cost of the approach (Adriaansen et al., 2006).  
In contrast, the in vivo strategy involves the direct delivery of genes, usually by viral vectors 
containing the therapeutic gene at the site where therapeutic protein expression is needed 
and involves genetic modification of the target cells (Robbins et al., 2003; Chernajovsky et al., 
2004). In the context of in vivo gene delivery directly into RA joints, the transcriptional and 
translational machinery of the transduced cells can produce and secrete the therapeutic 
proteins into the joint space to provide sustained intra-articular expression of therapeutic 
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proteins and potential long-term amelioration of chronic joint disease after a single or a limited 
number of gene delivery procedures (Gouze et al., 2007).  
In vivo gene therapy has been studied with varying success in animal models of RA mainly 
using recombinant adenoviral, recombinant adeno-associated virus, retroviral and lentiviral 
vectors. One of the most difficult challenges in gene therapy is the development of vectors 
and delivery approaches that are safe, efficient and targeted. Substantial progress has been 
made in the application of gene therapy by acknowledging the fundamental differences 
between gene delivery vectors i.e. vector capacity, duration of transgene expression, the 
ability to target dividing or non-dividing cells, extrachromosomal or genomic integration, 
immunogenicity and safety (Gould and Favorov, 2003). Both viral and non-viral vectors have 
been explored as a means of transporting therapeutic genes into target cells.  
 
1.2.2. Non-viral vectors  
Non-viral vectors include any method of gene transfer that does not involve the production of 
a viral particle and can be divided into two classes: (1) RNA or DNA amplified in bacteria or 
eukaryotic cells, which do not require a viral particle for transfer into cells e.g. plasmid DNA or 
(2) oligonucleotides or related chemically synthesised molecules (Ponder, 2001). Plasmid 
DNA is commonly used for gene expression studies and the main advantages of plasmid DNA 
vectors are their large packaging capacities, cheap and simple production, their lack of 
accessory proteins and their generally non-immunogenic profile, which has been further 
improved by the removal of immunogenic unmethylated CpG motifs (Krieg et al., 1995). 
Plasmid DNA lacks the inherent ability to enter cells and localise to the nucleus and therefore 
relies on physical or chemical methods to enter cells. Such delivery methods include 
electroporation, direct injection into tissue or the circulation and DNA complexing reagents 
such as cationic lipids which condense DNA thereby protecting it from degradation and 
facilitating DNA uptake by endocytosis (Gould and Favorov, 2003; Gould and Chernajovsky, 
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2007). Following cell entry, the plasmid DNA enters the nucleus and exists as 
extrachromosomal DNA which is transcribed and translated using the cell machinery. 
However, because the DNA can be degraded or is lost during mitosis, gene expression is 
transient.   
There has been limited success with direct intra-articular injection of plasmid DNA encoding 
therapeutic genes for example, Bloquel et al., (2007) who demonstrated decreased joint 
destruction in the ankles of mice with collagen-induced arthritis (CIA), following the intra-
articular delivery with electroporation of TNF-receptor encoding plasmid DNA (Bloquel et al., 
2007). With the exception of skeletal muscle where gene expression can last for months to 
years (Wolff et al., 1992), intra-articular plasmid DNA expression is generally low with poor 
efficacy and longevity which limits their use for local RA gene therapy. 
 
1.2.3. Viral vectors  
Viral vectors are derived from viruses with either RNA or DNA genomes and are either 
integrating or non-integrating vectors (Verma and Weitzman, 2005). The viral vectors 
employed for experimental gene delivery to inflamed joints are adenoviruses, adeno-
associated viruses (AAVs), retroviruses, herpes simplex viruses (HSV) and lentiviruses. The 
genomes of these viruses have been significantly altered to create safer vehicles for gene 
delivery (Kay et al., 2001) and have different advantages and disadvantages, as summarised 
in Table 1.2.   
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Vector Genetic material Immunogenicity 
Vector yield 
(TU/ml) 
Transgene 
capacity 
Vector genome 
forms 
Transgene 
expression 
Transduction of 
quiescent cells Genotoxicity 
Retrovirus RNA Low Moderate (1x1010) Upto 8 kb Integrated 
Long term 
(years) No 
Integration 
might induce 
oncogenesis 
Lentivirus RNA Low Moderate (1x1010) Upto 8 kb Integrated 
Long term 
(years) Yes 
Integration 
might induce 
oncogenesis 
Herpes 
simplex virus 
(HSV) 
dsDNA High High (1x1012) ~ 35 kb Episomal Transient Yes Low 
Adenovirus 
(gutless) dsDNA 
High (but less 
than 1st and 2nd 
generation Ad 
High 
(1x1012) ~ 35 kb Episomal 
Short term 
(weeks) Yes Low 
Adeno-
associated 
virus (AAV) 
ssDNA Low High (1x1012)    ~ 4 kb 
Integrated (10%) 
 
Episomal  (90%) 
Medium to long 
term (year) Yes 
Needs more 
investigation 
 
Table 1.2. The properties of viral vectors. Table adapted from Gould and Favorov (2003) and Bouard et al., (2009).  
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Although adenoviruses are commonly used in experimental gene transfer, these vectors are 
highly immunogenic and exhibit short-term transgene expression, which undermines the 
efficacy of the therapy. Despite their low transgene capacity, AAVs have been identified as 
the vector of choice for human gene therapy clinical trials (Evans et al., 2013). In contrast, the 
main advantages of retroviral and lentiviral vectors, over the other vectors, are their ability to 
permanently integrate into the host genome, thus conferring stable transmission and long-
term gene expression in the target cells and subsequent progeny cells. Additionally, both 
vectors have relatively large packaging capacities that can accommodate upto 8 kb transgene 
cassettes and have reduced in vivo immunogenicity compared to other gene therapy viral 
vectors i.e. adenoviruses, which minimises the risk of inducing a host immune reaction against 
the viral vector and/or transduced cells (Buchschacher and Wong-Staal, 2000). However, 
retroviral vectors can only transduce dividing cells which limits their application for gene 
therapy to ex vivo gene transfer. In contrast, lentiviral vectors have low immunogenicity and 
have the unique ability to transduce both dividing and non-dividing cells making them attractive 
candidates as delivery vectors for in vivo gene therapy (Kay et al., 2001; Sinn et al., 2005),  
 
 
 
 
 
 
 
 
1.2.3.1. Lentivirus life cycle 
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Early research into Acquired Immune Deficiency Syndrome (AIDS) significantly improved the 
understanding of the structure and biology of the causative Human Immunodeficiency Virus-
1 (HIV-1), which also laid the foundation for the development of HIV-based lentiviral vectors 
for gene therapy. HIV-1 belongs to the genus lentivirus, which is part of the Retroviridae family. 
Both retroviruses and lentiviruses are RNA-based viruses that replicate through a DNA 
intermediate, however, lentiviruses have a more complex genome and mechanisms that 
control their stages of infection (Buchschacher and Wong-Staal, 2000). Figure 1.3 
schematically depicts the structure and genome of the HIV-1 lentivirus.  
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Figure 1.3. Schematic diagram of a HIV-1 mature virion and genome. The HIV-1 mature 
virion contains the RNA genome, envelope glycoproteins gp120 and gp41, matrix protein p17, 
capsid protein p24, as well as the integrase, protease and reverse transcriptase enzymes [A] 
(HIV-1 virion figure was redrawn, with modifications, from the image by Kumar et al. (2007) in 
Robbins Basic Pathology, 8th edition). The wildtype HIV-1 genome consists of the 5’- and 3’- 
long terminal repeats (LTR), RNA packaging sequence (Ψ), the gag, pol, and env genes which 
encode the capsid, polymerase and envelope proteins, respectively and the genes encoding 
the transactivator of transcription (tat), regulator of virion protein expression (rev), negative 
regulatory factor (nef), virion infectivity factor (vif), viral protein U (vpu) and viral protein R (vpr) 
[B].  
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The HIV-1 life cycle can be divided into two temporally distinct phases: (1) infection, which 
results in the entry of the viral genome into the cell and (2) replication, which includes the early 
and late phases of gene expression when viral regulatory products and structural genes are 
expressed and assembled into viral particles (Kay et al., 2001).  
 
1. Virion binding and entry 
The initial step in the HIV-1 replication cycle (early phase of infection) is the binding of gp120 
to the CD4 molecule on the surface of host CD4+ T-cells and macrophages. This interaction, 
which is facilitated by the viral entry co-receptors CCR5 or CXCR4 results in a conformational 
change in the transmembrane gp41 protein, exposing the hydrophobic fusion domain at the 
N-terminus of gp-41, allowing the fusion between the viral and cell membranes and 
internalisation of the capsid (Melikyan, 2008).  
 
2. Reverse transcription 
In the cytoplasm, the virions undergo structural changes to form the reverse transcription 
complex (RTC), which is the site of viral DNA synthesis. Reverse transcription is initiated with 
the binding of the specific cellular tRNA (tRNALys3) primer to the primer binding site (PBS), 
followed by extension of the primer until the end of the genomic RNA (gRNA) molecule at the 
5’-end. The RNA portion within the resulting RNA/DNA duplex is degraded by the RNase H 
subunit of the reverse transcriptase (RT) enzyme to form the minus-strand DNA, which is 
subsequently transferred to the 3’-end of the gRNA in the complementary R region during the 
process of first ‘minus-strand DNA’ transfer. Minus-strand DNA synthesis is continued and the 
viral RNA is degraded by RNase H, except for the central polypurine tract (cPPT) and the 3’-
polypurine tract (PPT), which serve as primers for the synthesis of the plus-strand DNA. The 
plus-strand DNA is extended from the PPT primer until the 3’-LTR and the PBS region which 
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is followed by the second (plus-strand) DNA transfer. Synthesis of the transferred plus-strand 
DNA continues upto the cPPT, after which the process is terminated, thereby creating a 99 bp 
central DNA flap between the cPPT and the central termination sequence (CTS), which is 
thought to facilitate nuclear entry. DNA synthesis of plus- and minus-DNA strands is continued 
to the ends of both templates until a double stranded viral DNA is formed. The resulting viral 
DNA subsequently binds to viral and cellular proteins, such as RT, IN, NC, Vpr and MA, to 
form the preintegration complex (PIC) which is actively transported into the nucleus via the 
nuclear pore complex (Pluta and Kacprzak, 2009; Sarafianos et al., 2009; Hu and Hughes, 
2012).  
 
3. Integration 
The integration of viral DNA into the host cell genome is catalysed by the lentiviral integrase 
(IN) enzyme which binds to the short terminal fragments called att in the U5 and U3 LTRs 
resulting in the bending of the DNA molecule. The first reaction, known as 3’-processing 
occurs in the cytoplasm within the PIC and involves the removal of two nucleotides from each 
3’- end of the viral DNA which exposures the OH group. The second reaction called DNA 
strand transfer takes place in the nucleus at the site of integration where the IN enzyme uses 
the 3’-OH groups to cleave the phosphodiester backbone of the host chromosomal DNA 
resulting in the joining of the viral 3’-ends to the 5’-target DNA. In the final reaction called gap 
repair, the extra nucleotides from the 5’-ends of the viral cDNA are removed and joined to the 
host DNA 3’-ends with the aid of host cell DNA repair enzymes (Poeschla, 2008).  
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4. Gene Expression 
Following integration, the provirus exploits the cellular transcriptional and translational 
machinery. During transcription, the LTR acts as the viral promoter where RNA polymerase II 
binds to the first nucleotide of the R region in the 5’-LTR, with low efficiency. The viral Tat 
transactivator protein binds to the transactivation-responsive region (TAR) in the 5’-end of the 
nascent mRNA transcript, which subsequently recruits the host elongation factor composed 
of cyclin CycT1 and kinase CDK9, to enhance the processitivity of RNA polymerase II. The 
p300/CREB-binding protein-associated factor (P-CAF) mediates the acetylation of Tat which 
liberates Tat from TAR. The free acetylated Tat protein recruits P-CAF to the phosphorylated 
RNA polymerase II to further stimulate transcript elongation (Karn and Stoltzfus, 2009; Pluta 
and Kacprzak, 2009). 
The encoding sequences of the Gag and Pol proteins are present in different reading frames 
and are translated from a full-length unspliced RNA in the cytoplasm. The translation of the 
Gag-Pro-Pol polyprotein requires a single -1 frameshift whereas the Env gene is transcribed 
as a full length mRNA which encodes the viral envelope glycoproteins gp120 and gp41 and 
the resulting proteins are assembled at the plasma membrane (Bolinger and Boris-Lawrie, 
2009).  
 
5. Assembly, budding and maturation 
The assembly process packages all of the components required for infectivity into the virion, 
which include two copies of the (+) sense genomic viral RNA, molecules for cDNA synthesis 
e.g. tRNALys, the viral Env protein, Gag polyprotein and the three viral enzymes, protease 
(PR), reverse transcriptase (RT) and integrase (IN). At the plasma membrane, the amino 
terminal Gag domain called MA, binds to the plasma membrane and recruits the viral Env 
glycoproteins. The protein-protein interactions required for immature virion assembly are 
mediated by the central domain of Gag called CA, which creates the capsid of the mature viral 
63 
 
core. The NC domain of Gag binds to the psi-packaging (Ψ) signal in the 5’-LTR of the viral 
genomic RNA during virus assembly. Following the trafficking of the Gag-RNA, Gag-Pro-Pol 
and Gag polyproteins and Env glycoproteins to the plasma membrane, the HIV-1 virus buds 
at the plasma membrane of the infected cells and is released as an immature virion. The virion 
undergoes maturation, mediated by the viral PR enzyme, which cleaves the Gag and Gag-
Pro-Pol polyproteins at ten different sites to produce the structural proteins MA, CA, NC, p6 
and the enzymatic proteins PR, RT and IN, resulting in a mature and fully infectious HIV-1 
virion (Sundquist and Krausslich, 2012). The HIV-1 life cycle is schematically depicted in 
Figure 1.4.  
 
  
 
 
  
Figure 1.4. HIV-1 life cycle. The HIV-1 virus binds to the host cell surface 
receptor [1] allowing fusion between the viral and cell membranes [2]. The 
viral RNA and proteins are released into the host cell cytoplasm [3] and the 
viral RNA is reverse transcribed to form the viral DNA [4]. The viral DNA is 
integrated into the host cellular DNA in the nucleus [5]. Two copies of the 
HIV RNA genome is formed following genomic replication [6] and the viral 
proteins are synthesised [7]. The virus components are assembled and 
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1.2.4. Lentiviral vectors 
Since the first demonstration of the ability of lentiviral vectors to transduce neurons in vivo 
(Naldini, et al., 1996a; 1996b), lentiviral vectors have been extensively modified to achieve 
high levels of efficiency and biosafety. These vectors are engineered to be replication-
defective, to permit infection and integration of the transgene into the target cells whilst 
preventing multiplication and spread of the virus to other cells and the emergence of 
replication-competent lentiviruses (Durand and Cimarelli, 2011). Early improvements in the 
development of lentiviral vectors were based on the concept of separating the cis-acting 
elements necessary for vector RNA synthesis, packaging, reverse transcription and cDNA 
integration from the trans-elements that encode viral enzymes, structural and accessory 
proteins, on two DNA strands that can be delivered in different plasmids. Vector-production 
systems typically consist of a packaging expression cassette (helper vector), a vector 
expression cassette containing the heterologous promoter driving expression of a transgene 
which is flanked by LTRs and cis-elements (transfer vector) and an envelope expression 
cassette (Pluta and Kacprzak, 2009). 
 
Significant efforts have been made to minimise the risk of replication-competent lentiviruses 
by modifying the transfer vector or the packaging vector to reduce areas of overlap between 
the two to prevent the reconstitution of replication-competent lentiviruses. The first-generation 
lentiviral vectors were created by a three plasmid transfection into a packaging cell line, where 
the packaging vector comprised all HIV genes except for the Env envelope gene, which was 
encoded in the envelope vector (Naldini et al., 1996a). This system was further improved in 
the second-generation lentiviral vectors where most of the accessory genes (vif, vpr, vpu and 
nef) encoding proteins that are likely to be virulence factors, were eliminated. However, the 
gag, pol, tat and rev were retained to enable transcriptional and posttranscriptional functions 
(Zufferey et al., 1997). Safety tests have confirmed the absence of replication-competent 
lentiviruses with this system and due to their good safety record and high efficiency, second-
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generation systems are the most frequently used systems for experimental purposes. 
Conversely, the packaging vector used to create third-generation lentiviral vectors have the 
tat gene eliminated and the rev gene is encoded by a fourth plasmid. Therefore, only three out 
of the nine genes are present in the genome; the gag, pol and rev genes, which further 
eliminates the possibility of reconstituting a wild-type virus through recombination, making this 
system more suitable for human gene therapy compared to the others (Dull et al., 1998).  
 
Following co-transfection of the plasmids into a packaging cell line i.e. Human Embryonic 
Kidney (HEK) 293T cells, the cells express the components of the vector and release the 
infectious lentiviral particles into the cell supernatant, which only permit a single round of 
infection. The lentivirus particles are then used to transduce the target cells, however, the 
tropism of the lentivirus is determined by the envelope protein. The vast majority of lentiviral 
vectors are pseudotyped with the Vesicular Stomatitis Virus glycoprotein (VSV-G) envelope 
and can target a broad range of cells due to the interaction of the VSV-G envelope with 
phospholipid components of the cell membrane of the majority of cell types. The VSV-G also 
provides structural stability to the lentivirus during ultracentrifugation, allowing concentration 
of the virus for further applications (Burns et al., 1993).  
 
Several modifications to the transfer vectors have contributed to increasing their biosafety and 
their performances of gene transfer. For example, a 400-nucleotide deletion in the promoter 
sequence of the 3’LTR generated ‘self-inactivating’ (SIN) vectors with abolished LTR promoter 
activity. During reverse transcription, the defective promoter in the 3’LTR is transferred to the 
5’LTR of the proviral DNA and inactivates proviral transcription, thereby minimising the risk of 
generating replication-competent lentiviruses. Also, following integration of proviral DNA, the 
promoter activity of the 3’LTR can activate expression of adjacent host genes through an 
enhancer effect, however SIN vectors lack the 3’LTR promoter activity which decreases the 
likelihood of such events occurring and improves the performance of the vector (Zufferey et 
al., 1998). Therefore, SIN vectors do not typically demonstrate insertional mutagenesis (in 
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vitro), which is frequently observed in lentiviral and gamma-retroviral vectors (Bokhoven et al., 
2009). Consequently, SIN transfer vectors consist of modified LTRs, a transgene driven by a 
suitable promoter of choice and the         Ψ-packaging sequence. Further modifications to the 
transfer vector include the incorporation of insulator elements such as the chromatin insulator 
from the 5’-end of the chicken β-globin locus (5’-cHS4), positioned to flank the heterologous 
promoter and transgene, function to shield the promoter from the action of distal promoters in 
the host cell genome (enhancer blocking effects) and protect the transgene against gene 
silencing by preventing the advancement of adjacent inactive condensed chromatin (barrier 
effects) (Pikaart et al., 1998). Also, the inclusion of the cPPT and the central termination 
sequence (CTS), has been shown to increase lentiviral vector transduction efficiency (Sirven 
et al., 2000) and the incorporation of the woodchuck posttranscriptional regulatory element 
(WPRE) immediately downstream of the stop codon increases the viral titre and improves 
transgene expression by increasing mRNA stability (Zufferey et al., 1999).  
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Figure 1.5 Lentiviral vector transfer, packaging and envelope constructs.  
(A) First, second and third generation packaging constructs. (B) Non self‐inactivating (SIN) and SIN lentiviral transfer vectors.  
(C) Envelope Construct, Vesicular Stomatitis Virus Glycoprotein (VSV-G) gene driven by the CMV promoter. 
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1.2.5. Targets for RA Gene therapy 
Logically, the success of both protein and gene therapy for the treatment of RA is dependent 
on the type of therapeutic agent used to target the activity of the inflammatory/destructive 
molecule. To date, anti-cytokine therapies e.g. anti-TNF and IL-1Ra, have been the most 
successful strategies to ameliorate inflammation and disease severity in both experimental 
arthritis and in humans. Notably, AAV-mediated delivery of genes encoding TNFR-Fc 
(etanercept) and IL-1Ra has entered clinical trials and these studies have reported variable 
success of the treatments (Evans et al., 2013).   
In addition to targeting pro-inflammatory cytokines, experimental (gene therapy) success has 
also been achieved through the use of vectors encoding therapeutic agents designed to inhibit 
gene expression of inflammatory/destructive molecules or overexpress natural therapeutic 
molecules. For example, Th2 cytokines such as IL-4, IL-10 and IL-13 are immunosuppressive 
and are known to inhibit the activities of IL-1β and TNFα. Overexpression of these cytokines 
by gene delivery has demonstrated beneficial effects on arthritis, particularly IL-4, which exerts 
bone and chondrocyte protective actions (van de Loo and van den Berg, 2002). Also, the 
inhibition of T-cell activation through the blockade of the CD28/CD80-86 co-stimulation 
pathway using adenoviral expressed CTLA-4-IgG1 fusion protein, efficiently suppressed 
established CIA (Quattrocchi et al., 2000).  
The invasion of articular cartilage and bone by the synovial pannus is a hallmark feature of 
joint destruction in RA, therefore the induction of synovial cell apoptosis offers another target 
for RA therapy. Synoviocyte depletion has been achieved by ex vivo gene transfer of Fas 
ligand, which upon recognition of Fas antigen, induces apoptosis (Okamoto et al.,1998) and 
also in vivo adenoviral gene transfer of the Fas-associated death domain (FADD) which binds 
to the intracellular death domain of Fas to promote Fas-mediated apoptosis (Kobayashi et al., 
2000). An alternative approach to induce cell death is through the delivery of the HSV 
thymidine kinase (TK)-mediated suicide gene, as demonstrated by Goossens and colleagues 
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(1999), who reported a reduction in joint swelling and ablation of the synovial lining layer in 
the joints of rhesus monkeys with CIA, following the i.a. delivery of Ad-HSK-TK delivery and 
parental treatment with the prodrug, ganciclovir (Goossens et al., 1999).  
Other targets for RA therapy include the prevention of cartilage destruction, for example the 
retroviral transduction of MMP-1 specific ribozymes inhibited MMP-1 production in RASF and 
reduced the invasiveness of the cells in a SCID mouse model of RA (Rutkauskaite et al., 
2004). Conversely, a cartilage regeneration approach has been demonstrated using 
adenoviral delivered insulin-like growth factor, which led to stimulation of new proteoglycan 
synthesis in cartilage in rabbit joints with antigen-induced arthritis (AIA) (Mi et al., 2000).  
NFκB plays a major role in the pathogenesis of RA and is highly expressed in RA tissues. 
Several studies have shown that the delivery of NFκB inhibitors decreases arthritis and 
inflammatory cytokine production in animal models of RA, for example, the local adenoviral–
mediated gene transfer of dominant-negative IKKβ exerted anti-arthritic effects by significantly 
decreasing NFκB DNA expression in the joints of rats with AIA (Tak et al., 2001). However, a 
major disadvantage of targeting ubiquitously expressed transcription factors is that the 
systemic dissemination of transcription factor inhibitors can potentially result in detrimental 
side effects, due to the vital role of NFκB in a wide range of physiological processes. 
Overall, a common feature of the gene therapy systems described above and numerous 
others, is the use of constitutive promoters e.g. CMV. The disadvantage of uncontrolled 
expression of therapeutic genes by these promoters is the potential side effects associated 
with continuous therapeutic gene expression, especially in non-target tissues. The 
incorporation of regulatable gene expression systems are an attractive alternative to 
constitutive gene expression, particularly for RA therapy, as they can improve the safety and 
efficacy of the therapy.  
 
1.2.6. Regulated gene expression 
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Due to the relapsing nature of RA, therapeutic gene expression could be engineered to follow 
the intermittent course of disease within the joints so that therapeutic molecules are maximally 
expressed during disease flare and marginally expressed during disease remission. This 
regulated approach can potentially enhance the therapeutic effects, reduce side effects and 
lower the amount of therapeutic vector required (Adriaansen et al., 2006). Many innovative 
gene regulation strategies have been developed to circumvent unwanted therapeutic gene 
expression and the approaches relevant to RA gene therapy typically employ the use of 
‘transcriptionally targeted’ vectors. Transcriptionally-regulated therapeutic gene expression for 
RA can be achieved by constructing pharmacological or physiological-regulated synthetic 
promoters, which are typically comprised of the binding site of an inducible transcriptional 
factor coupled to a core promoter motif e.g. TATA box (Khoury et al., 2007). Therefore, an 
understanding of the role of core promoters and transcription factors in eukaryotic transcription 
is particularly relevant to the rationale design and construction of synthetic promoters.  
 
1.2.6.1. Eukaryotic transcription  
The expression of protein-coding genes is primarily mediated by RNA polymerase II (RNA pol 
II) and a complex network of general transcription factors; TFIID, TFIIB, TFIIF, TFIIE and 
TFIIH. The core promoter fundamentally contributes to the transcriptional process by serving 
as a platform for the assembly of the transcriptional preinitiation complex (PIC), comprised of 
RNA pol II and its basal transcription factors, which functions to cooperatively specify the 
transcriptional start site (TSS) to initiate transcription (Butler and Kadonaga, 2002).  
 
Many polymerase II promoters have a TATA box (consensus sequence; TATAA/TA) which is 
a core promoter motif located -25 bp upstream of the transcriptional start site.  During 
transcription initiation, this sequence is recognised by the TATA-binding protein (TBP) subunit 
of the general transcription factor TFIID, which also consists of multiple TBP-associated 
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factors (TAFs) that regulate the DNA binding activity of TBP. TFIIB subsequently binds to TBP 
to form a TBP-TFIIB complex, which is bound by RNA pol II in association with TFIIF. Finally, 
TFIIE and TFIIH associate with the complex to form the PIC. Following PIC formation, TFIIH, 
which contains DNA helicase activity, uses ATP to unwind the DNA at the TSS, thereby 
exposing the template strand. TFIIH also phosphorylates the C-terminal domain of RNA pol II, 
inducing a conformational change which allows RNA pol II to be released from the general 
transcription factors and begin the elongation phase of transcription (Thomas and Chiang, 
2006).  
The formation of this PIC-promoter complex is sufficient for a basal level of transcription, 
however, activated transcription is dependent on the recruitment of gene-, stimuli- or tissue-
specific transcription factors to their cognate binding sites in the promoter regions of target 
genes. These transcription factors can influence the recruitment of general transcription 
factors and the assembly of the PIC to manipulate the activity of the basal machinery as well 
as regulating gene expression by assisting the processitivity of RNA pol II during elongation. 
This regulatory action of transcription factors allows cells to control the levels of specific gene 
transcription e.g. in response to various stimuli (Papadakis et al., 2004).  
Overall, the core promoter motifs (i.e. TATA box) and transcription factor binding sites are 
imperative for activated transcription and the coupling of these components in synthetic 
promoters represents an attractive strategy to harness the cellular transcriptional machinery 
and exploit the endogenous activity of pharmacologically- or physiologically-inducible 
transcription factors for transcriptionally-regulated gene therapy.  
 
1.2.6.2. Pharmacologically-regulated gene expression  
In pharmacological regulated systems, the synthetic promoter contains the binding sites of 
transcription factors responsive to antibiotics such as tetracycline where gene expression is 
reversibly turned ‘on’ or ‘off’ in the absence or presence of tetracycline (Tet) or doxycycline 
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(Dox; a Tet derivative). The Tet-regulated system is analogous to the lac operon in prokaryotes 
where the transcription of bacterial resistance genes is negatively regulated by the Tet 
repressor protein (TetR) binding to the Tet operator (TetO) DNA sequence. In the presence of 
Tet, Tet binds to TetR and prevents TetR from binding to the promoter region of the gene, 
thereby allowing transcription to proceed. The components of the system were adapted into a 
regulatory system suitable for eukaryotic cells by fusing the TetR to the         C-terminal domain 
of VP16 from HSV to create the synthetic transcription factor known as the tetracycline-
controlled transactivator (tTA), that activates transcription from Tet-responsive synthetic 
promoters (Ptet; 7 TetO repeats cloned upstream of the mCMV promoter), in the absence of 
Tet (Gossen and Bujard, 1992). An inducible Tet-On system was subsequently developed by 
mutating the TetR to generate the rtTA (reverse Tet-repressor), which displays the reverse 
phenotype and induces gene expression in the presence of the Tet analogue, Dox (Gossen 
et al., 1995). Both Tet-systems permit stringent control of gene expression in response to 
varying concentrations of Tet or Dox, with no immunogenicity in mouse and primate models 
and has been the pharmacological-inducible system of choice in both in vitro assays and in 
vivo gene therapy systems.  
Using the Tet-On system, therapeutic viral IL-10 expression from AAV vectors was 
successfully regulated and significantly reduced arthritis, following the intramuscular (i.m) 
delivery of the construct prior to disease onset in CIA mice (Apparailly et al., 2002). Using the 
same mouse model, Gould et al., (2004) also utilised the Tet-On promoter to regulate 
expression of the human dimeric soluble TNFR (dsTNFR) from plasmid DNA, following i.m. 
delivery by electroporation and disease progression was inhibited by constitutive and Tet-
regulated dsTNFR in mice with mild arthritis (Gould et al., 2004).  
The main disadvantage of the Tet-On system is the significant basal activity of the synthetic 
promoter in the absence of antibiotic, which undermines the efficacy of the system. This was 
addressed by developing the tetR-KRAB (tetracycline repressor-Kruppel associated box) 
which binds to the Ptet and reduces the basal activity (Forster et al., 1999). Also, an improved 
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transactivator rtTA2S-M2 was developed, which exhibits greater stability than rtTA, enhanced 
responsiveness to Dox and enhanced TetO binding (Urlinger et al., 2000). By incorporating 
these improved components Gould et al., (2007) demonstrated the inhibition of disease 
progression by dTNFR in CIA mice, following the i.m delivery of the improved Dox-regulated 
plasmid DNA system (Gould et al., 2007). However, another drawback associated with drug-
inducible synthetic promoters is the requirement to constantly monitor the disease in order to 
achieve optimal efficacy in RA. This is also made challenging by the variable and relapsing 
clinical course of RA, and therefore highlights the need for self-regulating inducible systems 
e.g. disease-inducible synthetic promoters.  
 
1.2.6.3. Physiologically-regulated gene expression  
Physiologically-regulated synthetic promoters are an attractive alternative to 
pharmacologically-regulated synthetic promoters, as they offer the advantage of 
autoregulation by harnessing the pathophysiological characteristics of the disease to regulate 
gene expression (Adriaansen et al., 2006). For example, inflammation-inducible promoters 
are ideal systems for RA gene therapy, as they can potentially induce high levels of anti-
inflammatory agents during disease flare and lower levels during disease remission, to mirror 
the clinical course and severity of the patients’ inflammatory response in the joint.  
Pro-inflammatory cytokines, heat shock proteins, acute phase proteins, some transcription 
factors and hypoxia-responsive genes are all associated with the pathogenesis of RA and their 
promoters or binding sites can be harnessed for disease-inducible gene expression. The 
pioneering research of Varley et al., (1997) reported the development of a two-component 
adenoviral expression system which was responsive to inflammatory stimuli in vivo. In this 
system, the complement factor 3 (C3) promoter regulates the transcription of the HIV 
transactivator of transcription (Tat) protein, and Tat then stimulates the HIV LTR promoter for 
downstream transgene expression in the same vector. Both the C3 and HIV LTR promoters 
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have NFκB binding sites and are therefore NFκB-responsive and inducible by inflammation. 
The feasible use of the C3-Tat/HIV promoter as an inflammation-inducible promoter in RA was 
demonstrated in different experimental arthritis models using adenoviral-vector delivered   hIL-
1Ra (Bakker et al., 2002) and hIL-10 (Miagkov et al., 2002) and both systems resulted in 
diminished disease activity and decreased paw swelling. Although this system can achieve 
autoregulated gene expression in response to inflammation, the foreign Tat protein has a high 
immunogenic potential which renders this system unsuitable for RA gene therapy. 
As an alternative approach, van de Loo et al., (2004) developed a human IL-1β/IL-6 synthetic 
promoter, comprised of the human IL-1β enhancer sequence upstream of the human IL-6 
promoter, and demonstrated low basal activity and high reporter gene expression during the 
inflammatory response (van de Loo et al., 2004). The therapeutic efficacy of regulated 
expression of locally delivered adenoviral IL-4 (Geurts et al., 2007), and lentiviral IL-10 
(Henningsson et al., 2012) under the control of the human IL-1β/IL-6 synthetic promoter was 
demonstrated in CIA mice, and confirmed the feasibility of inflammation-inducible synthetic 
promoters for RA gene therapy.  
Other innovative systems have exploited the upregulated expression of transcription factors 
in RA such as NFκB. These NFκB-responsive promoters contain NFκB binding sites and 
during inflammation, NFκB binds to its cognate binding sites within the synthetic promoter to 
induce therapeutic gene expression, as demonstrated by Khoury et al., (2007). In this study, 
the local intra-articular (i.a.) administration of AAV-anti-TNF agents, under the control of an 
NFκB-responsive promoter, delayed the disease onset and decreased the incidence and 
severity of joint damage in CIA mice and therapeutic gene expression was strongly correlated 
with joint inflammation (Khoury et al., 2007). Similarly, hypoxia-responsive promoters 
containing hypoxia-responsive elements (HRE) have demonstrated hypoxia-inducible gene 
expression, particularly in cancer gene therapy, following their delivery into hypoxic cancerous 
cells (Shibata et al., 2000). With focus on RA, Subang et al., (2012) recently constructed a 
novel hybrid promoter containing HRE and TetO in the same synthetic promoter, which was 
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inducible by hypoxia and doxycycline. This innovative system provided an additional layer of 
regulation as gene expression can be terminated by tetR-KRAB even in the presence of the 
pathophysiological stimuli, which cannot be achieved with standard transcription-factor 
responsive promoters (Subang et al., 2012).  
Overall, the suitability of transcription-factor responsive promoters and similar systems is 
highly dependent on the expression profile of the transcription factors during the 
pathophysiological conditions in the RA joint. The endogenous activity of numerous TFs can 
be harnessed to achieve disease-specific gene expression (i.e. inflammation or hypoxia-
inducible) due to their upregulated expression in response to the characteristic 
pathophysiological stimuli in RA, described below.      
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1.3. Transcription factors in RA  
Pathological conditions such as hypoxia and inflammation activate a range of transcription 
factors in RA which respond by initiating the transcription of target genes, many of which are 
involved in perpetuating the disease process. Therefore, transcription factors play a 
fundamental role in the pathophysiology of RA.   
 
1.3.1. Activator Protein-1 (AP-1)  
The activator protein-1 (AP-1) transcription factors are homodimers or heterodimers 
composed of members of the Jun (c-Jun, JunB and JunD), Fos (c-Fos, FosB, Fra-1 and Fra-
2), Jun dimerisation partners (JDP1 and JDP2) and related activating transcription factors 
(ATF2, LRF1/ATF3 and B-ATF) protein families. In contrast to the Fos proteins which can only 
form heterodimers with members of the Jun family, the Jun proteins can both homodimerise 
with each other or heterodimerise with Fos members to create transcriptionally active 
complexes (Shaulian and Karin, 2001). These AP-1 subunit proteins belong to the basic 
leucine zipper (bZIP) family of transcription factors which share a DNA-binding domain rich in 
basic amino acids and a leucine zipper structure required for protein-protein interactions. 
Despite these structural similarities, the various AP-1 dimers exert significant differences in 
their DNA binding affinity and specificity. For example, the AP-1 dimers Jun-Jun, Jun-Fos and 
Jun-Fra-2 usually bind to the heptamer consensus sequence 5’-TGA(C/G)TCA-3’, which is 
also known as the TREs (TPA (12-O-tetradecanoylphorbol-13-acetate) / PMA (phorbol-12-
myristate-13-acetate) response elements) based on their ability to induce transcription in 
response to the phorbol ester TPA/PMA (Angel et al., 1987).  
AP-1 activity is induced in response to various physiological and pathological stimuli including 
cytokines, stress signals, growth factors, bacterial and viral infections and also oncogenic 
stimuli. These signals are transferred by the stress-activated protein kinases (SAPK) p38 and 
JNK, and also to the extracellular signal-regulated kinase (ERK) which belong to the family of 
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mitogen-activated protein kinase (MAPK). The MAPK signalling pathways regulate the 
transcription of AP-1 sub-proteins that form the functional AP-1 transcription factor, which in 
turn binds to the AP-1 binding sites in the promoter regions of target genes involved in 
physiological and pathological processes including development, cell proliferation, 
organogenesis, bone cell biology, apoptosis and tumour development, as indicated by studies 
using cells and mice deficient in individual AP-1 proteins (Jochum et al., 2001). 
Many pro-inflammatory cytokines (i.e. TNFα and IL-1β), collagenase and MMPs are under the 
direct regulation of AP-1 via promoter binding, indicating the involvement of AP-1 in 
inflammatory responses and over the years, substantial evidence has identified AP-1 
(Fos/Jun) as an integral transcription factor involved in the pathogenesis of RA. Earlier studies 
by Asahara et al., (1997) showed that AP-1 had a high DNA-binding activity in the synovial 
tissues of RA patients compared to little or no activity in OA patients and this AP-1 activity was 
mainly detected in adherent cells, particularly in synovial cells and macrophages. Also, the 
AP-1 activity was significantly higher in mononuclear cells infiltrating into the RA synovium 
compared to RA peripheral blood mononuclear cells. Interestingly, the high DNA-binding 
activity of AP-1 in RA cells and tissues correlated with the increased expression of c-fos and 
c-jun mRNA in situ and also the disease activity. Furthermore, the constitutive upregulation of 
AP-1 in the RA synovium highlighted the potential role of AP-1 in synovial hyperplasia and 
abnormal immune responses (Asahara et al., 1997).  
RASFs are internally driven by upregulated AP-1 and release the IL-1β cytokine. Both AP-1 
and IL-1β influence each other’s gene expression and activity, resulting in a coordinated cross-
talk that is fundamental to arthritic joint destruction, such as the development of the 
characteristic synovial overgrowth or pannus (Shiozawa and Tsumiyama, 2009). AP-1 is 
upregulated during the G1 phase of the cell cycle and directly transactivates Wee1 kinase, 
which in turn, inhibits mitotic cell division by phosphorylating cdc2 and therefore, AP-1 
promotes the development of synovial hyperplasia (Kawasaki et al., 2003). This is consistent 
with earlier transfection studies which showed that the overexpression of c-Fos in cultured 
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synovial cells promoted the growth of the synovial cells in vitro (Kuroki et al., 1993). The 
hyperplastic synovial overgrowth contributes to cartilage degradation through the action of 
MMPs, many of which are transcriptionally regulated by AP-1. AP-1 is also involved in 
physiological bone development, however in RA, AP-1 is implicated in bone resorption. 
RANKL is a known inducer of JNK, which phosphorylates and activates the Jun proteins of 
AP-1. Subsequently, AP-1 stimulates NFATc1, which is a key transcription factor involved in 
osteoclast differentiation (Wagner and Matsuo, 2003). Other than osteoclasts, MMPs 
contribute to the bone destruction associated with RA, which supports the role of AP-1 in 
regulating the expression of important genes involved in the joint destruction in RA and 
highlights the potential of therapeutically targeting AP-1 for the treatment of RA.  
The effect of AP-1 inhibition has been studied to confirm the pathological roles of AP-1 in RA. 
For example, Shiozawa et al., (1997) delivered short double-stranded DNA oligonucleotides, 
containing the AP-1 consensus sequence, into CIA mice via intraperitoneal injection. These 
‘decoy’ oligonucleotides recognise and bind to AP-1, rendering the transcription factor 
incapable of binding to the promoters of their target genes. The authors reported the inhibition 
of arthritic joint destruction in a sequence-specific and dose-dependent manner by the ‘decoy’ 
AP-1 oligonucleotides, which inhibited gene expression at the transcriptional level (Shiozawa 
et al., 1997). Using a different approach, Aikawa et al., (2008) designed and synthesised a 
specific small inhibitor of c-Fos/AP-1 using 3D pharmocophore modelling based on the crystal 
structure of the AP-1-DNA complex. The daily oral administration of the drug, named T-5224, 
in CIA mice resulted in the inhibition of most MMPs, including MMP-3, -9, -13 as well as IL-1β 
and also inhibited activities of osteoclasts and synovial cells. These studies confirmed the 
important role of AP-1 in the pathogenesis of RA by selectively inhibiting AP-1, which resolved 
joint destruction in a preclinical model of RA (Aikawa et al., 2008).  
 
1.3.2. CCAAT/enhancer-binding protein (C/EBP) 
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The CCAAT/enhancer-binding proteins (C/EBP) are a family of six structurally similar yet 
functionally distinct basic leucine zipper (bZIP) transcription factors: C/EBPα, -β, -δ, -γ, -ε, and 
–ζ. These C/EBP family members are defined by their conserved carboxy-terminal domains 
consisting of a leucine-zipper dimerisation domain and basic DNA-binding domains and an 
amino terminal activation domain (Lekstrom-Himes and Xanthopoulos, 1998). Dimerisation to 
form homo- or heterodimers with related proteins is a prerequisite for the DNA-binding activity 
of C/EBP family members which is mediated by the basic region. With small variations, the 
C/EBP transcription factors recognise and bind to the consensus sequence 5’-
RTTGCGYAAY-3’, (where R is A/G and Y is C/T) in the promoter regions of target genes to 
regulate a range of physiological events including tissue differentiation, immune responses 
and energy metabolism (Osada et al., 1996; Ramji and Foka, 2002).  
The tissue/cell specific expression profile of the various C/EBP transcription factors has been 
observed at the mRNA and protein level however, the discrepancies between different reports 
may be due to species-specific differences and the use of different techniques and 
experimental conditions. In general, C/EBPα is highly expressed in the liver, intestine, lung, 
adipose tissue, adrenal gland and placenta whereas constitutive expression of C/EBPβ is 
highest in the liver, intestine, adipose tissue, lung, spleen, kidney and myelomonocytic cells. 
C/EBPδ is expressed in adipose tissue, lung and intestine, C/EBPγ, and C/EBPζ are 
ubiquitously expressed whilst expression of C/EBPε mRNA and protein are restricted to 
myeloid and lymphoid cells. Also, the expression profile of the various C/EBP isoforms is 
regulated by physiological and pathological signals by a range of extracellular mediators 
(Ramji and Foka, 2002). 
The C/EBPβ mRNA produces at least three isoforms, 38kDa (LAP*; liver-enriched 
transcriptional activating protein), 35kDa (LAP) and 20kDa (LIP; liver-enriched transcriptional 
inhibitory protein), where LAP and LIP are the major polypeptides produced in cells. The LAP 
protein shares sequence homology (71%) in its DNA-binding and leucine zipper domains with 
C/EBPα, and the LAP gene was shown to encode the liver-enriched transcriptional activator 
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protein that was identified as C/EBPβ (Descombes et al., 1990; Ossipow et al., 1993). The IL-
6 cytokine is known to stimulate the production of acute-phase proteins from the liver during 
inflammation and C/EBPβ was also identified as the nuclear factor for IL-6 expression (NF-
IL6) which is induced by LPS, IL-1 and IL-6 and binds to the IL-1 response elements within 
the IL-6 promoter. Interestingly, C/EBPβ (NF-IL-6) also binds to the promoter of several other 
cytokine genes such as TNFα, IL-8 and GM-CSF implying that C/EBPβ regulates the 
expression of genes involved in acute phase reactions, inflammation and haemopoiesis (Akira 
et al., 1990). Importantly, C/EBPβ is significantly upregulated in the synovial lining and 
sublining cells of synovial tissue from RA patients (Pope et al., 1999) and the correlated 
activation of C/EBPβ with serum C-reactive protein (CRP) and synovial IL-6 mRNA levels 
suggesting that C/EBPβ may play a regulatory role in the inflammatory process in RA joints 
(Nishioka et al., 2000).  
The transition from proliferation to hypertrophic differentiation of chondrocytes is an important 
process in the destructive process in RA. C/EBPβ promotes the hypertrophic phenotype of 
chondrocytes by directly transactivating the p57Kip2 cell cycle factor that plays a crucial role in 
chondrocyte proliferation and differentiation (Hirata et al., 2009). Hypertrophic chondrocytes 
produce cartilage degrading proteases which contribute to cartilage destruction in RA and 
C/EBPβ has been shown to directly bind to the MMP-13 promoter resulting in the enhanced 
expression of MMP-13 in chondrocytes in inflammatory arthritis (Hayashida et al., 2009).  
 
1.3.3. Egr-1 
Early growth response-1 (Egr-1) gene was independently discovered by a number of 
laboratories searching for factors regulating cell growth and proliferation. Egr-1 was first 
discovered following the stimulation of PCI2-cells with neuronal growth factor (NGF) in a model 
for neuronal differentiation and was initially referred to as nerve growth factor-induced clone 
A, NGFIA (Milbrandt, 1987) and later became also known as KROX24 (Chavrier et al., 1989), 
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TIS8 (Kujubu et al., 1987) and ZIF268 (Christy and Nathans, 1989). The name Egr-1 was 
eventually established by Sukhatme et al., (1988) who demonstrated the inducible expression 
of Egr-1 in growth-quiescent fibroblasts exposed to serum (Sukhatme et al., 1988).  
The ~3.4Kb Egr-1 transcript has a short half-life (10 to 20 minutes) and encodes a nuclear 
phosphoprotein predicted to contain 533 amino acids.  The protein is highly rich in proline and 
serine residues and the carboxyl terminal end has three tandem repeats of Cys2-His2 zinc 
finger domains specific for the consensus sequence 5’-CGCCCCCGC-3’ and acts as a 
transcription factor (Sukhatme, 1990). Other members of the Egr family include Egr-2, Egr-3 
and Egr-4 which have related DNA-binding zinc finger domains and share the same 
consensus sequence but the differences in their flanking regions suggest specific functions of 
the individual proteins (Decker et al., 2003).  
As an ‘immediately early’ gene product, the Egr-1 transcription factor is rapidly activated in a 
range of cells by multiple extracellular agonists such as growth factors and cytokines, and 
environmental stresses including hypoxia, fluid shear stresses and vascular injury. Also, the 
induction of Egr-1 by pharmacological activators, such as TPA, suggests that protein kinase 
C–dependent pathways are involved (Sukhatme, 1990). Following activation, Egr-1 is 
transiently expressed and binds to Egr-1 binding sites within the promoters of genes 
expressed in a range of cell types including thymocytes, B-cells, monocytes, fibroblasts, 
kidney cells and neurons and is associated in the differentiation of B-cells, T-cells, PC19 
embryonic cells and monocytes (Aicher et al., 1999a; Decker et al., 2003).  
Pathogenesis-relevant Egr-1 target genes include growth factors, cytokines, receptors and 
proteases. For example, the studies of Shin et al., (2010) showed that MMP-9 is directly 
targeted by the Egr-1 transcription factor, which together with NFκB, synergistically activates 
both the basal and TNFα-induced MMP-9 promoter activity (Shin et al., 2010). The TNFα 
promoter also contains Egr-1 binding sites, however, Egr-1 is thought to play an auxiliary role 
in TNFα gene regulation (Krämer et al., 1994). Using in situ hybridisation, Aicher et al., (1994) 
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detected elevated Egr-1 mRNA expression in regions of the synovial membrane 
predominantly populated by synovial macrophages and fibroblasts, compared to non-RA 
tissue (Aicher et al., 1994), which was also confirmed using RT-qPCR detection by the studies 
of Grimbacher et al., (1997). Egr-1 expression in RASFs is inducible by TNFα which may 
exacerbate the inflammatory process in the joint by autocrine stimulation and therefore the 
elevated Egr-1 expression may be used as a diagnostic marker to characterise synovial 
fibroblasts in RA patients (Grimbacher et al., 1998). In fibroblasts, the most proximal serum 
response element in the Egr-1 promoter is the major positive regulator whereas binding to a 
cAMP responsive element may serve as a negative regulatory signal for Egr-1 transcription in 
fibroblasts. Therefore, the overexpression of Egr-1 in RASFs may result from either the 
activation of the RASFs by PKC signals and serum response factor activity or the failure of 
Egr-1 repressing signals and also, the enhanced expression of Egr-1 suggests an important 
role in maintaining the activated phenotype of RASFs (Aicher et al.,1999b). 
 
1.3.4. Ets-1 
The Ets (E26 transformation-specific) proteins belong to a superfamily of transcription factors 
defined by their conserved winged helix-turn–helix ETS domain. This unique DNA binding 
domain (ETS domain) is composed of 85 amino acids and comprises three α-helices and four 
β-strands arranged in the order H1-S1-S2-H2-H3-S3-S4 (Dittmer, 2003). To date, 27 
mammalian ETS genes have been identified and are classified into 12 distinct subgroups 
based on their ETS domain sequence homology (Hollenhorst et al., 2004).  
The Ets transcription factors recognise and bind to the core 5’-GGA(A/T)-3’ Ets-binding site 
through their ETS domain, in the promoter regions of target genes (Nye et al., 1992). These 
transcription factors are known to act as positive or negative regulators of the expression of 
genes involved in a range of biological processes (e.g. signalling cascades, cellular 
proliferation, development, differentiation, haematopoiesis, adhesion, immune responses, 
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apoptosis, invasion, tissue remodelling and angiogenesis) in various cell types including B-
cells, endothelial cell, fibroblasts and neoplastic cells (Shaikhibrahim and Wernert, 2012).  
The highly conserved ETS-1 gene is considered to be the founding member of the ETS gene 
family of transcription factors and was originally discovered as the cellular progenitor of the 
retroviral v-ETS oncogene (v-ets) that is associated with v-MYB in the genome of the E26 
avian leukaemia retrovirus (Nunn et al., 1983). The human ETS-1 gene, located on 
chromosome 11, encodes a single mRNA of 6.8Kb (Watson et al., 1985) and Ets-1 has been 
established as an important transcription factor in the regulation of angiogenesis under both 
physiological and pathological conditions. By in situ hybridisation, Wernert et al., (1992) 
reported the upregulated expression of Ets-1 mRNA during angiogenesis e.g. in embryonic 
development, granulation tissue formation and especially during tumour vascularisation 
whereas mature vessels without angiogenic activity did not express Ets-1 mRNA. The in vitro 
studies in human umbilical vein endothelial cells (HUVECs), demonstrated transient and 
inducible expression of Ets-1 and urokinase-type plasminogen activator (u-Pa) mRNA by 
TNFα stimulation which suggested that Ets-1 may regulate the transcription of the matrix 
degrading proteases e.g. u-Pa during angiogenesis and tumour invasion (Wernert et al., 
1992).  
During angiogenesis, the endothelial cells produce matrix-degrading proteases which degrade 
the basement membrane that surrounds pre-existing capillaries or venules and are therefore 
important in the invasive properties of endothelial cells and the formation of new blood vessels. 
The studies of Iwasaka et al., (1996) not only demonstrated the inducible expression of Ets-1 
mRNA by the angiogenic growth factors, aFGF, bFGF, VEGF, EGF, in HUVECs, immortalised 
HUVECs and human omental microvascular endothelial cells (HOMECs) but also confirmed 
the role of Ets-1 in regulating the expression of proteinases during angiogenesis. Antisense 
oligodeoxynucleotides (ODNs) against Ets-1 mRNA efficiently blocked the synthesis of the 
Ets-1 transcription factor by human endothelial cells in response to angiogenic factors which 
also inhibited the expression of the proteases, u-Pa and MMP-1, as well as the migration of 
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endothelial cells (Iwasaka et al., 1996). Using a similar approach, Wernert et al., (1999) 
reported the in vivo reduction of angiogenesis in chick embryos following the delivery of Ets-1 
antisense ODNs (Wernert et al., 1999). Similarly, Hashiya et al., (2004) demonstrated the 
ability of Ets-1 to stimulate angiogenesis in a rat hindlimb ischemia model following Ets-1 gene 
delivery using hemagglutinating virus of Japan (HVJ)-liposome mediated transfection of 
plasmid DNA encoding the Ets-1 gene. The promoter regions of the angiogenic factors 
vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) contain Ets-1 
binding sites and overexpression of Ets-1 upregulated both VEGF and HGF in the rat hindlimb 
(Hashiya et al., 2004). Collectively, these results demonstrate that Ets-1 regulates 
angiogenesis through the upregulation of matrix degrading proteases e.g. u-Pa and MMP-1 
and the upregulation of angiogenic growth factors e.g. VEGF and HGF which bind to their 
specific receptors on endothelial cells and initiate a signal transduction cascade to activate 
the required transcription factors, thus placing Ets-1 upstream of the angiogenic cascade.  
Evidence also implicates the Ets-1 transcription factor in RA; using in situ hybridisation, 
immunohistochemistry and RT-qPCR, Redlich and colleagues (2001) reported the 
overexpression of Ets-1 mRNA in the synovial tissues from all RA patients evaluated, 
particularly in the synovial lining layer and the sublining areas. Both IL-1β and TNFα induced 
the upregulation and nuclear localisation of Ets-1 in cultured synovial fibroblasts from RA 
patients, suggesting the important role of Ets-1 in cytokine-mediated inflammatory cascade in 
RA (Redlich et al., 2001). Using similar experimental techniques, Wernert et al., (2002) 
reported the elevated expression of Ets-1 mRNA and Ets-1 protein within endothelial cells of 
newly developing small blood vessel (during angiogenesis) in the synovial membranes from 
patients with RA compared to weak Ets-1 expression in those from OA patients, suggesting 
the importance of Ets-1 in the regulation of inflammatory angiogenesis in RA (Wernert et al., 
2002). Taken together, Ets-1 is an important transcription factor in the pathogenesis of RA 
due to (1) the regulation of target matrix degrading enzymes and potential contribution to the 
destructive processes in RA, (2) the involvement of Ets-1 in angiogenesis, which may 
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contribute to pannus expansion and (3) due to the inducible expression of Ets-1 by TNFα and 
IL-1β and (4) the potential role of Ets-1 as a major mediator downstream of these pro-
inflammatory cytokines.  
 
1.3.5. Hypoxia Inducible Factor-1α (HIF-1α) 
The healthy synovium has a rich blood supply to provide the avascular articular cartilage with 
oxygen and nutrients (Walsh and Pearson, 2001). However in RA, synovial hyperplasia and 
the migrating, invasive pannus increases the distance between the proliferating cells and the 
nearest blood vessels which exceeds the oxygen diffusion limit (>100-200μm) resulting in local 
hypoxia and hypoperfusion (Gaber et al., 2005). Consequently, there is an increased demand 
of oxygen and nutrients which promotes the cellular transition from oxidative phosphorylation 
to anaerobic glycolytic metabolism and  stimulates the local formation of new capillary blood 
vessels, ‘angiogenesis’, from pre-existing vasculature to increase the blood supply to the 
synovium and improve the influx of oxygen and nutrients to the cells (Paleolog, 2002). Synovial 
angiogenesis also ensures a constant supply of cytokines and growth factors which 
perpetuates inflammation, synovial hyperplasia and infiltration of immune cells and therefore, 
angiogenesis is recognised as a key event in the pathophysiology and perpetuation of RA 
(Koch, 2003). 
Angiogenesis plays a central role in normal physiological processes such as embryonic 
development, wound and fracture healing and in the female reproductive cycle, and the 
process is closely correlated with the hypoxic environment (Paleolog, 2009). The existence of 
hypoxia in RA was demonstrated over forty years ago by Lund-Olesen (1970) who recorded 
the oxygen tension (pO2) measurements in the synovial fluid of patients with RA using a 
Clarke-type electrode and reported the mean synovial fluid pO2 in RA knee joints to be 
27mmHg which was significantly lower compared to 43mmHg in patients with OA and 
63mmHg in healthy controls (Lund-Olesen, 1970). Subsequent studies also reported 
decreased oxygen tension (hypoxia) and decreased glucose levels as well as increased 
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carbon dioxide, lactate and acetate levels in RA joints, which are consistent with anaerobic 
metabolism (Treuhaft and McCarty, 1971; Ahlqvist, 1984). Further confirmation was provided 
by the studies of Naughton et al., (1993) who used magnetic resonance spectroscopy to 
display a profile of low molecular weight metabolites consistent with hypoxia (Naughton et al., 
1993) and Peters et al., (2004) who reported the induction of hypoxia during inflammatory 
responses in AIA rat joints by using hypoxyprobe-1, which is a compound that binds to cells 
with low oxygen tension to detected hypoxia in structures such as the synovium, pannus, bone 
marrow and articular cartilage (Peters et al., 2004).   
Although there is much evidence reporting the increased blood supply to the hypoxic 
synovium, angiogenesis is unlikely to be adequate to compensate for the increased demand 
of oxygen and nutrients. In addition to synovial hyperplasia and increased metabolic demand, 
other contributory factors to hypoxia in RA joints include the accumulation of synovial fluid and 
joint movement, as evidenced by the studies of Jawed et al., (1997). This group demonstrated 
the significant increase in intra-articular pressure after isometric quadricep contractions in 
patients with RA synovitis, which temporally impedes synovial blood flow, causes oxidative 
injury and exacerbates the pre-existing hypoxic environment in the joint (Jawed et al., 1997).  
Hypoxia induces profound changes in the cellular gene expression profile with the ultimate 
aim of restoring oxygen homeostasis, fundamental for cell survival. The hypoxia-inducible 
factor (HIF) is a ‘master regulator’ of this cellular response to hypoxia and molecular cloning 
of the HIF-1 transcription factor by Wang et al., (1995) revealed that HIF-1 binds to the 3’-
enhancer region of the erythropoietin (EPO) gene and is necessary for transcriptional 
activation of EPO in hypoxia. The HIF-1 transcription factor is composed of a 120kDa          α-
subunit complexed with a 91-94 kDa β-subunit; HIF-1α is closely related to Sim and HIF-1β is 
also known as ARNT (aryl hydrocarbon receptor nuclear translocator) and both subunits are 
basic helix-loop-helix (bHLH) proteins which share highly similar PAS (Per/ARNT/Sim) 
domains (Wang et al., 1995). 
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Importantly, HIF-1β is constitutively expressed and oxygen independent whereas HIF-1α 
contains an ODD (oxygen-dependent degradation domain), which is essential for proteolytic 
regulation of this subunit under normoxia. In normal physiological conditions, HIF-1α 
undergoes rapid hydroxylation of the proline residues, Pro402 and Pro564 within the ODD by 
the prolyl hydroxylase enzymes (PHD) which also require molecular oxygen, iron and 2-
oxoglurate as fundamental co-factors in the reaction. The hydroxylated HIF-1α subunit is 
recognised by the tumour suppressor Von Hippel-Lindau protein (pVHL), which is a 
component of a multiprotein ubiquitin ligase complex (pVHL-E3-ligase complex) responsible 
for targeting HIF-1α for polyubiquitination. Following polyubiquitination, HIF-1α subunits are 
degraded by the 26S proteasome. The impaired function of pVHL or PHD or the inhibition of 
the hydroxylation reaction results in a constitutively stabilised HIF-1α and activated HIF 
transactivation, as demonstrated during hypoxia (Gaber et al., 2005; Kenneth and Rocha, 
2008).  
Cellular HIF-1α protein levels increase exponentially to a maximum level at approximately 
0.5% which corresponds to pO2 values of 10-15mmHg (Jiang et al., 1996). During these 
hypoxic conditions, hydroxylation of proline residues is suppressed due to the lack of oxygen 
and therefore, HIF-1α is not targeted by pVHL mediated proteasomal degradation resulting in 
the accumulation of high levels of HIF-1α, which subsequently translocates to the nucleus and 
binds to HIF-1β to form a stabilised, transcriptionally active HIF heterodimer, leading to HIF 
target gene expression (Kenneth and Rocha, 2008). The heterodimer contains an N-terminus 
bHLH domain which mediates the binding of the HIF transcription factor complex to hypoxia-
responsive elements (HREs) with the consensus sequence 5’-RCGTGG-3’ within the 
promoter region of HRE-containing target genes (Wang and Semenza, 1993). More than 60 
HIF targets have been identified and include genes involved in angiogenesis, erythropoiesis, 
glycolytic metabolism, iron metabolism, pH control, apoptosis, cell proliferation, cell migration 
and matrix metabolism (Gaber et al., 2005).  
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VEGF is the best characterised proangiogenic stimulus and VEGF gene transcription is 
directly activated by HIF-1α during hypoxia (Forsythe et al., 1996). VEGF levels are 
significantly higher in the serum and synovial fluid of RA patients compared to patients with 
OA or normal controls (Harada et al., 1998; Lee et al., 2001). Hypoxia is a potent stimulus for 
VEGF induction in RA synovial membrane cells and VEGF production is further increased in 
hypoxic RASFs in the presence of inflammatory cytokines such as IL-1β and TGFβ (Berse et 
al., 1999). VEGF, HIF-1α and the HIF-2α isoform are highly expressed in RA synovial 
macrophages and fibroblasts (Hollander et al., 2001; Giatromanolaki et al., 2003) and in an 
experimental AIA rat model (Peters et al., 2004), suggesting that pro-inflammatory cytokines 
during inflammation and synovial hypoxia promotes the upregulation of HIF-1α and 
transcriptional activation of VEGF in the joint leading to the induction of synovial angiogenesis 
which perpetuates synovitis. Targeting various points within the HIF-1α pathway, whether 
inhibiting the transcription factor itself or downstream products such as VEGF, have 
demonstrated anti-angiogenic effects in RA (Semenza, 2000).  
 
1.3.6. Nuclear Factor κB (NFκB) 
NFκB is a collective name for dimeric transcription factors which belong to the Rel family of 
proteins and include RelA (p65), c-Rel, RelB, NFκB1 (p50 and its precursor p105) and NFκB2 
(p52 and its precursor p100). These NFκB subunits form a variety of homodimers and 
heterodimers to produce the NFκB transcription factors, each of which positively or negatively 
regulate the expression of their own set of genes and also share a 300-amino acid N-terminal 
Rel homology domain (RHD), which mediates their DNA binding, dimerisation and nuclear 
translocation (Tak and Firestein, 2001). NFκB transcription factors can bind to different 
variations of the NFκB consensus sequence 5’-GGGRNWYYCC-3’ to activate, or sometimes, 
repress target gene transcription in a cell-type and stimulus-specifc manner. Only p65, c-Rel 
and RelB possess C-terminal transactivation domains (TADs), enabling them to initiate 
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transcription. However, despite the absence of TADs in p52 and p50, these subunits can 
positively regulate transcription through heterodimerisation with TAD-containing NFκB 
subunits or by interacting with non-Rel proteins capable of transactivation. Conversely, p50 
and p52 homodimers can compete with TAD-containing dimers for binding to κB sites on the 
DNA, to negatively regulate transcription. The most prevalent activated form of NFκB is a 
heterodimer consisting of a p50 or p52 subunit and p65, often referred to as the ‘classic’ NFκB 
and is involved in the ‘classical’ or ‘canonical’ NFκB pathway (Hayden and Ghosh, 2012). 
In unstimulated cells, canonical NFκB dimers are found sequestered in the cytosol and are 
rendered inactive by the Inhibitor of κB (IκB). All canonical IκB proteins (IκBα, IκBβ, IκBε) 
contain C-terminal ankyrin repeat domains (ARDs) which form a large interaction surface 
around the NFκB dimer and inhibits the nuclear localisation signals of NFκB to prevents its 
entry into the nucleus. A wide range of stimuli including pro-inflammatory cytokines (i.e. TNFα 
and IL-1β), chemokines, growth factors, bacterial products and viral proteins, UV radiation, 
ischemia/reperfusion and oxidative stress can activate the ubiquitous NFκB p65/p50 dimer 
through the canonical NFκB signalling pathway. During inflammatory signalling, the 
engagement of TNFR, IL-1R and TLRs with their cognate ligands results in the 
phosphorylation-dependent activation of the IκB kinases (IKK), composed of the two catalytic 
subunits IKKα and IKKβ, and the scaffolding protein IKKγ/NFκB essential modulator (NEMO). 
The p65/p50 NFκB complex is predominantly bound by IκBα and IKK phosphorylates IκBα 
and other IκB proteins, thereby targeting them for ubiquitination and degradation by the 26S 
proteasome. The NFκB nuclear localisation signal is exposed and enables the active NFκB to 
translocate into the nucleus and bind to the NFκB-binding site in the promoter regions of target 
genes. Many NFκB-target genes are involved in a broad range of physiological and 
pathological processes including; maintenance of the immune system, skeletal system, control 
of cell survival, differentiation, proliferation, inflammation, apoptosis and also the activation of 
genes involved in cancer, autoimmune diseases, neurodegenerative diseases, cardiovascular 
disease, diabetes, RA and many others (Hayden and Ghosh, 2012). The activation of NFκB 
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is often transient and the termination of NFκB activity is primarily achieved by the ability of 
NFκB upregulating its own inhibitors of the IκB family. The newly synthesised IκB enters the 
nucleus and removes NFκB from the DNA to relocate and sequester NFκB in the cytosol. 
However, during pathological conditions such as chronic inflammation, the continuous 
presence of NFκB-activating stimuli appears to outperform the inhibitory feedback loop, 
resulting in an elevated and constitutive activity of NFκB (Hoesel and Schmid, 2013).  
The non-canonical NFκB pathway is typically induced by the binding of CD40 ligand, BAFF, 
RANKL and lymphotoxin-β, to their cognate receptors, resulting in the activation of the NFκB 
inducing kinase (NIK) which phosphorylates and activates predominantly IKKα. IKKα 
phosphorylates the precursor protein p100 resulting in its ubiquitination and partial 
degradation to give rise to the mature p52 subunit and subsequently, the p52/RelB dimer, 
which can translocate to the nucleus to activate gene transcription. In contrast to the canonical 
pathway, the non-canonical pathway is dependent on IKKα and independent of IKKβ and 
NEMO (Simmonds and Foxwell, 2008).  
NFκB (particularly canonical p65/p50) is fundamental to the pathogenesis of RA by positively 
regulating a wide range of genes encoding molecules involved the disease, including 
cytokines (e.g. TNFα, IL-1β, IL-2, IL-6, IL-8, IL-12, IFNγ, GM-CSF), adhesion molecules (e.g. 
E-selectin, ICAM-1, VCAM-1), chemokines (e.g. MIP-1α, MCP-1, RANTES) and many other 
genes involved in cell proliferation, apoptosis and cell cycle progression. NFκB is also 
inducible by many of these pro-inflammatory cytokines resulting in a positive feedback loop, 
which promotes the constitutive and high activity of NFκB in RA (Roman-Blas and Jimenez, 
2006). Activated NFκB has been detected in human RA synovial tissue (e.g. Handel et al., 
1995) and particularly in RASFs (Miagkov et al., 1998) as well as in different animal models 
of RA including AIA rats, CIA mice, streptococcal cell wall (SCW)-induced and pristane-
induced arthritis in rats (Makarov, 2001). Substantial evidence has demonstrated the 
important role of NFκB in the various processes in RA, especially, during synovial inflammation 
which underlies the pathology of RA. It is widely recognised that NFκB regulates the 
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expression of the vast majority of pro-inflammatory cytokines involved in RA, and studies 
including those which have inhibited the activity of NFκB (e.g. via the delivery of genes 
encoding dominant negative IKKβ mutant), have provided confirmation of the importance of 
NFκB for the induction of pro-inflammatory cytokines in human fibroblast-like synoviocytes 
(Aupperle et al., 2001).  
The characteristic synovial overgrowth is largely attributed to enhanced cell proliferation and 
decreased apoptosis. Many NFκB-target genes are pro-apoptotic stimuli e.g. TNFα and c-
Myc, and in the hyperplastic synovium, NFκB activation delivers anti-apoptotic signals which 
enhance cell survival. Therefore, NFκB contributes to the proliferation of synovial cells by 
inducing the expression of c-Myc and cyclin D1 proteins required for cell cycle progression, 
as well as inhibiting the cytotoxic effects of c-Myc and TNFα and inducing the expression of 
anti-apoptotic molecules such as B-cell CLL/lymphoma 2 (Bcl-2) family members (Barkett and 
Gilmore, 1999).  
Cartilage degradation and bone resorption by RASFs is also mediated by NFκB, which 
transcriptionally activates several MMPs e.g. MMP-1 which has NFκB-binding sites in its 
promoters, and NFκB is also important for the induction of MMP-3, -9 and -13. NFκB activation 
may also have an important role in the differentiation and maturation of osteoclasts in RA, as 
implied by the development of osteopetrosis in nfκb1-/-nfκb2-/- double-knockout mice due to 
the accumulation of immature osteoclasts (Iotsova et al., 1997). Furthermore, Jimi et al., 
(2004) showed that the delivery of a cell-permeable peptide inhibitor of the IKK complex, which 
is a selective inhibitor of the NFκB pathway, blocked osteoclastogenesis and prevented 
inflammatory bone destruction in CIA mice (Jimi et al., 2004). Overall, the inhibition of NFκB 
activity using knockout mice, decoy oligonucleotides, IκB mutants, or selective inhibitors of 
IKK complexes appear to be effective therapeutic strategies for the treatment of RA, however, 
the systemic blockade of NFκB activity can result in detrimental effects due to its involvement 
in numerous physiological processes. Nevertheless, these studies have confirmed the 
fundamental role of NFκB in the pathogenesis of RA.   
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1.3.7. Co-operative activity of the candidate transcription factors 
The candidate transcription factors HIF-1α, AP-1, Egr-1, Ets-1, C/EBPβ and NFκB orchestrate 
many of the inflammatory and destructive processes in RA and their                 co-
operative/synergistic activity has also been described in RA. Interestingly, the regulation of 
many promoters by ETS transcription factors often depends upon their physical interaction 
with unrelated transcription factors on composite DNA elements (Goetze et al., 2001). This is 
particularly true for Ets-1 which physically interacts with transcription factors bound to their 
cognate binding sites located close to the Ets-1-binding site. For example, Ets-1 family 
members and AP-1 (Fos/Jun) transcription factors functionally cooperate in a large number of 
promoters which is vital for the regulated expression of numerous genes including cytokines 
(Gottschalk et al., 1993), MMPs (Logan et al., 1996) and the TNFα promoter which contains 
Ets-1 binding sites in direct juxtaposition to the AP-1 binding sites (Krämer et al., 1995). Also, 
Ets-1, NFκB and AP-1 synergistically transactivate the human granulocyte-macrophage 
colony stimulating factor (GM-CSF) promoter in an interdependent manner in T cells (Thomas 
et al., 1997). 
In addition to homo- and heterodimersation of C/EBP transcription factors, these proteins can 
form protein-protein interactions with related and unrelated nuclear transcription factors. For 
example, C/EBPβ has been shown to synergistically interact with the NFκB to activate the 
transcription of IL-6 and IL-8, both of which contain adjacent C/EBPβ and NFκB binding sites 
in their promoters (Matsusaka et al., 1993). C/EBPβ is also known to cooperate with many 
other transcription factors including AP-1 in the regulation of genes including collagenase and 
cytokines such as IL-8 and TNFα (Ramji and Foka, 2002). 
Despite the ubiquitous synthesis of Egr-1 transcription factors, Egr-1-regulated genes are 
expressed in a tissue-specific manner and such specificity may be due to interactions with 
other transcription factors that bind to adjacent sites in a given promoter. For example, Egr-1 
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synergistically interacts with nuclear factor of activated T cells (NFAT) to form heterodimers 
which bind in close contact in the IL-2 and TNFα promoters to regulate the gene expression 
of these cytokines (Decker et al., 1998; Decker et al., 2003). Synergistic function of Egr-1 with 
other nuclear factors has also been reported e.g. with the homeobox protein Ptx1 and the 
steroidogenic factor Sf1 in the regulation of the luteinizing hormone LH-b expression 
(Tremblay and Drouin, 1999), with the p65 protein in NFκB p50 gene induction (Cogswell et 
al., 1997), with the CBP/p300 in the transcription of the lipoxygenase gene (Silverman et al., 
1998), and with the transcriptional inhibitors NGFI-A binding protein (NAB)-1 and NAB-2 
(Russo et al., 1995; Svaren et al., 1996), among others which contribute to tissue-specific 
expression of ubiquitously expressed nuclear factors such as Egr-1.  
Ets-1 and HIF-1α are colocalised in the hypoxic synovium of inflamed joints of rats with 
adjuvant-induced arthritis, suggesting that both hypoxia and HIF-1α may be involved in the 
upregulation of Ets-1 during joint inflammation (Peters et al., 2004). In addition to the HIF 
family, hypoxia activates a number of other important transcription factors such as NFκB, AP-
1, and p53 among others, where there is often crosstalk and cooperative activity between the 
transcription factors (Kenneth and Rocha, 2008).  
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1.4.    MicroRNAs 
1.4.1. MicroRNA discovery  
MicroRNAs (miRNAs) are endogenously produced, small (~22 nucleotides) non-coding RNAs 
involved in the post-transcriptional regulation of target messenger RNAs (mRNAs). MiRNAs 
were discovered by Lee et al., (1993) through screening for genes that control the 
developmental timing in the nematode Caenorhabditis elegans (C.elegans). It was revealed 
that the lineage-4 (lin-4) gene did not encode a protein but instead encoded two small 
transcripts, 22 and 61 nucleotides (nt) long; the longer 61nt transcript was predicted to be the 
stem-loop precursor of the functional 22nt transcript. Sequence comparisons of these lin-4 
RNA transcripts with the 3’ untranslated region (3’UTR) of the lin-14 mRNA revealed multiple 
antisense complementary sites to the lin-4 sequence within the lin-14 3’UTR (Lee et al., 1993; 
Wightman et al., 1993) which was in support of the earlier prediction that the lin-14 3’UTR was 
an important region involved in mediating lin-14 repression by the lin-4 transcripts (Wightman 
et al., 1991). It was subsequently demonstrated that lin-4 downregulated the LIN-14 protein 
without impairing the lin-14 mRNA levels by interacting with the lin-14 3’UTR to translationally 
repress lin-14 mRNA, which in turn, regulated the timing of stage transitions in the early 
development of C.elegans larvae (Lee et al., 1993; Wightman et al., 1993).  
Seven years later in 2000, Reinhart and colleagues identified the let-7 gene that transcribes a 
temporally regulated 21nt RNA involved in the late larval developmental stage in C.elegans. 
The let-7 RNA was demonstrated to regulate the expression of lin-14 and lin-28 in a similar 
mechanism to lin-14 regulation by lin-4 RNA, as described by Lee et al., (1993) and 
consequently, lin-4 and let-7 RNA were termed short temporal RNAs (stRNAs) due to their 
small size and temporal expression during C.elegans development (Reinhart et al., 2000). 
 
Let-7 homologs were identified in other bilateral animals including mammals (Pasquinelli et 
al., 2000) and soon after, over one hundred additional genes transcribing small RNA species 
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were identified in Drosophila, humans and in worms (Lagos-Quintana et al., 2001; Lau et al., 
2001; Lee and Ambros, 2001). Analogous to the lin-4 and let-7 stRNAs, these endogenously 
expressed RNA species were also ~22nt in length and potentially processed from larger stem 
loop precursors. These RNA products were generally conserved in evolution and few RNAs 
exhibited temporal expression whilst the majority displayed cell-specific expression profiles. 
Therefore, stRNAs and other tiny RNAs with similar features and unknown functions were 
referred to as microRNAs (Lagos-Quintana et al., 2001; Lau et al., 2001; Lee and Ambros, 
2001).  
MiRNAs have since been found in plants, animals, green algae and viruses (Griffiths-Jones et 
al., 2008) and are documented in the online miRBase repository for miRNA sequence data 
and annotation (miRBase version 20; www.mirbase.org), which currently contains 24,521 
entries from rodents, primates, birds, fish, worms, flies, plants and viruses. Interestingly, other 
types of small RNAs such as endogenous small interfering RNAs (siRNAs) (Reinhart and 
Bartel, 2002; Ambros et al. 2003) and Piwi-interacting RNAs (piRNAs) (Aravin et al., 2007) 
have been identified in animals, plants and fungi, which have similar RNA silencing functions 
to endogenous miRNAs but differ in their biogenesis.   
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1.4.2. MiRNA biogenesis  
The production of the functional, mature ~22nt miRNA involves multiple, complex enzymatic 
steps, summarised in Figure 1.6.  
 
Figure 1.6. A schematic representation of the biogenesis and function of microRNAs.  
The primary microRNA (pri-miRNA) is transcribed from the miRNA gene by RNA polymerase 
II and then processed by Drosha and Pasha/DGCR8 in the nucleus to form the hairpin 
precursor miRNA (pre-miRNA). Pre-miRNA is actively transported into the cytoplasm via the 
Exportin 5 pathway and then further processed by Dicer and TRBP to form the ~22nt mature 
miRNA duplex. The passenger strand (*) is degraded and the selected guide strand associates 
with Argonaute to translationally repress or degraded target mRNAs containing imperfect and 
perfect complementary miRNA target sites in their 3’UTR, respectively. Figure 1.6 was 
redrawn, with modifications, from Kai and Pasquinelli, (2010).  
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MiRNA genes are often expressed from their own promoters and are located in intergenic 
regions or on the antisense strand of annotated genes (Zhou et al, 2007). The majority of 
miRNA genes are commonly found in the introns of protein-coding genes or non-coding host 
genes while few miRNA genes are located in the exons of non-coding genes (Rodriguez et 
al., 2004). The transcription of multiple miRNAs as a single transcriptional unit, known as a 
‘cluster’ is a common phenomenon (Lau et al., 2001), which often results in these miRNAs 
being related and considered as family members. Generally, a family of miRNAs share 
nucleotides 2-8, called the ‘seed region’, located in the 5’-end of the miRNA, which is a vital 
sequence involved in target mRNA recognition (Bartel, 2004).  
MiRNA biogenesis proceeds in the nucleus with the transcription of primary miRNA           (pri-
miRNA) by RNA polymerase II (Lee et al., 2002), although evidence of RNA polymerase III-
mediated transcription has been reported (Borchert et al., 2006). The transcription of a miRNA 
cluster or an individual miRNA gene results in either a group of pri-miRNA stem-loop structures 
or a single hairpin pri-miRNA. The resulting pri-miRNAs (>1Kb) contain partial-self 
complementarity of ~33 nt, a terminal loop and internal runs of uridine residues, to form the 
stem-loop structure, flanked by a 5’-m7g cap and a 3’-polyadenylated tail which are 
characteristic of RNA polymerase II transcripts (Bartel, 2004).  
The initial processing of pri-miRNA occurs in the nucleus and involves the enzymatic activity 
of the RNase III endonuclease, Drosha and its dsRNA binding protein partners; DiGeorge 
Syndrome Critical Region Gene 8 (DGCR8) and Partner of Drosha (Pasha). These proteins 
assemble to form the Microprocessor complex which cleaves near the base of the stem loop 
of pri-miRNA to release the ~60-70nt precursor miRNA (pre-miRNA) hairpin-loop intermediate 
(Lee et al., 2003). 
Following nuclear processing, the pre-miRNA is actively exported from the nucleus to the 
cytoplasm. The specific length and the 3’ overhang of the pre-miRNA is recognised by the 
export receptor Exportin-5 and Ran-GTP and is transported through the nuclear pore (Yi et 
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al., 2003). The pre-miRNA is further processed by a second RNase III endonuclease Dicer 
and the HIV-transactivating response RNA-binding protein (TRBP). TRBP increases the 
cleavage efficiency of Dicer while Dicer cleaves the hairpin-loop of the pre-miRNA to release 
an unstable 19-25nt double stranded miRNA: miRNA* duplex. The mature miRNA serves as 
the ‘guide’ strand and is incorporated into the RNA-induced silencing complex (RISC), whilst 
the miRNA* ‘passenger’ strand is typically degraded. It has been proposed that miRNA guide 
strand selection is largely determined by the thermodynamic stability of the miRNA duplex and 
the strand that is less stably paired at its 5’-terminus is more likely to be selected as the guide 
strand (Khvorova et al., 2003; Finnegan and Pasquinelli, 2013).  
The guide miRNA is subsequently loaded onto a member of the Argonaute (Ago) protein family 
and the resulting miRNA-Ago complex forms the core subunit of the RISC complex. The 
Argonaute protein is directed by the mature miRNA to silence the target mRNAs by 
translational repression or mRNA cleavage; a fate that is dependent on the degree of 
complementarity between the microRNA seed region and the 3’UTR of the target mRNA. 
Perfect complementarity between the miRNA seed region and the target mRNA results in Ago-
2-catalysed mRNA cleavage, which is commonly observed in plant miRNAs. Similarly, 
double–stranded RNA molecules of an endogenous or exogenous source, are also processed 
by Dicer to generate short duplex small interfering RNA, siRNA, which typically silence gene 
expression by mRNA cleavage due to perfect base pairing to target mRNAs. In contrast, most 
animal miRNAs bind to their targets with imperfect complementarity due to mismatches and 
bulges between the miRNA seed region and the target mRNA 3’UTR, resulting in translational 
repression or deadenylation of the target mRNA leading to destabilisation and mRNA 
degradation (Bartel, 2004).  
Interestingly, the vast majority of animal miRNA target sites are found in the 3’UTR of the 
target mRNA however, there are examples of the miRNA target sites located in the 5’UTR 
(Lytle et al., 2007) and coding regions (Forman et al., 2008).  Nevertheless, the 6-8nt miRNA 
seed region is the most important region for mRNA post-transcriptional regulation. For 
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example, many miRNA family members share very similar or identical seed sequences, while 
the 3’-end of the miRNA can differ significantly and such similarities allow various miRNAs to 
regulate overlapping targets and one miRNA can potentially target multiple mRNAs. 
Therefore, the conservation of the miRNA seed region among species has proven to be an 
efficient criterion in predicting miRNA targets (Ghosh et al., 2007).  
 
1.4.3. MicroRNA target prediction and validation 
The accurate prediction and validation of miRNA targets is the foundation to associating each 
miRNA to a specific function which can provide insight into the role of miRNAs in biological 
processes. Computational predictions of miRNA targets are invaluable tools in narrowing 
down potential miRNA target sites for experimental validation and current computational 
prediction tools such as miRanda (Enright et al., 2003) and TargetScan (Lewis et al., 2003) 
apply methods that are both diverse in approach and performance. Nevertheless, the vast 
majority of these computational algorithms use four common characteristics of miRNAs and 
their target genes; (i) the seed region complementarity between miRNA and target genes; (ii) 
the conservation of the miRNA target sites among different species, (iii) the thermal stability 
of the miRNA/mRNA duplex (iv) the ability of the miRNA 5’-end to bind to the target gene 
stronger than that of the 3’-end (Peterson et al., 2014). Based on one or more of these 
principles, computational algorithms predict miRNA target genes which can be experimentally 
verified. Various experimental approaches have been employed for validation and differential 
expression analysis of predicted miRNA targets in biological samples.  
Earlier miRNA expression studies were commonly performed using northern blot analysis 
combined with polyacrylamide gels which simultaneously allowed quantification of the 
expression levels and size determination of the mature and precursor miRNAs (Lagos-
Quintana et al., 2001; Lau et al., 2001; Lee and Ambros, 2001). However, the laborious, poor 
sensitivity and limited sample throughout of northern blot analysis led to the development of 
100 
 
highly-sensitive and high-throughput miRNA expression profiling techniques such as Real-
time qPCR, miRNA-microarray analysis, and improved in situ hybridisation and northern 
blotting analysis using locked nucleic acid (LNA)-modified oligonucleotide probes.   
MiRNA in situ hybridisation is a variation of immunohistochemical staining which involves the 
hybridisation of a labelled RNA with a complementary strand within suitably prepared tissue. 
Although this method is not highly quantitative, in situ hybridisation enables the detection of 
miRNAs localised to specific parts of the tissue or specific cells. Similarly, miRNA northern 
blot analysis also employs labelled RNA to hybridise with complementary sequences in RNA 
samples after which the RNA bands are separated by gel electrophoresis and then probed. 
The practical disadvantage of both techniques is the relatively low sensitivity that has since 
been improved by using LNA-modified oligonucleotide probes. The exceptional hybridisation 
affinity of LNA-modified probes towards RNA has been exploited in northern blot analysis to 
demonstrate 10 times more sensitivity than traditional oligonucleotides (Valoczi et al, 2004) 
and high efficiency for miRNA profiling using in situ hybridisation (Kloosterman et al., 2006) 
and high throughput miRNA detection using miRNA-microarrays (Castoldi et al., 2006).  
Microarrays are powerful tools for miRNA expression analysis and also employ the principle 
of probe hybridisation with a complementary strand within the sample. In contrast to northern 
blot analysis in which each miRNA is detected separately, miRNA-microarray uses a single 
microarray chip containing thousands of probes e.g. LNA-modified oligonucleotides, to enable 
a highly efficient screening process to identify the expression of several hundreds of miRNAs 
in the same sample (Yin et al., 2008). Despite the practical advantages of microarray 
technology, this method is limited by the requirement of high concentrations of sample for 
efficient hybridisation and signal generation and the poor sensitivity for rare targets, therefore 
microarray validation is often coupled with a more sensitive technique such as Real-time 
qPCR (Schmittgen et al., 2004). Real-time qPCR is arguably the most commonly used miRNA 
expression profiling technique due to its high sensitivity, efficiency and its highly quantitative 
and high-throughput screening of miRNA expression in small amounts of sample. The 
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combination of bioinformatic target prediction and experimental validation studies have 
enabled the identification of miRNAs which exhibit specific expression profiles in a range of 
cell types. MiRNAs are no longer regarded as biological anomalies and there is substantial 
evidence implicating miRNAs in the regulation of an array of mRNAs involved in various 
physiological and pathological conditions.  
 
1.4.4. MicroRNAs in RA  
MiRNAs are important regulators of gene expression in many biological processes and 
therefore, changes in miRNA expression patterns can promote the development and/or 
exacerbate pathologies. Numerous miRNAs exhibit deregulated expression in RA, many of 
which play important roles in RASFs and therefore, the pathogenesis of RA.  
 
1.4.4.1. Overexpressed miRNAs in RA 
Taganov et al., (2006) reported the induced expression of miR-146a in response to a variety 
of microbial components and pro-inflammatory cytokines e.g. LPS, CpG, IFNα and TNFα in a 
human monocyte cell line (THP-1 cells) in an NFκB-dependent manner. It was proposed that 
miR-146a might negatively regulate cytokine signalling by downregulating its mRNA targets 
encoding TNF receptor-associated factor 6 (TRAF6) and IL-1 receptor-associated kinase 1 
(IRAK1), which are key molecules downstream of TNFα and IL-1β signalling (Taganov et al., 
2006). Interestingly, a specific polymorphism in the 3’UTR of IRAK1 is associated with 
increased susceptibility to developing RA, which opens the possibility to investigate how 
miRNAs and polymorphisms in their target mRNAs can lead to RA in specific ethnic groups 
and in association with environmental factors (Chatzikyriakidou et al., 2010).  
The upregulated expression of miR-146a is not confined to immune cells and has also been 
observed in the synovial fibroblasts and synovial tissue isolated from patients with RA 
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compared to OA patients and miR-146a was induced by TNFα and IL-1β, suggesting that miR-
146a mRNA is expressed in synovial fibroblasts in response to these pro-inflammatory 
cytokines. It was also revealed that miR-146a-expressing cells in the synovial tissues were 
predominantly CD68+ macrophages, CD3+ T cells and CD79+ B cells (Nakasa et al., 2008).  
Similarly, Stanczyk et al., (2008) reported the constitutive expression of miR-146a and also 
miR-155 in RASFs and RA synovial tissue compared to OA synovial fibroblasts and tissues 
and miR-155 expression in ex vivo RASFs was further induced by TNFα, IL-1β, LPS, bacterial 
lipoprotein and poly (I-C) stimulation. Interestingly, the overexpression of miR-155 in RASFs 
was associated with downregulated expression of MMP-3 and reduced induction of MMP-3 
and MMP-1 by TLR ligands and cytokines, suggesting the role of miR-155 in modulating the 
destructive properties of RASFs (Stanczyk et al., 2008).  
Evidently, miR-155 and miR-146a have proven to play important roles in various inflammatory 
responses but appear to have opposing impacts in RA. These observations were supported 
by in vivo studies. For example Nakasa et al., (2011) showed that the administration of the 
inhibitory double-stranded miR-146a prevented joint destruction in CIA mice but did not 
completely suppress inflammation (Nakasa et al., 2011). Conversely, Bluml et al., (2011) used 
CIA and K/BxN serum-transfer arthritis in wild type (WT) and miR-155-null mice to examine 
the role of miR-155 in the pathogenesis of autoimmune arthritis. Their data showed that the 
miR-155-null mice did not develop CIA or generate pathogenic autoreactive B- and T-cells, 
compared to WT mice. The miR-155-null mice also had significantly decreased levels of IL-17 
and IL-22, which impaired Th17 polarisation of miR-155-null mouse T cells. Furthermore, in 
the K/BxN serum-transfer arthritis model, which is dependent on innate effector mechanisms, 
the miR-155-null mice had significantly reduced local bone destruction due to reduced 
generation of osteoclasts. These studies demonstrated that miR-155 is essential in adaptive 
and innate immune reactions leading to autoimmune arthritis and may therefore represent a 
potential therapeutic target for the treatment of RA (Bluml et al., 2011). 
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Interestingly, Pauley et al., (2008) reported that the expression of miR-16, miR-132, miR-155 
and miR-146a was significantly higher in the circulating peripheral blood mononuclear cells 
(PBMCs) from RA patients compared to healthy control individuals and the high expression of 
miR-16 and miR-146a correlated with active disease. Importantly, the detection of miRNAs in 
the easily obtainable peripheral blood cells opens the possibility to identify biomarkers which 
can be monitored during the disease course without the need for invasive surgical procedures 
to isolate joint tissues and cells for miRNA analysis and the results of this study suggest that 
miR-16 and miR-146a might be useful biomarkers of disease activity (Pauley et al., 2008). 
This observation was confirmed by the studies of Murata et al., (2010) who reported the 
significantly elevated expression of miR-16, miR-146a, miR-155 and miR-223 in the synovial 
fluid from RA patients compared to OA control samples and showed a significant correlation 
of plasma miR-16 and miR-146a with tender joint counts and DAS28 score (Murata et al., 
2010). Furthermore, Fulci et al., (2010) showed that miR-223 is overexpressed in peripheral 
T-lymphocytes from RA patients compared to healthy individuals, particularly naive CD4+ T-
lymphocytes, which are one of the major infiltrating cells in the RA synovial tissues, suggesting 
that miR-223 could target T-cell responses and therefore contribute to the onset and 
pathogenesis of RA (Fulci et al., 2010).  
The IL-17 pro-inflammatory cytokine is recognised as a crucial factor in inflammation and bone 
destruction in RA due to its ability to induce the expression of pro-inflammatory cytokines and 
RANKL. Niimoto et al., (2010) reported the significant upregulation of let-7a, miR-26, miR-
146a/b, miR-150 and miR-155 in IL-17-producing CD4+ T lymphocytes from RA patients and 
reported the strong expression of miR-146a and IL-17 in PBMCs in patients with high disease 
activity. Also, miR-146a was intensely expressed in the hyperplastic RA synovium with high 
expression of IL-17 from RA patients with high disease activity and IL-17-producing cells 
expressing miR-146a, indicating that miR-146a is associated with IL-17 expression in the 
PBMC and synovium in RA patients (Niimoto et al., 2010).  
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Furthermore, Alsaleh et al., (2009) reported the upregulated expression of miR-346 in RASFs 
and showed that miR-346 was able to indirectly regulate the release of the pro-inflammatory 
cytokine IL-18 through indirect inhibition of the Bruton’s tyrosine kinase in LPS-activated 
RASFs, which is involved in the miR-346-regulated expression of IL-18 (Alsaleh et al., 2009).  
 
1.4.4.2. Suppressed miRNAs in RA 
Downregulated miRNAs have also been reported in RA. For example miR-124, which is 
involved in cell proliferation, exhibited significantly decreased expression in RASFs as 
compared with OASFs. This study by Nakamachi et al., (2009) showed that the transfection 
of miR-124 precursor (pre-miR-124) and therefore the overexpression of miR-124, led to 
suppressed proliferation of RASFs and arrested cell cycle at the G1 phase. Furthermore, the 
two targets of miR-124, CDK2 (cyclin-dependent kinase 2) and MCP-1 (monocyte chemotactic 
protein-1), which are involved in the inflammatory process of RA, were significantly 
downregulated by the induction of pre-miR-124a in RASFs, suggesting that     miR-124 plays 
an important role in the regulatory mechanisms of RASFs (Nakamachi et al., 2009). 
The interaction of pathogen-associated molecular patterns (PAMPs) and damage-associated 
molecular patterns (DAMPs) with pattern recognition receptors such as TLRs, has been shown 
to activate RASFs. TLR2 expression is strongly upregulated in RASFs in response to TLR2 
ligands and TLR2 mRNA is a target of miR-19. Interestingly, miR-19a and miR-19b belong to 
the same cluster and were found to be significantly downregulated in RASFs stimulated with 
LPS and BLP (bacterial lipopeptide Pam3CSK4). Overexpression of miR-19a/b using synthetic 
mimics decreased TLR2 protein expression and also IL-6 and MMP-3 secretion was 
significantly downregulated in activated RASFs transfected with either mimic. These studies 
demonstrated the important role for miR19a/b in the regulation of IL-6 and MMP-3 release by 
controlling TLR2 expression, suggesting that miR-19a/b can act as negative regulators of 
inflammation (Philippe et al., 2012). 
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The infiltration and accumulation of T cells in the synovium of RA joints is a hallmark 
pathological feature and Li et al., (2010) reported the elevated expression of miR-146a in CD4+ 
T cells isolated from RA synovial fluid, which was positively correlated with the levels of TNFα 
and also the downregulated expression of miR-363 and miR-498 in the same cells (Li et al., 
2010).  
Recently, Zhu et al., (2012) reported the significantly downregulated expression of miR-23b in 
inflammatory lesions of patients with RA or SLE as well as in the tissue samples from mouse 
models of lupus (lupus-prone MRL-lpr mice), RA (CIA mice) and multiple sclerosis 
(experimental autoimmune encephalomyelitis (EAE) mice). Interestingly, IL-17 significantly 
downregulated miR-23b expression in human primary fibroblast-like synoviocytes (FLS), 
mouse primary kidney cells and astrocytes. The authors showed that miR-23b suppressed IL-
17-, IL-1β-, and TNFα-mediated signalling by directly targeting the 3’UTR of TAK1-binding 
protein 2 (TAB2), TAB3 and IKKα mRNA, which are known to promote NFκB activation in 
response to TNFα and IL-1β. Therefore, miR-23b plays an important role in suppressing the 
pathology in multiple autoimmune diseases by limiting the pro-inflammatory signalling 
pathways in tissue-resident cells (Zhu, et al., 2012). 
 
1.4.5. Manipulating miRNA activity  
MiRNAs are integrally involved in health and disease and there is much evidence suggesting 
that the replacement or overexpression of miRNAs may be therapeutically beneficial in 
diseases, including cancer and RA. In general, there are two approaches of miRNA-based 
therapeutics; miRNA mimicry or miRNA inhibition.  
Endogenous miRNAs can be suppressed using decoy targets which inhibit endogenous 
miRNAs that show gain-of-function in disease. This method involves the cellular introduction 
of synthetic antisense oligonucleotides, termed antagomiRs or AMO (anti-miRNA 
oligonucleotides) which are modified miRNA targets designed with full or partial 
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complementarity to a specific miRNA and act by ‘inhibiting the inhibitor’. The antagomiRs bind 
with high affinity to the active miRNA strand to actively compete with endogenous mRNA 
targets for binding to the specific miRNA. Since binding of the antagomiR with the miRNA is 
irreversible, the miRNA:antagomiR duplex is unable to be processed by RISC and/or 
degraded resulting in silencing of the endogenous miRNA and consequently, increased 
expression of the target mRNA (Krutzfeldt et al., 2005). Synthetic antagomiRs can be modified 
to enhance stability against nucleases and resistance to degradation, improve base pairing 
thermodynamics and improve transfection efficient e.g. by including 2’-O-methyl (2’-OMe) 
modified ribose sugars, terminal phosphorothioates and also, a cholesterol group at the 3’-
end and LNA-modifications. The significant disadvantage of synthetic antagomiRs is their 
transient miRNA knockdown (days to weeks) and as demonstrated by Scherr et al., (2007) 
long-term inhibition of specific miRNA function can be achieved following the delivery of 
lentivirally encoded recombinant antagomiRs, highlighting the advantages of miRNA-gene 
therapy (Scherr et al., 2007). To date, antagomiRs have been successfully used in vivo and 
have also reached the stage of clinical trials in human patients (Hydbring and Badalian-Very, 
2013), with particular success in the phase II clinical trials of LNA-modified oligonucleotides 
designed to inhibit the liver specific miR-122 for the treatment of Hepatitis C virus (Miravirsen, 
Santaris Pharma A/S). 
The success of antagomiR oligonucleotides is generally dependent on delivering a dose 
sufficient to saturate the cellular pool of the target miRNA, which often requires repeated 
administration in large doses. However, an alternative gene therapy method developed by 
Ebert et al., (2007) showed that miRNA target sites expressed at a high level from a vector 
could also function as competitive inhibitors of the cognate miRNA. This method of inhibiting 
the action of endogenous miRNAs was achieved through the use of decoy targets called 
‘miRNA sponges’. MiRNA sponges are artificial transcripts expressed from strong promoters, 
containing multiple, tandem binding sites to the candidate miRNA, engineered into their 3’-
UTR. Following the delivery of the vector into the cells, the ‘sponge’ transcript containing the 
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miRNA target sites accumulate in the cell and deplete the endogenous miRNAs by acting as 
competitive inhibitors of the corresponding miRNAs thereby preventing miRNA interaction with 
their natural mRNA targets (Ebert et al., 2007). The level of miRNA suppression is dependent 
on the number of target sites in the transcript 3’-UTR and sponges with more copies of miRNA 
target sites have a greater affinity for their cognate miRNA which increases the overall target 
miRNA suppression. This effect can be enhanced by designing the miRNA binding sites with 
imperfect complementarity to the miRNA to enable saturation of the candidate miRNA at lower 
concentrations compared to perfectly complementary sites, which can be attributed to the 
different mechanisms of miRNA regulation (Brown and Naldini, 2009). The interaction of 
miRNAs with their target mRNAs is largely dependent on complementary base pairing 
between the miRNA seed region and mRNA 3’UTR, therefore, recombinant sponges can be 
engineered with binding sites complementary to the seed sequences of multiple miRNAs, 
allowing a single sponge to repress a whole family of related miRNAs, unlike antagomiRs 
which appear to be specific for one miRNA (Ebert et al., 2007). In addition to the number of 
miRNA target sites in the sponge, the efficacy of miRNA sponges is also dependent on the 
concentration of endogenous miRNA relative to the sponge miRNA. Maximal sponge 
expression can be achieved through the use of a strong promoter and lentiviral vectors to 
enable stable chromosomal insertions of the sponge and therefore, prolonged expression 
without the need for repeated administration (Ebert and Sharp, 2010). The use of miRNA 
sponges and antagomiRs in the induction of miRNA loss-of-function are attractive alternatives 
to genetic knockouts and provide a versatile approach to investigating miRNA biology in a 
broad range of cells as well as harbouring therapeutic potential (Gentner and Naldini, 2012).  
Conversely, some diseases may be caused by the loss or reduced expression of a specific 
miRNA, therefore the replacement of a specific miRNA may be therapeutically relevant. 
MiRNAs which exhibit loss-of-function in disease can be replaced by introducing enzymatically 
generated or chemically synthesised miRNAs into the cells, thus increasing the concentration 
of the candidate miRNA in the cell to induce post-transcriptional silencing of the upregulated 
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mRNA (Amarzguioui et al., 2005). The introduced double-stranded RNA (dsRNA) mimetics 
are similar in structure to siRNAs and essentially ‘mimic’ the endogenous activity of the specific 
miRNA to enhance regulation of the target mRNA. Exogenous miRNA mimics are often 
administered as individual dsRNA oligonucleotides however, as with antagomiRs for miRNA 
inhibition, the oligonucleotides require modifications such as the introduction of 2’-OMe and 
LNA, for improved stability and activity (Czauderna et al., 2003). However, transient 
expression and the requirement for multiple administration of the oligonucleotide to maintain 
the therapeutic effects are drawbacks associated with the delivery of miRNA mimic 
oligonucleotides and can be improved by expressing the short hairpin RNA (shRNA) from a 
strong promoter in a vector-based system, although limitations are also imposed by the choice 
of vector and promoter. Exogenous miRNAs expressed from promoters within vectors as a 
shRNA can mimic pre-miRNAs and are transported to the cytoplasm and processed by Dicer 
to yield the functional miRNA that target specific mRNAs (Amarzguioui et al., 2005). The 
miRNA mimics are practically indistinguishable from endogenous miRNAs and therefore, 
unlikely to cause toxicity. 
 
1.4.6. Exploiting endogenous miRNAs for regulated gene therapy 
Combining miRNA regulation with gene therapy allows regulation of gene expression at the 
post-transcriptional level. Substantial progress has been made in exploiting the endogenous 
activity and distinct expression profiles of miRNAs to achieve restricted gene expression in a 
desired cell type, tissue, developmental stage or in response to specific stimuli, while 
minimising gene expression elsewhere (Gentner and Naldini, 2012). This approach employs 
a similar vector design to miRNA sponges but produces the opposite outcome; the perfectly 
complementary candidate miRNA target sites are incorporated into the 3’UTR of a therapeutic 
transgene, thereby subjecting the transgene to post-transcriptional degradation by the specific 
miRNA and preventing gene expression in cells and/or environments that express high levels 
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of the corresponding miRNA. Therefore, the transgene will be expressed in a particular cell 
type and/or environment in which the miRNA is not expressed (Broderick and Zamore, 2011). 
The pioneering research of Brown et al., (2006) provided proof-of-principle of miRNA-
mediated regulation by gene transfer. This concept was developed on the observation that 
immune responses were elicited against the transgene product and vector, despite the use of 
a hepatocyte-specific promoter which was designed to restrict transgene expression to 
hepatocytes and prevent expression within other cells, especially in antigen-presenting cells, 
to induce immune tolerance. Therefore, the authors engineered a lentiviral vector with four 
perfectly complementary target sites of the haematopoietic cell-specific miR-142-3p into the 
3’UTR of the GFP reporter gene and showed a 100-fold reduction in GFP expression in 
haematopoietic cells, particularly monocytes and dendritic cells (i.e. antigen presenting cells 
(APCs), whilst retaining high GFP expression in non-haematopoietic cells (Brown et al., 2006). 
As expected, the i.v. injection into haemophilia B mice (factor IX knockout) with the lentiviral 
vector expressing the human coagulation factor IX gene under the control of a hepatocyte-
specific promoter, triggered an anti-factor IX immune response and the clearance of 
transduced hepatocytes (Brown et al., 2007c). However, following the systemic delivery of the 
hepatocyte-specific promoter combined with four miR-142-3p target sites in the 3’UTR of the 
human factor IX gene within the lentiviral vector, the gene expression was confined to the 
hepatocytes resulting in the stable correction of haemophilia B mice without the induction of 
immune-mediated vector clearance. Furthermore, this strategy conferred human factor IX 
immune tolerance and the expression of miR-142-3p target did not cause saturation of miR-
142-3p or loss of endogenous miR-142-3p function, which are vital concerns about the safety 
of this approach (Brown et al., 2007b).  
MiRNAs have also been exploited for stem cell gene transfer, for example, Papapetrou et al., 
(2009) generated lentiviral-encoded antigen receptors with miR-181 target sites, which is 
highly expressed in thymocytes. The vectors were introduce into mouse haematopoietic stem 
cells (HSCs) and the expression of the antigen receptors was suppressed in late thymocytes, 
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thereby enabling the cells to avoid clonal deletion in the thymus. Consequently, receptor 
expression was fully restored in post-thymic T cells to confer protection against a subsequent 
challenge with antigen-expressing hCD19+ tumours, thereby demonstrating its potential 
application in cancer immunotherapy (Papapetrou et al., 2009).  
MiRNA-mediated regulation of gene expression has also demonstrated promising results in 
cancer gene therapy where many groups have exploited the differential miRNA expression 
between normal and cancer cells to improve tumour targeting. Similar to the strategy 
described above, the vector containing target sites complementary to a highly expressed 
miRNA in normal tissue but low or absent in tumour cells, can induce high gene expression in 
tumour cells with minimal expression in normal cells due to the abundance of the 
corresponding miRNA. For example, the studies of Suzuki et al. (2008) were conducted on 
the observation that intratumoural injection of adenoviral vectors often disseminate into the 
systemic circulation and transduce the liver resulting in severe hepatotoxicity. Therefore to 
overcome this problem, the authors incorporated four perfectly complementary target sites to 
the liver-specific miR-122 into the 3’UTR of the suicide gene. Following the intratumoural 
delivery of the vector, the suicide gene was highly expressed in the tumour cells to achieve 
significant anti-tumour effects and dramatically reduced HSV-thymidine kinase-ganciclovir-
induced hepatotoxicity, thereby demonstrating a safe and efficient suicide gene therapy 
strategy (Suzuki et al., 2008).   
MiRNA-mediated concepts have been successfully applied to other platforms including the 
redirected oncolytic virus tropism (Kelly et al., 2008) and reducing the toxicity of viral vaccines 
(Barnes et al., 2008). Taken together, the exploitation of endogenous miRNAs holds great 
promise for efficient gene regulation to achieve targeted and stable gene expression. 
However, the success of this approach relies on the incorporation of multiple, tandem and 
perfectly complementary target sites, differential miRNA expression in the 
cell/tissue/environment under study and importantly, a high threshold of miRNA concentration 
(Brown et al., 2007b). MiRNA targeting could potentially be harnessed to regulate therapeutic 
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gene expression in response to inflammation as a novel approach to achieve inflammation-
regulated gene expression by exploiting inflammation-repressed miRNAs in the diseased 
tissue, i.e. miR-23b in RASFs.  
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1.5. Thesis Aims and Objectives  
The underlying aim of this study is to create a novel gene therapy lentiviral vector which 
exploits the endogenous activity of differentially expressed transcription factors and miR-23b 
to transcriptionally and post-transcriptionally regulate gene expression, respectively, during 
inflammation and/or hypoxia. The objectives are: 
 
1.5.1. Transcriptional regulation of gene expression  
1. To construct and screen plasmid DNA with inflammation-inducible composite 
promoters  
The endogenous activities of the upregulated candidate transcription factors (AP-1, C/EBPβ, 
Egr-1, Ets-1, HIF-1α and NFκB) will be exploited by constructing novel composite synthetic 
promoters, comprised of their cognate binding sites positioned upstream of a minimal CMV 
promoter and the firefly (Photinus pyralis) luciferase gene, using random ligation and 
Assembly PCR cloning techniques.  
I hypothesise that the inflammation-inducible composite promoters will be multi-responsive to 
respective stimuli and induce synergistic luciferase gene expression during combined 
inflammatory and hypoxic stimulation, as a result of simultaneous binding of the respective 
inducible transcription factors. High-throughput transfection of the plasmid DNA constructs 
into 293T cells will enable the identification of the best synthetic promoters for further analysis, 
as determined by luciferase quantification.  
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2. To construct and screen lentiviral inflammation-inducible composite promoters and 
assess their activity in vivo  
Lentiviral vectors possess attractive features for experimental gene therapy i.e. the ability to 
integrate into the host genome with low immunogenicity and allow long-term and stable gene 
expression. Therefore, the selected composite promoters will be cloned into lentiviral vectors 
and the resulting lentiviral particles will firstly be used to generate stable cell lines: assessment 
of composite promoter kinetics will further refine the selection of suitable promoters for 
analysis in vivo. The lentiviral particles of the selected composite promoters will also be 
delivered into the paws of mice with carrageenan-induced paw inflammation.  
Bioluminescence imaging will be used to monitor the changes in luciferase gene expression 
during inflammation and the best composite promoter will be used to transcriptionally-regulate 
therapeutic gene expression in vivo.  
 
3. Assessment of the therapeutic efficacy of mTNFR-Fc and IL-1Ra genes expressed 
from lentiviral inflammation-inducible composite promoters  
The luciferase gene in the selected composite promoter will be replaced with mTNFR-Fc and 
IL-1Ra therapeutic genes, in individual constructs. Therapeutic protein expression from 
lentivirally-transduced cells will be quantified using ELISA. The therapeutic efficacy of 
transcriptionally-regulated mTNFR-Fc and IL-1Ra expression will be assessed following the 
local delivery of the candidate lentiviral particles into the paws of mice with carrageenan-
induced paw inflammation.   
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1.5.2. Post-transcriptional regulation of gene expression  
1. To construct a novel inflammation-responsive miR-23b-regulated system  
The inflammation-repressed expression profile of miR-23b in NIH3T3 mouse embryonic 
fibroblasts will be confirmed using Real-time qPCR. Luciferase gene expression will be post-
transcriptionally regulated by cloning the binding sites of miR-23b into the 3’UTR of the 
luciferase gene, positioned downstream of constitutive CMV and SFFV promoters in plasmid 
DNA and lentiviral constructs, respectively.  
I hypothesise that luciferase gene expression will be highest during the inflamed state (when 
miR-23b activity is repressed) and significantly downregulated during the uninflamed state 
(when miR-23b activity is highest), in transiently transfected and lentivirally-transduced 
NIH3T3 mouse embryonic fibroblasts.  
 
1.5.3. Dual regulation of gene expression  
1. To construct a novel transcriptionally and post-transcriptionally regulated system  
The binding sites of the inflammation-repressed miR-23b will be cloned into the 3’UTR of the 
luciferase gene, positioned downstream of an inflammation-inducible NFκB-responsive 
synthetic promoter, in a plasmid DNA construct.  
I hypothesise that luciferase gene expression will be highest during the inflamed state (when 
NFκB is activated and miR-23b activity is repressed) and significantly downregulated during 
the uninflamed state (when NFκB is inactivated and miR-23b activity is highest) in NIH3T3 
mouse embryonic fibroblasts.  
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CHAPTER 2: 
Materials and Methods 
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2.1.    Tissue culture 
2.1.1. Culture of adherent cell lines 
Human embryonic kidney 293T cells and mouse embryonic fibroblast NIH3T3 cells were 
grown in complete Dulbecco’s Modified Eagle’s Medium (DMEM) (Lonza Group Ltd., 
Switzerland) containing 10% heat-inactivated foetal bovine serum (Hi-FBS; Gibco, Life 
Technologies Corp, California, USA), 4.5 g/L glucose (Sigma-Aldrich Corp, St Louis, MO, 
USA), 100 IU/ml penicillin (Sigma-Aldrich), 100 μg/ml streptomycin (Sigma-Aldrich) and                 
2 mM L-glutamine (Sigma-Aldrich). Cells were maintained at 37°C in a humidified 10% CO2 
incubator. Growth medium was changed every three days and cells were trypsinised using 
Trypsin-Versene® (Trypsin-EDTA; Lonza Ltd) when 80-90% confluent.   
 
2.1.2. Long term storage of cell lines 
Following trypsinisation of a 70-80% confluent cell monolayer, the cells were pelleted by 
centrifugation at 1200 rpm for 4 minutes at room temperature. The cell pellet was resuspended 
in 3 ml freezing medium, comprised of 90% Hi-FBS and 10% dimethylsulfoxide (DMSO; 
Sigma-Aldrich) and stored in cryovials in 1 ml aliquots. The cells were frozen slowly by 
initialling storing the cells at -70°C overnight and then transferring the cells to liquid nitrogen 
for long-term storage. Frozen cells were re-cultured by rapidly thawing the cells in a water bath 
at 37°C, with gentle agitation. The DMSO was removed from the cells by adding 9 ml complete 
DMEM medium to the thawed cells and centrifuging the tubes at 1200 rpm for 4 minutes at 
room temperature. The cell pellet was resuspending in 2 ml complete DMEM medium and 
transferred to a 75 cm2 flask containing 10 ml complete DMEM medium.  
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2.1.3. Routine mammalian cell transfections using FuGENE® 6 Transfection Reagent 
To minimise experimental variability, mammalian cells were routinely co-transfected in       96-
well tissue culture plates with a total concentration of 200 ng/well DNA (180 ng firefly 
expressing recombinant plasmid DNA and 20 ng renilla expressing plasmid pRL-CMV 
(Promega Corp., Madison, WI) using FuGENE® 6 Transfection Reagent (Promega), unless 
stated otherwise. The day before transfection, 293T or NIH3T3 cells were trypsinised and the 
live cells were counted using 0.4% Trypan-Blue (Sigma-Aldrich) exclusion on a 
haemocytometer and 2x104 cells/well were seeded in 96-well tissue culture plates in 100 μl of 
complete DMEM medium. Briefly, 0.6 μl FuGENE® was diluted in serum-free DMEM medium, 
vortexed for one second and incubated at room temperature for 5 minutes. A total 
concentration of 200 ng/well DNA was added to the diluted FuGENE® and incubated at room 
temperature for 15 minutes to allow the formation of the FuGENE®: DNA complex. Following 
incubation, 6 µl of the FuGENE®: DNA complex was added to the cells, in a ‘drop-wise 
manner’. Triplicate transfections were performed in each experiment, unless stated otherwise. 
Twenty-four hours post-transfection, the cells were stimulated with various stimuli. 
 
2.1.4. Mammalian cell stimulation 
The choices of stimuli were collated from published studies (Chapter 1). Following 24 hours 
post-transfection, the cell medium was removed from the transfected cells and replaced with 
100 μl of 0.5% FBS DMEM alone for the unstimulated control cells. For the activation of    HIF-
1α, 100 μl of 0.5% FBS DMEM alone was added to the cells and the plate was incubated in 
hypoxic conditions at 0.1% O2, 10% CO2 and 89.9% N2 in a CO2 incubator (New Brunswick, 
an Eppendorf company, Hamburg, Germany) for 18 hours. For the activation of inflammation-
responsive transcription factors and/or all transcription factors, the cells were treated with 100 
μl of 0.5% FBS DMEM containing 10 ng/ml human TNFα (30001A; Peprotech, NJ, USA), 10 
ng/ml PMA (P1585; Sigma-Aldrich) or a combination of 10 ng/ml TNFα and 10 ng/ml PMA in 
0.1% hypoxia for 18 hours.          
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For the downregulation of miR-23b expression, the cells were treated with 100 μl  of 0.5% 
FBS DMEM containing 10 ng/ml TNFα or 50 ng/ml human or mouse IL-17A (hIL-17A 
#8928SC, mIL-17A #5227SC; Cell Signalling Technology Inc, MA, USA) or a combination of 
10 ng/ml TNFα and 50 ng/ml hIL-17A/mIL-17A for 18 hours.  
 
2.2.    Quantification of protein expression   
2.2.1. Firefly luciferase assay 
Post-stimulation (18 hours), the cell medium was removed and the cells were lysed in 50 µl 
1x Passive Lysis Buffer (Promega) and the firefly luciferase expression was quantified using 
the Luciferase Assay System (Promega) following the manufacturer’s instructions, with minor 
modifications. The cell debris was pelleted by centrifugation at 3,000 rpm for 5 minutes and 
10 μl of the cell lysate was transferred into a 96-well opaque luminometer plate (Costar, 
Corning Inc, Corning, New York, USA). The intracellular firefly luciferase expression in the cell 
lysates was quantified by adding 50 µl of Luciferase Assay Reagent (Promega), which was 
preloaded into the luminometer (MLX Microtiter® Plate Luminometer, Dynex Technologies 
Inc, Chantilly, VA, USA), to the lysates. The Revelation Software (Dynex Technologies Inc) 
was programmed to perform a 2 second measurement delay and then a 10 second 
measurement read for luciferase activity, which was expressed as relative light units (RLU). 
After use, the luminometer tubing was thoroughly washed with water and 70% ethanol.  
 
2.2.2. Renilla luciferase assay 
The intracellular renilla luciferase expression was quantified using the Renilla Luciferase 
Assay System (Promega) following the manufacturer’s instructions, with minor modifications. 
Briefly, 10 μl of the cell lysate was transferred into a 96-well opaque luminometer plate and 20 
μl of Renilla Luciferase Assay Reagent (Promega) was dispensed into each well from the 
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preloaded luminometer. Renilla luciferase expression was quantified using the same method 
as firefly luciferase expression quantification (section 2.2.1). After use, the luminometer tubing 
was thoroughly washed with water and 70% ethanol. Firefly luciferase values were normalised 
to renilla luciferase values in the same sample, to minimise experimental variability, unless 
otherwise stated.  
 
2.2.3. BCA protein assay 
The total protein concentration in the lysates of transfected and transduced stable cells was 
quantified using the Pierce® BCA Protein Assay Kit (Thermo Scientific, Rockford, IL, USA) 
following the manufacturer’s protocol. The protein concentration was measured from the 
bovine serum albumin (BSA) standard curve which ranged from 2 mg/ml - 0.03 mg/ml BSA in 
sterile distilled H2O (dH2O). In duplicate, 10 μl of each BSA serial dilution or 10 μl of cell lysate 
was transferred into each well of a 96-well microtiter plate. A volume of 200 μl of Working 
Reagent (50 parts BCA Reagent A and 1 part BCA Reagent B) was added to each well and 
incubated at 37°C for 30 minutes. The measurement of absorbance at 562 nm was performed 
using a Tecan Genios microplate reader (Tecan Group Ltd, Mannedorf, Switzerland) with 
Magellan 4 software. The BSA standard curve was plotted as the BSA standards 
concentration (mg/ml) versus absorbance at OD562nm, using GraphPad® Prism 5 (GraphPad® 
Software Inc, California, USA). The linear equation obtained from the BSA standard curve was 
used to calculate the protein concentration of the lysate samples. Firefly luciferase values 
were normalised to the total protein concentration in the same samples and expressed as 
relative light units per milligram of protein (RLU/mg), unless stated otherwise.   
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2.3.    Bacterial manipulation 
2.3.1. Preparation of chemically-competent DH5α and GT115 E.Coli cells 
Escherichia coli (E.coli) DH5α and GT115 strains were treated with calcium chloride to 
produce chemically-competent bacterial cells. Miller Luria Bertani (LB) media (10 g Tryptone, 
10 g NaCl and 5 g Yeast Extract in 1L sterile dH2O, pH 7.5) and low salt Lennox LB media            
(10 g Tryptone, 5 g NaCl and 5 g Yeast Extract in 1L sterile dH2O, pH 7.5) was used to grow 
DH5α and GT115 cells respectively.  
Frozen glycerol stocks (stored at -80°C) of DH5α or GT115 bacteria were streaked on 
antibiotic-free LB-agar plates (10 g tryptone, 10 g NaCl, 5 g yeast extract and 15 g agar in     
1L sterile dH2O, pH 7.5) and low-salt LB-agar plates (10 g tryptone, 5 g NaCl, 5 g yeast extract 
and 15 g agar in 1L sterile dH2O, pH 7.5) respectively and the plates were incubated at 37°C 
overnight. A single colony of DH5α or GT115 bacteria was inoculated directly into     5 ml 
antibiotic-free LB media or low-salt LB media, respectively and incubated overnight at 37°C 
with shaking at 225 rpm. The following day, the 5 ml DH5a and GT115 inoculums were 
transferred into 500 ml of LB media and low-salt LB media, respectively and incubated at 37°C 
with agitation at 225 rpm until the OD600 reached 0.4-0.6. The culture was transferred into two 
250 ml centrifuge tubes and centrifuged at 4°C for 10 minutes at 5,000 rpm. The LB 
supernatant was discarded and the bacterial pellet was resuspended in 50 ml of cold 0.1M 
MgCl2 and centrifuged at 4°C for 10 minutes at 2,000 rpm. The supernatant was discarded 
and the bacterial pellet was resuspended in 50 ml of cold 0.1M CaCl2 and incubated on ice for 
20 minutes and then centrifuged at 4°C for 10 minutes at 2,000 rpm. The supernatant was 
discarded and the bacterial pellet was resuspended in 12.5 ml of cold 0.1M CaCl2 containing 
14% glycerol (v/v) and stored immediately at -80°C in 100 μl aliquots.  
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2.3.2. Ligation reactions and transformation of chemically-competent bacterial cells  
Ligation of DNA fragments was performed using a vector to insert ratio of 1:3 (molar) or an 
excess of x3 insert per molar of vector DNA. The reaction volume of 20μl contained the 
plasmid DNA vector, DNA insert, 2 μl 10x T4 DNA Ligase Buffer (New England Biolabs, NEB 
Inc., Ipswich, UK) and 1 μl T4 DNA Ligase (400,000 U/ml, NEB). Ligation reactions were 
incubated overnight at 4°C and transformed into chemically-competent DH5α or GT115 cells 
using the heat-shock method. Recombinant pGL3 plasmids containing the f1 origin of 
replication (ori) were transformed into DH5α cells. In contrast, recombinant pCpG plasmids, 
containing the R6Kγ ori were transformed in GT115 cells, which are a pir mutant E.coli strain 
also deficient in Dcm methylation. 
An aliquot of 100 μl of chemically-competent E.coli bacterial cells was thawed on ice and 
incubated with the 20 μl ligation reaction on ice for 30 minutes. The bacterial cells were     heat-
shocked at 42°C for 90 seconds and immediately incubated on ice for 2 minutes. The bacterial 
cells were added to 5 ml of antibiotic-free LB media and low-salt LB media, for the DH5α and 
GT115 bacterial transformations, respectively. The tubes were incubated at 37°C with shaking 
at 225 rpm for 90 minutes and 400 μl of the DH5α and GT115 bacterial cultures were streaked 
on LB-agar plates containing 100 μg/ml Carbenicillin (Carbenicillin Direct, UK) and low-salt 
LB-agar plates containing 25 μg/ml Zeocin (Invitrogen Corp., Paisley, UK) respectively and 
incubated overnight at 37°C.  
 
2.3.3. Amplification and purification of miniprep plasmid DNA 
Single DH5α or GT115 transformed bacterial colonies were picked from agar plates using 
sterile 10 μl pipette tips and selectively grown in 5 ml of LB media containing 100 μg/ml 
Carbenicillin or 5 ml of low-salt LB media containing 25 μg/ml Zeocin, respectively and 
incubated overnight at 37°C with shaking at 225 rpm. Miniprep plasmid DNA was purified from 
bacteria using the PureLink® Quick Plasmid Miniprep Kit (Invitrogen) following the 
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manufacturer’s instructions. DH5α and GT115 bacterial cells were pelleted in 1.6 ml 
Eppendorf tubes by centrifuging the tubes at room temperature at 12,000 g for 4 minutes and 
resuspending the pellet in 250 μl Resuspension Buffer (containing RNase A). The 
resuspended bacterial cells were lysed with 250 μl Lysis Buffer and mixed by inverting the 
tube 6 times and incubating at room temperature for 5 minutes. The cell debris and proteins 
were precipitated and removed from the lysates by adding 350 μl Precipitation Buffer to the 
lysates and centrifuging the samples at 12,000 g for 10 minutes at room temperature.  The 
supernatant was loaded onto the Spin Columns, placed inside a 2 ml Wash Tube and 
centrifuged at 12,000 g for 1 minute at room temperature. The flow-through was discarded 
and the column was washed with 500 μl Wash Buffer W10 and centrifuged at 12,000 g for 1 
minute at room temperature. The flow-through was discarded and the column was further 
washed with 700 μl Wash Buffer W9 and centrifuged at 12,000 g for 1 minute at room 
temperature. Residual wash buffer was removed from the column by centrifugation at   12,000 
g for 2 minutes at room temperature. Plasmid DNA was eluted from the column by adding 75 
μl of TE Buffer (10 mM Tris HCl and EDTA 1 mM, pH 8.0), preheated to 65°C, to the column, 
incubating at room temperature for 1 minute and centrifuging at 12,000 g for 2 minutes at room 
temperature. The correct construction of recombinant plasmid DNA and also the integrity of 
the DNA was analysed by restriction enzyme digestion and/or DNA sequencing. Purified 
miniprep DNA was stored at -20°C.  
 
2.3.4. Amplification and purification of maxiprep plasmid DNA  
The overnight DH5α or GT115 miniprep bacterial cultures (50 μl) were amplified in 250 ml of 
LB media containing 100 μg/ml Carbenicillin or 250 ml of low-salt LB media containing        25 
μg/ml Zeocin, respectively. The cultures were incubated overnight at 37°C with shaking at 225 
rpm and the maxiprep DNA was purified from the bacteria using the PureLink® HiPure Plasmid 
DNA Purification Kit (Invitrogen) according to the manufacturer’s guidelines. After 18-20 hours, 
the bacterial cells were harvested by centrifugation at 4,000 g for 10 minutes at 4°C in a 
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Beckman XL-90 Ultracentrifuge (Beckman Coulter, CA, USA) and then resuspended in 10 ml 
Resuspension Buffer (containing RNase A). The bacterial cells were lysed with 10 ml Lysis 
Buffer, mixed and then incubated at room temperature for 5 minutes. A precipitate was then 
formed by adding 10 ml Precipitation Buffer to the lysate and immediately mixed to obtain a 
homogenous solution. The cell debris and proteins were removed from the lysate by 
centrifugation at 6,000 g for 45 minutes at 4°C (Beckman XL-90 Ultracentrifuge) and the 
supernatant was loaded onto the HiPure Maxi Column (which had been pre-equilibrated with 
30ml Equilibration Buffer) and the solution was allowed to drain from the column by gravity 
flow. The column was washed with 60 ml Wash Buffer which flowed by gravity flow and the 
flow-through fraction was discarded. The purified DNA was eluted from the column by adding 
15 ml Elution Buffer to the column, in a sterile 50 ml Falcon Tube (Corning Inc.). The DNA 
was precipitated by adding 10.5 ml Isopropanol to the eluate, thoroughly mixed, stored at -
20°C for 60 minutes and then centrifuged at 4,000 g for 60 minutes at 4°C in an Eppendorf 
5810R Centrifuge. The supernatant was discarded and the DNA pellet was washed with 5 ml 
70% Ethanol at room-temperature and centrifuged at 4,000 g for 30 minutes at 4°C (Eppendorf 
5810R Centrifuge). The supernatant was removed and the DNA pellet was air-dried for 5 
minutes and resuspended in 500 μl TE Buffer. Purified maxiprep DNA was stored at -20°C 
and the integrity of the DNA was analysed by restriction enzyme digestion and/or DNA 
sequencing.  
 
2.3.5. Quantification of nucleic acids  
The quantity of nucleic acids (plasmid DNA, PCR products and/or RNA) was calculated using 
the NanoDrop ND-1000 Spectrophotometer (Thermo Fisher Scientific, Massachusetts, USA) 
by measuring the absorbance of light with a wavelength of 260 nm (A260). An absorption of 1 
at A260 equals a concentration of 50 μg/ml double-stranded DNA.  
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2.4.    DNA analysis and cloning 
2.4.1. Analytical restriction enzyme digestion 
Approximately 1 μg plasmid DNA was routinely digested with restriction enzymes (NEB) to 
verify and/or identify correctly constructed recombinant plasmid DNA. The reaction comprised 
1 μg plasmid DNA, restriction enzyme(s), compatible 10x NEB Buffer and sterile dH20 in a 
final volume of 20 μl. The volume of enzyme used in the reactions varied depending on the 
total volume of the reaction but never exceeded 10% (v/v) to prevent star activity of the 
restriction enzyme. Reactions were incubated for 1-2 hours at the optimal temperature of the 
restriction enzyme in the compatible 10x NEB buffer, as recommended by NEB. DNA digestion 
was verified by agarose gel electrophoresis.  
 
2.4.2. Standard agarose gel electrophoresis   
The integrity of RNA and/or DNA was verified by horizontal gel electrophoresis on a 0.8-2% 
(w/v) agarose gel in 0.5 x TAE buffer (National Diagnostics, GA, USA), depending on the size 
of the fragment. The gels were prepared by dissolving agarose in 0.5 x TAE buffer   (0.02 M 
Tris-acetate, 0.5 mM EDTA, pH 8.3) by boiling in a microwave oven. Once cooled, ethidium 
bromide (10 mg/ml in H2O; BDH Ltd, UK) or SYBR® Safe (10,000X concentrate in DMSO, 
Invitrogen) was added to obtain a final concentration of 1 μg/ml ethidium bromide or 1x SYBR® 
Safe, for visualisation of DNA bands. The gel was cast into a mould and combs were inserted 
horizontally into the gel, which was set at room temperature. A final concentration of 1x 
Loading dye (8 ml glycerol, 500 μl 10x TBE buffer (890 mM Tris-borate, 890 mM boric acid, 
20 mM EDTA, pH 8.3), 0.025 g bromophenol blue, 0.025 g xylene cyanol and sterile dH2O to 
10 ml total volume) was mixed with the RNA or DNA samples before loading onto the agarose 
gels. A 1Kb+ or 50 bp DNA ladder (Invitrogen) was simultaneously loaded alongside the DNA 
samples to provide size markers. Gels were electrophoresed using the voltage and duration 
required for the separation of the required DNA/RNA bands, which was typically at 90V for 45-
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90 minutes, and then visualised by exposure to ultra-violet (UV) light at 570-640 nm using a 
CCD camera on a gel documentation system (UVP BioDoc-It® Imaging System; UVP LLC, 
CA, USA). The image was captured using the adjoining Sony Digital Graphic Printer (UP-
D897; Sony Corp).  
 
2.4.3. Gel extraction of DNA fragments 
DNA fragments excised from agarose gels were purified from agarose using the PureLink® 
Quick Gel Extraction kit (Invitrogen) according to the manufacturer’s instructions. The band of 
interest was excised from the agarose gel using a sterile scalpel blade under UV light at 570-
640 nm using a UV transilluminator (Syngene, Cambridge, UK) and the gel slice transferred 
into a sterile 1.6 ml Eppendorf tube and weighed. For routinely used ≤2% agarose gels, 1 
volume of gel was dissolved in three volumes of Gel Solubilisation Buffer (L3) and incubated 
at 50°C for a total of 15 minutes, with mixing by regular inversions at 3 minute time-intervals.  
One gel volume of isopropanol was added to the dissolved gel slice and the mixture was 
subsequently applied onto the Quick Gel Extraction Column, placed inside a wash tube, and 
centrifuged at 12,000 g for 1 minute (Eppendorf 5415 microcentrifuge). The flow-through was 
discarded and 500 μl Wash Buffer (W1) was added to the column and centrifuged at 12,000 
g for 1 minute. The flow-through was discarded and the residual wash buffer and ethanol was 
removed from the column by centrifugation at maximum speed for 2 minutes. The column was 
placed in a sterile 1.6 ml Eppendorf tube and the DNA was eluted from the column by adding 
50 μl Elution Buffer (E5) and incubating the DNA for 1 minute at room temperature following 
by centrifugation at 12,000 g for 1 minute. 
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2.4.4. Purification of plasmid DNA and PCR products  
Plasmid DNA and PCR products were purified using the PureLink® PCR purification Kit 
(Invitrogen) according to the manufacturer’s instructions. The Binding Buffer B2 was routinely 
used for DNA and/or PCR product purification, unless the use of Binding Buffer HC was stated. 
Approximately 4 volumes of the appropriate Binding Buffers (B2 or HC) were mixed with 1 
volume of the PCR product or plasmid DNA (50-100 μl) and the sample was applied to the 
PureLink® Spin Column. The column was placed in a collection tube and centrifuged at room 
temperature at 10,000 g for 1 minute (Eppendorf 5415 microcentrifuge), after which the flow-
through was discarded. The column was washed by adding 650 μl Wash Buffer and 
centrifugation at room temperature at 10,000 g for 1 minute. The flow-through was discarded 
and the residual Wash Buffer was removed by centrifugation at 12,000 g at room temperature 
for 3 minutes. The column was transferred into a sterile 1.6 ml Eppendorf tube and the DNA 
was eluted from the column by adding 50 μl Elution Buffer and incubating the column at room 
temperature for 1 minute followed by centrifugation at the 12,000 g for 2 minutes. The 
recovered DNA was used for subsequent cloning, unless stated otherwise.  
 
2.5. Random Ligation Cloning Method: construction of pGL3-4bp-composite synthetic 
promoters 
2.5.1. Expression construct: pGL3mCMV  
The promoter-less pGL3-Basic plasmid (Promega) encoding the luciferase reporter gene    (25 
µg) was digested with 2.5 μl XhoI (NEB), 2.5 μl HindIII (NEB), 10 μl 10x NEB Buffer 2 and 
sterile dH2O in a 100 µl reaction mixture. Following an overnight incubation at 37°C, the      
4797 bp DNA fragment was isolated by gel extraction using the PureLink® Quick Gel Extraction 
Kit (Invitrogen) to generate the pGL3-Basic cloning vector. Oligonucleotides containing the 
minimal region of the human cytomegalovirus promoter (mCMV promoter) from -52 bp to -14 
bp of the wild-type promoter (Boshart et al., 1985; GenBank Accession    #K03104) were 
synthesised with 5’-XhoI and 3’-HindIII overhangs by Sigma-Aldrich. The oligonucleotides 
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(Table 2.1) were resuspended in sterile TE buffer (10 mM Tris-HCl, 0.1 mM EDTA, pH 8.0) at 
a final concentration of 2 mg/ml. The forward and reverse mCMV oligonucleotides were 
annealed using the boiling method; 2 µl of each mCMV-oligonucleotide was added to 46 µl of 
TE buffer in a reaction volume of 50 μl and boiled for 5 minutes in a water bath and then 
allowed to cool to room temperature overnight. The annealed mCMV-oligonucleotides were 
cloned into the equivalent XhoI/HindIII site of pGL3-Basic vector in a ligation reaction 
comprising 10 µl annealed mCMV oligonucleotides, 1 µl pGL3-Basic vector, 2 µl 10x T4 DNA 
Ligase Buffer (NEB), 1 µl T4 DNA Ligase (NEB) and        6 µl H2O and incubated at 4°C 
overnight. The resulting construct was referred to as pGL3mCMV (Fig 3.2 A, section 3.2.1). 
The ligation reactions were used to transform chemically-competent DH5α E.coli cells and the 
plasmid DNA was selectively grown in LB media containing 100 µg/ml Carbenicillin. Large 
scale plasmid DNA was isolated using the PureLink® HiPure Plasmid DNA Purification Kit 
(Invitrogen) and the positive recombinant pGL3mCMV constructs were verified by restriction 
analysis and DNA Sanger sequencing (Genome Centre, Queen Mary, London, UK) using the 
reverse sequencing primer GL2, which anneals to the 5’ end of the luciferase gene and 
sequences towards the promoter (Appendix 2).  
 
2.5.2. Cloning vector: pGL3mCMV 
pGL3mCMV (25 μg) vector was linearised in a reaction comprising 3 µl NheI, 10 µl 10x NEB 
Buffer 2 and sterile distilled water in a final reaction volume of 100 µl. Following an overnight 
incubation at 37°C, the linear DNA was separated from uncut and/or partially cut DNA by gel 
electrophoresis. The linear DNA was gel extracted using the PureLink® Quick Gel Extraction 
Kit (Invitrogen) and subsequently dephosphorylated using Calf Intestinal Phosphatase (CIP) 
(NEB) to prevent religation of the linear DNA. Dephosphorylation of the 5’- and 3’- ends of 
pGL3mCMV required incubating 50 μl pGL3mCMV, 3 μl CIP (NEB), 10 μl 10x NEB Buffer 2 
and sterile dH2O in a final volume of 100 μl for 1 hour at 37°C. A final concentration of         50 
mM EDTA was added to the reaction to inhibit the CIP enzyme and the DNA was subsequently 
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purified using the PureLink® PCR Purification Kit (Invitrogen) to yield 50 μl of the linear 
pGL3mCMV cloning vector (Fig 3.2 B, section 3.2.1).  
 
2.5.3. Oligonucleotide design for pGL3-4bp-composite synthetic promoters 
The oligonucleotides containing the TFBSs for AP-1, C/EBP, Egr-1, Ets-1, HIF-1α and      NFκB 
were designed with phosphorylated 5’-CTAG overhangs complementary to the NheI 
overhangs. The oligonucleotides were synthesised at Sigma-Aldrich as HPLC purified forward 
and reverse oligonucleotides (Table 2.1) and each oligo was resuspended at            2 mg/ml 
in sterile TE buffer and annealed using the boiling method, as previously described in section 
2.5.1.  
 
 
 
2.5.4. Construction of pGL3-4bp-composite synthetic promoters   
 Oligonucleotide Sequences  (5’‐3’) 
Forward XhoI 
 mCMV Oligo 
5’‐ TCGAGGCCTGTAGGCGTGTACGGTGGGAGGCTTATATAAGCAGAGCTCA ‐3’ 
Reverse HindIII 
mCMV Oligo 
5’‐ AGCTTGAGCTCTGCTTATATAAGCCTCCCACCGTACACGCCTACAGGCC ‐3’ 
AP‐1 Forward Oligo  5’‐ CTAGTGAGTCA ‐3’       
AP‐1 Reverse Oligo  5’‐ CTAGTGACTCA ‐3’    
C/EBPβ Forward Oligo 5’‐ CTAGATTGCGCAAT ‐3’ 
C/EBPβ Reverse Oligo 5’‐ CTAGATTGCGCAAT ‐3’ 
Egr‐1 Forward Oligo 5’‐ CTAGTTGCGTGGGCGT ‐3’ 
Egr‐1 Reverse Oligo 5’‐ CTAGACGCCCACGCAA ‐3’ 
Ets‐1 Forward Oligo 5’‐ CTAGCCGGAAGTTCC ‐3’ 
Ets‐1 Reverse Oligo 5’‐ CTAGGGAACTTCCGG ‐3’ 
HRE Forward Oligo 5’‐ CTAGACGTGG ‐3’ 
HRE Reverse Oligo 5’‐ CTAGCCACGT ‐3’ 
NFκB Forward Oligo 5’‐ CTAGGGAATTTC ‐3’ 
NFκB Reverse Oligo 5’‐ CTAGGAAATTCC ‐3’ 
Table 2.1. List of TFBS-oligonucleotides for cloning the pGL3-4bp-
composite synthetic promoter constructs. Overhangs are underlined 
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The annealed TFBS-oligonucleotides, with phosphorylated 5’-CTAG overhangs, were pooled 
together and cloned into the equivalent site of the pGL3mCMV vector in a reaction comprising 
1 µl of each annealed TFBS-oligonucleotide (n=6), 2 μl pGL3mCMV vector, 2 μl 10x T4 DNA 
Ligase Buffer, 1 μl T4 DNA ligase and sterile dH2O to a final volume of 20 μl. The ligation was 
incubated at 4°C overnight and then transformed into chemically-competent DH5α E.coli cells 
and purified using the PureLink® Quick Plasmid Miniprep Kit (Invitrogen). Positive recombinant 
plasmid DNA constructs from this ligation were referred to as         pGL3-4bp-composite 
synthetic promoters (Fig 3.2 C, section 3.2.1).  
 
2.6.  Random Ligation Cloning Method: construction of pCpG-4bp-composite 
synthetic promoters 
2.6.1.  Expression construct: pCpGmCMV-Luc+ 
The pCpGmCMV-Luc+ expression vector was generated by the ligation of two fragments from 
two different expression vectors; pCpG-mSEAP (InvivoGen, San Diego, CA, USA) and 
pGL3mCMV (section 2.5.1). The mCMV promoter and luciferase reporter gene was isolated 
from the pGL3mCMV expression vector by digesting 25 µg pGL3mCMV with 2.5 µl NheI,    2.5 
µl AfeI, 10 µl 10x NEB Buffer 4 and sterile dH2O in a final reaction volume of 100 µl. Following 
an overnight incubation at 37°C, the DNA fragments were separated by agarose gel 
electrophoresis and the 2143 bp DNA fragment was isolated by gel extraction using PureLink® 
Quick Gel Extraction Kit (Invitrogen) (Fig 3.8 A, section 3.3.3) 
The pCpG-mSEAP plasmid contains two nuclear matrix attachment regions from the            5’-
region of the human IFN-β gene and the β-globin gene. This fragment was isolated by 
digesting 25 µg pCpG-mSEAP with 3 µl SbfI, 10 µl 10x NEB Buffer 4 and sterile dH2O in a 
100 µl reaction and incubated overnight at 37°C. The reaction was purified using the PureLink® 
PCR Purification Kit (Invitrogen) and the DNA was treated with Klenow (DNA polymerase I, 
Large Klenow fragment, NEB) to generate blunt ended DNA which can be ligated to the AfeI 
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blunt overhang of the pGL3mCMV DNA. Briefly, 50 µl of purified linear pCpG-mSEAP DNA 
was incubated with 3 µl Klenow (NEB), 10 µl 10x NEB Buffer 2, 10 μl 2 mM dNTPs and sterile 
dH2O in a final reaction volume of 100 μl at 25°C for 15 minutes. The reaction was stopped 
following the addition of a final concentration of 10mM EDTA and the Klenow enzyme was 
heat-inactivated by incubating the reaction at 75°C for 20 minutes. The DNA was purified using 
the PureLink® PCR Purification Kit (Invitrogen) and the resulting 50 µl DNA was digested with 
2.5 µl NheI, 2.5 μl XbaI, 10 µl 10x NEB Buffer 4 and sterile dH2O in a final reaction volume of 
100 µl and incubated at 37°C overnight. The DNA fragments were separated by agarose gel 
electrophoresis and the 2194 bp fragment was isolated by gel extraction using PureLink® 
Quick Gel Extraction Kit (Invitrogen) to produce 50 μl of purified pCpG-mSEAP vector (Fig 3.8 
B, section 3.3.3). 
The pCpGmCMV-Luc+ construct was generated by ligating 6 μl pGL3mCMV fragment,         2 
μl pCpG-mSEAP vector, 2 µl 10x T4 DNA Ligase Buffer (NEB), 1 µl T4 DNA ligase (NEB) and 
sterile dH2O in a ligation reaction of 20 µl. The ligation reaction was incubated at 4°C overnight 
and then transformed into chemically-competent GT115 E.coli bacterial cells. The resulting 
large scale recombinant pCpGmCMV-Luc+ DNA was purified using the PureLink® HiPure 
Plasmid DNA Purification Kit (Invitrogen) (Fig 3.8 C, section 3.3.3). 
 
2.6.2. Cloning vector: pCpGmCMV  
The pCpGmCMV-Luc+ construct (25 μg) was digested with 2.5 μl NheI, 2.5 μl XhoI, 10 μl 10x 
NEB Buffer 2 and sterile dH2O in a 100 µl reaction. Following an overnight incubation at 37°C, 
the DNA fragments were separated by gel electrophoresis and the DNA was purified from the 
agarose using the PureLink® Quick Gel Extraction Kit (Invitrogen) to yield 50 μl of purified 
pCpGmCMV vector (Fig 3.8 C, section 3.3.3). 
 
2.6.3. Cloning vector: pCpGmCMV-66bp spacer 
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Forward and reverse spacer-oligonucleotides with 5’-XbaI, 3’-XhoI overhangs and an internal 
NheI restriction enzyme site were synthesised by Sigma-Aldrich (Table 2.2) to achieve a 66 
bp space between the proximal TFBS and the TATA box within the pCpGmCMV vector. The 
oligonucleotides were resuspended to 2 mg/ml in sterile TE Buffer and annealed using the 
boiling method. The spacer oligonucleotides were ligated into the compatible NheI/XhoI site 
within the pCpGmCMV vector (section 2.6.2) in a ligation which was subsequently transformed 
into chemically-competent GT115 cells. The resulting maxiprep pCpGmCMV-66bp DNA (25 
μg) was linearised with 3 μl NheI (NEB), 10 μl 10x NEB Buffer 2 and sterile dH2O in a 100 µl 
reaction and incubated overnight at 37°C. The linear DNA was separated by gel 
electrophoresis and the DNA was purified from the excised agarose using the PureLink® Quick 
Gel Extraction Kit (Invitrogen). The resulting linear pCpGmCMV-66bp vector was 
dephosphorylated by adding 50 μl purified pCpGmCMV-66 bp vector to 3 μl CIP (NEB), 10 μl 
10x NEB Buffer 2 and sterile dH2O in a final volume of 100 μl and incubating the reaction at 
37°C for 1 hour. A final concentration of 50 mM EDTA was added to the reaction to inhibit the 
CIP enzyme which was then purified using the PureLink® PCR Purification Kit (Invitrogen) to 
yield 50 μl of the linear pCpGmCMV-66bp vector (Fig 3.18 A and B, section 3.4). 
 
2.6.4. Oligonucleotide design for pCpG-4bp-composite synthetic promoters 
The oligonucleotides containing the TFBSs for AP-1, HIF-1α and NFκB were designed with 
phosphorylated 5’- CTAG overhangs which are complementary to the NheI overhang of the 
pCpGmCMV-66bp cloning vector. The HPLC purified forward and reverse oligonucleotides 
were synthesised at Sigma-Aldrich (Table 2.2) and were resuspended at 2 mg/ml in TE buffer 
and annealed using the boiling method, as previously described in section 2.5.1.  
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 Oligonucleotide Sequences  (5’‐3’) 
AP‐1 Forward Oligo  5’‐ CTAGTGAGTCA ‐3’       
AP‐1 Reverse Oligo  5’‐ CTAGTGACTCA ‐3’    
HRE Forward Oligo 5’‐ CTAGACGTGC ‐3’ 
HRE Reverse Oligo 5’‐ CTAGGCACGT ‐3’ 
NF‐κB Forward Oligo 5’‐ CTAGGGGACTTTCC ‐3’ 
NF‐κB Reverse Oligo 5’‐ CTAGGGAAAGTCCC ‐3’ 
Forward Spacer‐66bp Oligo 5’‐ CTAGACGCGTGCTAGCTCGCGATCTTATGATCTGGATCCATGC‐3’ 
Reverse Spacer‐66bp Oligo 5’‐TCGAGCATGGATCCAGATCATAAGATCGCGAGCTAGCACGCGT‐3’ 
 
Table 2.2. List of TFBS-oligonucleotides used to construct the pCpG-4bp-composite 
synthetic promoter constructs. Overhangs are underlined and TFBSs are highlighted in 
bold. The internal NheI restriction enzyme site within the spacer-66bp-oligonucleotides is also 
underlined. 
 
2.6.5. Construction of pCpG-4bp-composite synthetic promoters 
The annealed oligonucleotides, with phosphorylated 5’-CTAG overhangs, were cloned into 
the compatible site within the NheI digested pCpGmCMV-66bp vector in a ligation reaction 
comprising equimolar 3 μl AP-1, 3 μl HRE and 3 μl NFκB annealed oligonucleotides, 2 µl             
pCpGmCMV-66bp vector, 2 μl 10x T4 DNA Ligase Buffer (NEB), 1 μl T4 DNA ligase (NEB), 
and sterile dH2O to a final volume of 20 μl. The ligation reaction was incubated at 4°C overnight 
and the resulting library of miniprep recombinant plasmid DNA, which were purified from 
transformed GT115 positive colonies, were referred to as pCpG-4bp-composite synthetic 
promoter constructs (Fig 3.18 C, section 3.4).  
 
2.7.    Assembly PCR Cloning Method 
2.7.1. Design of oligonucleotides for Assembly PCR  
The oligonucleotides required for the Assembly PCR reaction were ordered from Sigma-
Aldrich and contained an NFκB (variable or fixed), HRE, AP-1 motif or a spacer sequence, 
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flanked by annealing sequences of 10 bp, 15 bp, 20 bp or 25 bp. The 5’-Stop-NheI and 3’-
Stop-XhoI oligonucleotides contained NheI and XhoI restriction enzyme sites, respectively, 
and annealing sequences of 10 bp, 15 bp or 20 bp. All oligonucleotide sequences were 
screened using the TRANSFAC® database (Wingender et al., 2000) to verify the absence of 
other mammalian TFBSs. The desalted oligonucleotides were resuspended at 100 µM in 
sterile TE buffer and all oligonucleotides used in the Assembly PCR reactions described in 
this thesis are listed in Table 2.3.  
 DNA Sequence (5’-3’) 
Variable NFκB- 30 bp 
Forward primer 
5’‐ATCTCTGCGATGAACCTCACCATGTGGGRNNYYCCACAAGGTGCCTCTTATGATCTGGAT‐3’ 
Variable NFκB- 30 bp      
Reverse primer 5’‐ GTGAGGTTCATCGCAGAGATCTTGTGGRRNNYCCCACATGATCCAGATCATAAGAGGCAC‐3’ 
Fixed NFκB- 30 bp 
Forward primer 
5’‐ATCTCTGCGATGAACCTCACCATGTGGGACTTTCCACAAGGTGCCTCTTATGATCTGGAT‐3’ 
Fixed NFκB- 30 bp 
Reverse primer 
5’‐ GTGAGGTTCATCGCAGAGATCTTGTGGAAAGTCCCACATGATCCAGATCATAAGAGGCAC‐3’ 
Fixed NFκB- 20 bp 
Forward primer 
5’‐ATCTCTGCGATGAACCTCACGGGACTTTCCGTGCCTCTTATGATCTGGAT‐3’ 
Fixed NFκB- 20 bp 
Reverse primer 
5’‐ GTGAGGTTCATCGCAGAGATGGAAAGTCCCATCCAGATCATAAGAGGCAC‐3’ 
Fixed NFκB- 15 bp 
Forward primer 
5’‐TGCGATGAACCTCACGGGACTTTCCGTGCCTCTTATGATC‐3’ 
Fixed NFκB- 15 bp 
Reverse primer  
5’‐ GTGAGGTTCATCGCAGGAAAGTCCCGATCATAAGAGGCAC‐3’ 
Fixed AP-1- 30 bp 
Forward primer 
5’‐ATCTCTGCGATGAACCTCACCATGTTGAGTCAACAAGGTGCCTCTTATGATCTGGAT‐3’ 
Fixed AP-1- 30 bp 
Reverse primer 
5’‐ GTGAGGTTCATCGCAGAGATCTTGTTGACTCAACATGATCCAGATCATAAGAGGCAC‐3’ 
Fixed AP-1- 20 bp 
Forward primer 
5’‐ATCTCTGCGATGAACCTCACTGAGTCAGTGCCTCTTATGATCTGGAT‐3’ 
Fixed AP-1- 20 bp 
Reverse primer 
5’‐ GTGAGGTTCATCGCAGAGATTGACTCAATCCAGATCATAAGAGGCAC‐3’ 
Fixed AP-1- 15 bp 
Forward primer 
5’‐TGCGATGAACCTCACTGAGTCAGTGCCTCTTATGATC‐3’ 
Fixed AP-1- 15 bp 
Reverse primer 
5’‐ GTGAGGTTCATCGCATGACTCAGATCATAAGAGGCAC‐3’ 
Fixed HRE- 20 bp 
Forward primer 
5’‐ATCTCTGCGATGAACCTCACACGTGCGTGCCTCTTATGATCTGGAT‐3’ 
Fixed HRE- 20 bp 
Reverse primer 5’‐GTGAGGTTCATCGCAGAGATGCACGTATCCAGATCATAAGAGGCAC‐3’ 
Fixed HRE- 15 bp 
Forward primer 
5’‐TGCGATGAACCTCACACGTGCGTGCCTCTTATGATC‐3’ 
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Fixed HRE- 15 bp 
Reverse primer 5’‐GTGAGGTTCATCGCAGCACGTGATCATAAGAGGCAC‐3’ 
Fixed HRE- 10 bp 
Forward primer 
5’‐TGAACCTCACACGTGGGTGCCTCTTA‐3’ 
Fixed HRE- 10 bp 
Reverse primer 
5’‐ GTGAGGTTCAGCACGTTAAGAGGCAC‐3’ 
5nt Spacer -20 bp 
Reverse primer 
5’‐ GTGAGGTTCATCGCAGAGATCATGGATCCAGATCATAAGAGGCAC‐3’ 
5nt Spacer -15 bp 
Reverse primer 
5’‐ GTGAGGTTCATCGCACATGGGATCATAAGAGGCAC‐3’ 
10nt Spacer -20 bp 
Reverse primer 5’‐ GTGAGGTTCATCGCAGAGATACAGACATGGATCCAGATCATAAGAGGCAC‐3’ 
10nt Spacer -15 bp 
Reverse primer 
5’‐ GTGAGGTTCATCGCAACAGACATGGGATCATAAGAGGCAC‐3’ 
5’- Stop-NheI            
20 bp primer 5’‐CAGTTGCTAGCGTGCCTCTTATGATCTGGAT‐3’ 
5’- Stop-NheI             
15 bp primer 
5’‐CAGTTGCTAGCGTGCCTCTTATGATC‐3’ 
5’- Stop-NheI             
10 bp primer 5’‐CAGTTGCTAGCGTGCCTCTTA‐3’ 
3’- Stop-XhoI             
20 bp primer 5’‐GGATTCTCGAGATCCAGATCATAAGAGGCAC‐3’ 
3’- Stop-XhoI             
15 bp primer 
5’‐GGATTCTCGAGGATCATAAGAGGCAC‐3’ 
3’- Stop-XhoI             
10 bp primer 5’‐GGATTCTCGAGTAAGAGGCAC‐3’ 
3’- Stop-XhoI- 0bp-SalI 
20 bp primer 5’‐GGATTGTCGACTCGAGATCCAGATCATAAGAGGCAC‐3’ 
3’- Stop-XhoI- 5bp-SalI 
20 bp primer 5’‐GGATTGTCGACCATGGCTCGAGATCCAGATCATAAGAGGCAC‐3’ 
3’- Stop-XhoI- 9bp-SalI 
20 bp primer 5’‐GGATTGTCGACCAGACATGGCTCGAGATCCAGATCATAAGAGGCAC‐3’ 
3’- Stop-XhoI- 14bp-SalI 
20 bp primer 5’‐GGATTGTCGACGGATACAGACATGGCTCGAGATCCAGATCATAAGAGGCAC‐3’ 
 
Table 2.3. List of oligonucleotides used for the Assembly PCR method. TFBSs are 
highlighted in bold. The NheI, XhoI or SalI restriction sites within the ‘Stop’ oligonucleotides 
are underlined.  
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2.7.2. Assembly reaction (x10 cycles) 
Modifications were made to an online published Assembly PCR protocol by Team Heidelberg 
(http://2009.igem.org/Team:Heidelberg/Project_Synthetic_promoters). Briefly, an initial 
oligonucleotide mix containing 5 µl of 100 μM forward TFBS-oligonucleotide, 5 µl of 100 μM 
reverse TFBS-oligonucleotide, 12.8 µl of 100 μM 5’-Stop-NheI and 12.8 μl of 100 μM 3’-Stop-
XhoI oligonucleotides in a final reaction volume of 35.6 μl. The oligonucleotide mix was diluted 
1:100 in sterile dH2O and a volume equal to the final reaction volume before dilution was 
added to the assembly PCR reaction (x10 cycles). For example, 35.6 μl diluted oligonucleotide 
mix was added to 12 μl 5x Phusion HF Buffer (NEB), 6 µl 2 mM dNTPs (Invitrogen), 0.5 µl 
Phusion DNA Polymerase (NEB) and sterile dH2O to a final volume of     60 µl. The 
oligonucleotides were assembled in a ten cycle PCR reaction to create a double stranded 
DNA template using the thermocycler program: heated lid at 110°C, initial denaturation at 
95°C for 5 minutes, 10 cycles of 95°C for 30 seconds, 60°C for 45 seconds, 72°C for 45 
seconds and an additional extension at 72°C for 2 minutes in the G-Storm Thermocycler 
(model GS482, Gene Technologies Limited, Essex, UK). The reaction was purified from 
excess dNTPs and unassembled oligonucleotides using the PureLink® PCR Purification Kit 
(Invitrogen) to yield 50 μl of purified double stranded assembled PCR products.  
 
2.7.3. Amplification reaction (x25 cycles) 
Purified assembled PCR products were used as the template for the amplification PCR 
reaction (x25 cycles). Three identical reactions comprising 15 μl of assembled PCR products, 
10 µl 5x Phusion HF Buffer (NEB), 5 µl 2mM dNTPs (Invitrogen), 5 μl 10 μM        5’-Stop-NheI, 
5 μl 10 μM 3’-Stop-XhoI oligonucleotides and 0.5 µl Phusion DNA Polymerase (NEB) and 
sterile dH2O to a final volume of 50 µl was PCR amplified using the thermocycler program: 
heated lid at 110°C, initial denaturation of 95°C for 5 minutes, 25 cycles of 95°C for 30 
seconds, 60°C for 45 seconds, 72°C for 45 seconds and an additional extension at 72°C for 
136 
 
5 minutes (G-Storm Thermocycler GS482).  After PCR, the three identical reactions were 
combined and purified following two successive high cut-off PCR purification steps using the 
Binding Buffer HC provided in the PureLink® PCR Purification Kit (Invitrogen) which served as 
an alternative to gel extraction. The high cut-off property of Buffer HC eliminated PCR products 
<300 bp which included the amplification primers and failed PCR products.  
 
2.7.4. Routine digestion of Assembly PCR products 
The amplified PCR products (50 μl) were digested with 2.5 μl NheI (NEB), 2.5 μl XhoI (NEB), 
10 μl 10x NEB Buffer 2 and sterile dH2O to a final volume of 100 μl. The reaction was incubated 
at 37°C overnight, followed by a high cut-off purification using the PureLink® PCR Purification 
Kit (Invitrogen). The digested PCR products were cloned upstream of the mCMV promoter 
within the equivalent NheI/XhoI site of the pCpGmCMV cloning vector (section 2.6.2) or within 
the pCpGmCMV-Xbp cloning vectors, where X bp is the spacer length which was introduced 
to increase the spacing between the proximal TFBS and the TATA box (section 2.9.1). 
 
2.8. Assembly PCR Cloning Method: Construction of NFκB and AP-1-responsive 
promoters with increased spacing between the TFBSs  
PCR products with NFκB or AP-1 motifs, separated by varied degrees of spacing between the 
TFBSs, were generated by assembling TFBS-oligonucleotides and spacer-oligonucleotides 
with different length annealing sequences. Nine promoter libraries with a       15 bp – 60 bp 
space between the NFκB or AP-1 motifs were constructed by combining the oligonucleotides 
specified in Table 2.4 using the Assembly PCR method described in the preceding section 2.7 
(schematically presented in Fig 3.11, section 3.3.5). 
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15bp 
between 
TFBS 
20bp 
between 
TFBS 
30bp 
between 
TFBS 
35bp 
between 
TFBS 
40bp 
between 
TFBS 
45bp 
between 
TFBS 
50bp 
between 
TFBS 
55bp 
between 
TFBS 
60bp 
between 
TFBS 
Forward TFBS oligo 
30 bp annealing sequence   •      •  •  
Reverse TFBS oligo 
30 bp annealing sequence   •        
Forward TFBS oligo 
20 bp annealing sequence  •     •  •    
Reverse TFBS oligo 
20 bp annealing sequence  •         
Forward TFBS oligo 
15 bp annealing sequence •    •  •      
Reverse TFBS oligo 
15 bp annealing sequence •          
5nt spacer reverse oligo  
20 bp annealing sequence      •   •   
10nt spacer reverse oligo  
20 bp annealing sequence       •   •  
5nt spacer reverse oligo  
15 bp annealing sequence    •       
10nt spacer reverse oligo  
15 bp annealing sequence     •      
5’- Stop-NheI             
20 bp annealing sequence  •  •    •  •  •  •  
3’- Stop-XhoI             
20 bp annealing sequence  •  •    •  •  •  •  
5’- Stop-NheI             
15 bp annealing sequence •    •  •      
3’- Stop-XhoI             
15 bp annealing sequence •    •  •      
Table 2.4. List of oligonucleotides incorporated into the x10 cycle PCR reaction to generate promoters with nine 
variations of spacing between the TFBSs. The four oligonucleotides indicated by a dot were assembled in the x10 cycle PCR 
reaction to generate the specified spacing between the TFBSs. 
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2.9.  Assembly PCR Cloning Method: construction of NFκB and AP-1-responsive 
promoters with increased spacing between the proximal TFBS and TATA box 
2.9.1.  Cloning vectors: pCpGmCMV-Xbp  
The cloning vectors pCpGmCMV-Xbp, where X bp is the spacing between the proximal TFBS 
and the TATA box, were generated by initially combining 5 μl of 100 μM forward HRE-
oligonucleotide, 5 μl of 100 μM reverse HRE-oligonucleotide, 12.8 μl of 100 μM 5’-Stop-NheI 
oligonucleotide and 12.8 μl of the various 3’-Stop XhoI oligonucleotides (100 μM) listed in 
Table 2.5, in four individual reactions of 35.6 μl. All oligonucleotides contained 20 bp annealing 
sequences to generate the specific spacing between the proximal TFBS and the TATA box.  
Spacing between proximal 
TFBS and TATA box 60bp 66bp 70bp 74bp 
 
Forward TFBS oligo 
20 bp annealing sequence •  •  •  •  
Reverse TFBS oligo 
20 bp annealing sequence •  •  •  •  
5’- Stop-NheI 
20 bp annealing sequence •  •  •  •  
3’- Stop-XhoI- 0bp- SalI 
20 bp annealing sequence •     
3’- Stop-XhoI- 5bp- SalI 
20 bp annealing sequence  •    
3’- Stop-XhoI- 9bp- SalI 
20 bp annealing sequence   •   
3’- Stop-XhoI- 14bp- SalI 
20 bp annealing sequence    •  
 
 
Table 2.5. List of 3’-Stop-XhoI-oligonucleotides incorporated into the x10 cycle PCR 
reaction to generate promoters with spacing between the proximal TFBS and the TATA 
box. The four oligonucleotides indicated by a dot were assembled in the x10 cycle PCR 
reaction. The PCR products were amplified using the standard 5’-Stop-NheI and         3’-Stop-
XhoI primers in the x25 cycle PCR reaction.  
The four individual oligonucleotide mixtures were diluted 1:100 in sterile dH2O and assembled 
and amplified following the Assembly PCR protocol described in section 2.7. The resulting 
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purified PCR products contained a 5’-NheI, an internal XhoI and a 3’-SalI restriction enzyme 
site. Therefore, 50 μl PCR product was digested with 2.5 μl NheI (NEB), 2.5 μl SalI-HF (high-
fidelity, NEB), 10 μl 10x NEB Buffer 4 and sterile dH2O to a final volume of 100 μl. The reaction 
was incubated at 37°C overnight, followed by a high cut-off purification using the PureLink® 
PCR Purification Kit (Invitrogen). The NheI/SalI digested PCR products were cloned into the 
compatible NheI/XhoI site of the pCpGmCMV cloning vector (section 2.6.2) in four standard 
ligation reactions which were then transformed into chemically-competent GT115 cells from 
which the plasmid DNA constructs were isolated.  
The pCpG-Xbp cloning vectors were generated by digesting the four individual plasmid DNA 
constructs (25 μg) with 2.5 μl NheI (NEB), 2.5 μl XhoI (NEB), 10 μl 10x NEB Buffer 2 and 
sterile dH2O in a reaction volume of 100 μl. The reaction was incubated at 37°C overnight and 
the DNA fragments were separated by gel electrophoresis. The DNA was purified from 
agarose using the PureLink® Gel Extraction Kit (Invitrogen) to yield 50 μl of purified pCpG-Xbp 
cloning vectors for the Assembly PCR products (Fig 3.15, section 3.3.6).  
Table 2.6 lists the pCpG-Xbp cloning vectors used to generate the specified spacing between 
the proximal TFBS and the TATA box.  
3’-Stop- XhoI primers  
20 bp annealing sequence 
pCpGmCMV-Xbp- cloning vector 
(digested with NheI/XhoI) 
Distance between proximal TFBS 
and TATA box within the promoter 
3’-Stop- XhoI (current) pCpGmCMV 55 bp 
3’-Stop- XhoI- 0bp- SalI  pCpGmCMV-0bp 60 bp 
3’-Stop- XhoI- 5bp- SalI  pCpGmCMV-5bp 66 bp 
3’-Stop- XhoI- 9bp- SalI  pCpGmCMV-9bp 70bp 
3’-Stop- XhoI- 14bp- SalI  pCpGmCMV-14bp 74 bp 
 
Table 2.6. List of pCpGmCMV-Xbp-cloning vectors used to generate the required 
spacing between the proximal TFBS and the TATA box.  
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2.9.2. Construction of synthetic promoters with increased spacing between proximal 
TFBS and TATA box 
PCR products with NFκB or AP-1 motifs, each separated by 20 bp space, were generated 
using the Assembly PCR protocol described in section 2.7. The resulting NheI/XhoI digested 
PCR products were cloned into the equivalent site within the pCpGmCMV (section 2.6.2) or 
the pCpGmCMV-Xbp cloning vectors (section 2.9.1) to generate NFκB- and AP-1-responsive 
promoters with various degrees of spacing between the proximal TFBS and the TATA box 
(Table 2.6).  
 
2.10. Construction of pCpG-20bp-composite synthetic promoters 
The oligonucleotide mix used to construct the composite promoters included 1.6 μl  of each 
100 μM forward NFκB-, AP-1- and HRE-oligonucleotides with 1.6 μl of each 100 μM reverse 
NFκB-, AP-1- and HRE-oligonucleotides, 12.8 μl 5’-Stop-NheI and 12.8 μl 3’-Stop-XhoI 
oligonucleotides in a final volume of 35.2 μl. All oligonucleotides contained 20 bp annealing 
sequences. The oligonucleotide mix was diluted 1:100 in sterile dH2O and assembled and 
amplified using the Assembly PCR protocol (section 2.7). The resulting NheI/XhoI digested 
PCR products were cloned into the NheI/XhoI site within the pCpGmCMV-5bp cloning vector 
(section 2.9.1) to generate constructs with a 20 bp space between the TFBSs and a 66 bp 
between the proximal TFBS and the TATA box (Fig 3.20, section 3.5). 
 
2.11. Construction of pCpG-cluster composite promoters 
2.11.1. Cloning vector: pCpG-proximal TFBS cluster  
The pCpG-6NFκB-Luc+, pCpG-8AP-1-Luc+, pCpG-6HRE-Luc+ which contain 6NFκB, 8AP-1 
and 6HRE clusters and 20 bp between the TFBSs, respectively, were selected from the 
various promoters libraries in sections 2.8 and 2.9. Each construct (25 μg) was digested with 
3 μl NheI (NEB), 10 μl 10x NEB Buffer 2 and sterile dH2O to a final volume of 100 μl and 
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incubated at 37°C overnight. The linear DNA was separated by gel electrophoresis and 
purified from the agarose using the PureLink® Gel Extraction Kit (Invitrogen). The DNA was 
dephosphorylated following incubation with CIP enzyme (NEB) and subsequently purified 
using the PureLink® PCR Purification Kit (Invitrogen) to yield 50 μl of the linear cloning vectors; 
pCpG-proximal 6NFκB, pCpG-proximal 8AP-1, pCpG-proximal 6HRE (Fig 3. 23 A, section 
3.6).              
 
2.11.2.  Construction of pCpG-clustered composite promoters 
The 6NFκB, 8AP-1 and 6HRE clusters were isolated from their respective plasmid DNA 
constructs by digesting 25 μg of each construct with 2.5 μl NheI (NEB), 2.5 μl XhoI (NEB), 10 
μl 10x NEB Buffer 2 and sterile dH2O in a final volume of 100 μl and incubated at 37°C 
overnight. The DNA fragments were separated by gel electrophoresis and the 6NFκB, 8AP-1 
and 6HRE clusters were purified from the agarose using the PureLink® Gel Extraction Kit 
(Invitrogen). The concentration of the purified clusters was quantified using the Nanodrop and 
equal concentrations of NheI/XhoI digested 8AP-1 and 6HRE clusters were cloned into the 
NheI linear pCpG-proximal-6NFκB vector. Similarly, equal concentrations of 6NFκB and 6HRE 
clusters were cloned into the pCpG-proximal-8AP-1 vector and 6NFκB and 8AP-1 clusters 
were cloned into the pCpG-proximal-6HRE vector in standard ligation reactions of 20 μl. Due 
to the cloning strategy, the pCpG-clustered synthetic promoters were comprised of a minimum 
of 3 clustered TFBSs with the second cluster being cloned in the reverse orientation (Fig 3. 
23 B and C, section 3.6).              
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2.12. MiRNA-mediated regulation of gene expression  
2.12.1. Real-time qPCR: miRNA expression profiling 
2.12.1.1. Isolation of small RNA from NIH3T3 mouse embryonic fibroblasts 
Prior to RNA purification, all surfaces and equipment were cleaned with RNase AWAY® (Fisher 
Scientific Ltd, Leicestershire, UK) and gloves were changed regularly to prevent RNase 
contamination and/or RNA degradation. NIH3T3 mouse embryonic fibroblasts were 
maintained in complete DMEM medium and harvested at ~70% confluency. The cells were 
seeded at 1 x 106 cells into 10 cm2 tissue culture dishes in 10 ml complete DMEM medium. 
After 24 hours, the medium was aspirated and replaced with 10 ml of 0.5% FBS DMEM 
medium only or 0.5% FBS DMEM medium containing 50 ng/ml mouse IL-17A or 10 ng/ml 
TNFα or a combination of 50 ng/ml mIL-17A with 10 ng/ml TNFα for 18 hours. Post-incubation, 
the cells were washed with 1 ml sterile PBS and the RNA fraction enriched with small RNA 
species was isolated using the mirVANATM miRNA Isolation Kit (Ambion/Applied Biosystems, 
Texas, USA), following the manufacturer’s instructions.  
The PBS was carefully removed from the cells and the dish was then placed on ice. The cells 
were lysed with 600 µl Lysis/Binding Solution and the lysates were collected using a sterile 
rubber policeman and transferred into a 1.6 ml Eppendorf tube. The tubes were briefly 
vortexed to completely lyse the cells and 1/10th of the lysate volume of miRNA Homogenate 
Additive was added to the cell lysate, vortexed and incubated on ice for 10 minutes. Acid 
Phenol: Chloroform was added in a volume equal to that of the original lysate volume, and 
vortexed for 1 minute. Following centrifugation at 10,000 g for 5 minutes at room-temperature 
(Eppendorf microcentrifuge 5415D), the aqueous phase was transferred into a new sterile 1.6 
ml Eppendorf tube. The resulting semi-pure RNA sample was then purified using the glass-
fiber filter method, where a third of the volume of 100% ethanol was added to the aqueous 
phase, briefly vortexed and then transferred onto the filter cartridge. The lysate/ethanol sample 
was then passed through the filter cartridge by centrifugation at 10,000 g for 15 seconds and 
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the filtrate was collected and measured and two-thirds volume of 100% ethanol was added to 
the filtrate, briefly vortexed and passed through a second filter cartridge. The sample was 
centrifuged at 10,000 g for 15 seconds and the flow-through was discarded. The step was 
repeated until the entire sample had been filtered. Following successive washes with Wash 
Solutions 1 and 2/3, respectively, the filter was transferred into a fresh collection tube. The 
RNA was eluted with 100 µl of pre-heated (95°C) nuclease-free water and centrifuged at 
maximum speed for 30 seconds to yield a 100 µl small RNA-containing eluate. The RNA 
concentration (ng/μl) was quantified using the Nanodrop spectrophotometer.  
 
2.12.1.2. cDNA Synthesis 
Small RNA was used as a template to synthesise cDNA using the QuantiMir RT Kit Small RNA 
Quantitation System (Systems Biosciences, California, USA). The polyA tail was added to the 
RNA template in a reaction comprising 10 ng small RNA, 2 µl 5x PolyA Buffer, 1 µl     25 mM 
MnCl2, 1.5 µl 5 mM ATP, 0.5 µl PolyA Polymerase and RNase-free H2O in a final volume of 
10 μl and incubated at 37°C for 30 minutes. After incubation, 0.5 µl Oligo dT Adaptor was 
added to the reaction and incubated for 5 minutes at 60°C and then cooled at room 
temperature for 2 minutes. The final cDNA synthesis step involved the addition of 4 µl 5x RT 
Buffer, 2 µl dNTP mix, 1.5 µl 0.1M DTT, 1.5 µl RNase-free H2O and 1 µl Reverse Transcriptase 
and incubation at 42°C for 60 minutes and 95°C for 10 minutes. The cDNA samples were 
stored at -20°C.  
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2.12.1.3. Preparation of miRNA standards using end-point PCR 
The sequences of mature miR-23b and the control miR-17-5p, miR-103-3p and miR-191-5p 
sequences were obtained from the miRBase database (www.mirbase.org) and synthesised 
as desalted oligonucleotides from Sigma-Aldrich (Table 2.7) to serve as forward PCR primers. 
The control miR-16-5p and U6 forward PCR primers were supplied with the QuantiMir Kit.  
 PCR primer sequences (5’-3’) 
Forward hsa-miR-23b-3p primer 5’- ATCACATTGCCAGGGATTACC -3’ 
Forward hsa-miR-17-5p control primer 5’- CAAAGTGCTTACAGTGCAGGTAG -3’ 
Forward hsa-miR-103-3p control primer 5’- AGCAGCATTGTACAGGGCTATGA -3’ 
Forward hsa-miR-191-5p control primer 5’- CAACGGAATCCCAAAAGCAGCTG -3’ 
Forward hsa-miR-16-5p control primer 5’- TAGCAGCACGTAAATATTGGCG -3’ 
Forward hsa-U6 control primer 5’- CGCAAGGATGACACGCAAATTC -3’ 
 
Table 2.7. Forward PCR primers of miRNAs. Forward PCR primers anneal to the mature 
candidate miRNA in cDNA samples.  
 
Each PCR primer was resuspended at 10 μM in sterile TE buffer and the cDNA samples were 
diluted 1:50 in nuclease-free water. The miRNAs listed in Table 2.7 were amplified from the 
unstimulated cDNA sample in an end-point PCR reaction to generate the miRNA standards 
for the subsequent Real-time qPCR reaction. Briefly, the diluted cDNA (1 μl) was added to 1 
μl 10 μM forward miRNA primer, 1 μl 10 μM Universal Reverse Primer (QuantiMir kit), 2 μl 
2mM dNTPs, 4 μl 5x Phusion HF Buffer, 0.5 μl Phusion DNA polymerase and nuclease-free 
water in a final volume of 20 μl, of six individual reactions for each miRNA. The PCR reaction 
proceeded with a heated lid at 110°C, initial denaturation at 98°C for 5 minutes followed by 30 
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cycles of 98°C for 10 seconds, 60°C for 60 seconds, 72°C for 30 seconds and a final extension 
at 72°C for 10 minutes (G-Storm Thermocycler GS482). The PCR reactions (20 μl) were 
separated on a 2.0% low melting agarose gel (Promega) and the PCR products (~68 bp) were 
excised from the gel using the PureLink® Quick Gel Extraction Kit (Invitrogen).  
The NanoDrop spectrophotometer was used to quantify the concentration of the purified PCR 
products (ng/μl) and the following calculation was used to calculate the copy number of each 
miRNA in their corresponding PCR products (1010g/μl), where A = concentration of the PCR 
product: 
Copy of each miRNA (1010 g/μl) = (A x 10-9 x (6.02 x 1023)) / (660 x (PCR product size))  
The following calculation was used to determine the initial volume of PCR product required to 
make the first serial dilution of 0.5 x 109 miRNA copies/μl standard sample: 
Volume of PCR product (μl) = ((0.5 x 109) x 100) / (copy number of miRNA) 
The first serial dilution of 0.5 x 109/μl standard sample was prepared by diluting the calculated 
volume of PCR product (μl) in 5 μg/ml tRNA in a total volume of 100 μl. Following a brief 
vortex, 5 μl of the diluted PCR product was further diluted in 45 μl tRNA in a total volume of 
50 μl to generate the 0.5 x 108 standard. The preceding standard was further diluted by 
combining 5 μl of 0.5 x 108/μl standard sample with 45 μl tRNA in a total volume of 50 μl to 
generate the 0.5 x 107/μl standard sample. This process was continued until serial dilutions to 
0.5 x 101/μl standard sample was prepared for each miRNA.  
 
 
 
2.12.1.4. Absolute quantification of miRNA expression using Real-time qPCR 
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Absolute Real-time quantitative PCR was used to quantify the copy number of miR-23b and 
the control miR-17-5p, miR-103-3p, miR-191-5p, miR-16-5p and U6 in unstimulated,       mIL-
17A, TNFα and mIL-17A + TNFα–stimulated cDNA from NIH3T3 cells. The 384       well-plate 
setup was performed using the ABI 7900 Sequence Detection System 2.4 (Applied 
Biosystems, Life Technologies Corp, California, USA) and the reactions were performed using 
the Applied Biosystems 7900HT Fast Real-time PCR System. 
Each reaction comprised 1 µl cDNA (unstimulated and stimulated cDNA diluted 1:50), 0.4 µl 
of 10 μM Universal Reverse Primer (QuantiMir), 0.4 µl of each 10 μM miRNA forward primer, 
5 µl of 2x Brilliant III qPCR Ultra-Fast SYBR® Green qPCR Master mix (600882; Agilent 
Technologies, CA, USA), 0.15 μl of 20 μM Rox reference dye (Agilent) and RNase-free water 
to a final volume of 10 µl.  
The reactions required to generate the standard curve comprised 1 μl of each standard 
(0.5x107 – 0.5 x 101 copies/μl), 0.4 µl of 10 μM Universal Reverse Primer (QuantiMir), 0.4 µl 
of each miRNA forward primer, 5 µl of 2x Brilliant III qPCR Ultra-Fast SYBR® Green qPCR 
Master mix (Agilent), 0.15 μl of 20 μM Rox reference dye (Agilent) and RNase-free water to a 
final volume of 10 µl.  
The no-template control (NTC) reaction comprised 1 μl of 5μg/ml tRNA, 0.4 µl of 10 μM 
Universal Reverse primer (QuantiMir), 0.4 µl of each 10 μM miRNA forward primer, 5 µl         2x 
Brilliant III qPCR Ultra-Fast SYBR® Green qPCR Master mix (Agilent), 0.15 μl of 20 μM Rox 
reference dye (Agilent) and RNase-free water to a final volume of 10 µl. 
The reactions were performed using the thermocycler program: stage 1 incubation at 60°C for 
2 minutes, stage 2 incubation at 95°C for 3 minutes, stage 3 with 40 cycles of 95°C for     5 
seconds, 60°C for 15 seconds, and stage 4 incubation at 95°C for 15 seconds, 60°C for 15 
seconds and 95°C for 15 seconds.  
2.12.1.5. Real-time qPCR data analysis and normalisation  
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The PCR data which included the standard curve plots, amplification plots, and dissociation 
curves was analysed using the SDS 2.4 Software (Applied Biosystems) and presented in 
Appendix 15. The copy numbers of each miRNA in the unstimulated and stimulated cDNA 
samples were calculated by comparing the cycle threshold (Ct) values to the standard curve 
for the corresponding miRNA. The copy numbers of the five control miRNAs quantified in each 
cDNA sample was entered into the Excel Add-In NormFinder Algorithm (Andersen et al., 2004) 
which identified the optimal normalisation miRNA among the set of candidates by evaluating 
the overall expression variability of the candidate normalisation miRNAs and also the variation 
between sample subgroups of the sample set. Due to low expression variability, miR-191 was 
selected as the ‘best normaliser’. The miR-23b copy numbers in each cDNA sample was 
normalised to the miR-191 copy numbers in the same samples by dividing the miR-23b copy 
number by the calculated miR-191 normalisation factors.   
 
2.12.2.    Construction of pcLuc+-miR-23b-target expression vectors 
2.12.2.1. Cloning vector: pcLuc+ 
The pcLuc+ expression vector (25 μg) (Gould et al., 2004) was digested with 2.5 μl XbaI (NEB), 
2.5 μl ApaI (NEB), 10 μl 10x NEB Buffer 4 and sterile dH2O to a final volume of 100 μl and 
incubated at 25°C for 16 hours for optimal ApaI activity and then at 37°C for 5 hours for optimal 
XhoI activity. The DNA fragments were separated by gel electrophoresis and purified from the 
agarose using the PureLink® Gel Extraction Kit (Invitrogen) to yield 50 μl of pcLuc+ cloning 
vector (Fig 6.2 A, section 6.1.1).  
 
 
 
2.12.2.2. pcLuc+-miR-23b-target expression vectors 
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The miR-23b-target oligonucleotides containing two miR-23b target sites were synthesised 
with 5’-CTAG and 3’-ApaI overhangs and internal XbaI and EcoRI restriction enzyme sites 
from Sigma-Aldrich (Table 2.8) and resuspended at 2mg/ml in sterile TE buffer.  
 Cloning oligonucleotide sequences (5’-3’) 
 
Forward hsa-miR-23b-3p 
cloning oligo 
 
5’-CTAGGGTAATCCCTGGCAATGTGATCGATGGTAATCCCTGGCA 
ATGTGATTCTAGAATTCGGGCC-3’ 
Reverse hsa-miR-23b-3p 
cloning oligo 
5’-CGAATTCTAGAATCACATTGCCAGGGATTACCATCGATCACATT 
GCCAGGGATTACC-3’ 
 
Table 2.8. Sequences of miR-23b target oligonucleotides. Oligonucleotides were HPLC 
purified. Overhangs are underlined and miR-23b target sites are highlighted in bold.  
 
Forward and reverse miR-23b-oligonucleotides were annealed using the boiling method and 
cloned into the compatible XbaI/ApaI site within the pcLuc+ cloning vector to create         pcLuc+-
miR-23b-2T, in a standard ligation reaction (Fig 6.2 B, section 6.1.1). The pcLuc+-miR-23b-4T 
constructs with four miR-23b target sequences were generated by digesting     25 μg pcLuc+-
miR-23b-2T with XbaI and ApaI and cloning a second miR-23b-target oligonucleotides into 
the equivalent site, using the same method described above. Standard ligation reactions of 
20 μl were transformed into DH5α E.coli cells and the DNA was isolated from positive colonies 
using the routine plasmid DNA purification protocols. Correct construction of recombinant DNA 
was verified by restriction enzyme digestion using EcoRI (Fig 6.2 D, section 6.1.1) and DNA 
sequencing using the End of Luc+ forward sequencing primer (Appendix 12.1 and 12.2).  
 
 
2.12.3.    Construction of pCpG-6NFκB-miR-23b-2T expression vector  
2.12.3.1. Cloning vector: 6NFκB-Luc+ 
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The pCpG-6NFκB-Luc+ construct (25 μg) was digested with 2.5 μl PpumI (NEB) and 2.5 μl 
FseI (NEB), 10 μl 10x NEB Buffer 4 and sterile dH2O to a final volume of 100 μl and incubated 
at 37°C overnight. The DNA fragment containing the 6NFκB synthetic promoter and the 5’-
portion of the luciferase gene were separated by gel electrophoresis and purified from the 
agarose using the PureLink® Gel Extraction Kit (Invitrogen) to yield 50μl of the 6NFκB-Luc+ 
cloning vector (Fig 6.9 A, section 6.6).  
 
2.12.3.2. pCpG-6NFκB-miR-23b-2T expression vector  
The 3’-portion of the luciferase gene and two miR-23b target sites were PCR amplified from 
the pcLuc+-miR-23b-2T construct using the PCR primers listed in Table 2.9. 
 
Table 2.9. PCR primers used to amplify miR-23b-2T from the pcLuc+-miR-23b-2T 
construct. PCR primers were synthesised by Sigma-Aldrich and resuspended to 10 μM. The 
FseI restriction enzyme site within the reverse PCR primer is underlined. 
 
The PCR product was digested with 2.5 μl PpumI (NEB) and 2.5 μl FseI (NEB), 10 μl 10x NEB 
Buffer 4 and sterile dH2O to a final volume of 100 μl and incubated at 37°C overnight and then 
purified using the PureLink® PCR Purification Kit (Invitrogen) (Fig 6.9 B, section 6.6). The PCR 
product, containing PpumI and FseI overhangs, was cloned into the equivalent site within the 
6NFκB-Luc+ cloning vector to create the 6NFκB-Luc+-miR-23b-2T construct (Fig 6.9 C, section 
6.6).   
2.12.4. Transfection of miRNA mimics 
 PCR primer sequences (5’-3’) 
Forward FseI PCR primer 5’-AGCGGTTGCCAAGAGGTTCCATCTGCCA-3’ 
Reverse FseI PCR primer 5’-ATGTCACGTAGGCCGGCCCGAATTCTAG-3’ 
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The regulation of luciferase mRNA expressed from pcLuc+-miR-23b-target constructs by the 
miR-23b was verified by co-transfecting the cells with the pcLuc+-miR-23b-target constructs 
and the synthetic miRNA mimics. Briefly, 3.2 x 104 293T cells were seeded on a 48-well plate 
with 200 μl of antibiotic-free 10% FBS DMEM medium. After 24 hours, 0.5 µl Lipofectamine® 
2000 transfection reagent (Invitrogen) was diluted in 25 μl Opti-MEM I reduced serum medium 
(Invitrogen), briefly vortexed and incubated for 5 minutes at room temperature. Following the 
incubation, a DNA mixture of 90 ng pcLuc+-miR-target DNA,     10 ng pRL-CMV and 1 µM 
miRNA mimic was diluted in Opti-MEM I reduced serum medium in a total volume of 25 μl, 
which was subsequently added to the diluted Lipofectamine®, briefly vortexed and incubated 
for a further 20 minutes at room temperature. The 50 μl DNA:miRNA mimic:Lipofectamine® 
complex was added to the cells in a drop-wise manner and the cells were incubated under 
standard conditions for 24 hours. The firefly and renilla luciferase expression was quantified 
using the Luciferase Assay System (Promega) and Renilla Luciferase Assay System 
(Promega), respectively, and the firefly luciferase expression was normalised to the renilla 
luciferase expression.  
 
2.13.   Lentiviral expression vector constructs  
2.13.1. Cloning vector: pLV.CMV 
The SIN lentiviral plasmid pLV.CMVenh.gp91.eGFP.cHS4, containing the eGFP reporter gene 
driven by the CMV promoter, positioned between cHS4 insulators, was purchased from 
Addgene (www.addgene.org; plasmid 30471; Barde et al., 2011) as a bacterial stab and 
renamed pLV.CMV.GFP for simplification. A sterile glass rod was inserted into the bacterial 
stab and the culture was streaked on a fresh LB-agar plate containing 100 μg/ml Carbenicillin. 
The plate was incubated at 37°C overnight after which a single bacterial colony was inoculated 
in 5 ml of LB media containing 100 μg/ml Carbenicillin and incubated overnight at 37°C, with 
shaking at 225 rpm. A maxiprep preparation was subsequently setup and the lentiviral plasmid 
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pLV.CMV.GFP was isolated using the PureLink® HiPure Plasmid DNA Purification Kit 
(Invitrogen).  
pLV.CMV.GFP (25 μg) was digested with 2.5 μl BamHI, 2.5 μl SalI, 10 µl 10x NEB Buffer 4 
and sterile distilled water in a total volume of 100 μl and incubated at 37°C overnight. The 
DNA fragments were separated by gel electrophoresis and the 8357 bp fragment was isolated 
using the PureLink® Quick Gel Extraction Kit (Invitrogen) to yield 50 µl of purified pLV.CMV 
cloning vector (Fig 4.1.1 A, section 4.1.1).    
 
2.13.2. Oligonucleotides for cloning the lentiviral vector constructs 
The PCR primers were synthesised as desalted oligonucleotides with specified 5’- and 3’-
restriction enzymes sites, at Sigma-Aldrich (Table 2.10). PCR primers were resuspended at 
100 μM in sterile TE buffer. The HPLC purified mCMV cloning oligonucleotides were 
synthesised with 5’- SnaBI and 3’-BamHI overhangs, at Sigma-Aldrich (Table 2.10). The 
forward and reverse mCMV oligonucleotides were resuspended at 2 mg/ml in TE buffer and 
annealed using the boiling method, as previously described in section 2.3.1 
 DNA Sequence (5’-3’) 
Forward Luciferase 
BamHI primer 5’- GATGAGCAGGATCCCATGGAAGACG -3’ 
Reverse Luciferase    
SalI primer 5’- ATGTACGCGTCGACTCTAGAATTAC -3’ 
Forward pCpGmCMV 
ClaI primer 5’- GTCGGATTATCGATGCTAGCGTGCC -3’ 
Forward pGL3mCMV 
and mCMV ClaI primer 5’- GTCGGATTATCGATGCGTGCTAGC -3’ 
Reverse all constructs    
BstBI primer 5’- ACTCGTAGTTCGAAGTACTCAGCGT -3’ 
Forward hIL-1Ra   
BamHI primer 5’- GATGAGCAGGATCCATGGAAATCTGCAGAGGC -3’ 
Reverse hIL-1Ra       
SalI primer 5’- ATGTACGCGTCGACCTACTCGTCCTCCTGGAA -3’ 
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Forward mTNFRII-Fc 
BamHI primer 5’- GATGAGCAGGATCCATGTACAGGATGCAACTC -3’ 
Reverse  mTNFRII-Fc 
XhoI primer 5’- ATGTACGCCTCGAGTCATTTACCAGGAGAGTG -3’ 
Forward pCpGmCMV 
SnabI primer 5’- TCGGATTTACGTAGGCCAGCTAG -3’ 
Reverse pCpGmCMV 
BamHI primer 5’- ATGTACGCGGATCCTGAGCTCTGCTTATATAA -3’ 
Forward mCMV SnabI 
overhang cloning oligo 5’- GTAGCCTGTAGGCGTGTACGGTGGGAGGCTTATATAAGCAGAGCTCG -3’ 
Reverse mCMV BamHI 
overhang cloning oligo 5’- GATCCGAGCTCTGCTTATATAAGCCTCCCACCGTACACGCCTACAGGCTAC -3’ 
Forward SFFV 
promoter SnabI primer 5’- GATGAGCATACGTA AATTCCTGCAGCCCCGAT -3’ 
Reverse SFFV 
promoter BamHI primer 5’- ATGTACGCGGATCCGGTGGCTTTACCAACAGT -3’ 
Forward lenti-miRNA      
MfeI primer  5’- CGTTAGCCAATTGGTAATTCTAG -3’ 
Reverse lenti-miRNA 
KpnI primer 5’- GGTGGATGGTACCGAATAGGGCCC -3’ 
 
Table 2.10. List of oligonucleotides used to construct the lentiviral expression 
cassettes. PCR primers and oligonucleotides were synthesised by Sigma-Aldrich. Underlined 
sequences indicate the candidate restriction enzyme site or overhang.  
 
2.13.3. Cloning vector: pLV.Luc+ 
The pGL3mCMV plasmid was diluted to 10 ng/μl and the luciferase gene was PCR amplified 
using forward and reverse primers with BamHI and SalI restriction enzyme sites, respectively 
(Table 2.10). The reaction comprised 1 μl of diluted pGL3mCMV, 2.5 μl 10 μM BamHI forward 
primer, 2.5 μl 10 μM SalI reverse primer, 5 μl 2 mM dNTPs, 10 μl 5x Phusion HF Buffer, 0.5 
μl Phusion DNA Polymerase and nuclease-free water in a total reaction volume of 50 μl. The 
reaction was performed using the thermocycler program: heated lid at 110°C, initial 
denaturation at 98°C for 5 minutes, 30 cycles at 98°C for 10 seconds, 60°C for 30 seconds, 
72°C for 30 seconds and a final extension at 72°C for 5 minutes.  
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The luciferase PCR product of 1656 bp was verified by gel electrophoresis and purified using 
the PureLink® PCR Purification Kit (Invitrogen). The purified PCR product (50 μl) was digested 
with 2.5 μl BamHI, 2.5 μl SalI, 10 µl 10x NEB Buffer 4 and sterile dH2O in a total volume of 
100 μl and incubated at 37°C overnight (Fig 4.1.1 B, section 4.1.1). The digested luciferase 
PCR product was cloned into the pLV.CMV cloning vector in a ligation reaction of 20 μl which 
was subsequently transformed into chemically-competent DH5α cells and the plasmid DNA 
was purified from positive bacterial transformants using the routine methodology described in 
section 2.3. The resulting purified DNA was referred to as pLV.CMV.Luc+. 
The CMV promoter and the 5’-portion of the luciferase gene was removed from the 
pLV.CMV.Luc+ construct by digesting 25 μg pLV.CMV.Luc+ with 2.5 μl PmeI, 2.5 μl BstBI,     10 
µl 10x NEB Buffer 4 and sterile dH2O in a total volume of 100 μl, which was incubated at 37°C 
for 12 hours for optimal PmeI activity and then at 65°C for 4 hours for optimal BstBI activity. 
The DNA fragments were separated by gel electrophoresis and the 7882 bp fragment was 
isolated from agarose using the PureLink® Quick Gel Extraction Kit (Invitrogen). The resulting 
purified pLV.Luc+ served as the cloning vector for the lentiviral synthetic promoters (Fig 4.1.1 
C, section 4.1.1).  
2.13.4. Construction of LV-composite synthetic promoters expressing luciferase  
The candidate pGL3-composite promoter and pCpG-composite promoter plasmid DNA were 
diluted to 10 ng/μl and the synthetic promoter and 5’- portion of the luciferase gene was PCR 
amplified from each construct using forward and reverse PCR primers with ClaI and BstBI 
restriction enzyme sites, respectively (Table 2.10). The reaction comprised 1 μl of diluted 
plasmid DNA, 2.5 μl 10 μM ClaI forward primer, 2.5 μl 10 μM BstBI reverse primer, 5 μl        2 
mM dNTPs, 10 μl 5x Phusion HF Buffer, 0.5 μl Phusion DNA Polymerase and nuclease-free 
water in a total reaction volume of 50 μl. The reaction was performed using the thermocycler 
program: heated lid at 110°C, initial denaturation at 98°C for 5 minutes, 30 cycles at 98°C for 
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10 seconds, 60°C for 30 seconds, 72°C for 30 seconds and a final extension at 72°C for 5 
minutes.  
The PCR products were purified using the PureLink® PCR Purification Kit and 50 μl of purified 
DNA was digested with 2.5 μl ClaI, 10 µl 10x NEB Buffer 4 and sterile distilled water in a total 
reaction volume of 100 μl and incubated at 37°C overnight. The DNA was purified using the 
PureLink® PCR Purification Kit and the ends of the DNA were blunted by incubating 50 μl 
purified DNA with 3 μl Klenow (NEB), 10 μl 10x NEB Buffer 2, 10 μl 2 mM dNTPs and sterile 
dH2O in a final reaction volume of 100 μl at 25°C for 15 minutes. The reaction was terminated 
by adding a final concentration of 10 mM EDTA to the reaction and heat inactivating the 
Klenow enzyme at 75°C for 20 minutes. The reaction was purified using the PureLink® PCR 
Purification Kit and 50 μl of purified DNA was digested with 2.5 μl BstBI, 10 µl 10x NEB Buffer 
4 and sterile dH2O in a reaction volume of 100 μl and incubated at 65°C overnight and then 
purified again. The PCR products with 5’-blunt ends and 3’-BstBI overhangs were cloned into 
the PmeI (blunt) and BstBI site within the pLV.Luc+ cloning vector in a standard ligation 
reaction, which restored the luciferase gene and incorporated the candidate synthetic 
promoters into the lentiviral vector. Following the transformation of DH5α cells, the DNA 
purified from positive colonies were referred to as LV- x -Luc+, where x is the designated 
number of the synthetic promoter, e.g. LV-2-Luc+ (Fig 4.1.1 D and E, section 4.1.1). 
 
2.13.5. Construction of LV-SFFV-Luc+  
The pUCL-Luc+ plasmid DNA was obtained from Professor Adrian Thrasher, Great Ormond 
Street, UK (Demaison et al., 2002). The constitutive SFFV promoter and the 5’-portion of the 
luciferase gene was isolated from pUCL-Luc+ by digesting 25 μg DNA with 2.5 μl EcoRI,     10 
µl 10x NEB Buffer 4 and sterile dH2O in a total volume of 100 μl. The reaction was incubated 
at 37°C for 12 hours and then purified using the PureLink® PCR Purification Kit (Invitrogen). 
The ends of the DNA were blunted using Klenow enzyme and purified again. The purified DNA 
(50 μl) was digested with 2.5 μl BstBI, 10 µl 10x NEB Buffer 4 and sterile dH2O in a reaction 
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volume of 100 μl and incubated at 65°C overnight and then purified again. The DNA fragments 
were separated on an agarose gel and the 730 bp DNA fragment was isolated and purified 
using the PureLink® Gel Extraction Kit (Invitrogen). The SFFV-Luc+ fragment was cloned into 
the pLV.Luc+ vector in a standard ligation reaction to restore the luciferase gene and 
incorporate the SFFV promoter into the lentiviral vector. The DNA purified from positive 
bacterial transformants was referred to as LV-SFFV-Luc+ (Fig 4.1.2, section 4.1.2). 
 
2.13.6. Cloning vectors: pLV.CMV.hIL-1Ra and pLV.CMV.mTNFRII-Fc 
The therapeutic genes hIL-1Ra and mTNFRII-Fc were amplified from pcIL-1Ra and pFuse-
mTNFRII-Fc DNA using PCR primers with BamHI and SalI restriction enzyme sites or BamHI 
and XhoI restriction enzyme sites, respectively (Table 2.10). The two individual reactions 
comprised 1 μl of the diluted respective insert DNA (10 ng/μl), 2.5 μl 10 μM BamHI forward 
primer, 2.5 μl 10 μM reverse primer (reverse hIL-1Ra SalI primer or reverse mTNFRII-Fc XhoI 
primer) 5 μl 2 mM dNTPs, 10 μl 5x Phusion HF Buffer, 0.5 μl Phusion DNA Polymerase and 
nuclease-free water in a total volume of 50 μl. The reaction was performed using the 
thermocycler program: heated lid at 110°C, initial denaturation at 98°C for 5 minutes, 30 cycles 
at 98°C for 10 seconds, 60°C for 30 seconds, 72°C for 30 seconds and a final extension at 
72°C for 5 minutes (G-Storm Thermocycler GS482). The correct sizes of PCR products were 
verified by gel electrophoresis and purified using the PureLink® PCR Purification Kit 
(Invitrogen). The purified DNA (50 μl) was digested with 2.5 μl BamHI, 2.5 μl SalI for hIL-1Ra 
(or 2.5 μl XhoI for mTNFRII-Fc), 10 µl 10x NEB Buffer 4 and sterile dH2O in a total volume of 
100 μl and incubated at 37°C overnight. The digested and purified PCR products were cloned 
into the BamHI/SalI site within the pLV.CMV cloning vector in a standard ligation reaction and 
the subsequent purified maxiprep DNA from positive DH5α transformants were named 
pLV.CMV.hIL-1Ra or pLV.CMV.mTNFRII-Fc. Each DNA construct (25 μg) was subsequently 
digested with 2.5 μl PmeI, 2.5 μl BamHI, 10 µl 10x NEB Buffer 4 and sterile dH2O in a total 
volume of 100 μl and incubated at 37°C overnight. The DNA fragments were separated by 
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agarose gel electrophoresis and the pLV.hIL-1Ra fragment (6931 bp) and the pLV.mTNFRII-
Fc fragment (7756 bp) were isolated and purified from agarose using the PureLink® Gel 
Extraction Kit (Invitrogen) to generate the pLV.hIL-1Ra and pLV.mTNFRII-Fc cloning vectors, 
respectively (Fig 5.1 B-E, section 5.1.1). 
 
2.13.7. Construction of LV- synthetic promoters expressing hIL-1Ra or mTNFRII-Fc 
The candidate synthetic promoters and SFFV promoter were PCR amplified from their 
corresponding pCpG-constructs and pUCL-Luc+ DNA respectively, using primers with SnaBI 
and BamHI restriction enzyme sites (Table 2.10). The PCR reaction comprised 1 μl of diluted 
plasmid DNA (10 ng/μl), 2.5 μl 10 μM SnaBI forward primer, 2.5 μl 10μM BamHI reverse 
primer, 5 μl 2 mM dNTPs, 10 μl of 5x Phusion HF Buffer, 0.5 μl of Phusion DNA Polymerase 
and nuclease-free water in a total reaction volume of 50 μl. The reaction was performed using 
the thermocycler program: heated lid at 110°C, initial denaturation at 98°C for 5 minutes, 30 
cycles at 98°C for 10 seconds, 60°C for 30 seconds, 72°C for 30 seconds and a final extension 
at 72°C for 5 minutes. The purified DNA (50 μl) was digested with       2.5 μl SnaBI, 2.5 μl 
BamHI, 10 µl 10x NEB Buffer 4 and sterile dH2O in a total volume of    100 μl and incubated 
at 37°C overnight. The digested and purified PCR products were cloned into the compatible 
PmeI/BamHI site within the pLV.hIL-1Ra and pLV.mTNFRII-Fc cloning vectors to generate 
the pLV.x.hIL-Ra and pLV.x.mTNFRII-Fc constructs respectively, where x is the designated 
number of the candidate synthetic promoter or the SFFV promoter (Fig 5.1 F-J, section 5.1.1). 
 
2.13.8. Cloning vector: pLV.SFFV.Luc+  
The pLV.SFFV.Luc+ DNA (25 μg) was digested with 2.5 μl EcoRI, 2.5 μl KpnI-HF, 10 µl 10x 
NEB Buffer 4 and sterile dH2O in a total volume of 100 μl and incubated at 37°C overnight. 
The SFFV fragment was excised and purified from the agarose gel following electrophoresis 
to serve as the pLV.SFFV.Luc+ cloning vector (Fig 6.6 A, section 6.5.1). 
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2.13.9. Construction of lentiviral-miR-23b cassettes 
The pcLuc+-miR-23b-2T and pcLuc+-miR-23b-4T plasmid DNAs were diluted to 10ng/μl and 
the miR-23b-target sites were PCR amplified using primers with MfeI and KpnI restriction 
enzyme sites. The individual reactions comprised 1 μl of each diluted DNA, 2.5 μl 10μM MfeI 
forward primer, 2.5 μl 10 μM KpnI reverse primer, 5 μl 2 mM dNTPs, 10 μl of 5x Phusion HF 
Buffer, 0.5 μl of Phusion DNA Polymerase and nuclease-free water in a total reaction volume 
of 50 μl. The reaction was performed using the thermocycler program: heated lid at 110°C, 
initial denaturation at 98°C for 5 minutes, 30 cycles at 98°C for 10 seconds, 50°C for 60 
seconds, 72°C for 30 seconds and a final extension at 72°C for 10 minutes. The purified DNA 
(50 μl) was digested with 2.5 μl MfeI, 2.5 μl KpnI, 10 µl 10x NEB Buffer 4 and sterile distilled 
water in a total volume of 100 μl and incubated at 37°C overnight. The digested and purified 
PCR products were cloned into the compatible EcoRI/KpnI site within the pLV.SFFV.Luc+ 
cloning vector to generate LV-SFFV-miR-23b-2T and LV-SFFV-miR-23b-4T (Fig 6.6 B and C, 
section 6.5.1). 
 
2.14.    Production and titration of lentiviral particles 
2.14.1. Production of VSV-G pseudotyped lentiviral particles 
All lentiviral work was performed following the safety guidelines of Queen Mary University and 
experiments were conducted in a designated lentivirus room using a ScanLaf Mars Safety 
Class 2 Hood. The recombinant lentiviral particles (LPs) were produced using a three-plasmid 
transient co-transfection into 293T cells which included the constructed recombinant lentiviral 
transfer plasmids, the gag-pol encoding packaging plasmid pCMVΔR8.2 (kindly provided by 
Inder Verma, Salk Institute, La Jolla, CA; Naldini et al., 1996b) and the vesicular-stomatitis 
virus glycoprotein (VSV-G) envelope encoding plasmid pMD.G (Naldini et al., 1996a). Prior to 
the day of transfection, 9 x 106 293T cells were seeded in 30 ml complete DMEM medium in 
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a 15 cm2 tissue culture dish and incubated overnight at 37°C in 5% CO2. After 24 hours, a 
DNA solution was prepared by combining 18 μg transfer plasmid, 18 μg pCMVΔR8.2, 4 μg 
pMD.G with OptiMEM medium (Invitrogen) to a final volume of 1 ml. Polyethyleneimine (PEI; 
Sigma-Aldrich) was diluted by combining      200 μl PEI and 800 μl of OptiMEM medium. The 
DNA:PEI complex was formed by incubating the DNA solution with the diluted PEI for 10 
minutes at room temperature. One hour before transfection, a final concentration of 25 μg/ml 
chloroquine was added to the cells to inhibit DNA degradation by lysosomes thereby improving 
the transfection efficiency. Subsequently, the transfection mix (2 ml) was added in a drop-wise 
manner to the 293T cells and incubated at 37°C in 5% CO2. After 16 hours, the medium was 
carefully removed from the cells and discarded in diluted Virkon® disinfectant and 30 ml of 
complete DMEM medium was added to the cells. Following 72 hours post-transfection, the 
medium containing the packaged LPs was collected and the cell debris was removed from the 
medium by filtration through a 0.45 μM low protein binding filter (Fisher Scientific) and 
transferred into a centrifuge tube. The LPs were concentrated and collected by 
ultracentrifugation in a Beckman XL-90 Ultracentrifuge at 23,000 rpm for 2 hours at 4°C. The 
LP pellets were resuspended in 300 μl of DMEM medium (alone), aliquoted in 20 μl volumes 
in sterile cryovials and then rapidly stored at -80°C until further use. 
 
 
 
 
2.14.2. Lentiviral particle titration: p24 ELISA assay 
The Lenti-X™ p24 Rapid Titer Kit (Clontech Laboratories, CA, USA) was used to quantify the 
p24 antigen in the concentrated lentiviral preparations as per the manufacturer’s instructions. 
Briefly, the LPs were diluted 1:20,000 in DMEM and a series of five p24 standard dilutions 
were generated from 200 pg/ml -12.5 pg/ml.  Lysis buffer (20 μl) was added to each anti-p24 
coated well. A volume of 200 μl of diluted lentivirus, each standard curve dilution and DMEM 
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medium (negative control) was dispensed into each well, and incubated at 37°C for 60 
minutes. The contents of the wells were aspirated and manually washed six times with 1x 
Wash Buffer (provided in the kit as 20x Wash Buffer) and thoroughly dried by firmly inverting 
the plate on an absorbent paper towel. The wells were incubated with 100 μl anti-p24 biotin 
conjugated detection antibody at 37°C for 60 minutes after which the contents of the wells 
were removed. The wells were washed and dried as previously described and 100 μl 
Streptavidin-HRP conjugate was dispended into the wells and incubated at room temperature 
for 30 minutes. Following the subsequent removal of the well contents, washing and drying of 
the wells, 100 μl of Substrate Solution was immediately dispensed into the wells and incubated 
at room temperature for 20 minutes. The reaction was stopped by adding 100 μl of Stop 
Solution to each well and the absorbance values were immediately read at 450 nm using a 
microtiter plate reader (Tecan, Magellan 4 Software). The p24 values of the LPs were 
determined using the p24 standard curve and the LPs within the given concentration of p24 
were determined using the formulae below: 
• 1 LP contains 8 x 10-5 pg of p24 (derived from (2000) x (24 x 103Da) / (6x1023)) 
• 1 ng p24 is equivalent to ~ 1.25 x 107 LP 
• For a typical lentivirus vector, there is 1 IFU for every 100-1000 LP 
• Therefore, a supernatant titre of 107 IFU/ml ≈ 109 – 1010 LP/ml or 80-800 ng p24/ml 
  
 
2.14.3. Generation of stable cell lines 
Prior to the day of transduction, 5 x104 293T or NIH3T3 cells were seeded in 3 ml of complete 
DMEM medium in a 6-well plate. After 24 hours, 15μl of lentiviral particles was added to the 
cells containing 6 μg/ml polybrene (Sigma-Aldrich). After 72 hours, the cell medium was 
removed and discarded in diluted Virkon® disinfectant and the adherent cells were carefully 
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washed with PBS. The cells were trypsinised using the standard protocol and transferred into 
a 75 cm2 flask containing 10ml of complete DMEM medium.  
 
2.14.4. Stimulation of stable cell lines 
Approximately 2x104 stable 293T or NIH3T3 cells were seeded in a 96-well plate in 100 μl of 
complete DMEM medium. After 24 hours, the cell medium was removed from the stable 293T 
cells and replaced with 0.5% FBS DMEM alone (unstimulated) or incubated in hypoxia    (0.1% 
O2) or 0.5% FBS DMEM containing 10 ng/ml TNFα, 10 ng/ml PMA, or a combination of TNFα, 
PMA and hypoxia for 18 hours.  
At the same time point, the cell medium was removed from the stable NIH3T3 cells and 
replaced with 0.5% FBS DMEM alone or 0.5% FBS DMEM containing 50 ng/ml mIL-17A,    10 
ng/ml TNFα or a combination of mIL-17A with TNFα for 18 hours.  
After 18 hours, the cell medium was aspirated and replaced with 50 μl 1x Glo Lysis Buffer 
(Promega) to lyse the cells. The luciferase gene expression and total protein content of the 
lysates were quantified as described in section 2.2. The firefly luciferase expression was 
normalised to the titre of the corresponding LPs (lenti IFU/μl) and protein content in the cell 
lysate (mg/ml). In contrast, the therapeutic protein expression was quantified by a sandwich 
enzyme-linked immunosorbent assay (ELISA). 
 
 
 
2.15. ELISA quantification of therapeutic protein expression 
The therapeutic protein expression of hIL-1Ra and mTNFRII-Fc in the cell supernatant from 
unstimulated or inflammatory and/or hypoxic stimulated stable 293T cells was quantified using 
sandwich ELISA.  
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2.15.1. mTNFRII-Fc ELISA 
For mTNFRII-Fc protein quantification, each well of the high affinity protein-binding 96-well 
ELISA plate (Nunc Maxisorp®, eBioscience, CA, USA) was coated with 100 μl of rat 
monoclonal anti-TNFRII antibody (ab7369; Abcam Plc, Cambridge, UK) diluted 1:200 in     100 
mM bicarbonate/carbonate coating buffer (3.03g Na2CO3, 6g NaHCO3 in 1L dH2O final 
volume, pH 9.6). The plate was sealed with adhesive plastic to prevent evaporation and 
incubated overnight at 4°C. The next day, the diluted capture antibody was aspirated from the 
wells and the wells were washed 3 times with 200 μl 1x PBS-Tween (8g NaCl, 0.2g KCl, 1.44g 
Na2HPO4, 0.24g KH2PO4 and 0.05% (v/v) Tween-20 in 1L dH2O, pH 7.4) dried thoroughly by 
firmly blotting against clean paper towels. Non-specific binding sites in the coated wells were 
blocked by adding 200 μl of blocking buffer (4% Marvel dried skimmed milk in 1x PBS) to each 
well. The plate was sealed and incubated at room temperature for 2 hours. The blocking buffer 
was removed from the wells, which were subsequently washed 4 times with 200 μl 1x PBS-
Tween and dried thoroughly. Serial dilutions of mTNFRII-Fc standards from 374 ng/ml – 3.74 
pg/ml were generated in 0.5% FBS DMEM medium and    100 μl of each mTNFRII-Fc sample 
and the diluted mTNFRII-Fc standards were added to duplicate wells. The plate was sealed 
and incubated at room temperature for 3 hours. Following incubation, the contents of wells 
were aspirated and the wells were washed 4 times with 200 μl 1x PBS-Tween and dried 
thoroughly. The biotinylated goat polyclonal secondary detection antibody to mouse IgG 
(ab7067; Abcam) was diluted 1:1000 in 1xPBS-Tween and 100 μl was added to each well. 
The plate was sealed and incubated at room temperature for 1 hour after which the wells were 
washed 4 times with 200 μl 1x PBS-Tween and thoroughly dried. The streptavidin biotinylated 
horseradish peroxidase complex (890803; R&D Systems, MN, USA) was diluted 1:200 in 1x 
PBS-Tween and 100 μl was added to each well, the plate was sealed and incubated at room 
temperature for 1 hour. The wells were washed 7 times with 200 μl 1x PBS-Tween and dried 
thoroughly and 100 μl of a 1:1 mixture of Peroxidase Substrate Solution B (0.02% H2O2 in a 
Citric Acid Buffer; #506500; KPL Inc, MO, USA) and TMB Peroxidase Substrate (0.4 g/L 
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3,3',5,5'- tetramethylbenzidine in an organic base; #507601; KPL Inc) was added to each well. 
The plate was sealed and incubated at room temperature for 30 minutes in the dark. The 
reaction was stopped by adding 100 μl 4M sulphuric acid into each well and the absorbance 
values were immediately read at 450 nm using a microtiter plate reader (Tecan, Magellan 4 
Software). 
 
2.15.2. hIL-1Ra ELISA 
The hIL-1Ra protein concentration in the hIL-1Ra stable cell supernatants was quantified using 
the ELISA protocol described in the preceding section 2.15.1, with the modifications required 
for hIL-1Ra detection: 
• Recombinant human IL-1Ra/IL-1F3 monoclonal capture antibody (MAB280; R&D) 
was diluted 1:100 with 100mM bicarbonate/carbonate coating buffer.  
• Serial dilutions of hIL-1Ra standards from 40 ng/ml –0.4 pg/ml were generated in 0.5% 
FBS DMEM medium and 100 μl of each hIL-1Ra sample and the diluted        hIL-1Ra 
standards were added to duplicate wells. 
• Recombinant human IL-1Ra/IL-1F3 biotinylated polyclonal goat secondary detection 
antibody (BAF280; R&D) was diluted 1:200 in 1xPBS-Tween.  
Standard curves of mTNFRII-Fc and hIL-1Ra protein concentration versus absorbance at 450 
nm were plotted in GraphPad® Prism 5. The linear equation was used to calculate the 
mTNFRII-Fc and hIL-1Ra protein concentration in the samples, which was normalised to the 
lentiviral titre of their respective LPs.   
2.16.    In vivo procedures 
2.16.1. Animals  
Adult male CD1 mice (6-8 week old, 21-25g) were treated according to the approved UK Home 
Office and institutional guidelines.  
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2.16.2. Intraplantar delivery of lentivectors into mouse hind paws  
The mice were anaesthetised with AErrane (Isofluorane; Baxter Healthcare Ltd, Thetford, 
Norfolk) using Boyle’s apparatus (British Oxygen Company BOC, London, UK). The hind paws 
were sprayed with 70% ethanol to disinfect the site and 25 μl of lentiviral particles containing 
260,000 lentiviral IFU of luciferase lentivectors (LV-2-Luc+, LV-9-Luc+, LV-12-Luc+, LV-4NFκB-
Luc+, LV-mCMV-Luc+, LV-SFFV-Luc+) were delivered into both hind paws. 
For the subsequent experiments which delivered therapeutic lentivectors, 25 μl of lentiviral 
particles containing 830,000 lentiviral IFU of therapeutic lentivectors were delivered into the 
left hind paws by intraplantar injection and an equivalent volume of sterile saline was injected 
into the control right hind paw using the same method. The lentivectors were allowed to 
integrate into the cell genome for 7 days.  
 
2.16.3. Induction of carrageenan-induced paw inflammation 
Seven days post-lentiviral injection (luciferase or therapeutic LPs), paw inflammation was 
induced by an intraplantar injection of 50 μl of 1% λ-carrageenan solution (0.1g                     λ-
carrageenan powder (Sigma-Aldrich) in 10 ml sterile saline) into the left hind paws. The control 
right hind paws were injected intraplantarly with sterile saline.  
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2.16.4. Real-time bioluminescence imaging of luciferase gene expression 
At 0, 3, 24 and 72 hours post-carrageenan injection, the mice were injected intraperitoneally 
with 200 μl of luciferin K+ Salt (30 mg/ml; Promega) and anaesthetised with Isofluorane using 
Boyle’s apparatus. After exactly 15 minutes, the anaesthetised mice were photographed (0.2-
second exposure) and imaged for light emission (5 minutes on medium sensitivity) with the 
IVIS® Lumina II (Caliper Life Sciences Corp, Hopkinton, MA, USA). Bioluminescence images 
were overlaid on gray-scale photographs which were obtained with a 12-cm field of view, a 
binning of 8 and a 1/ f stop and open filter. The regions of interest (ROI) were defined manually 
over both hind paws and the background photon flux was defined in control regions of the 
same size. Light emission was quantified as photons per steradian per square centimetre 
(photons/second/cm2/sr) using Living Image® Software (Caliper Life Sciences Corp.).  
 
2.16.5. Paw caliper measurements 
The thickness of hind paws was measured at 0, 3, 24, 48, 72 and 96 hours post-carrageenan 
injection using POCO 2T calipers (Kroeplin Längenmesstechnik, Schlüchtern, Germany). 
After 96 hours post-carrageenan injection, the mice were terminated by cervical dislocation.  
 
2.17. Statistical analyses 
Comparisons between the specified experimental and control groups was calculated using the 
two-tailed, unpaired Student’s t-test (Microsoft Excel 2007, Microsoft Corp., Redmond, WA, 
USA), unless stated otherwise. Values for p≤0.05 were considered statistically significant. 
Graphs were drawn using GraphPad® Prism 5, where the numbers (or titles) on the X-axis 
correspond to the individual constructs and the data represents the mean ± SD of triplicate 
values, unless stated otherwise. 
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CHAPTER 3: 
Transcriptional Regulation of Luciferase Gene 
Expression during Disease Activity:  
Design and initial in vitro selection of 
transcriptionally regulated promoters 
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3.1. Introduction  
Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disease which predominantly 
affects the synovial joints. Pro-inflammatory cytokines, such as TNFα and IL-1β, coordinate 
many of the inflammatory and destructive processes in RA joints. In addition, RA joints are 
often hypoxic, where low oxygen concentrations initiate angiogenesis which facilitates the 
infiltration of immune cells and provides oxygen and nutrients to the hypoxic tissue, promoting 
further overgrowth of the synovium. The inflammatory and hypoxic environment activates 
various transcription factors (TFs) such as NFκB and HIF-1α respectively, resulting in the 
transcription of pro-inflammatory mediators that further exacerbate chronic inflammation within 
the RA joint. 
The endogenous activity of inflammation and/or hypoxia-responsive TFs can be exploited by 
constructing gene therapy vectors with composite synthetic promoters, containing the binding 
sites of responsive TFs (TFBSs). In this way, therapeutic gene expression can be controlled 
at the transcriptional level through interactions of TFs with their TFBSs within the composite 
synthetic promoter to create inflammation-inducible, multi-responsive and synergistically-
inducible expression systems. Localised delivery of inflammation-regulated therapy into the 
RA joint would allow high expression of the therapeutic proteins during disease flare and 
minimal therapeutic protein concentrations during periods of remission, as schematically 
depicted in Figure 3.1.  
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Figure 3.1. Inflammation-inducible synthetic promoters can regulate therapeutic 
protein expression in response to the level of disease activity in RA joints. During the 
relapsed phase of RA, the joint is significantly inflamed and often hypoxic, resulting in the 
activation of responsive TFs. Upon activation, the TFs bind to their cognate binding sites within 
the synthetic promoter to initiate transcription of the downstream therapeutic gene e.g. soluble 
TNFRII-Fc (sTNFRII-Fc). The resulting sTNFRII-Fc proteins can bind to TNFα to form 
sTNFRII-Fc/TNFα complexes which reduce the concentration of free TNFα within the joint to 
prevent TNFα-mediated signalling and consequently decrease the level of inflammation [A]. 
In contrast, during the remission phase of RA, the level of inflammation/hypoxia is substantially 
lower resulting in low level activation of the responsive TFs. Subsequently, the therapeutic 
protein will be expressed at a low level to sustain remission [B]. 
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The aim of the work described in Chapter 3 is to verify the concept of inflammation-inducible 
regulation of gene expression by composite synthetic promoters. The level of firefly luciferase 
gene (Luc+) expression serves as a surrogate marker for the expected expression levels of 
therapeutic genes. Therefore, the initial in vitro functional analysis of promoter activity was 
correlated to the magnitude of luciferase gene expression, thus serving as a readout for the 
activity of the synthetic promoter. 
Due to the presence of different TFBSs within the composite promoters, I predicted that the 
composite promoters would be multi-responsive to different individual stimuli and additively or 
synergistically-inducible in response to combined inflammatory and hypoxic stimulation. This 
unexplored concept for RA gene therapy is evaluated in Chapter 3.   
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3.2. Characterisation and functional analysis of inflammation-inducible                  
pGL3-4bp-composite synthetic promoters  
 
3.2.1.  Construction of the pGL3-4bp-composite synthetic promoter library using the 
Random Ligation Cloning Method  
The schematic diagram below (Fig 3.2) depicts the cloning procedure used to generate the 
pGL3mCMV-composite synthetic promoter constructs.  
 
A. pGL3 Basic construct was digested with XhoI and HindIII to serve as the cloning vector. 
The annealed mCMV oligonucleotides with 5’- XhoI and 3’- HindIII overhangs were 
cloned between these sites, upstream of the luciferase gene within the pGL3 Basic 
vector to generate pGL3mCMV (Fig 3.2 A) (DNA sequence in Appendix 2).  
 
 
 
 
 
 
 
B. pGL3mCMV was digested with NheI. The 5’ and 3’ ends of pGL3mCMV were 
dephosphorylated by incubating the linear DNA with Calf Intestinal Phosphatase (CIP) 
enzyme to prevent recircularisation of the pGL3mCMV cloning vector (Fig 3.2 B).   
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C. Oligonucleotides containing the candidate TFBSs  were ordered with phosphorlyated 
5’-CTAG overhangs, which were compatible to the NheI overhang. The six         
annealed TFBS-oligonucleotides were randomly ligated (in tandem) upstream of the 
mCMV promoter within the pGL3mCMV vector to generate a library of constructs with 
varying composition and numbers of TFBSs (separated by a 4bp space) within the 
composite promoters (Fig 3.2 C). The selected pGL3-4bp-composite promoters were 
sequenced (Appendix 3). 
 
 
 
 
 
 
 
 
 
     
Figure 3.2. Schematic representation of the random ligation cloning method used to 
generate the pGL3-4bp-composite synthetic promoters. The pGL3 Basic construct was 
systematically modified to generate a library of constructs containing composite synthetic 
promoters with diverse TFBSs, separated by a 4bp space.  
3.2.2.  Characterisation and functional analysis of pGL3-4bp-composite synthetic 
promoters  
5’‐phosphorylated 
TF‐oligos with CTAG
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To examine the concept of inflammation-regulated, multi-responsive and synergistically-
inducible composite synthetic promoters, a library of 250 pGL3-4bp-composite promoters 
were generated and transfected into 293T cells. The cells were treated with a combined 
stimulus of hIL-1β (10 ng/ml) and hypoxia (0.1% O2) to induce all candidate TFs and to mimic 
the inflammatory and hypoxic microenvironment within the RA joint. This preliminary screening 
of synthetic promoter activity identified the most inducible promoters which displayed 
moderate/high fold inductions in response to combined hypoxia and hIL-1β stimulation (n=25).  
The functionality of the selected 25 promoters was further characterised by co-transfecting the 
plasmid DNA constructs with pRL-CMV in 293T cells. Transfected 293T cells were 
unstimulated, incubated in hypoxia (0.1% O2) or stimulated with TNFα (10 ng/ml), PMA      (10 
ng/ml) or their combination (TNFα and PMA, in hypoxia). The normalised firefly luciferase 
values are presented in Figure 3.3 and fold inductions are presented in Figure 3.4. 
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Figure 3.3. Functional characterisation of the pGL3-4bp-composite 
promoters. 293T cells (20,000) were seeded in a 96 well plate. After 24 
hours, the selected pGL3-composite promoter constructs (n=25; 180 ng) 
were co-transfected with pRL-CMV (20 ng) into 293T cells. The cells were 
unstimulated, incubated in hypoxia [A], stimulated with TNFα [B], PMA [C] or 
their combination [D] for 18 hours. Transfections were carried out in triplicate 
and normalised to renilla luciferase from pRL-CMV. The hypoxia responsive 
construct pGL3-HIF10 and inflammation-responsive GNL6 were included in 
[
[
[C
[
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Figure 3.4. Fold inductions of the pGL3-4bp-composite 
promoters. The fold inductions were calculated by dividing the 
normalised induced luciferase values by the uninduced luciferase 
[A
[B
[C
[D
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Figure 3.3 confirmed the multi-responsiveness of the composite synthetic promoters, which 
was due to the presence of diverse TFBSs. Interestingly, when visually compared to the 
pGL3mCMV negative control construct, many of the synthetic promoters displayed high basal 
luciferase expression levels which were sometimes comparable to their induced luciferase 
gene expression (Fig 3.3). Consequently, such promoters displayed modest fold inductions 
(Fig 3.4). 
DNA sequence analysis of the composite promoters confirmed that the responsiveness of the 
promoter to a particular stimulus was often reflected by its sequence composition. For 
example, synthetic promoters comprising the binding sites of inflammation-responsive TFs 
were significantly induced by TNFα and PMA inflammatory stimulation. However, it appeared 
that the presence of HIF-1α binding sites (HRE motifs) within the composite promoters did not 
guarantee hypoxia-responsiveness. For example, many composite promoters possessed 
HRE motifs (flanked by other TFBSs) yet failed to respond to hypoxic stimulation i.e. pGL3-
14, -96, -176 (ns, p >0.05). In contrast, the synthetic promoters which possessed only a single 
HRE motif were highly responsive to hypoxia i.e. pGL3-204             (* p=0.04) and pGL3-207 
(** p=0.006), which displayed 18.6 fold and 10.3 fold induction, respectively (Fig 3.4 A).  
Further comparisons between the level of hypoxia induction and the DNA sequences of the 
composite promoters revealed that the promoters unresponsive or marginally responsive to 
hypoxia often had HRE motifs flanked by the other TFBSs whereas the hypoxia-responsive 
promoters had HRE motifs proximal to or positioned close to the TATA box. For example, 
pGL3-204 (* p=0.04), and -207 (** p=0.006) possessed single proximal HRE motifs and pGL3-
245 (*** p=0.001) was comprising of two HRE motifs and a pair of proximal NFκB sites and 
these promoters exhibited significantly greater hypoxia-responsiveness than the vast majority 
of composite promoters with HRE motifs flanked by other TFBSs (Fig 3.4 A) which suggests 
that the positioning of the HRE motif relative to the TATA box may be an important determinant 
of hypoxia-inducibility.  
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As anticipated, the vast majority of the composite synthetic promoters possessed the binding 
sites of inflammation-responsive NFκB, AP-1, C/EBPβ, Egr-1 and Ets-1 transcription factors. 
Consequently, these promoters were highly responsive to TNFα with fold inductions of upto 
27 fold (displayed by pGL3-78, **** p<0.0001) and robust PMA inducibility i.e. pGL3-17, -96 
and -148 (all ** p< 0.01) displayed 9.7, 8.5 and 13.9 fold induction in response to PMA, 
respectively (Fig 3.4 C). Interestingly, the DNA sequencing revealed that these promoters 
possessed either a proximal AP-1 or NFκB motif, which implies that the proximal TFBS 
influences the general responsiveness of the promoter to the corresponding stimulus (Fig 3.3 
C and 3.4 C).  
To assess the capability of additive/synergistic induction of luciferase gene expression from 
the composite promoters, the transfected 293T cells were stimulated with TNFα, PMA and 
hypoxia, to mimic the inflammatory and hypoxic environment within the RA joint. Interestingly, 
only pGL3-22 and -245 displayed synergistic luciferase expression whereas the other 
composite promoters (n=23) exhibited significant increases in luciferase gene expression 
following combined stimulation but unchanged or lower luciferase gene expression levels 
compared to when stimulated with a single stimulus (Fig 3.3 D and 3.4 D). This observation 
highlighted the possibility of spatial constraints of TFBSs which may have arisen due to the 
close proximity of the TFBSs (4 bp space). It is likely that during combined inflammatory and 
hypoxic stimulation, the binding of the TF to its binding site may have sterically hindered the 
binding of other TFs to the adjacent binding sites which consequently, impaired 
additive/synergistic induction. 
Overall, the promoters were generally multi-responsive, however, the fundamental 
requirements of low basal and additive/synergistic induction of gene expression (to combined 
inflammatory and hypoxic stimulation) was not achieved by the majority of the composite 
promoters, which highlighted the need for an alternative, systematic cloning method to 
construct composite synthetic promoters with improved expression profiles.  
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3.3. Construction of inflammation-inducible composite synthetic promoters using 
the Assembly PCR Cloning Method  
The important questions to emerge from the data in section 3.2 was whether the spacing 
between the TFBSs and also the distance between the proximal TFBS and the TATA box had 
any effect on the level of gene expression induced by the synthetic promoters. This was 
investigated using the Assembly PCR cloning method, which is a method traditionally used to 
synthesise genes from multiple short oligonucleotides. Increased spacing was introduced 
between the TFBSs relative to one another and also relative to the TATA box whilst retaining 
the random arrangement of the TFBSs within the composite synthetic promoters. This high-
throughput and rational cloning approach represented an attractive alternative to the random 
ligation cloning method. The concept of the Assembly PCR cloning method is schematically 
depicted in Figure 3.5.  
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3.3.1.  Concept of the Assembly PCR cloning method 
The Assembly PCR method was adapted to construct composite synthetic promoters with the 
binding sites of inflammation and/or hypoxia-responsive transcription factors (Fig 3.5) 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5. Schematic diagram illustrating the construction of inflammation-inducible 
synthetic promoters using the Assembly PCR cloning method.  
The oligonucleotides used to generate the sense strand of the PCR product contained a TFBS 
flanked by two annealing sequences (AS-2a and AS-1a) whereas the anti-sense strand of the 
178 
 
PCR product consisted of oligonucleotides containing the reverse sequence of the TFBS 
flanked by the complementary annealing sequences (AS-2b and AS-1b). The     5’-‘stop’ 
oligonucleotide contained the NheI restriction enzyme site whereas the 3’-‘stop’ 
oligonucleotide contained the XhoI restriction enzyme site, for downstream cloning purposes.  
The forward and reverse TFBS-oligonucleotides were pooled together with the ‘stop’ 
oligonucleotides and diluted. These oligonucleotides were assembled in a 10 cycle assembly 
PCR reaction to generate double stranded DNA which served as the template DNA for the 
subsequent 25 cycle amplification PCR reaction. The PCR products were then digested with 
NheI and XhoI and cloned upstream of the mCMV promoter within the pCpGmCMV vector to 
generate inflammation and/or hypoxia-inducible synthetic promoters.  
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3.3.2. Optimisation of the Assembly PCR method  
There are several limitations of the Assembly PCR method which hinder the success of the 
cloning method. These constraints were overcome by designing unflawed oligonucleotides 
and optimising the oligonucleotide concentrations to develop a high-throughput method for 
generating synthetic promoters.  
The first imperative step in the design of the Assembly PCR oligonucleotides was to generate 
annealing and spacer sequences which were devoid of mammalian TFBS. Inadequately 
designed annealing and spacer sequences containing mammalian TFBS could give rise to 
promoters with unnecessary TFBSs and therefore, negatively impact the promoter activity. 
The annealing and spacer sequences were screened using the TRANSFAC® database to 
verify the absence of mammalian TFBS.  
The length of the annealing sequences and the use of spacer oligonucleotides determine the 
degree of spacing between the TFBS. Therefore, in order to investigate the effect of spacing 
between the TFBSs on gene expression, the oligonucleotides were designed to contain a 
TFBS flanked by annealing sequences of specified lengths to generate a library of promoters 
with varied spacing between the TFBS.  
In order to determine the minimal length of the annealing sequence required for successfully 
assembling and amplifying PCR products using the Assembly PCR reaction, the 
oligonucleotides with 10 bp, 15 bp and 20 bp annealing sequences were used to generate 
PCR products which were visualised by agarose gel electrophoresis, shown in Figure 3.6.  
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A successful Assembly PCR reaction generates PCR products of different sizes which can be 
confirmed by the presence of a smear following gel electrophoresis, as demonstrated in Figure 
3.6. The resulting PCR products containing the TFBSs can be isolated and cloned into the 
expression vector to generate the synthetic promoter construct. 
Figure 3.6 B shows that the oligonucleotides with 15 bp and 20 bp annealing sequences 
formed PCR products that were large enough to isolate from the ‘stop’-oligonucleotide primers. 
However, the PCR products generated using the oligonucleotides with 10 bp annealing 
sequences were very small and indistinguishable from the ‘stop’ oligonucleotide primers, 
which could introduce the risk of contaminating the PCR products with the ‘stop’-
oligonucleotides during the isolation of the PCR products. Therefore, 10 bp annealing 
sequences were not sufficient to enable the assembly method and 15 bp or 20 bp annealing 
sequences were used in the subsequent reactions.  
Figure 3.6. The synthesis of HRE-containing PCR products with 
different annealing sequence lengths. Standard PCR reaction 
components were combined with 5 μl of 100 μM forward and reverse HRE 
oligonucleotides (comprised of 20 bp, 15 bp and 10 bp annealing 
sequences) and 40 nM of ‘stop’ oligonucleotides, in individual PCR 
reactions. The oligonucleotides were assembled in a 10 cycle assembly 
PCR reaction [A] and 15 μl of the assembled dsDNA was amplified in a 25
[A] [B] 
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The success of the Assembly PCR method is also heavily dependent on the ‘stop’ 
oligonucleotide concentration in the assembly reaction (x10 cycle reaction). These 
oligonucleotides serve three important functions: 
1. Firstly, the ‘stop’ oligonucleotides prevent further assembly of the PCR product in the 
x10 cycle assembly reaction thereby truncating the PCR product to prevent indefinite 
oligonucleotide assembly.  
2. Secondly, high concentrations of the ‘stop’ oligonucleotides (1 µM final) serve as 
amplification primers in the x25 cycle amplification reaction. The ‘stop’ oligonucleotides 
incorporated into the DNA template during the assembly reaction (x10 cycle) serve as 
binding sites for the amplification primers. The inefficient incorporation of ‘stop’ 
oligonucleotides in the initial assembly reaction will lower the efficiency of the 
subsequent amplification reaction due to the potential absence of the amplification 
primer binding sites.  
3. Thirdly, the ‘stop’ oligonucleotides contain restriction enzyme sites (5’-NheI and      3’-
XhoI) for downstream cloning of the PCR product into the expression vector. The 
inefficient incorporation of ‘stop’ oligonucleotides in the assembly reaction (x10 cycle) 
will also lower the efficiencies of restriction digestion and ligation reactions due to the 
potential absence of the NheI and XhoI restriction sites and overhangs within the PCR 
products, respectively,  which consequently impairs the following cloning steps.  
 
To confirm the importance of optimal ‘stop’ oligonucleotide concentrations on the success of 
the Assembly PCR method, forward and reverse oligonucleotides with HRE motifs, flanked by 
20 bp annealing sequence, were randomly pooled together with increasing concentrations of 
‘stop’ oligonucleotides. The resulting PCR products were visualised by gel electrophoresis on 
an ethidium-bromide containing agarose gel, presented in Figure 3.7.  
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Figure 3.7. The assembly and amplification of HRE-containing PCR products. Standard 
PCR reaction components were combined with 5 μl of 100 μM forward and reverse HRE 
oligonucleotides (with 20 bp annealing sequence) and increasing concentrations of ‘stop’ 
oligonucleotides. No oligonucleotides were added to the negative control PCR reaction. The 
diluted HRE and ‘stop’ oligonucleotides were assembled in a 10 cycle assembly PCR reaction 
[A]. Fifteen microlitres of the assembled dsDNA was amplified with 1 µM final concentration 
of ‘stop’ oligonucleotides and PCR reaction components in a 25 cycle amplification PCR 
reaction [B]. Five microlitres of assembled [A] and amplified [B] PCR products were visualised 
by gel electrophoresis on an ethidium bromide containing 0.5 x TAE agarose gel and 
approximate sizes of the PCR products were determined by comparisons to the 1Kb+ DNA 
ladder. 
 
As anticipated, the size of the PCR products decreased with increasing ‘stop’ oligonucleotide 
concentration in the initial assembly reaction (Fig 3.7). The amplified PCR products containing 
16 nM of ‘stop’ oligonucleotides were very large and exceeded 12Kb in size confirming the 
inefficient truncation of the PCR products in the assembly reaction, due to the low 
concentration of ‘stop’ oligonucleotides (Fig 3.7 B). In contrast, the amplified PCR products 
containing 260 nM of ‘stop’ oligonucleotides were substantially smaller confirming the 
presence of a large proportion of truncated PCR products and therefore efficient primer 
binding and amplification (Fig 3.7 B).  Consequently, 210 nM of ‘stop’ oligonucleotides was 
selected as the optimal concentration to be used in the assembly reaction (x10 cycles) which 
should generate PCR products of 300 bp - 2000 bp in size.  
[A] [B
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The presence of residual ‘stop’ oligonucleotides following the amplification reaction can also 
impede the efficiencies of restriction digests and ligation reactions due to the ability of the 
‘stop’ oligonucleotides annealing together and potentially being cloned into the vector. Gel 
extraction of the PCR smear significantly decreased the yield of DNA which also decreased 
the efficiency of the ligation reaction and subsequently resulted in extremely low numbers of 
E.coli transformants.  As an alternative, the amplified PCR products were purified using the 
high cut-off purification binding buffer B3 (Purelink PCR Purification Kit) which eliminated 
amplification primers and PCR products less than 300 bp and prevented the excessive loss of 
DNA. Two successive high cut-off purifications were performed and the PCR products were 
digested with NheI and XhoI and cloned into the equivalent site within the pCpGmCMV vector.  
 
  
184 
 
3.3.3. Construction of the pCpGmCMV cloning vector  
The schematic diagram below (Fig 3.8) depicts the cloning procedure used to construct the 
pCpGmCMV cloning vector for the assembly PCR products.   
 
A. pGL3mCMV was digested with NheI and AfeI to release the 2143 bp fragment 
containing the mCMV promoter and the luciferase gene (Fig 3.8 A).  
 
 
 
 
 
 
 
 
B. The AfeI enzyme produces blunt ended fragments, therefore pCpG-mSEAP was 
digested with SbfI and incubated with Klenow to produce a blunt ended fragment. The 
DNA was then digested with NheI and XbaI to release the 2194 bp fragment which 
contained the IFNβ-S/MAR and βGlo-MAR components, to generate the cloning vector 
pCpG (Fig 3.8 B). 
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C. The mCMV and luciferase gene were cloned into the pCpG vector to generate 
pCpGmCMV-Luc+ (DNA sequence; Appendix 4), which was then digested with NheI 
and XhoI to serve as the cloning vector for the assembly PCR products (Fig 3.8 C).  
 
 
 
Figure 3.8. Schematic diagram illustrating the construction of the pCpGmCMV cloning 
vector. Sequential restriction digest reactions were visualised on an ethidium-bromide 
containing 0.5 x TAE agarose gel to confirm the correct size of the digested fragment prior to 
isolation and subsequent cloning.  
 
The pCpGmCMV expression vector was generated by the ligation of two fragments from two 
different expression vectors; pCpG-mSEAP (InvivoGen, San Diego, CA, USA) and 
pGL3mCMV (section 3.2.1). The pCpG-mSEAP backbone plasmid contains two nuclear 
matrix attachment regions from the 5’ region of the human IFN-β gene and the β-globin gene, 
which serve as insulators to form transcriptional barriers between independently regulated 
domains. The synthetic promoters and luciferase gene were cloned between these insulator 
elements to insulate the promoter from external influences on gene expression. 
The PCR products with NheI and XhoI overhangs were cloned into the NheI/XhoI site within 
the pCpGmCMV cloning vector to generate a library of pCpGmCMV-TFBS plasmids, each 
harbouring multimerised TFBSs within their synthetic promoters. The constructed plasmids 
were verified by digestion with NheI and XhoI, which releases the PCR product containing the 
TFBSs and can be visualised by agarose-gel electrophoresis, as shown in Figure 3.9. 
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Figure 3.9. Analytical restriction enzyme digest of pCpG-HRE constructs. Each 
recombinant plasmid construct was digested with NheI and XhoI to release the PCR product. 
The digested DNA was visualised on an ethidium-bromide containing 0.5 x TAE agarose gel 
to confirm the successful incorporation of the PCR products. Released fragments larger than 
100 bp confirmed the presence of multimerised HRE motifs within the pCpG-HRE constructs.  
 
Interestingly, the released fragments in Figure 3.9 were much smaller than their amplified PCR 
products from the x25 cycle Assembly PCR reaction (Fig 3.7 B). This was probably due to the 
annealing of synthesised PCR products via the 5’-NheI and 3’-XhoI sequences which can bind 
to their complementary sequences to form a concatemer of several PCR products. Following 
digestion of the concatemeric PCR products with Nhe and XhoI, the individual PCR products 
were released and cloned into the pCpGmCMV vector. Therefore, analytical digests of the 
recombinant plasmid DNA constructs using NheI and XhoI should resemble the results in 
Figure 3.9.  
  
pCpGmCMV 
vector
PCR products 
(multimerised HRE)
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3.3.4. Inflammation-inducible synthetic promoters exhibit varied transcription    
activities due to diversity of the consensus sequence 
Divergence in gene expression between different cells and species is mediated by the ability 
of TFs to recognise numerous variations of their general consensus sequence and bind with 
different affinities to induce varied gene expression levels (Wittkopp, 2010). For example, 
various NFκB dimers can recognise and bind to the different variations of the general NFκB 
consensus sequence, GGGRNNYYCC (where R = A/G, Y= C/T and N= any nucleotide). The 
PCR component of the Assembly PCR method was exploited to incorporate non-specific 
nucleotides within the GGGRNNYYCC sequence to construct a variable                         NFκB-
synthetic promoter library in order to investigate the effect of sequence diversity of the NFκB 
binding site on the functional activity of the synthetic promoters. In addition, synthetic 
promoters with fixed NFκB sequences were also generated to determine the effect of NFκB 
copy number on gene expression.  
The fixed NFκB sequence, GGGACTTTCC, is preferentially bound by the p65/p50 NFκB dimer 
(Urban and Baeuerle, 1991) which is a highly expressed TF in synovial tissue and cells from 
RA patients (Handel et al., 1995). Six copies of this sequence are present within the highly 
inflammation-responsive GNL6 construct (created by Khoury et al., 2007), which served as a 
positive control for TNFα or PMA stimulation in the experiments within this thesis. The PCR 
oligonucleotides were comprised of the fixed or variable NFκB sequences (forward and 
reverse NFκB) flanked by 30 bp annealing sequences to introduce a 30 bp space between the 
fixed or variable NFκB motifs, respectively. The PCR products were digested with NheI and 
XhoI and cloned into the equivalent site within the pCpGmCMV vector. The plasmid DNA 
constructs were co-transfected with pRL-CMV into 293T cells which were unstimulated or 
stimulated with TNFα. Functional comparisons were made between the activities of the 
synthetic promoters with fixed and variable NFκB motifs to determine the effect of NFκB 
sequence diversity and fixed NFκB copy number on gene expression (Fig 3.10).  
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Figure 3.10. Comparative analysis of the functional activities of synthetic promoters 
comprised of variable or fixed NFκB binding sites. Oligonucleotides with the variable 
(GGGRNNYYCC) or fixed (GGGACTTTCC) NFκB motifs, flanked by 30 bp annealing 
sequences, were assembled and amplified using the Assembly PCR method. Following 
cloning, the plasmid DNA constructs (180 ng) were co-transfected with pRL-CMV (20 ng) in 
triplicate into 293T cells (20,000 cells in a 96-well plate) and were either unstimulated or 
stimulated with TNFα (10 ng/ml) for 18 hours [A] and the fold inductions were calculated [B]. 
The data represents the mean ± SD of triplicate values normalised to renilla luciferase. The 
statistical significance between unstimulated and TNFα-stimulated luciferase gene expression 
was calculated using the Student's t-test (ns= p>0.05, * = p≤0.05, ** = p≤0.01). The number 
of NFκB motifs in the promoters is stated e.g.  2NFκB. 
[
[
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Evidently, the synthetic promoters with fixed NFκB sequences were highly inflammation-
inducible and displayed upto 70 fold induction in response to TNFα stimulation              (pCpG-
fixed-12NFκB) (Fig 3.10 B). In contrast, the synthetic promoters with variable NFκB motifs 
displayed very low and variable gene expressions, with a maximal fold induction of upto 7.2 
fold (pCpG-variable-10NFκB). All of the synthetic promoters displayed similar basal gene 
expressions and therefore, the vast differences in fold inductions can be attributed to the 
robust TNFα-inducibility displayed by the fixed NFκB-promoters, in contrast to the marginal 
TNFα-induced gene expression by the variable NFκB-promoters.  
Due to the use of the fixed NFκB sequences, it was possible to determine the effect of NFκB 
copy number on gene expression. As anticipated, the luciferase gene expression increased 
with increasing numbers of NFκB motifs, following TNFα stimulation.  For example, pCpG-
fixed-2NFκB displayed 9 fold induction, although the change in gene expression following 
TNFα stimulation was not statistically significant (ns, p=0.07). In contrast, pCpG-fixed-12NFκB 
displayed 70 fold induction to TNFα stimulation (* p=0.03), which was due to greater copy 
numbers of the fixed NFκB motifs within the latter promoter. Interestingly, the synthetic 
promoters with 6, 8 and 12 fixed NFκB motifs displayed 63, 62 and 70 fold inductions 
respectively, which suggests that the synthetic promoters reached a saturation point where 
increasing the TFBS copy number had minimal effects on the level of gene expression. The 
observation that very similar levels of gene expression can be induced by a promoter with 
fixed 6NFκB motifs (* p=0.05) or fixed 12NFκB motifs (* p=0.03) indicates that high-inducibility 
can be achieved in compact synthetic promoters, with minimal copy numbers of TFBSs (Fig 
3.10 A) 
In contrast, the diversity in gene expression induced by the variable NFκB-promoters was not 
solely attributed to the number of NFκB motifs within the promoters. For example, promoters 
6a, 6b and 6c all possessed six variable NFκB motifs but display poor and varied fold 
inductions to TNFα stimulation, suggesting that the different NFκB sequences was 
accountable for the variation in their promoter activities, despite the changes in gene 
190 
 
expression being statistically insignificant (ns, p>0.05). Interestingly, the synthetic promoter 
within the pCpG-variable-10NFκB construct displayed 7.2 fold induction, although the change 
in gene expression following TNFα stimulation was not statistically significant (ns, p>0.05). 
The sequence analysis of this promoter revealed that some of the NFκB motifs had a very 
similar sequence to the fixed GGGACTTTCC NFκB sequence (DNA sequence: Appendix 5), 
which may have been accountable for the higher TNFα-induced gene expression by this 
promoter. These results also, to an extent, highlight the preferential binding of the TNFα-
inducible p65/p50 NFκB dimer to the fixed NFκB binding sites and similar sequences.  
Overall, minor variations within the NFκB binding site can have dramatic effects on the activity 
of the synthetic promoters and as shown in Figure 3.10, these changes can result in 
unpredictable promoter activities, which is undesirable. Synthetic promoters within the fixed 
NFκB library displayed consistently high responsiveness to TNFα and therefore, the fixed 
sequences of the NFκB (GGGACTTTCC), AP-1 (TGAGTCA) and HIF-1α (ACGTGC) binding 
sites will be used to generate the composite synthetic promoters.  
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3.3.5. Increased spacing between the TFBSs results in decreased basal and induced 
luciferase gene expression  
Composite synthetic promoters were previously generated using the random cloning method 
(section 3.2). These synthetic promoters contained the core binding sites of AP-1, C/EBPβ, 
Egr-1, Ets-1, HIF-1α and NFκB transcription factors, with only a 4bp space between each 
TFBS and it is possible that the close proximity of the TFBSs introduced steric hindrance of 
the TFs which may have impaired the induction of synergistic gene expression following 
combined inflammatory and hypoxic stimulation. In order to determine whether increasing the 
spacing between TFBSs could alleviate the potential steric hindrance of the TFs to allow 
synergistic gene expression, it was important to first investigate the general effects of 
increased spacing between the TFBSs on gene expression.  
In the Assembly PCR method, the length of the annealing sequence determines the degree 
of spacing between the TFBSs and this spacing can be extended by replacing the reverse 
TFBS-oligonucleotide with a reverse spacer-oligonucleotide. Figure 3.11 depicts the assembly 
of oligonucleotides with different lengths of the annealing and spacer sequences which were 
used to generate synthetic promoters with specified degrees of spacing between the TFBSs.  
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5’- ATCTCTGCGATGAACCTCACCATGTTGAGTCAACAAGGTGCCTCTTATGATCTGGAT                 ATCTCTGCGATGAACCTCACCATGTTGAGTCAACAAGGTGCCTCTTATGATCTGGAT-3’ 
3’-CACGGAGAATACTAGACCTAGTACAACTCAGTTGTTCTAGAGACGCTACTTGGAGTG-5’        
AP‐1 30bp AP‐1
AP‐1 Reverse
5’- TGCGATGAACCTCACTGAGTCAGTGCCTCTTATGATC       TGCGATGAACCTCACTGAGTCAGTGCCTCTTATGATC-3’                          
3’-CACGGAGAATACTAGACTCAGTACGCTACTTGGAGTG-5’        
AP‐1 15bp AP‐1
AP‐1 Reverse
5’- ATCTCTGCGATGAACCTCACTGAGTCAGTGCCTCTTATGATCTGGAT       ATCTCTGCGATGAACCTCACTGAGTCAGTGCCTCTTATGATCTGGAT-3’                          
3’-CACGGAGAATACTAGACCTAACTCAGTTAGAGACGCTACTTGGAGTG-5’        
AP‐1 20bp AP‐1
AP‐1 Reverse
5’- TGCGATGAACCTCACTGAGTCAGTGCCTCTTATGATC     TGCGATGAACCTCACTGAGTCAGTGCCTCTTATGATC-3’                          
3’-CACGGAGAATACTAGGGTACACGCTACTTGGAGTG-5’        
AP‐1 35bp AP‐1
5nt Spacer
5’- TGCGATGAACCTCACTGAGTCAGTGCCTCTTATGATC          TGCGATGAACCTCACTGAGTCAGTGCCTCTTATGATC-3’                          
3’-CACGGAGAATACTAGGGTACAGACAACGCTACTTGGAGTG-5’        
AP‐1 40bp AP‐1
10nt Spacer
5’- ATCTCTGCGATGAACCTCACTGAGTCAGTGCCTCTTATGATCTGGAT          ATCTCTGCGATGAACCTCACTGAGTCAGTGCCTCTTATGATCTGGAT-3’                
3’-CACGGAGAATACTAGACCTAGGTACAGACATAGAGACGCTACTTGGAGTG-5’        
AP‐1 50bp AP‐1
10nt Spacer
5’- ATCTCTGCGATGAACCTCACCATGTTGAGTCAACAAGGTGCCTCTTATGATCTGGAT     ATCTCTGCGATGAACCTCACCATGTTGAGTCAACAAGGTGCCTCTTATGATCTGGAT-3’     
3’-CACGGAGAATACTAGACCTAGGTACTAGAGACGCTACTTGGAGTG-5’        
AP‐1 55bp AP‐1
5nt Spacer
5’- ATCTCTGCGATGAACCTCACCATGTTGAGTCAACAAGGTGCCTCTTATGATCTGGAT          ATCTCTGCGATGAACCTCACCATGTTGAGTCAACAAGGTGCCTCTTATGATCTGGAT-3’
3’-CACGGAGAATACTAGACCTAGGTACAGACATAGAGACGCTACTTGGAGTG-5’        
AP‐1 60bp AP‐1
10nt Spacer
5’- ATCTCTGCGATGAACCTCACTGAGTCAGTGCCTCTTATGATCTGGAT     ATCTCTGCGATGAACCTCACTGAGTCAGTGCCTCTTATGATCTGGAT-3’                     
3’-CACGGAGAATACTAGACCTAGGTACTAGAGACGCTACTTGGAGTG-5’        
AP‐1 45bp AP‐1
5nt Spacer
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Figure 3.11. Assembly of oligonucleotides to generate PCR products with specified spacing 
between the TFBSs. Oligonucleotides comprising the AP-1 (and fixed NFκB) binding sites flanked 
by annealing sequences of specified lengths were assembled using the Assembly PCR method. 
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The oligonucleotides with different annealing sequence lengths and spacer nucleotides were 
assembled in specific combinations to generate synthetic promoter libraries with 15 bp space 
to 60 bp space between the AP-1 and NFκB motifs (n=6 per group). 
The assembly of oligonucleotides with forward and reverse TFBSs flanked by 15 bp, 20 bp 
and 30 bp annealing sequences generated promoters with 15 bp, 20 bp and 30 bp space 
between the TFBSs, respectively. The annealing of a forward TFBS oligonucleotide with 15 
bp annealing sequence to either a reverse 5 nt spacer-oligonucleotide or a reverse 10 nt 
spacer-oligonucleotide generated promoters with 35 bp and 40 bp space between the TFBSs, 
respectively. A spacing of 45 bp and 50 bp between the TFBSs was achieved by annealing a 
forward TFBS oligonucleotide with 20 bp annealing sequence to either a reverse 5 nt spacer-
oligonucleotide or a reverse 10 nt spacer-oligonucleotide, respectively. Finally, the promoters 
with TFBSs separated by 55 bp and 60 bp space were generated by annealing of a forward 
TFBS oligonucleotide with 25 bp annealing sequence to either a reverse 5 nt spacer-
oligonucleotide or a reverse 10 nt spacer-oligonucleotide, respectively.  
The synthetic promoters with the specified spacing between the AP-1 binding sites (Fig 3.12 
A) or the NFκB binding sites (Fig 3.12 B) were constructed to investigate the effect of spacing 
between the TFBSs on the transcriptional activity of the synthetic promoters. The PCR 
products were cloned into the pCpGmCMV vector and the recombinant plasmid constructs 
were co-transfected with pRL-CMV into 293T cells. Transfected cells were either unstimulated 
or stimulated with PMA (10ng/ml) or TNFα (10ng/ml) to activate AP-1 or NFκB, respectively.  
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Figure 3.12. Increased spacing between the TFBSs negatively impacts the 
transcriptional activity of the synthetic promoters.  Increased spacing was introduced 
between the AP-1 [A] and NFκB motifs [B] within the AP-1 and NFκB-responsive synthetic 
promoters (n=6, per group). The promoter constructs (180 ng) were co-transfected with pRL-
CMV (20 ng) into 293T cells (20,000 cells in a 96-well plate). Transfected cells were 
unstimulated or stimulated with PMA (10 ng/ml) or TNFα (10 ng/ml) for 18 hours. The data 
represents the mean ± SD of triplicate values normalised to renilla luciferase.  
 
Interestingly, increasing the spacing between the TFBSs had a profound effect on the 
transcriptional activity of the synthetic promoter. A clear trend can be observed; with increased 
spacing between the TFBSs, there was a gradual decrease in the basal (unstimulated) and 
induced (PMA and TNFα stimulated) luciferase gene expression. This trend was more 
[
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noticeable when the basal and induced luciferase gene expression data were plotted 
separately in Figure 3.13. 
  
 
  
 
   
 
[
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  Figure 3.13. The basal and induced luciferase gene expression 
decreases with increased spacing between the TFBSs. The basal and 
induced gene expression data from AP-1-responsive synthetic promoters 
[A] and [C], respectively and from NFκB-responsive synthetic promoters 
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As demonstrated in the preceding section 3.3.4, the number of TFBSs within the synthetic 
promoters can impact the transcriptional activity of the promoter. Therefore, to eliminate the 
influence of TFBS copy number on the gene expression, the basal and induced luciferase 
gene expression from synthetic promoters with 8NFκB motifs (selected from 5 spacer groups) 
were re-plotted from Figure 3.12 (DNA sequencing in Appendix 6). In this way, all variables 
were kept constant except for the degree of spacing between the TFBSs, in order to determine 
the effect of spacing between the TFBSs on promoter activity (Fig 3.14). 
 
 
  
 
  
[
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Figure 3.14. Synthetic promoters with clustered TFBSs have higher 
basal and induced gene expression than synthetic promoters with 
sparse TFBSs. Synthetic promoters with 8NFκB motifs were selected 
from 5 spacer groups. The basal alone [A] and basal and TNFα-induced 
[B] luciferase gene expressions were re-plotted from the data in Figure 
3.12. The data represents the mean ± SD of triplicate values normalised 
to renilla luciferase. The statistical significance between the basal 
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Figure 3.14 demonstrated that the synthetic promoter with 15bp space between NFκB motifs 
had a significantly higher basal expression than pCpGmCMV (** p=0.002) and the highest 
TNFα-induced gene expression (**** p=0.0001). In contrast, the synthetic promoter with 45bp 
space between NFκB motifs had a significantly lower basal expression than pCpGmCMV (** 
p=0.002) and the lowest TNFα-induced gene expression (*** p=0.001). The results in Figure 
3.14 comply with the trend observed in Figure 3.12, therefore, the effect of TFBS number on 
luciferase gene expression was negated (in this experiment), and the general activities of the 
synthetic promoters with diverse TFBS spacing were comparatively analysed to determine the 
effect of TFBSs spacing on gene expression induced by the synthetic promoters.  
Interestingly, the synthetic promoters with a 15 bp space between the AP-1 and NFκB motifs 
had higher basal luciferase expressions than the negative control backbone plasmid 
pCpGmCMV, which is undesirable. Generally, the synthetic promoters with a 15bp space 
between TFBSs had higher basal luciferase gene expression than the synthetic promoters 
with sparse TFBSs (Fig 3.13 A and B). Figures 3.13 C and 3.13 D showed that with increased 
spacing between the TFBSs, there was also a decrease in the PMA and TNFα-induced 
luciferase gene expression by the AP-1 and NFκB-responsive synthetic promoters, 
respectively. Interestingly, the synthetic promoters with 45-60 bp spacing between the TFBSs 
had dramatic lower induced luciferase gene expression levels than the other promoters. 
Overall, the observed trend in Figure 3.12 provided a filtering parameter to select the spacing 
between the TFBSs which permitted the sought-after characteristics of inflammation-inducible 
synthetic promoters. Promoters with a 20 bp space between the TFBSs displayed low basal 
gene expression (comparable to the pCpGmCMV control) and high induced luciferase gene 
expression and therefore, composite synthetic promoters will be constructed with a 20 bp 
space between the TFBSs, which may alleviate the proposed steric hindrance associated with 
the close proximity of TFBSs.  
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3.3.6.  Construction of cloning vectors used to investigate the effect of spacing 
between the proximal TFBS and the TATA box 
During transcription, activated TFs bind to their respective binding sites and with the aid of 
general transcription factors, RNA polymerase II is positioned on the TATA box to form a 
preinitiation complex (PIC), for transcription to proceed. The experiment in section 3.3.2 
highlighted that the pGL3-4bp-composite promoters with proximal HRE motifs had greater 
hypoxia-inducibility than promoters with HRE motifs flanked by other TFBSs, which may have 
been due to the facilitated accessibility of the proximal HRE to interact with the closely located 
RNA polymerase II and PIC on the TATA box.  
To investigate the effect of spacing between the proximal TFBS and the TATA box on gene 
expression, the Assembly PCR method was implemented to generate synthetic promoters 
with increased spacing between these two components. This was achieved by incorporating 
specified degrees of spacing between the XhoI and SalI sites within the various 3’-XhoI ‘stop’ 
primers, listed in Table 3.1. 
 
 
 
 
 
Table 3.1. List of 3’-XhoI ‘stop’ PCR primers, with 20bp annealing sequence, used to 
create PCR products with specified spacing between the proximal TFBS and the TATA 
box. The specified spacings between the proximal TFBS and the TATA listed above will only 
be generated with 3’-XhoI ‘stop’ primers which have 20bp annealing sequence. If the 
annealing sequence length is changed, the distance between the TFBS and the TATA box will 
also change.  
Figure 3.15 schematically depicts the construction of synthetic promoters with various spacing 
between the proximal TFBS and the TATA box, using the Assembly PCR method. 
3’-XhoI ‘stop’ primers  
with 20bp annealing sequence 
Distance between proximal TFBS 
and TATA box within the promoter 
XhoI-primer (current) 55 bp (current) 
0bp-SalI primer 60 bp 
5bp-SalI primer 66 bp 
9bp-SalI primer 70bp 
14bp-SalI primer 74 bp 
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Figure 3.15. Cloning strategy used to construct synthetic 
promoters with varied spacing between the TFBS and the TATA 
box. Specified spacing was introduced between the proximal TFBS 
and the TATA box (T) by cloning existing PCR products into various 
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Using Assembly PCR, four individual PCR reactions were set up with the standard PCR 
components, forward and reverse oligonucleotides with HRE motifs flanked by 20 bp 
annealing sequences, 5’-NheI ‘stop’ primer and the four different 3’-XhoI ‘stop’ primers to 
generate PCR products with a 20 bp space between HRE motifs and specified spacings 
between the XhoI and SalI restriction enzyme sites. Following purification, the four different 
PCR products were digested with NheI and SalI and cloned into the NheI/XhoI digested 
pCpGmCMV vector. The ligation of compatible SalI and XhoI overhangs generated the hybrid 
GTCGAG sequence, which is unrecognisable by any restriction enzyme, thereby destroying 
the XhoI overhang within the vector. The resulting constructs (DNA sequencing; Appendix 7) 
were digested with NheI and XhoI to release the HRE PCR product and generate four different 
pCpG-Xbp cloning vectors, where X is 0 bp, 5 bp, 9 bp or 14 bp between the XhoI overhang 
and XhoI/SalI destroyed restriction enzyme site. The existing PCR products with a 20 bp space 
between the TFBSs were cloned into the four different cloning vectors to introduce specific 
spacings (listed in Table 3.1) between the proximal TFBS and the TATA box.  
Successful assembly and amplification of the PCR products was confirmed by visualising on 
an ethidium bromide containing 0.5 x TAE agarose gel (Fig 3.16).                                          
     
 
 
3.3.7. Proximal TFBSs exhibit positional preferences relative to the TATA box  
[A [B
Figure 3.16. Assembly and amplification of PCR products used to 
generate cloning vectors with varying distances between the TFBS 
and the TATA box. Five microlitres of assembled [A] and amplified [B] 
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Synthetic promoters with increased spacing between proximal AP-1 and NFκB motifs and the 
TATA box were generated by cloning existing PCR products with 8AP-1 or 6NFκB motifs into 
the various cloning vectors constructed in section 3.3.6 (DNA sequencing; Appendix 8). The 
resulting plasmid DNA constructs were co-transfected with pRL-CMV into 293T cells and were 
either unstimulated or stimulated with PMA or TNFα to activate AP-1 or NFκB, respectively 
(Fig 3.17).  
    
 
 
       
 
                            
[A
[B [C
204 
 
                       
               
Figure 3.17. Increased spacing between the proximal TFBS and the TATA box 
negatively affects the basal and induced gene expression induced by the synthetic 
promoter. PCR products with 8AP-1 [A], [B] and [C] and 6NFκB motifs [D], [E] and [F] were 
cloned into different expression vectors which allowed 55 bp to 74 bp spacing between the 
proximal TFBS and the TATA box. The resulting constructs (180 ng) were co-transfected with 
pRL-CMV (20 ng) into 293T cells (20,000 cells in a 96-well plate). Transfected cells were 
unstimulated or stimulated with PMA (10 ng/ml) or TNFα (10 ng/ml) for 18 hours to activate 
AP-1 or NFκB, respectively. The data represents the mean ± SD of triplicate values normalised 
to renilla luciferase. The statistical significance was calculated using the Student’s t-test (ns = 
p>0.05, * = p≤0.05, ** = p≤0.01, *** = p≤0.001, **** = p≤0.0001). The statistical differences 
between the unstimulated and stimulated luciferase gene expressions are shown in [A] and 
[D], whilst the statistical differences between the basal expressions of the constructs 
compared to that of pCpGmCMV are shown in [B] and [E]. Fold inductions are shown in [C] 
and [F].  
[D
[E] [F]
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Interestingly, the synthetic promoters with a proximal TFBS located closer to the TATA box 
had the highest basal and induced luciferase gene expression levels. As the proximal TFBSs 
was positioned further from the TATA box, the basal and induced gene expression gradually 
decreased. This trend was observed in both the AP-1-responsive promoters (Fig 3.17 A and 
B) and the NFκB-responsive promoters (Fig 3.17 D and E). Due to equivalent decreases in 
both the basal and induced luciferase gene expressions levels, the overall fold inductions were 
very similar for the AP-1-responsive promoters (Fig 3.17 C) and the NFκB-responsive 
promoters (Fig 3.17 F). 
Overall, the promoters with a 66 bp space generally displayed low basal and highly induced 
luciferase gene expression and will be applied to construct the composite synthetic promoters.  
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3.4. pCpG-4bp-composite synthetic promoters exhibit impaired synergistic gene 
expression, potentially due to steric hindrance of TFs  
For simplification purposes, a revised pCpG-4bp-composite promoter library was generated 
so that all of the composite promoters possess the same pCpG vector, the same degree of 
spacing between the proximal TFBS and the TATA box (66 bp space) and the same TFBS 
sequences (NFκB, AP-1 and HRE motifs), to eliminate the influences of dissimilar 
components. In this way, all factors remained constant, with the exception of the degree of 
spacing between the TFBS in order to confidently determine whether increasing the spacing 
between the TFBS can permit synergistic gene expression. The construction of the revised 
pCpG-4bp-composite promoters is schematically depicted in Figure 3.18.  
 
A. A spacer oligonucleotide was ordered with 5’-XbaI and 3’-XhoI overhangs to allow a 
66bp space between the proximal TFBS and the TATA box. The XbaI overhang      5’-
CTAG, is compatible to the NheI overhang, and the ligation of XbaI and NheI 
overhangs generates the sequence 5’-GCTAGA, which is unrecognisable by any 
restriction enzyme and destroys the NheI site. Therefore, the annealed spacer 
oligonucleotide was cloned into the NheI/XhoI site, upstream of the mCMV promoter 
within the pCpGmCMV vector to generate the pCpGmCMV-66bp cloning vector (Fig 
3.18 A).   
 
 
 
 
 
B. The spacer oligonucleotide 
contains an internal NheI site, 
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therefore the   pCpGmCMV-66bp construct was digested with NheI to generate the 
linear pCpGmCMV-66bp cloning vector. The linear vector was incubated with CIP to 
dephosphorylate the ends of the DNA to prevent re-ligation of the vector (Fig 3.18 B).       
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C. The oligonucleotides comprised of the fixed NFκB, AP-1 and HIF-1α binding site 
sequences were ordered with phosphorlyated 5’-CTAG overhangs, which are 
compatible to the NheI overhang.  The annealed oligonucleotides were cloned at 
random into the pCpGmCMV-66bp cloning vector to generate a library of composite 
promoters with varying compositions and numbers of TFBSs, with a 4bp space 
between each TFBS and a 66bp space between the proximal TFBS and the TATA box 
(Fig 3.18 C). The DNA sequences of selected pCpG-4bp-composite promoters are 
presented in Appendix 9.    
 
   
 
 
 
 
 
 
Figure 3.18. A schematic diagram of a pCpG-4bp-composite synthetic promoter. Using 
the random ligation method, each TFBS was separated by a 4bp space. The proximal TFBS 
and the TATA box (T) were separated by a 66bp space. 
 
The pCpG-4bp composite promoter constructs (n=20) were co-transfected with pRL-CMV into 
293T cells. Transfected 293T cells were unstimulated, incubated in hypoxia (0.1% O2) or 
stimulated with TNFα (10 ng/ml), PMA (10 ng/ml) or their combination. The normalised 
luciferase expression was plotted in Figure 3.19. 
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Figure 3.19. The pCpG-4bp-composite promoters display multi-
responsiveness and impaired synergistic gene expression. pCpG-
4bp-composite promoters (180 ng) were co-transfected with pRL-CMV 
(20 ng) into 293T cells (20,000 cells in a 96 well-plate) which were either 
unstimulated, incubated in hypoxia (0.1% O2) [A], or stimulated with 
TNFα (10 ng/ml) [B], PMA (10 ng/ml) [C] or their combination [D] for 18 
hours. The data represents the mean ± SD of triplicate values normalised 
[
[
[
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Similar to the pGL3-4bp-composite promoters (section 3.2.2), the pCpG-4bp composite 
promoters also displayed very high basal luciferase gene expression which were almost 
comparable to their induced luciferase gene expression. Both of these data strongly support 
the results in section 3.3.5 (Fig 3.12) which demonstrated that synthetic promoters with closely 
located TFBSs induce high basal and high induced luciferase gene expression.  
Despite the significant increases in gene expression following combined inflammatory and 
hypoxic stimulation, the majority of the pCpG-4bp-composite promoters exhibited impaired 
synergistic gene expression when compared to their level of gene expression following 
stimulation with a single stimulus, which strengthens the notion that the cloning of TFBSs in 
close proximity impedes the induction of additive/synergistic gene expression.   
Overall, the expression profiles of the pGL3-4bp-composite promoters (section 3.2.2) and the 
revised pCpG-4bp-composite promoters (described in this section), were very similar and both 
promoter libraries displayed high basal, high induced gene expression, multi-responsiveness 
and impaired additive/synergistic induction. Therefore, the ability to induce synergistic gene 
expression by increasing the spacing between the TFBSs was assessed by constructing 
composite promoters with a 20 bp space between the NFκB, AP-1 and HIF-1α binding sites.  
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3.5. pCpG-20bp-composite synthetic promoters display differential, multi-responsive 
and synergistically-inducible luciferase gene expression  
Using the Assembly PCR method, the forward and reverse oligonucleotides with NFκB, AP-1 
or HIF-1α binding sites, flanked by 20 bp annealing sequences, were pooled together with the 
standard 5’-NheI and 3’-XhoI ‘stop’ primers and PCR reaction components. The PCR products 
were digested with NheI and XhoI and cloned into the equivalent site within the pCpG-5bp 
cloning vector to introduce a 66 bp space between the proximal TFBS and the TATA box. The 
resulting pCpG-20bp-composite synthetic promoters (n=20) each had different compositions 
and numbers of the NFκB, AP-1 and HRE motifs, as schematically depicted in Figure 3.20. 
 
 
Figure 3.20. A schematic diagram of a pCpG-20bp-composite synthetic promoter. Each 
TFBS was separated by a 20 bp space. The proximal TFBS and the TATA box (T) were 
separated by a 66 bp space. The DNA sequences of selected pCpG-20bp-composite 
promoters are presented in Appendix 10.  
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The structural components comprising the three distinct composite promoter libraries are 
compared in Table 3.2.  
 
Table 3.2. Structural comparisons of three composite synthetic promoter libraries. The 
structures of the pGL3-4bp-composite promoters, pCpG-4bp-composite promoters and the 
pCpG-20bp-composite promoters are compared.  
 
The pCpG-4bp-composite promoters and the pCpG-20bp-composite promoters possessed 
the same components with the exception of different spacing between the TFBSs. Therefore, 
the functional activities of the composite promoters within these two libraries can be reliably 
compared to determine the effect of increased TFBS spacing on synergistic induction. The 
pCpG-20bp-composite promoter constructs (n=20) were co-transfected with pRL-CMV into 
293T cells and were either unstimulated, incubated in hypoxia (0.1% O2) or stimulated with 
TNFα (10 ng/ml), PMA (10 ng/ml) or their combination. The normalised luciferase gene 
expression was plotted in Figure 3.21. 
 pGL3-4bp composite promoters  
pCpG-4bp composite 
promoters 
pCpG-20bp 
composite promoters 
Results section  Section 3.3.2 Section 3.4 Section 3.5 
Backbone vector pGL3mCMV pCpGmCMV pCpGmCMV 
Spacing between the TFBSs 4 bp 4 bp 20 bp 
Distance between proximal 
TFBS and TATA box 45 bp 66 bp 66 bp 
NFκB sequence GGGAATTTC GGGACTTTCC GGGACTTTCC 
HIF-1α sequence ACGTGG ACGTGC ACGTGC 
AP-1 sequence TGAGTCA TGAGTCA TGAGTCA 
C/EBPβ, Egr-1 and Ets-1 
sites included  Yes No No 
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Figure 3.21. pCpG-20bp-composite synthetic promoters display 
multi-responsiveness and additive/synergistic gene 
expression. The pCpG-20bp composite promoters (180 ng) were 
co-transfected with pRL-CMV (20 ng) into 293T cells (20,000 cells in 
a 96-well plate) which were either unstimulated, incubated in hypoxia 
(0.1% O2) [A], or stimulated with TNFα (10ng/ml) [B], PMA (10ng/ml) 
[C] or their combination [D] for 18 hours. The data represents the 
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Encouragingly, the synthetic promoters displayed low basal and relatively high luciferase gene 
expression in response to individual stimuli, which was the expression profile particular to 
promoters with a 20 bp space between the TFBS and a 66 bp space between the proximal 
TFBS and the TATA box (as identified in sections 3.3.5 and 3.3.7, respectively). As 
anticipated, the vast majority of the composite synthetic promoters displayed significant multi-
responsiveness to individual stimuli (p≤0.05 to p≤0.0001), which can be attributed to the 
diversity in their sequence compositions. Importantly, all of the promoters exhibited significant 
increases in luciferase gene expression in response to combined inflammatory and hypoxic 
stimulation (p≤0.05 to p≤0.0001), where numerous promoters displayed additive/synergistic 
luciferase gene expression. For example, promoters 1, 4, 9, 17, 19 and 20 were multi-
responsive to the individual stimuli and were synergistically induced with combined stimuli. 
Similarly, several promoters displayed additive luciferase gene expression following combined 
stimulation e.g. promoters 2, 6, 7, 11, 13, 14 and 16. These observations strongly suggest that 
the steric hindrance associated with the close proximity of TFBSs had been alleviated by 
increasing the spacing between the TFBSs from a 4bp to 20bp space, which potentially 
permitted the induction of additive/synergistic gene expression.  
As previously speculated in section 3.2.2, the proximal TFBS appeared to influence the overall 
responsiveness of the promoter to the corresponding stimulus. However, comparisons 
between the functional analysis data (Fig 3.21, above) and the DNA sequences of the 
composite synthetic promoters (Fig 3.22, below) revealed that the presence of a single 
proximal TFBS did not always ensure high responsiveness to the equivalent stimulus. For 
example, promoter 5 possessed a proximal AP-1 motif and according to my initial proposal, 
this promoter should have induced the greatest gene expression in response to PMA and/or 
TNFα stimulation, irrespective of the presence of other TFBSs. Contrary to this prediction, the 
promoter was more inducible by hypoxia than to PMA or TNFα stimulation, which may have 
been due to the presence of 3 consecutive HRE motifs followed by a single proximal AP-1 
motif.  
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A noticeable observation was that the synthetic promoters with pairs or triplicates of the same 
TFBS often had very high responsiveness to the corresponding stimulus but displayed 
unchanged or slightly decreased gene expression following combined inflammatory and 
hypoxic stimulation. For example, promoter 18 was comprised of two separate pairs of NFκB 
motifs (amongst the other TFBSs) and a proximal HRE motif and this promoter was 
significantly induced by TNFα and PMA but was unresponsive to hypoxia and displayed 
slightly reduced gene expression in response to combined stimulation (Fig 3.22). Similarly, 
promoter 3 possessed a pair of HRE motifs (flanked by unpaired AP-1 and NFκB motifs) and 
also a pair of proximal HRE motifs. This promoter was significantly responsive to hypoxia and 
marginally, but significantly inducible, by inflammatory stimulation and displayed unchanged 
gene expression in response to combined stimulation, suggesting that the presence of 
unevenly distributed clusters of the same TFBS permit high-responsiveness to corresponding 
stimuli but hinder the induction of strong additive/synergistic gene expression.  
In contrast, the synthetic promoters with relatively evenly distributed single TFBSs generally 
displayed low responsiveness to individual stimuli but exhibited strong synergistic gene 
expression e.g. promoters 9, 14 and 19. Similarly, the even distribution of paired/triplicate 
TFBSs appeared to permit high gene expression in response to individual stimuli as well as 
strong synergistic gene expression e.g. promoter 4 which possessed multiple pairs and/or 
triplicates of NFκB, AP-1 and HRE motifs (Fig 3.22), which highlighted the importance of 
evenly distributed and potentially clustered TFBSs on high gene expression in response to 
individual and combined stimulation.   
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For simplification, the sequences of the promoters discussed in this section are schematically 
presented in Figure 3.22 (DNA sequencing data in Appendix 10).  
 
Figure 3.22. Schematic representation of the sequences of selected pCpG-20bp 
composite promoters.  The DNA sequences of the selected composite synthetic promoters 
from Appendix 10 are schematically presented above.  
 
 
Overall, the majority of the promoters exhibited the required differential, highly-inducible and 
multi-responsive gene expression. The introduction of a 20 bp space between the TFBSs 
appeared to alleviate the steric hindrance associated with a 4 bp space between the TFBSs 
and permit the induction of additive/synergistic gene expression.  
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3.6.  The pCpG-clustered composite synthetic promoters exhibit stimuli-specific 
induction of luciferase gene expression   
DNA sequence analysis and functional characterisation of the pCpG-20bp composite 
synthetic promoters (previous section 3.5) highlighted that the synthetic promoters with evenly 
distributed clusters of the same TFBSs were highly-inducible to individual and combined 
stimuli and clustered TFBSs appeared to dominate the overall responsiveness of the promoter 
to the corresponding stimulus. To verify these observations, composite synthetic promoters 
with randomly cloned clusters of 6NFκB, 8AP-1 or 6HRE and systematically cloned proximal 
6NFκB, 8AP-1 or 6HRE motifs were constructed, as depicted in Figure 3.23. 
 
A. The plasmid DNA constructs pCpG-6NFκB, pCpG-8AP-1 and pCpG-6HRE were 
digested with NheI to serve as cloning vectors with proximal 6NFκB, 8AP-1 and 6HRE 
motifs, respectively. Re-ligation of the linear vector was prevented by 
dephosphorylating the DNA ends using CIP enzyme (Fig 3.23 A).   
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B. The plasmid DNA constructs pCpG-6NFκB, pCpG-8AP-1 and pCpG-6HRE were also 
digested with NheI and XhoI to isolate the 6NFκB, 8AP-1 and 6HRE fragments (Fig 
3.23 B).   
 
  
 
 
 
 
C. Equimolar concentrations of the digested 6NFκB, 8AP-1 and 6HRE fragments were 
cloned at random into the NheI site within the different vectors (proximal 6NFκB, 8AP-
1 and 6HRE vectors) to generate the pCpG-clustered composite promoter constructs 
(Fig 3.23 C).  
 
 
 
 
 
Figure 3.23. Schematic diagram of a pCpG-clustered composite synthetic promoter 
with randomly cloned clusters of 8AP-1, 6HRE and 6NFκB. Each cluster had a 20 bp space 
between the TFBSs and the distance between the proximal TFBS and the TATA box was 
66bp. The reverse orientation of the middle TFBS is indicated by a left-pointing arrow. 
219 
 
The presence of multimerised clusters within the pCpG-clustered composite promoters was 
confirmed by an EcoRI/StuI analytical digest and gel electrophoresis (Fig 3.24). 
     
    
    
 
 
 
 
  
Figure 3.24. Analytical restriction enzyme digest of pCpG-
clustered composite promoters. The plasmid DNA constructs with 
proximal 6NFκB [A], proximal 8AP-1 [B] and proximal 6HRE [C] motifs 
were digested with EcoRI and StuI to release the PCR product (and an 
excess of 247 bp). Therefore, the size of the promoter was calculated 
by subtracting 247 bp from the size of the excised fragment using the
[
[
[
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Figure 3.24 shows the EcoRI and StuI restriction digests of the pCpG-clustered composite 
promoters with proximal 6NFκB, 8AP-1 and 6HRE motifs (Fig 3.24 A-C, respectively). Due to 
the cloning method, the release of EcoRI/StuI digested fragments from the pCpG-clustered 
composite promoters larger than the fragments isolated from their respective vector, indicated 
that the promoter contained at least 3 clustered motifs (6NFκB, 8AP-1 and/or 6HRE), two of 
which differed from the proximal TFBS (DNA sequencing: Appendix 11). The pCpG-clustered 
composite promoters containing at least 3 clustered motifs were selected and co-transfected 
with pRL-CMV into 293T cells (n=8, per group). Transfected cells were unstimulated, 
incubated in hypoxia (0.1% O2) or stimulated with TNFα (10 ng/ml), PMA (10 ng/ml) or their 
combination. The normalised luciferase gene expressions were plotted in Figure 3.25. 
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Figure 3.25. Functional analysis of pCpG-clustered composite 
promoters. The       pCpG-clustered composite promoters (180 ng) were 
co-transfected with pRL-CMV (20 ng) into 293T cells (20,000 cells in a 
96-well plate), which were either unstimulated, incubated in hypoxia 
(0.1% O2) [A] or stimulated with TNFα (10 ng/ml) [B], PMA (10 ng/ml) [C] 
or their combination [D] for 18 hours. The data represents the mean ± SD 
f t i li t l li d t ill l if Th t ti ti l
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Generally, the promoters exhibited significant increases in gene expression to different 
individual stimuli but importantly, the proximal TFBSs appeared to dictate the overall 
responsiveness of the composite promoter to the corresponding stimulus e.g. composite 
promoters with proximal 6HRE displayed the greatest hypoxia-inducibility (p≤0.01 to 
p≤0.0001), irrespective of the presence of HRE motifs within the proximal-6NFκB and -8AP-1 
promoters. Similarly, proximal-6NFκB and -8AP-1 promoters were significantly responsive to 
TNFα and PMA respectively, but marginally inducible by hypoxia. 
Interestingly, despite the statistically significant increases in luciferase gene expression 
following combined stimulation, the composite synthetic promoters with proximal 6NFκB and 
8AP-1 had impaired synergistic gene expression which is in agreement with the previous 
observation that composite promoters with paired/triplicate TFBSs displayed unchanged or 
slightly reduced gene expression in response to combined inflammatory and hypoxic 
stimulation (section 3.5). In contrast, the composite promoters with clustered proximal 6HRE 
displayed marginally increased luciferase gene expression following the same treatment. 
Strikingly, the promoters with proximal 6NFκB motifs were highly and significantly responsive 
to TNFα but displayed markedly lower gene expression (upto 50% reduced fold induction) in 
response to the combined inflammatory and hypoxic stimulation. An important question to 
emerge from these observations is ‘which TFBS should be positioned closest to the TATA 
box?’. This is an important consideration when constructing multi-responsive composite 
synthetic promoters because the promoter will need to be constructed according to the most 
dominant pathological feature of the disease under study. With focus on RA, inflammation is 
the main pathological feature and therefore, the composite promoters are required to be highly 
inflammation-inducible which can be achieved by positioning AP-1 or NFκB, preferably 
clustered motifs, proximal to the TATA box. However, as demonstrated in the results above, 
the presence of clustered proximal NFκB and AP-1 motifs hinders the induction of synergistic 
gene expression and unless optimised, precludes the further application of composite 
promoters with clustered proximal NFκB and AP-1 motifs. 
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3.7. Discussion 
An integral component of this thesis was to engineer and functionally characterise composite 
synthetic promoters, which were comprised of randomly cloned core TFBS for inflammation 
and/or hypoxia-responsive TFs. The experiments in Chapter 3 expanded on the concept of 
exploiting the endogenous activity of diverse TFs which are activated during inflammation 
and/or hypoxia, to transcriptionally regulate therapeutic gene expression using composite 
synthetic promoters. The functional activities of the pGL3-4bp-composite synthetic promoters 
revealed several structural parameters which negatively impacted the transcriptional activity 
of the promoter and highlighted the requirement to optimise the composite promoter structure. 
An alternative Assembly PCR method was implemented to control the spatial arrangement of 
TFBSs and the functional activities of the resulting promoters revealed that increased spacing 
between the TFBS and also increased spacing between the proximal TFBS and the TATA box 
resulted in decreased basal and induced luciferase gene expression. Application of the optimal 
spatial preferences of TFBSs, relative to one another and also to the TATA box, generated 
improved, highly-inducible, multi-responsive and synergistically-inducible composite synthetic 
promoters, which are promising novel candidates for local RA gene therapy.  
The feasibility of synthetic promoters for disease-regulated gene therapy has been 
successfully demonstrated by a number of publications, for example, an NFκB-responsive 
synthetic promoter has been used to control anti-TNFα therapeutic gene expression in an 
inflammation-inducible manner (Khoury et al., 2007) and HIF-1α-responsive synthetic 
promoters are commonly used for cancer gene therapy (Shibata et al., 2000). However, these 
synthetic promoters respond to limited stimuli which restrict their application to the treatment 
of diseases characterised by a single dominant pathological condition. The concept of 
combining TFBSs within composite promoters has significant advantages over single-
responsive promoters for RA gene therapy. Notably, the use of composite promoters for local 
RA gene therapy represents a means to harness the endogenous activity of different TFs to 
regulate therapeutic gene expression in response to multiple pathological stimuli in the RA 
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joint and the potential to induce synergistic therapeutic gene expression, which is an ideal 
system for RA gene therapy. 
 
3.7.1.  Composite synthetic promoters with a 4bp space between TFBS exhibit 
impaired synergistic gene expression, potentially due to steric hindrance of TFs 
Section 3.2.2 proceeded with the construction of the initial pGL3-4bp-composite synthetic 
promoter library, which were comprised of the core binding sites of NFκB, HIF-1α, AP-1, 
C/EBPβ, Egr-1 and Ets-1, known to be activated in RA. The design of the composite synthetic 
promoters adhered to the requirements necessary for eukaryotic gene transcription; the 
synthetic promoters were comprised of TFBSs and a minimal cytomegalovirus (mCMV) 
promoter which consisted of a TATA box positioned in the forward orientation to direct RNA 
polymerase II transcription (Wang and Stumph, 1995).  
The conventional method for constructing synthetic promoters, as demonstrated by others, 
involves PCR amplification of the region of an endogenous promoter which contains the 
required TFBSs and cloning the fragment upstream of the transgene. For example, Geurts et 
al., (2009) rationally designed synthetic promoters suitable for RA gene therapy by combining 
computational analysis and experimental verification which identified that the binding sites of 
NFκB, AP-1 and C/EBPβ were over-represented within the proximal promoters (region 
containing TFBSs) of endogenous genes in the synovial tissues of mice with collagen-induced 
arthritis (CIA). Their studies led to the identification of the inflammation-inducible serum 
amyloid A3 (Saa3) proximal promoter (containing 3 C/EBPβ motifs and possibly other TFBSs), 
which was PCR cloned upstream of the IL-1 receptor antagonist (IL-1ra) therapeutic gene to 
transcriptionally regulate IL-1ra expression during inflammation. Based on their striking 
observation that numerous endogenous promoters of genes upregulated in CIA mice were 
comprised of different TFBSs i.e. NFκB, AP-1 and C/EBPβ, the studies of Geurts et al., (2009) 
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strengthened our concept of engineering composite synthetic promoters, using the above 
candidate TFBSs, for RA gene therapy. 
However, repeated PCR cloning of endogenous proximal promoters would not be a feasible 
method to generate compact composite promoters with multiple TFBSs, as this would require 
numerous PCR amplifications of multiple genes containing each of the TFBSs under study. 
This cloning strategy would result in extremely large synthetic promoters that could potentially 
hinder further cloning applications into limited capacity vectors. Furthermore, this cloning 
method would amplify the TFBSs as well as the intervening sequences between the TFBSs, 
which may exert unwarranted regulatory effects on the synthetic promoter activity. Therefore, 
oligonucleotides containing only the core TFBSs of the candidate TFs were randomly ligated 
via the NheI overhangs, which resulted in the construction of compact composite promoters 
with diverse arrangements and numbers of the TFBSs. The synthetic promoters were cloned 
upstream of the firefly luciferase reporter gene, which enabled an efficient functional readout 
of the promoter activity.     
The pGL3-4bp-composite promoters (section 3.2.2) were screened for the required 
expression profiles; low basal and highly induced gene expression, multi-responsiveness and 
synergistic-inducibility. The vast majority of the composite promoters demonstrated high basal 
luciferase gene expression and the gene therapy application of these synthetic promoters 
would result in ‘leaky’ therapeutic gene expression during the remission phase of the disease, 
which is an undesirable attribute. Unwarranted high concentrations of the therapeutic protein 
during remission could increase the risk of immunosuppression and other adverse effects 
thereby decreasing the safety and efficacy of the therapy. However, low/moderate basal 
therapeutic gene expression is essential to sustain remission and to prevent the disease from 
rebounding, which demonstrates the complexity of generating tightly-regulated synthetic 
promoters.   
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The induction of synergistic gene expression by the composite synthetic promoters is crucial 
to the development of a novel gene therapy for RA, however, the vast majority of the pGL3-
4bp-composite promoters displayed unchanged or reduced luciferase gene expression 
following combined inflammatory and hypoxic stimulation, which may have been due to the 
close proximity of the TFBSs. The relevance of optimal spacing between the TFBSs within the 
composite synthetic promoters can be logically explained by the endogenous TF-DNA 
interactions during transcription. Upon activation, TFs rapidly locate and bind to their TFBS 
along the DNA to regulate expression of the downstream gene(s). Published thermodynamic 
principles of TF-DNA interactions report that the search mechanism of TFs involves a 
combination of 3D diffusion through the cell volume and 1D sliding along the DNA, which has 
been a widely accepted model over the past 30 years (Berg et al., 1981; Halford and Marko, 
2004). These principles of TF-DNA interactions can be applied to interpret the interactions 
between the candidate TFs and the composite synthetic promoters with a 4bp space between 
the TFBSs. During combined hypoxic and inflammatory stimulation, the TFs become activated 
and diffuse through the cell volume and bind to the DNA where they adopt one of two 
conformations; the TFs loosely bind to the DNA and slide along the DNA by 1D diffusion in 
search of their respective binding sites or the TFs become immobile by tightly associating with 
the DNA (Hu et al., 2008). During the sliding search process, it is likely that DNA-bound TFs 
impede the efficient search processes of other TFs and loosely bound TFs are possibly 
dislodged. Once the TF has successfully located its binding site within the synthetic promoter, 
it undergoes an irreversible conformational transition to a final bound state (Hu et al., 2008). 
Therefore, the impaired synergistic expression by pGL3-4bp-composite promoters may have 
been a consequence of cloning the TFBSs in close proximity where the irreversibly bound TF 
could have sterically hindered the binding of another TF to the adjacent binding site, rendering 
some TFBSs inaccessible. 
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The impaired synergistic induction may have also been a consequence of DNA torsional stress 
induced by the arrangement of the TFBSs within the synthetic promoters. One turn of the DNA 
helix is approximately 10.5 bp (Wang, 1979) and a 4bp space between the TFBS, equates to 
less than half a turn of the DNA helix. This positions the TFBSs on alternating sides of the 
DNA which can induce additional DNA torsional stress and impede efficient transcription 
(Schleif, 1992). The topological state of the DNA is a major regulator of the transcriptional 
process and it is well known that RNA polymerase II introduces a degree of torsional stress in 
DNA during transcription which effects the expression of downstream gene(s) (Mirkin, 2001). 
During transcription, the DNA loops to allow remote regulatory elements to interact with the 
transcription initiation complex assembled on the TATA box (Ptashne, 1986). In response to 
combined inflammatory and hypoxic stimulation, the accessible TFBSs within the composite 
synthetic promoters become occupied by their respective TFs. Looping and repeated twisting 
to allow the interaction of each TF-TFBS complex with the TATA box may have induced 
excessive DNA torsional stress which potentially decreased the efficiency of the transcriptional 
process and consequently impaired the induction of synergistic gene expression. DNA 
torsional stress and subsequent supercoiling of closed circular plasmid DNA are energetically 
unfavourable, therefore the changes to relax the local DNA become favourable (Benham, 
1979). A possible means to relax the DNA can be to avoid repeated twisting by excluding 
energetically unfavourably positioned TF-TFBS complexes and only allowing the TF-TFBS 
complexes positioned every 10-12bp (equal to integral multiples of DNA helical repeats) to 
interact with the TATA box. This may explain why the vast majority of the pGL3-4bp-composite 
promoters containing one or more HRE motifs (flanked by other TFBS) failed to display 
hypoxia-inducibility. 
Interestingly, the pCpG-4bp-composite promoters (section 3.4) displayed very similar 
expression profiles to the pGL3-4bp-composite promoters, as discussed above. Both 
composite promoter libraries were constructed using the random ligation cloning method and 
demonstrated high basal and high induced luciferase gene expression, multi-responsiveness 
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to individual stimuli and impaired synergistic gene expression following combined stimulation, 
irrespective of dissimilar structural components between the two promoter libraries. These 
observations supported the implication of a 4bp space between TFBSs as the cause of 
hindered synergistic gene expression and encouraged the reconstruction of the synthetic 
promoters using an alternative cloning method.   
 
3.7.2. Optimisation and application of the Assembly PCR method to fine-tune 
constraining parameters of gene expression 
Section 3.3 provided a detailed account on the optimisation of the Assembly PCR method and 
its application to generate synthetic promoters which demonstrated that the spatial 
organisation of the TFBSs had profound effects on the luciferase gene expression induced by 
synthetic promoters.  
The Polymerase Chain Assembly (PCA) method is a two-step PCR technique traditionally 
used to synthesise genes from oligonucleotides comprising the sequence of the gene of 
interest: the overlapping oligonucleotides are assembled using PCA and then amplified using 
PCR to create the synthetic gene (Stemmer et al. 1995). The Assembly PCR method is an 
adaptation of the PCA method and research conducted by Team Heidelberg (International 
Genetically Engineered Machine (iGEM) Competition, 2009) has demonstrated the feasibility 
of the Assembly PCR method to construct single-responsive synthetic promoters. However, 
the functional activities of their NFκB-responsive synthetic promoters varied considerably, with 
some promoters displaying minimally induced GFP reporter gene expression. Also, the gene 
expression induced by the most responsive promoter did not exceed 2.6 fold induction in 
response to 2.5 μM TNFα in U2OS cells. The studies of Team Heidelberg also reported that 
their HIF-1α and p53 synthetic promoters failed to induce sufficient gene expression. The 
incorporation of random spacer oligonucleotides and oligonucleotides with random TFBS 
sequences generated libraries of promoters with extremely variable TFBS organisation and 
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TFBS sequence composition which was reflected by their highly variable promoter strengths. 
Their concept of constructing spatially diverse promoters, from a single PCR reaction, 
represented an inefficient method of identifying the optimal spacing between TFBS, which was 
one of my objectives. Therefore, the Assembly PCR method described in section 3.3 adhered 
to the method by Team Heidelberg but with systematic and optimised modifications to 
rationally design single- and composite-synthetic promoters.  
The oligonucleotides used in this thesis were modified to incorporate the TFBSs flanked by 
two annealing sequences of specified lengths, in individual PCR reactions. This rational 
approach to generating different libraries of promoters with specific TFBS spacing facilitated 
the investigation on the effect of increased spacing between TFBSs on gene expression. 
Section 3.3 described the optimisation of the Assembly PCR method, which expanded on the 
observations by Wu et al. (2006) and TerMaat et al., (2009) who showed that the efficiency of 
the PCA reaction is affected by several parameters i.e. the concentrations of assembly 
oligonucleotides and amplification primers and the choice of polymerase enzyme. These 
parameters provided a guideline for the optimisation of the Assembly PCR reaction described 
in this thesis. 
The use of Phusion DNA polymerase enzyme, which is a high-fidelity enzyme with 50 times 
greater fidelity than Taq polymerase (www.neb.com), ensured correct and efficient assembly 
and amplification of the PCR products, which was fundamental for the error-free construction 
of synthetic promoters. The ‘stop’ oligonucleotide concentration in the initial assembly reaction 
was also optimised and demonstrated that the PCR product size decreased with increasing 
‘stop’ oligonucleotide concentration. In turn, the successful incorporation of the ‘stop’ 
oligonucleotides increased the efficiencies of the subsequent amplification reaction, restriction 
enzyme digestion, ligation and cloning steps, which strongly corroborated the results of Wu et 
al., (2006) and TerMaat et al., (2009). 
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The PCR products were cloned into the pCpGmCMV vector which had more suitable 
properties for in vitro and potential in vivo gene expression analysis than the pGL3mCMV 
vector. The pCpGmCMV vector is a modified construct of the pCpG free-mSEAP plasmid 
which is completely devoid of CpG dinucleotides. It has been demonstrated that CpG-devoid 
plasmid DNA has significantly increased long-term gene expression compared to CpG-replete 
analogues (Hodges et al., 2004) where the presence of unmethylated CpG dinucleotides can 
elicit strong immunogenic responses (Krieg et al., 1995) which may hinder the safety and 
efficacy of the gene therapy. The pCpGmCMV vector also possesses two matrix attachment 
regions (MARs) from the 5’-region of the human IFN-β gene and the        β-globin gene, which 
function as insulators by preventing external enhancers from influencing the promoter when 
placed between them, to enhance long-term gene expression and prevent expression 
variability (Recillas-Targa et al., 2002). The absence of CpG dinucleotides and the action of 
‘enhancer blocking' properties of the pCpGmCMV vector limits toxicity and increases the 
durability of gene expression.  This vector was intended for in vitro promoter analysis however, 
due to the aforementioned attributes of the pCpGmCMV vector, the pCpG-promoter 
constructs have the potential to be delivered in vivo, thereby serving as a reserve plan should 
the promoters fail to induce significant gene expression in the lentiviral constructs.  
Endogenous promoters consist of many conserved properties therefore it was important to 
adhere to the favourable characteristics of endogenous promoters as well as incorporating 
additional properties when constructing the synthetic promoters. One common feature of 
endogenous promoters is diversity within the TFBSs among different genes, which mediates 
divergence in gene expression between different cells and species, to control the gene activity 
levels globally (Wittkopp, 2010). The PCR component of the Assembly PCR reaction was 
exploited to introduce sequence diversity within the general NFκB consensus sequence, 
GGGRNNYYCC, to determine the effect of NFκB sequence diversity on the activity of 
promoters with variable NFκB motifs. As anticipated, the variable NFκB promoters displayed 
diverse expression profiles in response to TNFα, which can be explained by the promiscuous 
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nature of TFs, which bind to the different variations of their consensus sequence with different 
affinities to induce diverse gene expression (Bradley et al., 2010). Noticeably, the number of 
variable NFκB sites had no effect on gene expression and a striking observation was that the 
two most active variable NFκB promoters possessed NFκB sequences which were very similar 
to the fixed NFκB sequence, which highlighted that the TF binding sequence is more important 
for achieving high-level gene expression than TFBS copy number, as also demonstrated by 
Sharon et al., (2012).  
Interestingly, the fixed NFκB promoter consistently induced high luciferase gene expression 
following TNFα stimulation where the magnitude of gene expression was dependent on fixed 
NFκB copy number within the promoter. However, saturation was observed for promoters with 
6 or more fixed NFκB motifs where further addition of NFκB motifs within the promoters 
marginally increased gene expression. A similar observation was described by Shibata et al., 
(2000) who demonstrated that increasing the number of HRE motifs within the synthetic 
promoters increased hypoxia-responsiveness upto 5HRE motifs, at which point the luciferase 
gene expression reached a maximal gene expression plateau. Taken together, the 
observations from this experiment led to the incorporation of the ‘high affinity’ fixed NFκB 
binding sites in the composite promoters to favour high inflammation-inducibility.  
 
3.7.3. Increased spacing between the TFBSs and the proximal TFBSs relative to the 
TATA box negatively impacts gene expression of synthetic promoters.  
The Assembly PCR method was implemented to explore the functional significance of 
increased spacing between the TFBSs and also to determine whether the changes in the 
position of the proximal TFBS relative to the TATA box influences gene expression. The 
experiments in section 3.3.5 confirmed the importance of optimal structural arrangements of 
the TFBSs and its effect on the activity of the synthetic promoter.  
232 
 
Nine NFκB and AP-1 promoter libraries with 15 bp-60 bp spaces between the NFκB or AP-1 
binding sites were generated using the Assembly PCR method. The functional activities of 
these promoters confirmed the influence of TFBS spatial arrangement on gene expression 
and displayed a clear trend; synthetic promoters with closely located TFBSs displayed high 
basal and high induced luciferase gene expressions compared to lower gene expressions 
induced by promoters with sparse TFBSs. 
Many in silico studies have developed computational models which correlate the structural 
properties of active endogenous promoters to their gene expression profiles, for example, 
Gotea et al., (2010) revealed that endogenous promoters often possess clusters of the same 
type of TFBSs (homotypic clusters), which appear to play an important role in the gene 
regulation in human and other vertebrae genomes (Gotea et al., 2010). Other studies have 
suggested that the presence of homotypic TFBS within locally dense clusters might enhance 
TF recruitment and the TF search process (Brackley et al., 2012) and increase gene 
expression (Sharon et al., 2012), which is consistent with the expression profile trend 
presented in Figure 3.12. For example, the synthetic promoters with a 15bp space between 
the TFBSs displayed the highest basal and induced luciferase gene expressions which could 
be attributed to the high local density of the clustered homotypic TFBSs (NFκB or AP-1 binding 
sites) and facilitated the TF search process which induced higher levels of gene expression 
compared to promoters with sparse TFBS (i.e. 45-60 bp space).  
Encouragingly, this appeared to be a general trend among NFκB and AP-1, which belong to 
two distinct transcription factor families. In addition, the pGL3-4bp- and pCpG-4bp-composite 
promoters also comply with this trend, as these promoters had a 4 bp space between the 
TFBSs and exhibited very high basal and induced luciferase gene expression levels. The 
experiment described in section 3.3.5 confirmed that changes in promoter architecture could 
affect gene expression and the identified trend in Figure 3.12 served as a reliable filtering 
parameter to exclude promoters with unfavourable attributes, i.e. promoters which induced 
high basal ‘leaky’ expression and also promoters which failed to induce sufficient gene 
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expression following stimulation. Therefore, a 20 bp space was selected as the optimal 
spacing between the TFBSs as these promoters display the required low basal and high 
induced luciferase gene expression.  
During transcription, RNA Pol II is recruited to the TATA box (Parker and Topol, 1984) and 
ample evidence supports the fundamental role of the TATA box during transcription 
(Breathnach and Chambon, 1981). This section described the construction and functional 
analysis of NFκB- or AP-1-responsive promoters with 55 bp – 74 bp spacer insertions between 
the proximal TFBS and the TATA box. Interestingly, Geurts et al., (2009) observed that the 
majority of over-represented NFκB and AP-1 binding sites present in the proximal promoters 
of genes upregulated in the tissues of CIA mice were spatially conserved and typically located 
-170/-50 bp and -290/-30 bp upstream of the TATA box, respectively, which is in line with the 
location of the proximal NFκB and AP-1 within the synthetic promoters described in section 
3.3.7.  
Although the NFκB and AP-1 sites were positioned in the conserved spatial window, these 
TFBSs were removed from their normal genomic context and the respective TFs may have 
performed differently within the synthetic promoters. Interestingly, the results in section 3.3.7 
showed that systematically increasing the distance between the proximal TFBS (NFκB or AP-
1) and the TATA box within the synthetic promoters resulted in reduced basal and induced 
luciferase gene expression levels. These results are in line with many studies that 
demonstrated, using synthetic promoter variants, that expansion of the distance between 
upstream elements i.e. TFBSs and the TATA box can reduce transcriptional activation 
(Guarente and Hoar, 1984; McKnight, 1982; Takahashi et al., 1986, Wu and Berk, 1988; Smith 
et al., 1995; Dobi and Winston, 2007; Sharon et al., 2012). Although their observations may 
depend on the origin of the tested promoter, taken together, these publications suggest that 
the transcriptional initiation process requires specific alignments between TFBSs and the 
proteins assembled on the TATA box. Therefore, it is likely that positioning the proximal TFBS 
closer to the TATA box facilitates their interactions, which favour high gene expression.  
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Overall, the optimisation and application of the Assembly PCR method to construct synthetic 
promoters has offered the clear advantage of a high-throughput, inexpensive and efficient 
method to systematically design and construct synthetic promoters. The experiments 
discussed in this section have confirmed the biological implications of TFBS sequence 
diversity and TFBS spatial preferences on gene expression and have enabled the 
identification of 20bp as the optimal spacing between the TFBS and 66bp as the optimal 
distance between the proximal TFBS and the TATA box, which were applied to construct 
improved composite synthetic promoters. 
 
3.7.4. Comprehensive analysis of gene expression induced by pCpG-4bp-composite 
promoters, pCpG-20bp-composite promoters and pCpG-clustered composite 
promoters.  
Section 3.5 described the modifications applied to the composite promoter architecture which 
introduced a 20bp space between randomly cloned NFκB, HRE and AP-1 motifs with a 66bp 
space between the proximal TFBS and the TATA box. Encouragingly, the functional activities 
of these pCpG-20bp-composite promoters demonstrated that the vast majority of these 
promoters were significantly multi-responsive, displayed low basal and high induced gene 
expression and additive/synergistic gene expression following combined inflammatory and 
hypoxic stimulation, all of which are fundamental requirements of composite synthetic 
promoters for RA gene therapy. The induction of additive/synergistic gene expression strongly 
suggests that the spatial hindrance associated with a 4bp space between the TFBSs, (as 
demonstrated in the pGL3-4bp and pCpG-4bp-composite promoters) had been alleviated by 
increasing the spacing between the TFBSs from 4bp to 20bp which permitted synchronous 
binding of the TFs to induce additive/synergistic gene expression. 
Interestingly, the DNA sequencing data of the pCpG-20bp-composite promoters revealed that 
promoters displaying high induction to a particular stimulus possessed pairs/triplicates of the 
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same TFBS (homotypic cluster), which supported the results of Gotea et al., (2010) and also, 
the results in section 3.3.2 demonstrating that promoters with dense homotypic TFBSs (within 
clusters) induced greater gene expression than promoters with sparse TFBSs. The 
sequencing data also highlighted that the presence of paired proximal TFBSs governed the 
overall responsiveness of the promoter to a particular stimulus, irrespective of the presence 
of other TFBSs. However, the presence of unevenly distributed paired/triplicate TFBSs 
appeared to confer high inducibility to an individual stimulus but hindered the induction of 
strong additive/synergistic gene expression. In contrast, the composite promoters with evenly 
distributed paired/triplicate TFBSs displayed similar expression levels to each individual 
stimulus and exhibited robust synergistic gene expression. These observations comply with 
the finding that clustered TFBSs induce high gene expression in response to the 
corresponding stimulus.  
The subsequent results in section 3.6 confirmed that the systematic positioning of 6NFκB, 
8AP-1 or 6HRE clusters proximal to the TATA box dominated the overall responsiveness of 
the pCpG-clustered composite promoter to TNFα, PMA and hypoxia stimulation, respectively. 
However, composite promoters with clustered proximal 6NFκB and 8AP-1 exhibited impaired 
synergistic gene expression whilst the proximal 6HRE appeared to permit modest additive 
gene expression, which strengthen the observations in section 3.5.  
Overall, hypoxia-inducibility is a favourable characteristic but not a prerequisite of composite 
synthetic promoters for RA gene therapy. However, high inflammation-inducibility and the 
induction of synergistic gene expression are undoubtedly required. The induction of high 
inflammation-inducible gene expression at the expense of synergistic induction by the 
composite promoters with clustered proximal 6NFκB and 8AP-1 precluded the further 
application of clustered composite promoters. Nevertheless, the introduction of optimal TFBS 
spatial arrangements permitted additive/synergistic gene expression by the pCpG-20bp-
composite synthetic promoters with randomly arranged TFBSs.  
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CHAPTER 4: 
In Vitro and In Vivo Translational Studies of 
Luciferase Gene Expression from Lentiviral 
Integrated Synthetic Promoters 
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4.1. Introduction 
The in vitro characterisation of transiently transfected synthetic promoter constructs in Chapter 
3 enabled the selection of eight candidate promoters which displayed favourable gene 
expression profiles: promoters 2, 9, 11, 12 and 14 (pCpG-20bp composite promoters), 
promoters 4 and 6 (pCpG-clustered proximal 6HRE) and promoter 245 (pGL3-4bp-composite 
promoter). The synthetic promoters were further characterised by cloning into lentiviral vectors 
(LV) which offer the advantage of allowing integration of the synthetic promoter and transgene 
into the genome of dividing and non-dividing cells to confer long-term and stable transgene 
expression, which is ideal for experimental gene therapy strategies. 
 
4.1.1. Construction of Lentiviral Composite Synthetic Promoters for Regulation of 
Luciferase Gene Expression 
The self-inactivating (SIN) lentiviral plasmid, pLV.CMV.eGFP (Addgene plasmid 30471; Barde 
et al., 2011) was used as the primary lentiviral cloning vector. The schematic diagram below 
illustrates the cloning strategy used to clone the candidate composite synthetic promoters into 
the lentiviral plasmid DNA (Fig 4.1.1.). 
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A. pLV.CMV.eGFP was digested with BamHI and SalI to release the eGFP gene. The 
resulting 8357 bp fragment served as the pLV.CMV cloning vector (Fig 4.1.1 A). 
 
 
 
B. The luciferase gene was PCR amplified from pGL3mCMV using forward and reverse 
PCR primers with BamHI and SalI restriction sites, respectively (Fig 4.1.1 B). 
 
 
 
 
 
 
 
C. The luciferase PCR product was digested with BamHI and SalI and cloned into the 
equivalent site within the pLV.CMV vector to generate pLV.CMV.Luc+ (DNA sequence 
in Appendix 13.1). The resulting plasmid was digested with PmeI and BstBI to release 
the CMV promoter and a 5’-portion of the luciferase gene. The 7882 bp fragment 
served as the cloning vector, pLV.Luc+(Fig 4.1.1 C). 
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D. The candidate synthetic promoters (n=8) were amplified from their equivalent pCpG- 
or pGL3-composite promoter constructs using forward ClaI and reverse BstBI PCR 
primers. The synthetic promoters and the 5’-portion of the luciferase gene were 
amplified (Fig 4.1.1 D).  
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E. The PmeI restriction enzyme produces blunt ended DNA fragments. Therefore the 
PCR products were digested with ClaI and the 5’-overhang was blunted using Klenow 
enzyme to generate blunt ended PCR products. Following Klenow treatment, the PCR 
products were digested with BstBI and ligated with the pLV.Luc+ vector to generate a 
lentiviral plasmid containing the composite synthetic promoter and the restored 
luciferase gene (Fig 4.1.1 E). The resulting lentiviral-luciferase constructs (transfer 
plasmids) were confirmed by DNA sequencing (Appendix 13.2- 13.10).  
 
 
 
 
F. Following the successful construction of the lentiviral synthetic promoter constructs, 
lentiviral particles were produced using a second generation packaging system. This 
involved a three-plasmid transient transfection into 293T cells with the transfer, 
packaging and envelope plasmids to generate lentiviral particles pseudotyped with the 
VSV-G envelope glycoprotein. The VSV-G pseudotyped lentiviral particles were 
transduced into 293T cells to generate a stable 293T cell line with the integrated 
synthetic promoter and luciferase gene. 
 
Figure 4.1.1. Schematic diagram illustrating the cloning method used to generate the 
lentiviral composite synthetic promoter constructs expressing the luciferase gene. The 
pLV.CMV.eGFP lentiviral plasmid was systematically modified to generate the lentiviral 
constructs expressing the luciferase gene under the control of inflammation-inducible 
composite synthetic promoters.   
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4.1.2. Construction of lentiviral NFκB-responsive and SFFV synthetic promoters 
(controls) for luciferase gene expression 
The constitutive SFFV-promoter and the inflammation-inducible 4NFκB-promoter were 
included in the in vivo experiment as positive controls.  The 4NFκB promoter contained a     20 
bp space between the motifs and a 66 bp space between the proximal NFκB and the TATA 
box and was cloned into the lentiviral vector using the method described in section 4.1.1. 
(above). The schematic diagram below illustrates the cloning strategy used to clone the SFFV 
promoter into the lentiviral plasmid DNA (Fig 4.1.2.). 
 
A. The pUCL-Luc+ plasmid was digested with EcoRI, purified and then incubated with the 
Klenow enzyme to generate a 5’-blunt end which can ligate to the PmeI blunt end of 
the pLV.Luc+ vector. The fragment was subsequently digested with BstBI to release 
the SFFV promoter and 5’-portion of the luciferase gene (730 bp fragment) (Fig 4.1.2 
A). 
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B. The SFFV-Luc+ fragment (730 bp) was cloned into the PmeI/BstBI site within the 
pLV.Luc+ vector to restore the luciferase gene and generate pLV.SFFV.Luc+ (Fig 4.1.2 
B), which was confirmed by DNA sequencing (Appendix 13.11).  
 
 
 
 
 
 
 
 
 
 
Figure 4.1.2. Schematic diagram illustrating the cloning method used to generate the 
lentiviral SFFV-promoter positive control construct. The SFFV promoter from the pUCL-
Luc+ construct was cloned into the lentiviral vector to generate the LV-SFFV-Luc+ construct 
expressing the luciferase gene under the control of the constitutive SFFV promoter.  
 
 
  
+
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4.2.  In Vitro functional analysis of luciferase gene expression induced by lentiviral 
integrated composite synthetic promoters 
4.2.1. Comparative analysis of the transcriptional activities of transiently transfected 
plasmid DNA synthetic promoters and lentiviral integrated synthetic promoters  
The luciferase expression induced by the eight candidate promoters in plasmid vectors were 
combined in a single graph for comparative purposes and presented in Figure 4.2. The 
lentiviruses encoding the expression cassettes were used to transduce 293T cells to generate 
stable 293T cell lines expressing the luciferase gene under the control of the integrated 
composite synthetic promoter. An initial screen of the magnitude of luciferase gene expression 
from the stable 293T cells was performed to identify three composite promoters demonstrating 
the greatest inflammation-inducibility and synergistic gene expression (Fig 4.3).  
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Figure 4.2. Functional analysis of transiently transfected inflammation-inducible 
synthetic promoters, from various promoter libraries. The luciferase gene expression of 
the promoters [A] and luciferase fold induction data [B], from separate experiments, were 
combined in one graph to compare the expression profiles of the candidate synthetic 
promoters. The data represents the mean ± SD of triplicate values from independent 
experiments described in Chapter 3. The statistical difference between the unstimulated and 
stimulated luciferase gene expression was calculated using the Student’s t-test (ns = p>0.05, 
* = p≤0.05, ** = p≤0.01, *** = p≤0.001, **** = p≤0.0001). 
  
[
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Figure 4.3. Luciferase gene expression induced by lentiviral (LV) composite synthetic 
promoters. Stable 293T cells expressing the luciferase gene under the control of each of the 
eight composite promoters were seeded at 20,000 cells per well in a 96 well plate. After 24 
hours, the stable 293T cells were unstimulated, incubated in hypoxia (0.1% O2) or stimulated 
with TNFα (10 ng/ml), PMA (10 ng/ml) or their combination [A] for 18 hours. Fold inductions 
were calculated by dividing the induced luciferase values by the uninduced luciferase values 
[B]. Luciferase expression was normalised to the protein content in the cell lysate and lentiviral 
titre of the corresponding lentiviral preparation (expressed as RLU/mg protein/lenti IFU). The 
data represents the mean ± SD of triplicate values, from the same experiment. The statistical 
difference between the unstimulated and stimulated luciferase gene expression was 
calculated using the Student’s t-test (ns = p>0.05, * = p≤0.05,              ** = p≤0.01, *** = 
p≤0.001, **** = p≤0.0001).  
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Figure 4.2 graphically presents the combined gene expression profiles of the composite 
synthetic promoters selected in Chapter 3 (n=8). These promoters displayed differential and 
multi-responsive luciferase gene expression in response to the individual stimuli and exhibited 
diverse magnitudes of additive/synergistic gene expression following combined inflammatory 
and hypoxic stimulation.  
Comparisons between the expression profiles of transiently transfected promoter constructs 
(Fig 4.2) and the lentiviral integrated promoters (Fig 4.3) demonstrated that the stable 
integration of the composite promoters significantly improved the magnitude of induced 
luciferase gene expression and exhibited low basal luciferase gene expression. Also, the vast 
majority of the composite promoters displayed greater additive/synergistic gene expression in 
the stable 293T cells than in plasmid transfected cells.  
Interestingly, the lentiviral promoter LV-2 displayed synergistic luciferase gene expression in 
response to combined inflammatory and hypoxic stimulation, with high fold induction of 988 
fold (Fig 4.3 B). However, the basal expression of promoter LV-2 (6193 RLU/mg protein/lenti 
IFU) was higher than the basal gene expression levels displayed by the other promoters. 
Consequently, the overall fold induction displayed by promoter LV-2 was lower than many of 
the other promoters, e.g. promoter LV-12 displayed an extremely low basal luciferase 
expression (232 RLU/mg protein/lenti IFU) and so that the induced expression resulted in a 
maximal fold induction of 5450 fold following combined inflammatory and hypoxic stimulation.  
In contrast, the luciferase gene expression induced by the lentiviral promoter LV-4 was the 
lowest compared to the other promoters (Fig 4.3), which was not observed following the 
transient transfection of the plasmid DNA equivalent (Fig 4.2). Lentiviral integration of 
promoter LV-4 resulted in a modest 27.5 fold induction in response to combined inflammatory 
and hypoxic stimulation (* p= 0.04, increase in gene expression), which was considerably 
lower than the high fold inductions displayed by the other promoters. Nevertheless, on the 
basis of the expression profile demonstrated with the transiently transfected promoter 
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construct (Fig 4.2A), the plasmid DNA promoter 4 displayed greater gene expression in 
response to hypoxia than to inflammatory stimulation, which is not ideal for RA gene therapy, 
as inflammation is the dominant pathological characteristic.  
The single-responsive promoter 4NFκB in both the plasmid DNA (Fig 4.2) and lentiviral 
construct (Fig 4.3) was responsive to inflammatory stimulation but exhibited reduced or 
unchanged luciferase gene expression following combined inflammatory and hypoxic 
stimulation, respectively. These observations further support our strategy of utilising 
composite promoters to achieve multi-responsive and synergistic gene expression, compared 
to the use of single-responsive synthetic promoters.  
Interestingly, there were slight variations in the expression profiles of the synthetic promoters 
in response to individual stimuli. For example, plasmid DNA promoters 2, -11 and -12 were 
more responsive to TNFα than to PMA (Fig 4.2). However, the lentiviral promoters LV-2,    LV-
11 and LV-12 induced greater gene expression to PMA than to TNFα (Fig 4.3). Despite these 
discrepancies, these promoters retained their ability to respond highly to various inflammatory 
stimuli and induce synergistic gene expression in response to combined stimulation, which 
was a fundamental requirement of the composite synthetic promoters.  
In general, the fold change of luciferase gene expression induced from lentiviral integrated 
composite synthetic promoters greatly exceeded that demonstrated by transiently transfected 
promoter constructs. The composite promoters generally displayed similar expression profiles 
and some had improved synergistic gene expression e.g. LV-2, LV-9 and LV-12. Promoters 
LV-2 and LV-9 exhibited significant increases in gene expression in response to all treatments 
and promoter LV-12 displayed robust fold inductions following individual and combined 
stimulation. Therefore, these three composite promoters were selected for further detailed 
analysis of their induction profile.   
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4.2.2. Dose-response and time-course kinetic assays of luciferase gene expression 
of lentiviral integrated composite synthetic promoters 
293T cells, which stably expressed the luciferase gene under the control of the composite 
promoters, facilitated further functional characterisation in time-course and dose-response 
assays. These experiments provided knowledge on the sensitivity, and the rate and duration 
of promoter activation, to facilitate the selection of the optimal composite promoter for 
regulating gene expression in vivo.   
 
4.2.2.1. Lentiviral composite synthetic promoters are highly sensitive and display 
dose-dependent induction  
The changes in the inflammatory status of the RA joint promote the different relapse and 
remission phases of RA. Therefore, it is imperative that the composite promoter for RA gene 
therapy responds accordingly to the magnitude of disease activity within the RA joint: the 
candidate synthetic promoters require a high degree of sensitivity to the inflammatory 
environment in order to induce the appropriate level of therapeutic gene expression and 
subsequently reduce joint inflammation. 
Dose-response experiments were conducted to evaluate the sensitivity of lentiviral composite 
promoters to TNFα or PMA stimulation over the concentration range                      0.001 – 100 
ng/ml (Figure 4.4) and the fold inductions are presented in Figure 4.5.  
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Figure 4.4. Responsiveness of lentiviral composite promoters to inflammatory mediator 
stimulation. Stable 293T cells expressing luciferase under the control of the synthetic 
promoters LV-2 [A], LV-9 [B], LV-12 [C] and LV-mCMV [D] were seeded at 20,000 cells per 
well in a 96-well plate in triplicate wells. After 24 hours, the cells were unstimulated (0 ng/ml) 
or treated with 0.001 ng/ml –100 ng/ml of TNFα and PMA to generate a dose-response curve. 
The cells were harvested 18 hours after stimulation and the luciferase expression was 
normalised to the protein content in the cell lysate and the lentiviral titre of the corresponding 
lentiviral preparation (expressed as RLU/mg protein/ lenti IFU). The data represents the mean 
± SD of triplicate values. The statistical significance compared to the unstimulated luciferase 
gene expression (at 0 ng/ml) was calculated using the Student’s t-test (ns = p>0.05, * = p≤0.05, 
** = p≤0.01, *** = p≤0.001, **** = p≤0.0001, where green and blue asterisks correspond to 
TNFα and PMA datasets, respectively).  
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Figure 4.5. Fold induction of lentiviral composite promoters in response to 
inflammatory mediator stimulation. The changes from basal luciferase gene expression of 
the composite promoters LV-2 [A], LV-9 [B], LV-12 [C] and LV-mCMV [D] were calculated 
using the data in Figure 4.4. The data represents the mean ± SD of triplicate values. 
 
 
 
 
 
  
[ [
[ [
252 
 
Encouragingly, the composite promoters displayed dose-dependent increases of           TNFα-
induced luciferase gene expression and to an extent, with PMA-induction                 (Fig 4.4 
A-C and Fig 4.5 A-C). In contrast, the negative control promoter LV-mCMV (Fig 4.4 D and 4.5 
D) was generally unresponsive to inflammatory stimulation, although marginal increases in 
TNFα-induced gene expression was observed.  
The composite promoters were highly sensitive to low concentrations of TNFα and PMA and 
induced significant increases in luciferase gene expression (p≤0.05 to p≤0.001) in response 
to 0.1 ng/ml of TNFα or PMA stimulation. Generally, the induced luciferase gene expression 
peaked in response to 1-10 ng/ml of TNFα or PMA stimulation. However, noticeable 
differences can be observed in the induced luciferase expression profiles of the composite 
promoters e.g. the luciferase gene expression of promoter LV-2 peaked in response to        10 
ng/ml PMA (*** p=0.001) but gene expression significantly decreased with higher PMA 
concentrations (50-100 ng/ml). In contrast, LV-2-induced-gene expression increased with 
increasing TNFα concentration and the luciferase gene expression induced by promoters LV-
9 and LV-12 also displayed similar trends with both TNFα and PMA stimulation.  
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4.2.2.2. Lentiviral composite synthetic promoters are rapidly activated and display 
time-dependent increases in luciferase gene expression  
Time-course kinetics of luciferase gene expression induced by the composite promoters was 
evaluated by stimulating stable 293T cell lines with 10 ng/ml of TNFα or PMA or their 
combination and monitoring luciferase gene expression for 2, 8, 12, 24 or 48 hours (Fig 4.6). 
The fold inductions are presented in Figure 4.7.     
 
 
 
  
Figure 4.6. Lentiviral composite promoters are rapidly activated and 
display peak activation 24 hours after inflammatory mediator stimulation. 
Stable 293T cells expressing luciferase under the control of the synthetic 
promoters LV-2 [A], LV-9 [B], LV-12 [C] and LV-mCMV [D] were seeded at 
20,000 cells per well in a 96-well plate in triplicate wells. After 24 hours, the cells 
were either unstimulated (0 hours) or stimulated with TNFα (10 ng/ml), PMA (10 
ng/ml) or a combination of TNFα and PMA for 2, 8, 12, 24 or 48 hours. At 24 
hours, the inflammatory stimulus was removed from the selected wells 
(indicated by the dotted line) and replaced with low serum medium after which 
the luciferase expression was monitored for a further 24 hours (48 hour time-
point). Cell lysates were harvested at the stated time points and the luciferase 
expression was quantified and normalised to the protein content in the cell lysate 
and the lentiviral titre of the corresponding lentiviral preparation (expressed as
[ [
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Figure 4.7. Kinetics of lentiviral composite promoters expressed as fold inductions. The 
changes from the basal luciferase gene expression induced in the composite promoters LV-2 
[A], LV-9 [B], LV-12 [C] and LV-mCMV [D] from the data in Figure 4.6 was calculated as fold 
inductions. The data represents the mean ± SD of triplicate values. 
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Figures 4.6 and 4.7 confirmed the rapid activation of composite promoters, which generally 
peaked after 12 hours of exposure to inflammatory stimulation (p≤0.05 to p≤0.001). 
Interestingly, LV-9 and LV-12 promoter activation was steadily maintained from 24-48 hours 
in contrast to the luciferase expression induced by promoter LV-2 which sharply decreased 
beyond 24 hours. The composite synthetic promoters displayed significant synergistic 
activation, at most time-points, in response to combined inflammatory stimulation. It is possible 
that the variation of values within specific datasets may have been the cause for the low or 
absent statistical significance in datasets which clearly had increased gene expression 
following stimulation (Fig 4.6 A-C and Fig 4.7 A-C).  
To mimic the fluctuations of inflammation within the RA joint, the inflammatory stimulus was 
removed from cells and replaced with low serum medium (indicated by the dotted line, 
statistical significance indicated by black asterisks). Removal of the inflammatory stimulation 
at 24 hours generally resulted in decreased luciferase gene expression in comparison to 
relatively sustained luciferase gene expression in response to continued inflammatory 
stimulation which corroborates the high sensitivity and rapid responsiveness of the composite 
synthetic promoters to the presence, removal and various concentrations and durations of 
exposure to inflammatory stimulation. Also, similarities between the induced luciferase 
expressions at the 24 hour time point in Figure 4.6 to the results obtained from the same stable 
293T cells presented in section 4.2.1 (Fig 4.3) shows that there was no compromise in 
promoter activity after four weeks in cell culture. 
The dose-response and time-course kinetics of luciferase gene expression confirmed the 
appropriate responsiveness, high-sensitivity and rapid activation induced by the composite 
promoters LV-2, LV-9 and LV-12. These studies provide encouraging evidence to progress to 
monitoring promoter activation during paw inflammation.  
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4.3.  In vivo functional analysis of luciferase gene expression from lentiviral 
integrated synthetic promoters 
The activation profiles of the lentiviral composite promoters were assessed in a carrageenan-
induced paw inflammation mouse model. The lentiviruses expressing the luciferase gene 
under the control of the composite promoters LV-2, LV-9, and LV-12, the inflammation-
inducible promoter LV-4NFκB, the positive control promoter LV-SFFV, and the negative 
control promoter LV-mCMV, were prepared at 260,000 lentiviral IFU in 25 μl. Male adult CD1 
mice (n=3 per group) received an intraplantar injection of 25 μl of the candidate lentiviral 
particles into both hind paws 7 days before carrageenan administration to allow sufficient time 
for integration of the vector genome. After 7 days, paw inflammation was induced by an 
intraplantar injection of 50 μl of 1% λ-carrageenan solution into the left hind paw. The right 
hind paws received 50 μl of sterile saline intraplantarly, serving as the control.  
Quantification of in vivo luciferase gene expression was monitored using an IVIS 
bioluminescent imaging system, which measured real-time bioluminescence in photons, 
following an intraperitoneal injection (200 μl) of the luciferin substrate. Imaging was performed 
before inflammation (0 hours) and 3, 24 and 72 hours post-carrageenan injection at a binning 
of 8 for 5 minutes. The light emission in a defined region of interest (ROI), around each hind 
paw, allowed the luciferase expression to be monitored for consecutive images at each time 
point (Fig 4.8 A-G). The footpad thickness was measured before inflammation (0 hours) and 
3, 24, 48, 72 and 96 hours post-carrageenan injection, using a dial caliper (Fig 4.8 H). 
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Figure 4.8. Composite synthetic promoters exhibit inflammation-specific luciferase 
gene expression in carrageenan-induced inflamed mouse paws. Representative images 
are shown of CD1 mouse hind paws 7 days post-injection with lentiviral particles                      LV-
mCMV-Luc+ [A], LV-SFFV-Luc+ [B], LV-4NFκB-Luc+ [C], LV-2-Luc+ [D], LV-9-Luc+ [E],           LV-
12-Luc+ [F]. The left hind paws received an intraplantar injection of 50 μl of 1%                      λ-
carrageenan whereas the control right paws were injected with 50 μl of saline. The luciferase 
expression was monitored before inflammation (0 hours) and 3, 24 and 72 hours post-
inflammation. Light emission (photons/second/cm2/sr) was measured using an IVIS CCCD 
camera at a binning of 8 for 5 minutes. The quantitative bioluminescence data within the 
defined region of interest over individual paws represents the mean ± SD of n= 3 mice, per 
group [G]. The statistical significance compared to baseline gene expression was calculated 
using the Student t-test (ns = p>0.05, * = p≤0.05, ** = p≤0.01) and only statistically significant 
points are labelled. Paw thickness was measured before inflammation (0 hours) and 3, 24, 48, 
72 and 96 hours post-inflammation, using a dial caliper where each time-point represents the 
mean ± SD of n= 3 mice, per group [H].  
[
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As anticipated, at 0 hours (before inflammation) there was no detectable luciferase expression 
induced by the negative control promoter LV-mCMV. In contrast, the constitutively active LV-
SFFV positive control promoter induced constitutive luciferase gene expression whereas 
inflammation-inducible promoters LV-4NFκB, LV-2, LV-9 and LV-12 induced low basal 
luciferase expression (Figure 4.8 A-F). 
Encouragingly, at 3 hours post-carrageenan injection, the inflammation-inducible LV-2, LV-9 
and LV-4NFκB promoters induced robust inflammation-specific luciferase expression which 
was comparable to that of the strong viral LV-SFFV promoter (Fig 4.8 G), however only the 
induction by LV-2 was statistically significant (* p=0.03). In parallel to the in vitro expression 
profile of promoter LV-12, this promoter induced low, albeit inflammation-specific, luciferase 
gene expression at 3 hours post-inflammation (Fig 4.8 A-F). 
The caliper measurements of the saline control right paws, which were also injected with 
lentivirus, provided consistently low baseline measurements of paw thickness throughout the 
96 hour monitoring period, therefore, the changes in luciferase expression in the treated left 
paw can be attributed to the level of inflammation within the paw. The peak-intensity of 
carrageenan-induced paw inflammation was observed at 24-48 hours post-inflammation (Fig 
4.8 H). However, at 24 hours post-inflammation, there was a slight decrease in luciferase 
expression from the LV-4NFκB, LV-2 and LV-9 treated left hind paws (Fig 4.8 C-E). It is 
feasible that the substantial paw thickness potentially impaired photon emission which 
consequently, resulted in decreased quantified luciferase gene expression. Nonetheless, the 
gene expression levels at 24 hours post-inflammation were still comparable to the luciferase 
expression induced by the constitutively active LV-SFFV promoter, at the same time-point (Fig 
4.8 G). At 72 hours, paw thickness was generally lower than at the previous time points but 
had not returned to baseline (Fig 4.8 H) and the luciferase expression from the induced 
promoters had also declined (Fig 4.8 G).  
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4.4. Discussion  
The requirements of successful gene therapy approaches include efficient gene delivery, 
sustained expression of the transgene, limited biodistribution and non-immunogenicity, which 
are characteristics governed by the mode of delivery and gene-delivery vector. Many gene 
therapy vectors are limited by their storage capacity, duration of transgene expression and 
immunogenic profile, which restrict their utility. Non-viral vectors i.e. plasmid DNA commonly 
yield low gene transfer efficiency because they persist episomally in the nucleus and lack the 
inherent ability to enter cells and localise to the nucleus. In contrast, lentiviral vectors (LV) 
offer the advantage of stable genomic integration of the transgene into dividing or non-dividing 
cells to provide long-term gene expression with low-immunogenicity (Gould and Favorov, 
2003).  
Earlier concerns regarding the safety profile of lentiviral-mediated gene delivery have been 
overcome by extensively modifying the structure of the lentiviral vector. A major step towards 
clinical acceptability has been the development of self-inactivating (SIN) lentiviral vectors with 
a 400-nucleotide deletion in the 3’-long terminal repeat (LTR). These deletions eradicate the 
TATA box and the LTR promoter to decrease the emergence of replication-competent viruses 
without affecting the viral titres or transgene expression, thereby improving the biosafety 
profile of lentiviral vectors (Zufferey et al., 1998). Chapter 4 reports the in vitro and in vivo 
translational studies of luciferase gene expression induced by the candidate composite 
synthetic promoters within the SIN lentiviral vector LV-Luc+.  
Comparisons between the luciferase gene expression of the composite promoters in plasmid 
DNA and lentiviral vectors (section 4.2.1) demonstrated the dramatic improvements in the 
magnitude of luciferase expression following lentiviral transduction of 293T cells. The overall 
performance and fold inductions of the lentiviral integrated promoters greatly surpassed that 
displayed by analogous plasmid DNA promoters. Encouragingly, many of the composite 
promoters acquired improved synergistic expression profiles whilst other promoters retained 
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their synergistic gene expression and overall, the lentiviral promoters displayed better 
expression profiles than their plasmid DNA equivalents. This initial screening of lentiviral-
mediated luciferase expression facilitated the selection of the composite promoters LV-2, LV-
9 and LV-12 which generally exhibited low basal and high induced luciferase expression, multi-
responsiveness and robust synergistic inducibility following combined stimulation.  
In agreement with our concept of combining inflammation-inducible regulatory elements for 
enhanced gene expression, the IL-1/IL-6 hybrid synthetic promoter developed by van de Loo 
et al., (2004) exhibited additive luciferase gene expression in response to combined 
inflammatory stimulation. However, the fold inductions observed following stimulation with 
combined LPS, PMA and dbcAMP in HIG82 cells (5.3 fold) and RAW 264.1 cells (18 fold)  
following transient transfection of plasmid DNA and combined TNFα, IL-1β and IL-18 in an 
adenoviral infected murine chondrocyte cell line (upto 4 fold) were substantially lower than the 
fold changes induced by the plasmid and lentiviral composite synthetic promoters described 
in this chapter, which strengthens the notion of constructing composite promoters for 
synergistic transcriptional activation.  
The stable and long-term luciferase expression conferred by lentiviral genomic integration 
enabled the kinetics of luciferase expression induced by the composite promoters LV-2,    LV-
9 and LV-12 to be monitored in stable 293T cells (section 4.2.2). These experiments provided 
evidence of dose- and time-dependent increases in luciferase gene expression which 
confirmed the high-sensitivity (Fig 4.4) and rapid activation (Fig 4.6) of the composite 
promoters in response to various concentrations and durations of exposure to inflammatory 
stimulation, which further supported the choice of the promoters LV-2, LV-9 and LV-12 as 
candidates for local RA gene therapy. Also, the high induced luciferase expression in response 
to low concentrations of inflammatory stimuli (Fig 4.4) suggest that high therapeutic gene 
expression can potentially be induced by the composite promoters in conditions of relatively 
low inflammation, which may be beneficial for the early stages of RA disease relapse. In these 
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situations, the composite promoter can function prophylactically to reduce the level of 
inflammation before the onset of chronic inflammation in the RA joint. 
The limited gene expression variability between the plasmid DNA and lentiviral vector 
constructs and the retention of favourable gene expression profiles displayed by the lentiviral 
composite synthetic promoters can be attributed to the performance-enhancing modifications 
of the LV-Luc+ vector. For example, the similar expression profiles of the lentiviral integrated 
synthetic promoters to their plasmid DNA equivalents may have been due to the presence of 
the chromatin insulator from the 5’ end of the chicken β-globin locus (5’-cHS4) which flanks 
the composite promoter and luciferase gene within the LV-Luc+ vector. The HIV-1 lentiviral 
vectors preferentially integrate into transcriptionally active areas in the host cell genome 
(Schroder et al., 2002) and therefore are subject to influences by external factors. The 
presence of the 5’-cHS4 insulators shield the synthetic promoter from the action of external 
distal enhancers (enhancer blocking effect), which is likely to have prevented high basal gene 
expression from the lentivirally-integrated synthetic promoters. This enhancer-blocking activity 
is of great importance for gene therapy applications as it might prevent or reduce insertional 
gene activation of growth-regulatory genes or proto-oncogenes located near the vector 
insertion site. Also, the insulators protect the luciferase gene against the advancement of 
adjacent inactive condensed chromatin to confer protection against gene silencing (barrier 
effect) (Pikaart et al., 1998).  
Also, in contrast to the pCpG-Luc+ plasmid vector, the LV-Luc+ contains the woodchuck post-
transcriptional regulatory element (WPRE) in the 3’ untranslated region (UTR) of the luciferase 
gene, which has been demonstrated to substantially increase gene expression levels by 
functioning in the nucleus to stimulate gene expression post-transcriptionally and to increase 
the levels of nuclear transcripts which consequently increases protein expression (Zufferey et 
al., 1999). Therefore, the greatly enhanced luciferase gene expression induced by lentiviral 
composite promoters can be partly attributed to increased luciferase protein levels facilitated 
by the incorporation of the WPRE in the lentiviral vector.  
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Intra-articular injections of lentiviral vectors typically result in the transduction of tendons, 
ligaments, cartilage, muscle, adipose/areolar synovium and synoviocytes within the joint 
(Gouze et al., 2007). Lentiviral vectors pseudotyped with the VSV-G envelope have increased 
host-cell range due to the ability of the VSV-G envelope binding to phospholipid components 
of the cell membrane to mediate viral entry by membrane fusion (Burns et al., 1993) and 
therefore enable lentiviral-mediated delivery of the composite synthetic promoters into various 
cell types. Consequently, the VSV-G pseudotyped lentiviral particles were used to transduce 
cells in vivo, to monitor promoter activity during paw inflammation.  
Inflammation is the underlying pathology in RA which perpetuates the structural damage to 
the joint and many animal models of paw inflammation provide an accurate representation of 
the immunological and pathological events similar to those observed in human RA (Bendele, 
2001). In this chapter, carrageenan-induced paw oedema was used as an experimental model 
of mouse paw inflammation to examine the in vivo profile of luciferase gene expression 
induced by the inflammation-inducible composite synthetic promoters; LV-2, LV-9 and LV-12 
(section 4.2). The induction of paw inflammation by carrageenan in mouse paws was 
previously demonstrated by Levy et al., (1969), and similarly shown by Winter et al., (1962) in 
rats. The application of the carrageenan-induced paw oedema mouse model for the initial 
translation studies, described in section 4.3 offered several advantages over other 
experimental models of inflammation. 
Firstly, in the routinely used CIA mouse model, paw inflammation can occur in any of the paws 
after several days post-immunisation. In contrast, a single local intraplantar injection of 1% λ-
carrageenan into the mouse hind paw ensures the rapid induction of inflammation within hours 
which is confined to the paw injected with carrageenan, as described by Morris (2003). 
Therefore, this limits the inefficient use of valuable lentiviral composite promoter particles. 
Secondly, the carrageenan-induced paw oedema model has been shown to exhibit a biphasic 
profile where the inflammatory reaction first peaks at 4 hours and then at 72 hours following a 
local carrageenan injection and decreases thereafter (Henriques et al., 1987). As 
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demonstrated in the preceding time-course kinetic experiments (section 4.2.2), the composite 
promoters induced time-dependent increases in luciferase expression (upto 48 hours and 
potentially longer) which coincides with the time-course of carrageenan-induced inflammation 
and represents a quick initial screen of promoter activity in vivo. Thirdly, the inflammatory 
process induced by carrageenan is characterised by the production of prostaglandins and 
leukotrienes in addition to the release of other mediators by infiltrated immune cells, 
particularly neutrophils (Cuzzocrea et al., 1999). These mediators can directly or indirectly 
activate NFκB, AP-1 and possibly HIF-1α to induce additive/synergistic luciferase gene 
expression.  
The in vivo luciferase imaging results (section 4.3) confirmed the disease-specific induction of 
luciferase gene expression from the lentiviral composite synthetic promoters LV-2, LV-9 and 
LV-12 in the carrageenan-induced paw inflammation model, although only LV-2 induction at 3 
hours post-inflammation was statistically significant (* p=0.03). Nevertheless, mice injected 
with the inflammation-inducible LV-2, LV-9 and LV-4NFκB constructs displayed robust 
luciferase gene expression which was localised to the inflamed left hind paw and comparable 
to the luciferase expression induced by the strong viral promoter LV-SFFV, as confirmed by 
real-time bioluminescence imaging (Fig 4.8 A-G). 
Interestingly, the luciferase gene expression induced by the LV-SFFV promoter in the inflamed 
left paw continuously and significantly declined after 3 hours post-inflammation, whilst the 
luciferase expression from the control saline paw remained unchanged throughout the 72 hour 
monitoring period (Fig 4.8 G). In contrast, Garaulet et al., (2013) reported marginal fluctuations 
in the fold inductions of luciferase gene expression induced by the lentiviral-integrated SFFV 
promoter for 30 days in a zymosan-induced paw inflammation model. However, the authors 
did not disclose the specific luciferase gene expression values in the control and zymosan-
induced paws, since the data was represented as fold induction over unstimulated conditions, 
making it difficult to identify variations in the SFFV promoter activity over the course of 
inflammation. The decrease in LV-SFFV promoter activity described in this chapter (Fig 4.8 
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G) might indicate SFFV promoter silencing, however, definite confirmation e.g. using DNA 
methylation analysis, highlights an option for further work. 
The luciferase gene expression in the inflamed paws peaked at 3 hours post-inflammation 
(Fig 4.8 A-G) which corresponds to the reported trend of carrageenan induced-paw 
inflammation described by Henriques et al., (1987) but was contradicted by the dial caliper 
measurements of paw swelling (Fig 4.8 H) which showed the peak inflammation at 24-48 
hours post-carrageenan injection. It is feasible that the significant degree of paw swelling at 
24 hours may have obstructed the detection of luciferase expression by the IVIS machine, 
which consequently resulted in lower quantified luciferase gene expression. Interestingly, the 
second peak of inflammation at 72 hours reported by Henriques et al., (1987) was not 
observed in this experiment. Nonetheless, the lowest luciferase expression was observed at 
72 hours post-inflammation in mice injected with the composite synthetic promoters (Fig 4.8 
G), which was supported by the reduced paw swelling at this time point (Fig 4.8 H).  
Interestingly, the functional analysis data obtained from plasmid DNA transient transfections 
(section 4.2.1), lentivirus integrated 293T cells (section 4.2.1) and lentivirus infected mouse 
paws (section 4.3) showed that promoter LV-2 consistently displayed a low/moderate basal 
and very high induced luciferase gene expressions whereas promoter LV-9 induced a lower 
basal and a high induced luciferase gene expression and promoter LV-12 generally exhibited 
low basal and low induced luciferase gene expression. Therefore, it is feasible to expect 
similar expression profiles to be displayed by the composite promoters when regulating 
therapeutic gene expression during paw inflammation.  
Overall, the initial in vivo experiment described in this discussion confirmed the development 
of disease-regulated composite synthetic promoters which can be applicable for RA gene 
therapy. Using the luciferase reporter gene as a surrogate for a therapeutic gene, the lentiviral 
composite synthetic promoters have demonstrated versatility by displaying robust 
inflammation-inducible profiles in human kidney 293T cells (in vitro) and mouse synovial cells 
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(in vivo), which can be attributed to the ubiquitous activation of NFκB, AP-1 and HIF-1α in 
numerous cell types and broad cell tropism of the VSV-G envelope in the lentiviral vector. 
Collectively, the experiments described in Chapters 3 and 4 have enabled the selection of LV-
2 and LV-9 as the most promising promoters to regulate local therapeutic gene expression to 
potentially reduce joint inflammation in vivo.    
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CHAPTER 5: 
Evaluating the Therapeutic Efficacy of Soluble 
mTNFRII-Fc and hIL-1Ra Expressed from 
Inflammation-Inducible Composite Promoters 
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5.1. Introduction 
There is substantial evidence implicating TNFα and IL-1β in the pathological processes in a wide 
range of chronic inflammatory diseases, particularly in RA (Feldmann and Maini, 2008). Selective 
inhibition of TNFα and IL-1β activity through the use of soluble TNF-receptors       (TNFR-Fc) and 
IL-1 receptor antagonist (IL-1Ra), respectively, has demonstrated reduced inflammation and 
suppression of disease in experimental models of paw inflammation. In this chapter, the regulated 
expression of mouse TNFRII-Fc (mTNFRII-Fc) and human IL-1Ra       (hIL-1Ra) therapeutic 
proteins using the inflammation-inducible composite promoters, LV-2 and LV-9 was quantified 
using ELISA and the therapeutic potential of the candidate promoter was assessed in the 
carrageenan-induced paw inflammation model.  
 
 
 
5.1.1.  Construction of lentiviral composite synthetic promoters regulating mTNFRII-Fc 
and hIL-1Ra therapeutic gene expression 
The schematic diagram below illustrates the cloning strategy used to clone the therapeutic 
genes downstream of the composite synthetic promoters in the lentiviral plasmid DNA (Fig 
5.1). 
A. pLV.CMV.eGFP was digested with BamHI and SalI to release the eGFP gene. The 
resulting 8357 bp fragment served as the cloning vector pLV.CMV (Fig 5.1 A).  
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B. The hIL-1Ra gene (540 bp) was amplified from pcIL-1Ra using forward BamHI and 
reverse SalI primers (Fig 5.1 B). 
 
 
 
 
C. The hIL-1Ra PCR product was digested with BamHI and SalI and cloned into the 
equivalent site within the pLV.CMV vector to generate pLV.CMV.hIL-1Ra. The 
resulting construct was digested with PmeI and BamHI to release the CMV promoter. 
The 6931 bp fragment served as the cloning vector pLV.hIL-1Ra (Fig 5.1 C). 
 
 
 
D. The mTNFRII-Fc gene (1356 bp) contains an internal 
SalI site therefore the reverse PCR primer contained an XhoI site. Restriction enzyme 
digestion with SalI and XhoI produce fragments with compatible 5’-TCGA-3’ overhangs 
therefore, the               mTNFRII-Fc gene was amplified from pFuse-mTNFRII-Fc using 
forward BamHI and reverse XhoI primers (Fig 5.1 D).  
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E. The mTNFRII-Fc PCR product was digested with BamHI and XhoI and cloned into the 
BamHI/SalI site within the pLV.CMV vector to generate pLV.CMV.mTNFRII-Fc The 
resulting construct was digested with PmeI and BamHI to release the CMV promoter. 
The 7756 bp fragment served as the cloning vector pLV.mTNFRII-Fc (Fig 5.1 E). 
   
 
F. The composite promoters were PCR amplified from the 
original                          pCpG-20bp-composite promoter constructs, respectively 
(Chapter 3), using forward SnaBI and reverse BamHI primers (Fig 5.1 F).  
 
 
 
 
 
 
G. The PmeI and SnaBI enzymes produce blunt ended fragments which can be ligated 
together. Therefore, the synthetic promoter PCR products were digested with SnaBI 
and BamHI and cloned into the PmeI and BamHI site within the pLV.hIL-1Ra and 
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pLV.mTNFRII-Fc cloning vectors to generate lentiviral constructs containing the 
composite promoters driving expression of the therapeutic genes hIL-1Ra and 
mTNFRII-Fc, respectively (Fig 5.1 G).  
 
 
 
 
 
 
 
 
H. Forward and reverse oligonucleotides containing the mCMV promoter sequence were 
ordered from Sigma-Aldrich with 5’-SnabI and 3’-BamHI overhangs. The 
oligonucleotides were annealed using the boiling method and cloned into the PmeI and 
BamHI site within the pLV.hIL-1Ra and pLV.mTNFRII-Fc cloning vectors to generate 
the LV-mCMV-IL-1Ra and LV-mCMV-mTNFRII-Fc negative control constructs, 
respectively.  
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I. The SFFV promoter (560 bp) was PCR amplified from the pUCL-Luc+ construct using 
forward SnaBI and reverse BamHI primers (Fig 5.1 I). 
 
 
 
 
 
 
J. The PCR products were digested with SnaBI and BamHI and cloned into the 
PmeI/BamHI site within the pLV.hIL-1Ra and pLV.mTNFRII-Fc cloning vectors to 
generate lentiviral constructs containing the constitutively active SFFV promoter 
driving expression of the therapeutic genes hIL-1Ra and mTNFRII-Fc, respectively 
(Fig 5.1 J).  
 
 
K. Following the successful construction of the lentiviral synthetic promoter constructs, 
the lentiviral particles were produced using a three-plasmid transient transfection into 
293T cells with the transfer, packaging and envelope plasmids to generate lentiviral 
particles pseudotyped with the VSV-G envelope glycoprotein. The VSV-G 
pseudotyped lentiviral particles were transduced into 293T cells to generate a stable 
293T cell line with the integrated synthetic promoters and the therapeutic genes. 
 Figure 5.1. Schematic diagram illustrating the cloning method used to generate the lentiviral composite synthetic promoters 
expressing soluble mTNFRII-Fc and hIL-1Ra. The 
pLV.CMV.eGFP lentiviral plasmid was systematically modified to 
generate the lentiviral constructs expressing the therapeutic genes
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5.2.  In vitro quantification of stable therapeutic protein expression regulated by 
inflammation-inducible composite synthetic promoters 
Inflammation-inducible regulation of soluble mTNFRII-Fc and hIL-1Ra therapeutic protein 
expression by the composite promoters LV-2 and LV-9 and the control promoters LV-mCMV 
and LV-SFFV were evaluated using ELISA quantification. The stable 293T cells were 
unstimulated, incubated in hypoxia or stimulated with TNFα, PMA or their combination. The 
following day, the cell supernatant was collected and soluble mTNFRII-Fc and hIL-1Ra protein 
expression was quantified by ELISA. The therapeutic protein expression induced by 
promoters LV-2 and LV-9 were compared to the protein levels induced by the negative and 
positive control promoters, LV-mCMV and LV-SFFV, respectively (Fig 5.2).  
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Figure 5.2. Promoters LV-2 and LV-9 demonstrate inflammation-inducible and 
synergistic expression of soluble mTNFRII-Fc and hIL-1Ra proteins. The stable 293T 
cells were seeded at a density of 50,000 cells per well in a 6-well plate and cultured at 37°C 
for 24 hours. After 24 hours, the cells were unstimulated, incubated in hypoxia (0.1% O2) or 
stimulated with TNFα (10 ng/ml), PMA (10 ng/ml) or a combination of TNFα and PMA in 
hypoxia for 18 hours. The cell supernatant was collected 18 hours post-stimulation and the 
expression of hIL-1Ra [A] and soluble mTNFRII-Fc [B] protein was quantified by ELISA and 
normalised to the lentiviral titre (expressed as pg/ml/lenti IFU). The data represents the mean 
± SD of triplicate values. The statistical significance between the unstimulated and stimulated 
luciferase gene expression was calculated using the Student’s t-test (ns = p>0.05, * = p≤0.05, 
** = p≤0.01, *** = p≤0.001, **** = p≤0.0001).  
[
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The inflammation-inducible regulation of therapeutic protein expression by the composite 
promoters LV-2 and LV-9 was confirmed by quantifying the secreted protein expression of 
mTNFRII-Fc and hIL-1Ra in the supernatant of unstimulated or stimulated LV-2, LV-9,        LV-
mCMV and LV-SFFV-stably transduced 293T cells, using ELISA. The sensitivity of mTNFRII-
Fc and hIL-1Ra detection was 37 pg/ml and 4 pg/ml, respectively.  
As anticipated, promoter LV-mCMV did not induce mTNFRII-Fc and hIL-1Ra therapeutic 
protein expression irrespective of stimulation (ns p>0.05). In contrast, constitutive therapeutic 
protein expression was induced by the constitutively active promoter LV-SFFV, although 
significant decreases in mTNFRII-Fc and hIL-1Ra expression can be observed following 
inflammatory stimulation (* p≤0.05). Generally, the composite promoters LV-2 and LV-9 
retained their differential, multi-responsive and synergistically-inducible gene expression 
profiles. In the absence of stimulation, the LV-2 induced low/moderate basal protein 
expression of mTNFRII-Fc and hIL-1Ra whereas LV-9 induced very low basal expression of 
mTNFRII-Fc and barely detectable hIL-1Ra protein expression. Encouragingly, the 
low/moderate basal expression exhibited by promoter LV-2 in comparison to the very low 
basal expression induced by promoter LV-9 was consistent with all of the previous functional 
analysis data of these promoters in Chapters 3 and 4.  
Following hypoxia incubation, there were marginal increases in mTNFRII-Fc and hIL-1Ra 
protein expression induced by promoters LV-2 and LV-9, which is in accordance with the 
previously demonstrated low hypoxia-inducibility of these promoters. However, there were 
significant but modest increases in hIL-1Ra protein expression induced by LV-2 and LV-9, in 
response to TNFα and PMA stimulation (p≤0.01 to p≤0.001). In contrast, robust mTNFRII-Fc 
protein expression was induced by LV-2 and LV-9 following TNFα and PMA stimulation 
(p≤0.02 to p≤0.0001). Noticeably, promoters LV-2 and LV-9 demonstrated highly significant 
synergistic induction of mTNFRII-Fc and hIL-1Ra protein expression following combined 
inflammatory and hypoxic stimulation (p≤0.01 to p≤0.0001). Therefore, on the basis of 
low/moderate basal and high inflammation-inducible gene expression levels, promoter LV-2 
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was selected as the most promising promoter to regulate mTNFRII-Fc and hIL-1Ra 
therapeutic protein expression to potentially reduce paw inflammation. 
 
5.3. Evaluating the therapeutic efficacy of soluble mTNFRII-Fc and hIL-1Ra protein 
expression regulated by the inflammation-inducible composite promoter LV-2 
during paw inflammation 
The therapeutic efficacy of soluble mTNFRII-Fc and hIL-1Ra therapeutic proteins regulated 
by the inflammation-inducible composite promoter LV-2, the negative control LV-mCMV 
promoter and the positive control LV-SFFV promoter was assessed in a carrageenan-induced 
paw inflammation model (Fig 5.3). 
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[A] 
[B] 
Figure 5.3.  Comparative analysis of the therapeutic effect of mTNFRII-
Fc and hIL-1Ra protein expression regulated by the inflammation-
inducible composite promoter LV-2. Adult CD1 male mice (n=6 per group) 
were injected intraplantarly with 830,000 lentiviral IFU (25 μl) into the left 
hind paw with LV-mCMV-hIL-1Ra, LV-2-hIL-1Ra, LV-SFFV-hIL-1Ra [A] and 
LV-mCMV-mTNFRII-Fc, LV-2-mTNFRII-Fc, LV-SFFV-mTNFRII-Fc [B]. After 
7 days, the left hind paws received an intraplantar injection of 50 μl 1% λ-
carrageenan whereas the control right paws were injected intraplantarly with 
50 μl of saline. Paw thickness was measured before inflammation (0 hours) 
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The lentiviral particles expressing the therapeutic proteins were administered 7 days prior to 
the induction of carrageenan-induced paw inflammation. During this time interval before 
inflammation, the synthetic promoters are expected to induce basal expression of the 
therapeutic gene; the SFFV promoter is expected to induce a high level of constitutive 
therapeutic gene expression, the LV-2 promoter should display low/moderate basal 
expression whereas the mCMV promoter should induce negligible therapeutic gene 
expression during this un-inflamed state, as confirmed by the ELISA experiment in Figure 5.2. 
It was proposed that mice injected with LV-mCMV-mTNFRII-Fc and LV-mCMV-hIL-1Ra would 
not have reduced inflammation due to the lack of therapeutic protein expression induced by 
the LV-mCMV promoter thus serving as the negative control group for comparisons to the 
other data groups.  
As anticipated, Figure 5.3 A shows that the mice treated with LV-SFFV-hIL-1Ra had the lowest 
degree of paw swelling at all time-points, which was significantly lower than the paw thickness 
of LV-mCMV-hIL-1Ra treated mice at 3 hours (* p=0.04) and 72 hours (* p=0.05) post-
inflammation only. The general reduction of paw thickness in the LV-SFFV-hIL-1Ra treated 
mice (compared to mice treated with LV-mCMV-hIL-1Ra) is consistent with the principle of IL-
1Ra therapy: IL-1Ra blocks IL-1-mediated signalling by competitively binding to the IL-1 
receptors and after the onset of carrageenan-induced inflammation, some of the IL-1 receptors 
were occupied by IL-1Ra induced by the constitutive SFFV promoter, thereby reducing the 
overall level of paw inflammation in the LV-SFFV-hIL-1Ra treated mice. High molar excess of 
IL-1Ra, preferably before the onset of disease is required for high therapeutic efficacy of IL-
1Ra therapy and despite the lower magnitudes of paw inflammation compared to the LV-
mCMV-hIL-1Ra treated mice, the level of paw inflammation continued to increase in the LV-
SFFV-hIL-1Ra treated mice. These observations suggest that the         LV-SFFV promoter 
may not have produced sufficient concentrations of IL-1Ra to block IL-1 activity and prevent 
progressive paw inflammation, which would indicate that suboptimal lentiviral titres were used 
in this experiment. Similarly, the administration of LV-2-hIL-1Ra did not reduce paw 
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inflammation following carrageenan-induced paw inflammation which may be due to the low 
basal IL-1Ra expression from the LV-2 promoter and possibly, the delivery of suboptimal 
lentiviral titres.  
In contrast, the principle of mTNFRII-Fc therapy is to bind free TNFα at a 1:1 ratio thereby 
serving as a decoy receptor to prevent TNFα-mediated cell signalling. It was expected that 
mTNFRII-Fc expressed from the constitutive LV-SFFV promoter would achieve the greatest 
reduction in paw inflammation due to high constitutive mTNFRII-Fc protein concentrations. It 
was also expected that the LV-2 promoter would synergistically-induce therapeutic protein 
expression during peak carrageenan-induced inflammation (~24 hours post-carrageenan 
injection) to subsequently reduce paw inflammation after this time point. These actions would 
require high therapeutic protein concentrations however, neither LV-SFFV nor LV-2 promoter 
induced sufficient mTNFRII-Fc protein expression to reduce paw inflammation, when 
compared to the LV-mCMV-mTNFRII-Fc treated mice (Fig 5.3 B). The general reduction of 
paw inflammation observed in Figure 5.3 (A and B) is consistent with the profile of 
carrageenan-induced paw inflammation observed in section 4.3 (Fig 4.8 H), which implies that 
although the carrageenan-induced paw inflammation was reliably reproduced in both 
experiments, the local delivery of therapeutic proteins did not reduce paw inflammation.  
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5.4. Discussion  
It is widely recognised that the pro-inflammatory cytokines TNFα and IL-1β are abundant in 
the RA joint and play crucial roles in the pathogenesis of RA. TNFα and IL-1β-mediated cell 
signalling induces the expression of downstream pro-inflammatory mediators and destructive 
enzymes which exacerbate chronic inflammation and promote cartilage and bone resorption 
(Feldmann and Maini, 2008). The notion of neutralising the biological activities of TNFα and 
IL-1β led to the development of anti-cytokine therapy for the treatment of RA and significant 
experimental evidence has been demonstrated by local and systemic administration of soluble 
TNFRII-Fc and IL-1Ra, respectively. 
The soluble TNFRII-Fc consists of the extracellular binding domain of the p75 TNFα receptor 
fused to the Fc region of mouse IgG1. This fusion protein is a competitive inhibitor of TNFα 
which binds to and neutralises TNFα preventing TNFα-mediated signal transduction 
(Moreland et al., 1997). IL-1Ra inhibits the biological activity of IL-1 (α and β) by competitively 
binding to the type-1 IL-1 receptor and preventing IL-1 receptor mediated signalling (McIntyre 
et al., 1991). The recombinant human therapeutic proteins, soluble TNFR-Fc and IL-1Ra, are 
commercially known as Etanercept (Enbrel®) and Anakinra (Kineret®), respectively and 
Etanercept is a routine ‘biological’ therapy for treating RA. Although significant therapeutic 
efficacy has been demonstrated with IL-1Ra therapy in experimental models of RA, Anakinra 
is not recommended for the treatment of RA, except in the context of a controlled, long-term 
clinical study due to the imbalance in clinical benefits and cost effectiveness (NICE clinical 
guideline 79: Rheumatoid Arthritis).  
Despite clinical success of anti-TNFα protein therapy in RA patients, the systemic and 
repeated administrations of such biological therapies at high-doses continue to raise safety 
concerns such as immunosuppression which increases the risk of developing infections. An 
attractive alternative is the local delivery of therapeutic genes expressed from inflammation-
inducible composite synthetic promoters which offer anti-inflammatory effects during disease 
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flares and reduced activity during disease remission (van de Loo et al., 2004). Although many 
inflammation-inducible systems have demonstrated therapeutic efficacy in animal models of 
paw inflammation, the feasibility of multi-responsive and synergistically-inducible composite 
synthetic promoters for local RA gene therapy has yet to be demonstrated and this was a 
central component of my PhD. 
Section 5.2 described the in vitro quantification of soluble mTNFRII-Fc and hIL-1Ra proteins 
in the supernatant of unstimulated or stimulated LV-mCMV, LV-SFFV, LV-2 and LV-9 stable 
293T cells using ELISA. These results verified the high expression of the therapeutic proteins 
by LV-2 and LV-9 composite promoters in a synergistic and inflammation-inducible manner, 
compared to the constitutive and the undetected therapeutic protein expressions induced by 
the LV-SFFV and LV-mCMV promoters, respectively.   
Based on the consistent and favourable expression profile of promoter LV-2, the therapeutic 
potential of LV-2-regulated therapeutic protein expression was evaluated in a carrageenan-
induced paw inflammation model. Unfortunately, LV-2 promoter-driven hIL-1Ra and    
mTNFRII-Fc protein expression did not reduce paw inflammation. However, mice treated with 
LV-SFFV-hIL-1Ra displayed lower paw inflammation at all time-points throughout the 96 hour 
monitoring period, although only the changes at 3 hours and 72 hours post-inflammation were 
statistically significant (both * p≤0.05). This effect might be due to the high and constitutive 
hIL-1Ra gene expression and semi-efficient blockade of the IL-1 receptors with IL-1Ra during 
the 7 days prior to carrageenan-induced paw inflammation. This observation is in agreement 
with the suggestion that IL-1Ra therapy is more effective when administered before the onset 
of disease, which ensures that the IL-1 receptors are occupied with IL-1Ra to block IL-1 cell 
signalling (Bakker et al., 1997). However, following carrageenan-injection, paw inflammation 
in the LV-SFFV-hIL-1Ra treated mice still continued to increase (albeit lower), which suggests 
that the lentiviral titres were not enough to achieve high hIL-1Ra protein concentrations to 
efficiently block the IL-1 receptors and elicit the desired therapeutic effects. This observation 
corroborates the finding that efficient biological inactivation of in vitro and in vivo IL-1-
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meditated signalling requires a large molar excess (10-1000 fold) of IL-1Ra over IL-1 (Arend 
et al., 1990; Fischer et al., 1991) and more than 95% of IL-1 receptors need to be occupied 
by IL-1Ra to efficiently block IL-1 signalling (Arend, 2002) which may not have been achieved 
due to the low lentiviral titre. Also, the very low hIL-1Ra protein expression in vitro (Fig 5.2 A) 
is in accordance with the absence of LV-2-IL-1Ra mediated reduction in paw swelling 
observed in Figure 5.3 A.  
The delivery of mTNFRII-Fc (and soluble TNFRII) has been demonstrated to successfully 
reduce paw inflammation in experimental mouse models of paw inflammation due to the 
inhibition of TNFα-mediated signalling (Khoury et al., 2007; Hughes et al., 2010). Using the 
carrageenan-induced paw inflammation mouse model, Mazzon et al., (2008) demonstrated 
that the systemic administration of Etanercept (2 hours before inflammation) significantly 
attenuated the development of paw inflammation to a similar extent as that seen in TNFα 
receptor-1 knockout mice, which confirmed the importance of TNFα in this model, particularly 
during the early phase of paw inflammation. In contrast to the findings of Mazzon et al., (2008), 
the results presented in Figure 5.3 B showed that the mice treated with mTNFRII-Fc induced 
by promoters LV-2 and LV-SFFV did not display reduced paw inflammation when compared 
to the level of paw inflammation in LV-mCMV-mTNFRII-Fc treated mice, which is inconsistent 
with published research and provides further evidence that the suboptimal lentiviral titre of 
particles expressing mTNFRII-Fc may have also been too low to efficiently block TNFα-
mediated signalling. 
In a recent study by Garaulet et al., (2013), the authors developed an inflammation-inducible 
E-selectin (ESEL) synthetic promoter-based lentiviral-expression system. The intraplantar 
delivery of the lentiviral particles encoding the ESEL-promoter into the paws of mice resulted 
in inflammation-specific therapeutic IL-10 gene expression which reduced paw inflammation 
following the induction of zymosan-induced paw inflammation. Their experiments were of a 
similar format to the experiments discussed in this chapter, however, the titre of lentiviral 
particles encoding therapeutic IL-10 gene (2x107 transducing units) was substantially higher 
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than that used in the experiments in section 5.3 (830,000 lentiviral IFU). The authors also 
noted that the zymosan-induced mouse model was a suitable model for their experiment due 
to the high induction of inflammatory-interleukins following local zymosan injection, which 
could be reduced by therapeutic IL-10 expression (Garaulet et al., 2013). This logically implied 
that the efficacy of the administrated therapy is dependent on the presence of the target 
inflammatory mediators in the experimental model. 
For example, in order to efficiently evaluate the anti-inflammatory effects of locally expressed 
mTNFRII-Fc and hIL-1Ra proteins, the target pro-inflammatory cytokines TNFα and IL-1β 
should play a major role in the inflammatory process in the carrageenan-induced inflammation 
mouse model. Carrageenan-induced paw inflammation in mice is invariably characterised by 
elevated production of histamine, serotonin, bradykinin, prostaglandins, nitric oxide and 
infiltrating neutrophils (Posadas et al., 2004) and with the exception of Rocha et al., (2006) 
and Mazzon et al., (2008) who showed that TNFα plays a role in carrageenan-induced paw 
inflammation, there is limited research implicating TNFα (and IL-1β) as key inflammatory 
mediators in this model. With hindsight, the therapeutic effects of soluble TNFRII-Fc and IL-
1Ra could be more effective in experimental models of paw inflammation mediated by TNFα 
and IL-1β such as the CIA or AIA models, which share more similarities to human RA than the 
carrageenan-induced inflammation model. Mouse CIA and AIA models also offer the 
advantage of longer durations of inflammation and the ability to reactivate inflammation to 
mimic the relapse/remission phases of the RA would enable longer monitoring periods to fully 
evaluate the therapeutic efficacy of therapeutic genes expressed from inflammation-inducible 
composite synthetic promoters. Due to time constraints, this experiment could not be repeated 
in a more suitable mouse model of arthritis and/or paw inflammation, and represents an 
important option for further investigation.  
In the preceding Chapter 4, the luciferase gene was used as a surrogate for the therapeutic 
genes and promoter LV-2 successfully demonstrated inflammation-specific luciferase 
expression in the carrageenan-induced inflamed paw as confirmed by real-time 
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bioluminescent imaging. In contrast to the highly sensitive detection of luciferase gene 
expression using adjustable bioluminescent imaging, the functional readout of the therapeutic 
efficacy of soluble mTNFRII-Fc and hIL-1Ra proteins was their ability to significant reduce the 
level of paw inflammation, which was a more challenging task that will require optimisation. 
Overall, the reduction of inflammation in mice treated with LV-2-regulated mTNFRII-Fc and 
hIL-1Ra proteins was anticipated but not observed.  It is likely that the lack of significant 
reductions in paw inflammation may have been due to 1) suboptimal lentiviral titres which 
impaired the abundant expression of the therapeutic proteins prior to and during inflammation, 
2) low basal expression of IL-1Ra which failed to efficiently occupy the IL-1 receptors to 
prevent IL-1-mediated signalling or 3) the use of the carrageenan-induced inflammation model 
where the roles of TNFα and IL-1β have not been fully defined. To conclude, these limitations 
can potentially be rectified by optimising the lentiviral titre, reconstructing the composite 
promoters to achieve higher basal and induced gene expression levels and utilising other 
mouse models of paw inflammation, all of which are interesting future work options.   
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CHAPTER 6: 
Post-Transcriptional Regulation of Luciferase 
Gene Expression by Inflammation-responsive 
miR-23b 
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6.1. Introduction 
The development of inflammation-responsive gene expression systems, which harness the 
endogenous transcriptional and post-transcriptional cellular machinery, is the central concept 
of the experiments described in this thesis. In this chapter, I investigate the possibility of post-
transcriptional regulation of constitutive luciferase gene expression using microRNAs 
(miRNAs), whose expression is regulated by inflammatory signals.   
Mature miRNAs are small (~21 nt), noncoding RNA species which bind to their target sites 
within the 3’ untranslated region (3’UTR) of mRNAs to negatively regulate gene expression by 
promoting the degradation or inhibiting the translation of target mRNAs (Bartel, 2004). Many 
recent publications have demonstrated the feasibility of exploiting the endogenous activity of 
miRNAs by incorporating the target sequences of miRNAs into the 3’UTR of the transgene. In 
this way, the transgene mRNA is subjected to post-transcriptional regulation by the candidate 
miRNA, resulting in differential gene expression (Brown et al., 2007b; Brown and Naldini, 
2009). Analogous to this concept, the aim of the experiments in Chapter 6 is to provide proof-
of-principle of inflammation-specific gene expression mediated by an inflammation-repressed 
miRNA.  
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A promising candidate to demonstrate this concept was miR-23b (miR-23b-3p), which was 
identified by Zhu et al., (2012) to be:  
• downregulated in inflammatory lesions of patients with autoimmune RA and systemic 
lupus erythematosus (SLE)  
• downregulated in tissue samples from mice with collagen-induced arthritis (CIA) and 
experimental autoimmune encephalomyelitis (EAE)  
• downregulated in human fibroblast-like synoviocytes, mouse primary kidney cells and 
mouse embryonic fibroblasts treated with inflammatory stimuli 
• highly expressed in normal tissues 
 
Exploiting the differential expression of miR-23b between inflammation and the normal state 
holds great promise for the development of inflammation-regulated gene expression. Figure 
6.1 depicts the concept of miR-23b-mediated regulation of therapeutic gene expression. 
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Figure 6.1. Schematic diagram illustrating the concept of post-transcriptional 
regulation of therapeutic gene expression by inflammation-repressed miR-23b.   
Perfectly complementary miR-23b target sites can be cloned into 3’UTR of the therapeutic 
gene, driven by a constitutive promoter. Following transcription, the therapeutic mRNA 
containing miR-23b target sites will be subjected to regulation by inflammation-repressed miR-
23b. During RA remission, miR-23b is highly expressed and can bind to their cognate sites in 
the therapeutic mRNA 3’UTR and target the therapeutic mRNAs for degradation, resulting in 
low therapeutic protein concentrations [A]. During inflammation, the miR-23b expression is 
downregulated, therefore few or no miR-23b molecules will bind to their target sites in the 
therapeutic mRNA 3’UTR and the untargeted mRNAs can be translated into the therapeutic 
protein to reduce inflammation [B].  
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6.1.1. Construction of miR-23b-regulated luciferase expression cassettes 
 
The luciferase gene was used as a surrogate marker for the expression levels of a therapeutic 
gene. The schematic diagrams below (Fig 6.2) depict the cloning strategy used to construct 
the miR-23b-regulated luciferase expression cassettes. 
A. The plasmid DNA construct pcLuc+ (modified from pcDNA3.1+ by Gould et al., 2004) 
contains the constitutive CMV promoter driving expression of the luciferase gene 
(Luc+). The construct was digested with XbaI and ApaI, within the 3’UTR of the 
luciferase gene and upstream of the poly A signal, to create the pcLuc+ cloning vector 
(Fig 6.2 A).  
 
   
 
 
 
 
 
   
B. The miR-23b-target oligonucleotide contained two perfect complementary miR-23b 
target sites, which are the reverse complement sequences of human miR-23b-3p. The 
oligonucleotides were ordered with 5’-XbaI and 3’-ApaI overhangs and cloned into the 
XbaI/ApaI site within the pcLuc+ vector to generate the pcLuc+-miR-23b-2T construct 
(Fig 6.2 B).  
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C. Cloning of the miR-23b-target oligonucleotide into the pcLuc+ vector destroys the XbaI 
site and restores the ApaI restriction site. The miR-23b-target oligonucleotide contains 
an internal XbaI restriction site (5’-TCTAGA-3’, shown in green above). Therefore, the 
pcLuc+-miR-23b-2T construct was digested with XbaI and ApaI to clone an additional 
miR-23b-target oligonucleotide to generate the expression construct pcLuc+-miR-23b-
4T, containing four miR-23b target sites.  
 
D. Successful cloning of pcLuc+-miR-23b-2T and pcLuc+-miR-23b-4T constructs were 
authenticated by an EcoRI restriction enzyme digest, which released 1800 bp and 
1860 bp fragments, respectively (Fig 6.2 D). Positive constructs were verified by DNA 
sequencing (Appendix 12.1 and 12.2).  
         
 
Figure 6.2. Construction of pcLuc+-miR23b-target expression vectors. The pcLuc+ 
plasmid was systematically modified to generate constructs with two or four miR-23b target 
sites in the 3’UTR of the luciferase gene.  
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6.2. Successful knockdown of luciferase gene expression using synthetic          miR-
23b mimics              
Synthetic miRNA mimics are double stranded RNA molecules which ‘mimic’ the activity of 
endogenous miRNAs by post-transcriptionally downregulating target mRNAs. To investigate 
whether miR-23b can target and repress luciferase mRNAs containing miR-23b target sites, 
1 μM miR-23b mimic or 1 μM control miR-648 mimic was co-transfected with pcLuc+, pcLuc+-
miR-23b-2T or pcLuc+-miR-23b-4T and also pRL-CMV in 293T cells. The luciferase protein 
expression was quantified and presented in Figure 6.3.  
 
 
Figure 6.3. Successful knockdown of luciferase gene expression using a synthetic   
miR-23b mimic. 293T cells (32,000 cells) were seeded in a 48-well plate. After 24 hours, the 
pcLuc+, pcLuc+-miR-23b-2T and pcLuc+-miR-23b-4T constructs (90 ng) were co-transfected 
with the renilla expressing plasmid pRL-CMV (10 ng) and 1 µM miR-23b mimic and 1 µM miR-
648 mimic (control) using Lipofectamine 2000 in 293T cells. The data represents the mean ± 
SD of triplicate values normalised to renilla luciferase. The statistical significance compared 
to the corresponding ‘plasmid alone’ datasets for each group was calculated using the 
Student's t-test (ns= p>0.05, * = p≤0.05, ** = p≤0.01, *** = p≤0.001).  
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As anticipated, miR-23b or miR-648 mimic had marginal effects on the miRNA target-less 
luciferase mRNA expressed from pcLuc+ control vector (* p=0.02 and ns =0.94, respectively). 
Impressively, miR-23b mimic significantly reduced luciferase gene expression from the 
pcLuc+-miR-23b-2T (*** p=0.0002; 83% reduction) and pcLuc+-miR-23b-4T           (*** p=0.001; 
92% reduction), which contain two and four miR-23b target sites, respectively. In contrast, the 
non-specific miR-648 control mimic had a less significant effect on luciferase mRNAs with 
miR-23b target sites, expressed from pcLuc+-miR-23b-2T (** p=0.01; 22% reduction) and 
pcLuc+-miR-23b-4T (** p=0.01; 24% reduction).  
Luciferase mRNAs with four miR-23b target sites (expressed from pcLuc+-miR-23b-4T) were 
suppressed to a greater extent than luciferase mRNAs with two target sites which indicates 
that downregulation of gene expression by miRNAs is influenced by the number of miRNA 
target sites within the mRNA. 
This experiment strengthened the established concept of cloning miRNA target sites into the 
transgene 3’UTR to post-transcriptionally regulate transgene expression. The use of synthetic 
miRNA mimics confirmed that the miR-23b target sites were correctly cloned into the 
expression cassette and could potentially be targeted by endogenous miR-23b. 
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6.3. Inflammation-induced downregulation of endogenous miR-23b expression in 
NIH3T3 mouse embryonic fibroblasts 
 
Endogenous miR-23b is downregulated in autoimmune pathology and also downregulated in 
primary human FLS, mouse primary kidney cells and mouse embryonic fibroblasts treated 
with inflammatory stimuli (Zhu et al., 2012). Therefore, the differential expression of miR-23b 
in response to the presence or absence of inflammatory stimulation in NIH3T3 mouse 
embryonic fibroblasts was confirmed by Absolute Real-time qPCR. The miR-23b copy number 
(per cell) was quantified in unstimulated, mIL-17A, TNFα and TNFα+mIL-17A stimulated 
NIH3T3 cells using the standard curve method (Fig 6.4). The standard curve plots are 
presented in Appendix 15.  
 
   
  
Figure 6.4. miR-23b is significantly downregulated in response to 
inflammatory stimuli in NIH3T3 cells. NIH3T3 cells (1.5x106) were 
unstimulated or stimulated with mIL-17A (50 ng/ml), TNFα (10 ng/ml) or 
mIL-17A with TNFα for 18 hours. The small RNA fraction containing 
miRNAs was isolated and 100 ng RNA was reverse transcribed to generate 
cDNA. Each cDNA sample was amplified using miR-23b, U6 control, miR-
16 control, miR-17-5p control, miR-103 control, miR-191 control forward 
primers and a universal reverse primer in an Absolute Real-time qPCR 
reaction. Absolute quantification of the miRNAs was determined using the 
standard curve method and the control miR 191 was identified as the best
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This experiment shows that miR-23b is highly expressed in unstimulated NIH3T3 cells and is 
significantly downregulated in response to stimulation with mIL-17A (* p=0.048; 11% 
reduction), TNFα (*** p=0.0002; 55% reduction) and a combination of TNFα and mIL-17A       
(** p=0.01; 29% reduction) in the same cell type. These results confirmed the previously 
reported inflammation-repressed expression profile of endogenous miR-23b, which can 
potentially be harnessed for inflammation-responsive gene regulation.  
 
 
6.4 Efficient regulation of luciferase gene expression by inflammation-responsive 
endogenous miR-23b in NIH3T3 mouse embryonic fibroblasts 
 
The ability of endogenous miR-23b to achieve inflammation-specific luciferase gene 
expression was investigated in unstimulated and stimulated NIH3T3 and 293T cells. The cells 
were co-transfected with pcLuc+, pcLuc+-miR23b-2T, pcLuc+-miR23b-4T and also pRL-CMV. 
Human and mouse miR-23b sequences are identical, therefore the constructs can be active 
in both human and mouse cells (Fig 6.5).  
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Figure 6.5. Cell-specific and inflammation-responsive luciferase gene regulation 
mediated by endogenous miR-23b. NIH3T3 cells [A] and 293T cells [B] were seeded at 
20,000 cells/well in a 96 well plate. After 24 hours, pcLuc+, pcLuc+-miR-23b-2T or pcLuc+-miR-
23b-4T (180 ng) were co-transfected with pRL-CMV (20 ng) in NIH3T3 cells [A] and 293T cells 
[B]. Transfected NIH3T3 and 293T cells were unstimulated or stimulated with IL-17A (50 
ng/ml), TNFα (10 ng/ml) or TNFα + IL-17A for 18 hours. Mouse IL-17A (mIL-17A) and human 
IL-17A (hIL-17A) was used to stimulate the mouse NIH3T3 cells and human 293T cells, 
respectively. The data represents the mean ± SD of triplicate values normalised to renilla 
luciferase. The statistical significance was calculated using the Student’s t-test (ns = p>0.05, 
* = p≤0.05, ** = p≤0.01, *** = p≤0.001). The statistical significance shown in black compares 
the luciferase expression from each miR-23b target-bearing constructs (miR-23b-2T and -4T) 
to the target-less pcLuc+ construct during the same conditions. The statistical significance 
shown in red compares the luciferase expression during inflammatory stimulation compared 
to the basal expression induced by the same construct.  
 
 
In NIH3T3 cells, the presence of four miR-23b target sites in the luciferase mRNA resulted in 
a greater reduction in basal luciferase gene expression than the presence of two miR-23b 
target sites. The highly significant reduction in basal luciferase gene expression from                
pcLuc+-miR-23b-4T (** p=0.01, black) and pcLuc+-miR-23b-2T (* p=0.02, black) compared to 
pcLuc+, confirmed that suppression of gene expression by miR-23b was greater with 
increasing numbers of miR-23b target sites within the luciferase mRNA.  
The Real-time qPCR data (section 6.3) showed that miR-23b expression was significantly 
downregulated in NIH3T3 cells stimulated with inflammatory cytokines. However, in Figure 
6.5A, transfection of NIH3T3 cells with pcLuc+-miR-23b-4T resulted in the significant reduction 
in luciferase gene expression, irrespective of inflammatory stimulation when compared to 
gene expression induced from the target-less pcLuc+. Interestingly, the changes in miR-23b 
concentrations during inflammatory stimulation had a significant effect on luciferase gene 
expression from pcLuc+-miR-23b-4T when compared to its basal expression (* p=0.05 mIL-
17A red, * p=0.02 TNFα red and *** p=0.0003 mIL-17A+TNFα red), demonstrating that 
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inflammation-responsive gene regulation was still observed in        pcLuc+-miR-23b-4T. 
However, inflammatory stimulation did not decrease miR-23b expression to a level where 
luciferase mRNA remained untargeted and consequently, the luciferase gene expression 
levels in stimulated cells remained low (Fig 6.5 A).  
In contrast, when NIH3T3 cells were transfected with pcLuc+-miR-23b-2T and stimulated with 
inflammatory cytokines, the changes in luciferase expression were not significantly different 
from that induced by the target-less pcLuc+ construct (ns = p>0.05, black), indicating that the 
miR-23b concentration was significantly downregulated to a level where miR-23b had no 
significant effect on luciferase gene expression, which also corroborated the Real-time qPCR 
data (section 6.3). Furthermore, the significant changes in luciferase gene expression from 
pcLuc+-miR-23b-2T during the basal state compared to that in the presence of TNFα (** 
p=0.01, red) and mIL-17+TNFα stimulation (* p=0.03, red) show that the inflammation-
repressed expression of miR-23b in NIH3T3 cells permits high gene expression during 
inflammation and low gene expression during the uninflamed state, which is the desirable 
expression profile for miR-23b-mediated gene therapy (Fig 6.5 A). 
In contrast, the absolute copy number of miR-23b in 293T cells is low (Brown et al., 2007b), 
which corroborates the data in Figure 6.5B. In 293T cells, miR-23b generally had no significant 
effect on the luciferase mRNA expression, irrespective of the number of miR-23b target sites 
or inflammatory stimulation. These observations confirmed the cell-specific expression profile 
of miR-23b and also suggest that a threshold miR-23b concentration is required to achieve 
target mRNA downregulation in specific cells.   
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6.5. Evaluating the inflammation-responsive miR-23b regulation of luciferase mRNA 
expressed from lentiviral constructs 
To assist the potential in vivo application of miR-23b-mediated expression cassette, two or 
four miR-23b target sites were cloned into the 3’UTR of the luciferase gene within the lentiviral 
vector. The luciferase gene expression was driven by the constitutive SFFV promoter as this 
promoter is less susceptible to changes in activity due to inflammatory stimulation than the 
constitutive CMV promoter.  
 
6.5.1. Construction of lentiviral miR-23b-target constructs for regulation of stable 
luciferase gene expression 
The schematic diagram below (Fig 6.6) illustrates the cloning strategy used to incorporate              
miR-23b-target sites within the lentiviral vector.  
 
A. The pLV.SFFV.Luc+ construct (from Chapter 4) was digested with EcoRI and KpnI, 
immediately downstream of the luciferase gene and the woodchuck post-
transcriptional regulatory element (WPRE), to serve as the pLV.SFFV.Luc+ cloning 
vector for the miR-23b-2T and miR-23b-4T PCR products (Fig 6.6 A).  
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B. The miR-23b-target sequences were PCR amplified from pcLuc+-miR-23b-2T and 
pcLuc+-miR-23b-4T using forward and reverse PCR primers with MfeI and KpnI 
restriction sites, respectively (Fig 6.6 B).  
 
 
 
 
 
C. EcoRI and MfeI digested DNA have compatible ends therefore the miR-23b-target 
PCR products were digested with MfeI and KpnI and cloned into the EcoRI/KpnI site 
within the pLV.SFFV.Luc+ vector to generate pLV.SFFV.miR-23b-XT, where X is 2 or 
4 miR-23b target sites (Fig 6.6 C). The resulting constructs were verified by DNA 
sequencing (Appendix 12.3 and 12.4). 
 
 
 
 
D. Following the construction of the lentiviral miR-23b constructs, the lentiviral particles 
were produced by a three-plasmid transient transfection into 293T cells with the 
transfer, packaging and envelope plasmids to generate lentiviral particles pseudotyped 
with the VSV-G envelope glycoprotein. The VSV-G pseudotyped lentiviral particles 
were transduced into 293T and NIH3T3 cells to generate stable cell lines with the 
integrated luciferase gene containing miR-23b target sites. 
 Figure 6.6. Schematic diagram illustrating the cloning method 
used to generate the lentiviral miR-23b-target constructs. The 
lentiviral constructs express the luciferase gene under the control of 
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6.5.2. Synthetic miR-23b mimics significantly downregulate luciferase expression 
from lentivirally transduced 293T cells  
Similar to the experiments in section 6.2, the synthetic miR-23b mimics were used to confirm 
whether the luciferase mRNA with miR-23b target sites, expressed from lentivirally transduced 
293T cells, can be efficiently downregulated by a miR-23b mimic. The stable 293T cells were 
transfected with 1 μM miR-23b mimic or 1 μM miR-648 mimic (control) and the luciferase 
protein expression was quantified and presented in Figure 6.7.  
 
Figure 6.7. Significant downregulation of luciferase gene expression from stable 293T 
cells, using synthetic miR-23b mimics. 293T cells (50,000) were transduced with             LV-
SFFV-miR-23b-2T and LV-SFFV-miR-23b-4T lentiviral particles to generate stable 293T cells. 
The stable 293T cells (32,000 cells) were seeded in a 48-well plate. After 24 hours,     1 µM 
miR-23b mimic or 1 µM miR-648 mimic (control) were transfected into the stable 293T cells 
using Lipofectamine 2000 transfection reagent. Firefly luciferase was normalised to the protein 
content in the cell lysate (expressed as RLU/mg protein). The data represents the mean ± SD 
of triplicate values. The statistical significance compared to the corresponding ‘plasmid alone’ 
datasets for each group was calculated using the Student’s t-test (ns = p>0.05, *** = p≤0.001). 
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Analogous to the results in section 6.2, the transfection of the miR-23b mimic resulted in a 
significant downregulation of luciferase gene expression from LV-SFFV-miR-23b-2T and   LV-
SFFV-miR-23b-4T stable 293T cells (both *** p=0.001). In contrast, the non-specific miR-648 
control mimic had no-significant effect on the luciferase gene expression.  
This experiment confirmed the ability of miR-23b to target luciferase mRNAs expressed from 
the lentiviral SFFV promoter in stable 293T cells. Therefore, the ability of endogenous 
inflammation-responsive miR-23b to regulate luciferase gene expression in lentivirally 
transduced stable NIH3T3 cells was evaluated in section 6.5.3.  
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6.5.3. Endogenous miR-23b activity exhibits miR-23b-target number dependent and  
miR-23b concentration dependent regulation of luciferase gene expression in 
stable NIH3T3 cells 
 
To determine whether endogenous miR-23b can regulate luciferase mRNA expressed from 
lentivirally transduced stable NIH3T3 cells in an inflammation-responsive manner, the stable 
NIH3T3 cells were unstimulated, or stimulated with mIL-17A, TNFα or their combination. The 
luciferase protein was quantified and presented in Figure 6.8.  
 
 
 
  
Figure 6.8. miR-23b target-number and concentration-dependent 
regulation of luciferase gene expression. NIH3T3 cells (50,000) were 
transduced with LV-SFFV-Luc+, LV-SFFV-miR-23b-2T or LV-SFFV-miR-23b-
4T lentiviral particles to generate stable NIH3T3 cells. The stable NIH3T3 cells 
(20,000 cells) were seeded in a 96-well plate and after 24 hours, the cells were 
unstimulated or stimulated with mIL-17A, TNFα or their combination for 18 
hours. The luciferase protein was quantified and normalised to the lentiviral 
titre of the respective constructs (RLU/lenti IFU). The data represents the mean 
± SD of triplicate values and the statistical significance was calculated using 
the Student’s t-test (ns = p>0.05, * = p≤0.05, ** = p≤0.01, *** = p≤0.001). The 
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Interestingly, basal luciferase expressions from LV-SFFV-miR-23b-2T and -4T cassettes were 
significantly lower than expression from LV-SFFV-Luc+ in lentivirally transduced       NIH-3T3 
cells (both *** p=0.001, black, respectively). This indicates that basal levels of miR-23b were 
sufficient to effectively target luciferase mRNA. 
Importantly, the downregulation of miR-23b by inflammatory stimulation was not sufficient to 
reverse miR-23b-mediated suppression of luciferase expression from either cassette, as 
indicated by the absence of inflammation-regulated luciferase gene expression by miR-23b 
(ns= p>0.05, red). These results further corroborate that efficient regulation by miR-23b is 
dependent on the number of miR-23b target sites and also dependent on the concentration of 
miR-23b in the cell.  
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6.6 Inflammation-specific dual regulation of gene expression by an NFκB synthetic 
promoter and endogenous miR-23b in NIH3T3 cells 
 
The combination of inflammation-responsive synthetic promoters and miRNA target sites 
within the same vector offers the prospect of stringently regulating gene expression induced 
by synthetic promoters with high basal gene expression.  
The construct pCpG-6NFκB-Luc+, which contains 6NFκB motifs, previously demonstrated 
high inducibility to TNFα in 293T cells (Chapter 3). Inflammation-regulated gene expression in 
NIH3T3 cells was only observed with mRNAs containing two miR-23b target sites (section 
6.4) therefore, two miR-23b target sites were cloned into the 3’UTR of the luciferase gene, 
downstream of the synthetic promoter, in order to investigate whether miR-23b can reduce 
the basal gene expression without impairing the induced luciferase gene expression. Figure 
6.9 (below) schematically depicts the cloning strategy used to generate the dual-regulated 
construct 6NFκB-miR-23b-2T. 
 
A. pCpG-6NFκB-Luc+ was digested with PpumI and FseI to isolate the NFκB-responsive 
synthetic promoter and the 5’- portion of the luciferase gene. The resulting construct 
served as the cloning vector 6NFκB-Luc+ (Fig 6.9 A).  
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B. The 3’-portion of the luciferase gene and two miR-23b target sites were PCR amplified 
from the pcLuc+-miR-23b-2T construct using a forward PCR primer and a reverse PCR 
primer that contained an FseI restriction enzyme site (Fig 6.9 B).   
 
 
 
 
 
 
                  
 
C. The PCR product was digested with PpumI and FseI and cloned into the equivalent 
site within the 6NFκB-Luc+ vector to restore the luciferase gene and generate 6NFκB-
miR-23b-2T (Fig 6.9 C). The construct was confirmed by DNA sequencing (Appendix 
12.5).  
 
 
 
 
 
Figure 6.9. Schematic diagram depicting a dual-regulated construct with an 
inflammation-inducible synthetic promoter and two miR-23b target sites. The       pCpG-
6NFκB-Luc+ construct was modified to incorporate two miR-23b target sites within the 3’UTR 
of the luciferase gene, downstream of an inflammation-inducible promoter. 
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The 6NFκB-Luc+ and 6NFκB-miR-23b-2T constructs were co-transfected with pRL-CMV into 
NIH3T3 cells, which were then unstimulated or stimulated with TNFα. The luciferase gene 
expression is presented in Figure 6.10.  
 
Figure 6.10. Regulated luciferase expression from a transcriptionally and post-
transcriptionally responsive vector in NIH3T3 cells. The 6NFκB-Luc+ and 6NFκB-miR-
23b-2T constructs (180 ng) were co-transfected with pRL-CMV (20 ng) into NIH3T3 cells 
(20,000 cells in a 96-well plate) and were either unstimulated or stimulated with TNFα (10 
ng/ml) for 18 hours. Firefly luciferase was normalised to renilla luciferase and the data 
represents the mean ± SD of triplicate values. The statistical significance between the 
corresponding datasets was calculated using the Student’s t-test (ns= p>0.05, * = p≤0.05). 
 
Endogenous miR-23b significantly downregulated the basal luciferase gene expression from 
6NFκB-miR-23b-2T (* p=0.03, 84% reduction) when compared to luciferase expression from 
6NFκB-Luc+. Importantly, luciferase expression was induced by TNFα stimulation from both 
vectors. However, due to the reduced basal expression from 6NFκB-miR-23b-2T, the fold 
change following TNFα-stimulation was 7.1 fold compared to 1.5 fold for the unmodified 
vector, which represents a dramatic difference in the regulation of gene expression by the two 
constructs. Overall, Figure 6.10 confirmed the concept of exploiting the endogenous 
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transcriptional and post-transcriptional components to achieve dual-regulation of gene 
expression in an inflammation-responsive manner.  
6.7. Discussion  
The intra-articular synthesis of the therapeutic proteins expressed from constitutive promoters 
can potentially achieve sustained, local suppression of inflammation (Adriaansen et al., 2006). 
However, the constitutive promoters i.e. CMV and SFFV used in these systems induce 
continuous and unregulated gene expression which can lead to adverse effects in non-target 
tissues and/or disease states. The clinical course of RA is characterised by episodes of 
spontaneous remission and relapsing chronic inflammation, therefore, the prospect of 
inflammation-regulated gene expression systems offers the potential of permitting high 
therapeutic gene expression only during inflammation thus improving the safety and efficacy 
of local RA gene therapy. In this chapter, regulated gene expression induced by inflammatory 
stimuli was achieved by miRNA-mediated post-transcriptional regulation.   
As reviewed by Gentner and Naldini, (2012), the distinct expression profiles of numerous 
miRNAs have been exploited to achieve cell-, tissue- and disease-specific gene expression. 
However, exploiting the endogenous activities of inflammation-repressed miRNAs to achieve 
disease-specific gene expression is an unexplored concept and in this chapter, I explored the 
use of miR-23b to develop an inflammation-responsive gene expression system.  
A crucial element of miRNA-mediated, inflammation-responsive gene regulation was the 
choice of miRNA. The candidate miRNA was required to be highly expressed during the 
uninflamed state and significantly downregulated in inflammation and following extensive 
literature searches, miR-23b was identified to display the desired expression profile by Zhu et 
al., (2012), who used miRNA microarray and relative Real-time qPCR validation. This 
observation was confirmed by absolute Real-time qPCR in section 6.3 which verified that miR-
23b was highly expressed in the absence of inflammatory stimulation and significantly 
downregulated in NIH3T3 mouse embryonic fibroblasts stimulated with inflammatory 
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cytokines. Unlike the relative quantification method used by Zhu et al., (2012), the 
quantification of absolute miR-23b concentration in NIH3T3 cells facilitated logical 
interpretations of the miR-23b-mediated luciferase gene regulation data, which highlighted the 
important relationship between miR-23b concentration and efficient gene regulation.  
Using the basic principle of miRNA-mediated regulation, two and four perfectly complementary 
miR-23b target sites were cloned into the 3’UTR of the luciferase gene to subject the luciferase 
mRNA to inflammation-responsive regulation by miR-23b. The binding of miR-23b to the 
luciferase 3’UTR was investigated by target validation experiments (section 6.2) which 
confirmed the successful downregulation of the luciferase gene using synthetic miR-23b 
mimics.  
The importance of quantifying the absolute expression of the candidate miRNAs was 
highlighted by Brown et al., (2007b) who demonstrated that the target mRNA suppression is 
dependent on a threshold miRNA concentration. This group quantified the absolute 
expression of several miRNAs in 293T (kidney) and U937 (monocyte) cells using absolute 
Real-time qPCR and showed that miRNAs expressed at low levels (<100 copies/pg small 
RNA) do not significantly downregulate target mRNAs whereas highly expressed miRNAs 
(>1000 copies/pg small RNA) significantly repressed target mRNAs. Interestingly, they 
quantified miR-23b to have a relatively low concentration in unstimulated 293T cells (~400 
copies/ pg small RNA) which provided a logical explanation for the lack of miR-23b-mediated 
regulation that was observed in 293T cells (Fig 6.5 B). In addition to the relatively low miR-
23b concentrations in 293T cells, it is also possible that the number of miR-23b target sites 
may have exceeded the miR-23b concentration which resulted in poor miR-23b-mediated 
regulation of gene expression. Overexpression of miR-23b-target bearing luciferase mRNAs 
may have resulted from the amplification of the pcLuc+-miR-23b expression constructs 
(derived from pcDNA3) which contain an SV40 origin of replication (ori). Transient transfection 
of these constructs into 293T cells results in the episomal replication of the vector due to the 
presence of the SV40 Large T-antigen in 293T cells (Prelich et al., 1987). Therefore, the 
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combined effect of high constitutive luciferase expression driven by the CMV promoter, 
amplification of the expression vector in 293T cells and the low miR-23b concentration in 293T 
cells resulted in the ratio of low miR-23b concentration relative to the high expression of target 
luciferase mRNAs which may have impaired miR-23b-mediated regulation in 293T cells (Fig 
6.5 B). 
In contrast, the luciferase gene expression from lentivirally transduced stable NIH3T3 cells 
was significantly downregulated, irrespective of inflammatory stimulation (Fig 6.8). It is 
possible that the low transduction efficiency of NIH3T3 cells resulted in low luciferase mRNA 
levels which promoted a ratio of high miR-23b concentration relative to the low expression of 
target luciferase mRNA in stable NIH3T3 cells, ultimately resulting in strong suppression of 
luciferase gene expression. This data also suggested that the highly abundant miR-23b 
concentration in NIH3T3 cells was not downregulated by inflammatory-cytokine stimulation to 
an extent which prevented luciferase mRNA targeting, thereby further strengthening the 
concept that target mRNA suppression is dependent on a threshold miRNA concentration 
(Brown et al., 2007b).  
In the case of optimal miR-23b concentrations relative to the target mRNA levels, efficient 
regulation of gene expression can be achieved, as shown in Figure 6.5 A. In this experiment, 
the luciferase mRNAs containing two miR-23b target sites expressed in transiently transfected 
NIH3T3 cells were efficiently regulated in an inflammation-responsive manner. However, 
although inflammatory-regulation was observed with luciferase mRNAs containing four miR-
23b target sites, the overall luciferase expression was significantly lower than that observed 
with luciferase mRNAs containing two miR-23b target sites, which supported the finding that 
target mRNA suppression is also dependent on the number of miRNA target sites (Doench et 
al., 2003). This observation was also confirmed by the miR-23b mimic target validation 
experiments (Fig 6.3 and 6.7) which clearly demonstrated that luciferase mRNA suppression 
was greatest with four miR-23b target sites compared to two miR-23b target sites within the 
luciferase mRNA. Similarly, numerous publications have also implemented the findings of 
312 
 
Doench et al., (2003) to achieve greater target suppression of gene expression by 
incorporating four miRNA target sites.  
Encouraged by the inflammation-responsive regulation of luciferase gene expression in 
NIH3T3 cells by miR-23b, a dual-regulated expression system was generated by cloning two 
perfectly complementary miR-23b target sites into the 3’UTR of the luciferase gene, positioned 
downstream of an NFκB-responsive synthetic promoter (section 6.6). In this experiment, the 
ratio of miR-23b concentration relative to the luciferase mRNA levels were optimal which 
resulted in the significant downregulation of basal luciferase expression in unstimulated 
NIH3T3 cells by miR-23b, without significantly impairing the TNFα-induced luciferase gene 
expression. These results provided proof-of-concept of combining transcriptional and post-
transcriptional regulatory components to achieve stringent inflammation-responsive gene 
expression. This approach also provided a novel strategy to improve the safety profile of 
synthetic promoters with high basal gene expression in cells with inflammation-repressed 
expression of miR-23b, at the threshold concentration.  
Evidently, a fine balance between miR-23b concentrations and target mRNA levels is required 
for inflammation-regulated gene expression by miR-23b and profiling the absolute expression 
of miR-23b concentration within the cells served as a reliable predictor of efficient miR-23b-
mediated gene regulation. Table 6.1 summarises the luciferase gene regulation by 
endogenous miR-23b in transiently transfected 293T and NIH3T3 cells and lentivirally 
transduced stable NIH3T3 cells.  
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Cell type miR-23b concentration (Unstimulated state) 
Luciferase target 
mRNA expression 
Luciferase gene 
regulation 
Transient transfected 
293T cells Low 
High 
(miR-23b-2T) No significant effect 
Transient transfected 
293T cells Low 
Very high 
(miR-23b-4T) No significant effect 
Transient transfected  
NIH3T3 cells High 
Moderate 
(miR-23b-2T) 
Significant 
downregulation 
Transient transfected  
NIH3T3 cells High 
Moderate/High 
(miR-23b-4T) 
Significant 
downregulation 
Stable  NIH3T3 cells High Low (miR-23b-2T and 4T) 
Significant 
downregulation 
Transient transfection 
NIH3T3 cells  
Dual-regulated promoter 
 
High Moderate (miR-23b-2T) 
Significant 
downregulation 
 
 
 
Cell type miR-23b concentration (Inflammatory stimulation)
Luciferase target 
mRNA expression 
Luciferase gene 
regulation 
Transient transfected  
293T cells Low 
High 
(miR-23b-2T) No significant effect 
Transient transfected  
293T cells Low 
Very high 
(miR-23b-4T) No significant effect 
Transient transfected  
NIH3T3 cells Significantly reduced  
Moderate 
(miR-23b-2T) No significant effect 
Transient transfected  
NIH3T3 cells Significantly reduced 
Moderate/High 
 (miR-23b-4T) 
Significant 
downregulation 
Stable  NIH3T3 cells Significantly reduced Low (miR-23b-2T and 4T) 
Significant 
downregulation 
Transient transfection 
NIH3T3 cells  
Dual-regulated promoter 
 
Significantly reduced  Moderate (miR-23b-2T) No significant effect 
 
Table 6.1. Efficient luciferase gene regulation is dependent on the ratio between the 
level of luciferase target mRNA and the threshold miR-23b concentration within the cell. 
The differences in luciferase gene regulation by miR-23b during the unstimulated [A] and 
inflammatory-stimulated [B] states are shown.  
[A]
[B]
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A potential concern regarding the high expression of mRNAs with four miR-23b target sites is 
the inadvertent competition introduced between synthetic miR-23b (luciferase) target mRNAs 
and the endogenous miR-23b target mRNAs.  Endogenous miR-23b suppresses   IL-17, TNFα 
and IL-1β-induced NFκB activation by targeting the 3’UTR of mRNA encoding TAK1-binding 
protein 2 (TAB2), TAB3 and the IκB-kinase α (IKKα), resulting in repressed inflammation in 
autoimmune diseases such as RA and SLE (Zhu et al., 2012). Theoretically, the 
overexpression of synthetic miR-23b target mRNA (luciferase mRNA) can potentially disrupt 
the miR-23b-mediated targeting of endogenous mRNAs by acting as a ‘decoy’ target, which 
may result in the activation of the NFκB pathway and perpetuate inflammation by untargeted 
TAB2, TAB3 and IKKα.  
However, it is unlikely that the recruitment of miR-23b to the target sites within the luciferase 
mRNA would result in loss of regulation of endogenous miR-23b targets because firstly, the 
concentration of miR-23b is highly abundant in NIH3T3 cells and greatly exceeds the 
luciferase target mRNA expression. Secondly, endogenous mRNA targets often have several 
targeting miRNAs due to the similarities with their 5’-miRNA seed sequences (Brennecke et 
al., 2005) and therefore the endogenous miR-23b targets, i.e. TAB2, TAB3 and IKKα can be 
regulated by other targeting miRNAs. Thirdly, the incorporation of perfectly complementary 
miR-23b target sites increases the catalytic rate of the RISC complex which decreases the 
likelihood that the endogenous miRNAs become saturated. In agreement with these 
assumptions, the results of Brown et al., (2007b) experimentally demonstrated that the high 
expression of perfectly complementary miRNA target sites does not disturb the regulation of 
endogenous target mRNAs.  
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Logically, the cell-state specific expression profile of miR-23b limits the broad applicability of 
miR-23b-mediated regulation systems to specific cell types and tissues. Encouragingly,    miR-
23b expression is significantly downregulated in primary RA fibroblast-like synoviocytes (Zhu 
et al., 2012), which are the main target cells for the disease-regulated local gene therapy 
described in this thesis. Therefore, the miR-23b-mediated expression systems described in 
this chapter can potentially promote inflammation-regulated therapeutic gene expression in 
RA synovial fibroblasts, provided that these cells express sufficient miR-23b concentrations 
relative to the target therapeutic mRNA expression. Consequently, the unwanted high 
therapeutic gene expression driven by a constitutive promoter or synthetic promoter can 
potentially be downregulated by highly expressed miR-23b during the uninflamed state, whilst 
permitting high therapeutic gene expression during inflammation in RA joints.   
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Chapter 7: General Discussion and Conclusion 
Rheumatoid arthritis (RA) is characterised by elevated pro-inflammatory cytokines in the 
synovial joint, i.e. TNFα and IL-1β, which orchestrate many of the inflammatory and destructive 
processes in the disease and are therefore attractive therapeutic targets (McInnes and Schett, 
2011). At the molecular level, the inflammatory and hypoxic pathological environment in the 
RA joint activates responsive transcription factors which control the gene expression of pro-
inflammatory cytokines, chemokines, growth factors, cartilage degrading enzymes and other 
mediators integral to the pathogenesis of RA (Okamoto et al., 2008).  
Such advances in the understanding of the pathophysiology of RA have enabled researchers 
to exploit the endogenous activity of activated transcription factors using inflammation-
inducible synthetic promoters to regulate therapeutic gene expression in response to 
inflammation (Khoury et al., 2007; Geurts et al., 2007; Henningson et al., 2012 and Garaulet 
et al., 2013). These self-regulating promoters can potentially induce high levels of anti-
inflammatory agents during disease flare and lower levels during disease remission, to mirror 
the clinical course and severity of inflammation within the joint (Adriaansen et al., 2006). Gene 
therapy strategies utilising inflammation-inducible synthetic promoters for the treatment of 
arthritis in experimental animal models of RA have generally been successful (e.g. Geurts et 
al., 2007 and Henningson et al., 2012). However, the development and application of multi-
responsive and synergistically-inducible composite synthetic promoters for RA gene therapy 
has yet to be demonstrated by others and this was the primary objective of my PhD.  
This thesis details the rationale design, construction and functional characterisation of 
inflammation-inducible composite synthetic promoters for local RA gene therapy (Chapters 3-
5). Engineering of composite synthetic promoters to contain randomly arranged core binding 
sites of AP-1, HIF-1α, NFκB, and also C/EBPβ, Egr-1 and Ets-1 represented a means to 
exploit the simultaneous binding of the candidate TFs to potentially provide multi-responsive 
and additive/synergistic induction of gene expression in response to the multiple pathological 
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stimuli in the RA joint, in contrast to the single-responsive synthetic promoters such as those 
used by Shibata et al., (2000) and Khoury et al., (2007), which are restricted to hypoxia and 
inflammatory stimulation, respectively.  
Collectively, the in vitro functional characterisation of the composite promoters from different 
libraries revealed that changes in promoter architecture can have profound effects on gene 
expression. Interestingly, the impaired induction of transcriptional synergism by the composite 
promoters with a 4bp space between the TFBSs, generated by the random ligation cloning 
method, was suggestive of potential steric hindrance of TFs during combined inflammatory 
and hypoxic stimulation in transiently transfected 293T cells. Logical interpretations of these 
results were provided by the established principles of TF-DNA interactions, indicating that 
sliding TFs in search of their respective binding sites can dislodge DNA-bound TFs (Berg et 
al., 1981; Halford and Marko, 2004; Hu et al., 2008), which potentially impairs synergistic 
induction. Also, it is possible that many TFBSs were rendered inaccessible by adjacently 
bound TFs, due to the close proximity of the TFBSs, thereby preventing simultaneous TF 
binding which hindered the potential for synergistic gene expression (section 3.2.2 and 3.4). 
Subsequently, the spatial arrangements of TFBSs were reorganised using an optimised 
Assembly PCR cloning method which provided a comprehensive tool to engineer various 
composite promoter libraries containing randomly arranged yet evenly spaced TFBSs in high-
throughput PCR reactions. Functional characterisation of these synthetic promoters revealed 
that increasing the spacing between the TFBSs and also between the proximal TFBS and the 
TATA box resulted in decreased basal and induced luciferase gene expression levels. 
Supporting bioinformatic evidence by Gotea et al., (2010) reported that active endogenous 
promoters typically possess clusters of the same type of TFBS. These homotypic clusters are 
likely to enhance TF recruitment and the efficiency of the local search process (Brackley et 
al., 2012) which can increase gene expression. Also, many studies have shown that 
expanding the distance between upstream elements i.e. TFBSs and the TATA box can reduce 
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transcription (Guarente and Hoar, 1984; McKnight, 1982; Takahashi et al., 1986, Wu and Berk, 
1988; Smith et al., 1995; Dobi and Winston, 2007; Sharon et al., 2012).  
Without prior knowledge on the significance of computational biology in the design and 
functionality of synthetic promoters, the results discussed in Chapter 3 have demonstrated 
that studies from the field of synthetic biology are useful in interpreting the data. The strongest 
evidence supporting the majority of the results from Chapter 3 comes from the studies of 
Sharon et al., (2012). This group integrated computational biology to design a library of 6500 
promoters and also devised a high-throughput microarray-based method to measure the effect 
of systematic changes to TFBS location, number, affinity and organisation, when positioned 
upstream of the TATA box and the yellow fluorescence protein (YFP) reporter gene. Strikingly, 
their data showed that gene expression was reduced when TFBSs (i.e. Gal4 and Gcn4 sites) 
were positioned further away from the core promoter, gene expression increased with 
increasing number of TFBSs (upto 3-4 sites) and then saturated and the close proximity of 
adjacent Gal4 binding sites (1bp space) resulted in steric occlusion of Gal4 molecules, which 
was also weakly demonstrated by Gcn4 molecules binding to Gcn4 sites separated by 5bp 
space. Taken together, the data of Sharon et al., (2012) strongly supports many of the 
observed trends discussed in Chapter 3 and also highlights the advantages of integrating 
computational biology to rationally design synthetic promoters, as also demonstrated by 
Geurts et al., (2009). 
As anticipated, the vast majority of the composite synthetic promoters with the optimised 20bp 
space between the TFBSs and 66bp space between the proximal TFBS and the TATA box, 
exhibited low basal, multi-responsive and additively or synergistically-inducible gene 
expression (section 3.5), which was suggestive of alleviated steric hindrance of TFs. Although 
the sought-after expression profiles was observed in most of the optimised composite 
promoters, an inherent limitation to the screening method described in this thesis is that the 
identity and number of TFs binding to sites within the synthetic promoter has not been 
confirmed. An experimental technique such as chromatin immunoprecipitation (ChIP) would 
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have been useful in identifying the specific binding locations of the TFs, which might have 
provided more insight into the number of TFBSs needed for the desired level and pattern of 
gene expression. Although the in-depth investigation of TF binding was not a proposed 
research question, it is an interesting and important option for further research, where analysis 
of TF-TFBS interactions within the composite promoters could be useful in the rationale design 
of the synthetic promoters for optimal activity.  
Promoters 2, 9 and 12, displaying the best expression profiles, were cloned into a SIN lentiviral 
vector to confer long-term and stable gene expression in vitro and in vivo and their kinetics of 
gene expression were assessed in lentiviral-transduced stable 293T cells. The lentiviral 
promoters LV-2, LV-9 and LV-12 were highly sensitive and rapidly activated and generally 
exhibited dose- and time-dependent increases in luciferase gene expression in response to 
increasing concentrations and durations of exposure to TNFα and PMA stimulation, 
respectively. Importantly, the lentiviral promoters had dramatically improved induction levels 
and retained their favourable expression profiles (section 4.2.2). This may have been due to 
the presence of performance enhancing elements i.e. WPRE within the lentiviral vector or the 
presence of high copy numbers of integrated proviral DNA in the stable 293T cells, where the 
latter could have been confirmed by qPCR, had time permitted. 
Encouragingly, the local delivery of LV-2, LV-9 and LV-12 in the mouse paw resulted in 
disease-specific induction of luciferase gene expression following carrageenan-induced paw 
inflammation, as determined by real-time bioluminescence imaging. Although only LV-2 
induction was statistically significant (at 3 hours post-inflammation), both LV-2 and LV-9 
induced robust gene expression levels which were localised to the inflamed paw and 
comparable to gene expression induced by the constitutive LV-SFFV promoter (section 4.3). 
Due to the consistently favourable performance of promoter LV-2, this promoter was used to 
regulate the expression of mTNFR-Fc and IL-1Ra therapeutic genes in the carrageenan-
induced paw inflammation mouse model (section 5.3). In accordance with the principle of IL-
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1Ra therapy, the constitutive SFFV promoter expressed IL-1Ra before the onset of 
inflammation which was able to occupy the IL-1 receptors (McIntyre et al., 1991; Bakker et al., 
1997) and resulted in significantly inhibited paw inflammation. However, mice treated with LV-
2-driven therapeutic genes did not exhibit reduced paw inflammation. Furthermore, none of 
the vectors encoding mTNFRII-Fc inhibited inflammation in the model which may have been 
due to the delivery of suboptimal lentiviral titres resulting in insufficient expression of 
therapeutic proteins prior to and during inflammation. The lentiviral titre used in this experiment 
(830,000 IFU) was substantially lower than the lentiviral titre used by similar  studies such as 
Garaulet et al., (2013) who observed reduced paw inflammation following the local delivery of 
IL-10 encoding lentivectors (2x107 transducing units) expressed from an inflammation-
inducible synthetic promoter. Therefore, the optimisation of lentiviral titres used in the 
experiments described in section 5.3 represents an important direction for future work. 
A further objective of my PhD was to exploit the differential expression of miRNAs during 
inflammation to post-transcriptionally regulate gene expression induced by a constitutive 
promoter (Chapter 6). Absolute real-time qPCR was used to confirm the inflammation-
repressed expression of miR-23b in mouse embryonic fibroblasts, as previously identified by 
Zhu et al., (2012). The fundamental principles of microRNA-mRNA targeting were 
implemented to construct expression cassettes with two or four miR-23b target sites in the 
3’UTR of luciferase gene to subject the CMV-driven luciferase gene expression to regulation 
by miR-23b during inflammation. In agreement with the hypothesis, endogenous miR-23b 
significantly downregulated luciferase gene expression in unstimulated NIH3T3 cells (where 
miR-23b is highly expressed) and did not impair the high gene expression in NIH3T3 cells 
treated with inflammatory stimuli (where miR-23b is downregulated). Importantly, the 
efficiency of miR-23b-mediated gene regulation was highly dependent on the threshold     miR-
23b concentration in the cells, the level of target mRNA expression and also the number of 
miR-23b target sites in the mRNA 3’UTR, as confirmed by the pioneering studies of Brown et 
al. (2007b). Furthermore, the incorporation of two miR-23b-target sites in the 3’UTR of the 
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luciferase gene controlled by an NFκB-responsive promoter resulted in significantly reduced 
basal gene expression in unstimulated NIH3T3 cells and consistently high gene expression 
following TNFα stimulation. The coupling of an inflammation-inducible synthetic promoter with 
the target sites of an inflammation-repressed miRNA in a dual-regulated cassette represented 
a novel approach to improving the efficiency and safety of ‘leaky’ synthetic promoters by 
reducing unnecessarily high basal gene expression without impairing the induced gene 
expression. 
Encouragingly, Zhu et al., (2012) reported the downregulation of miR-23b expression in the 
synovial tissues from RA patients and CIA mice, in the kidney tissues from SLE (lupus) 
patients and the related MRL/lpr mice and in the spinal cords from EAE mice (multiple 
sclerosis mouse model) compared to healthy controls. Therefore, provided that miR-23b is 
expressed at the threshold concentrations in the target tissues, these miR-23b-regulated 
expression cassettes can be applicable for gene therapy to treat RA, lupus and multiple 
sclerosis. 
To conclude, the results in Chapters 3-5 have confirmed the development of a novel approach 
to construct transcriptionally-regulated inflammation-responsive composite synthetic 
promoters. The promoters exhibited differential expression, multi-responsiveness and 
synergistic induction in vitro and disease-specific induction of luciferase gene expression in 
vivo. However, the general lack of therapeutic efficacy by the candidate promoter LV-2 (and 
also LV-SFFV) may have been a result of suboptimal lentiviral titres. Nevertheless, the 
ubiquitous activation of TFs during inflammatory conditions offers the prospect of utilising 
these versatile composite promoters for gene therapy applications in other diseases 
characterised by local changes in transcription factor activation, which is currently underway 
(Professor Adrian Hobbs, William Harvey Heart Centre, UK). Furthermore, the results in 
Chapter 6 have proven the concept of post-transcriptional regulation of constitutive (CMV-
driven) and inducible (NFκB-driven) gene expression by the inflammation-repressed miR-23b, 
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which is a promising approach for a combined transcriptionally and post-transcriptionally 
responsive expression system for future RA gene therapy.  
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Chapter 8: Further Work 
The results in this thesis reveal the potential for further work in a few important areas. Further 
work would entail: 
 
• Investigating the binding interactions of the candidate TFs to their cognate binding 
sites within the composite promoters, using chromatin immunoprecipitation 
The level of gene expression from synthetic promoters is the functional readout of TF binding, 
however, these simple reporter gene assays provide no information regarding the specific TF 
binding location and how many TFs bind to the TFBSs within the synthetic promoter. A 
chromatin immunoprecipitation assay will be used to investigate TF-TFBS interactions to 
provide more insight into the pattern of TF binding during inflammatory and/or hypoxic 
conditions.  
 
 
• Optimising the lentiviral titre to achieve therapeutic effects in vivo  
Lentiviral titres will be optimised in an experimental model of RA i.e. CIA or AIA model, which 
would facilitate the monitoring of promoter activity for a longer duration, with the option of re-
inducing inflammation to fully characterise the promoter activity in vivo. When repeating this 
experiment, an additional control group treated with either TNFRII or IL-1Ra proteins will be 
included for comparison. Also, biodistribution analyses using qPCR will be performed to 
determine the distribution of the transgene to the target site (within the paw) and to non-target 
sites (e.g. liver), which should provide insight into the safety and efficacy of the delivered 
therapy. 
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• Construct composite promoters with higher basal and induced gene expression than 
promoter LV-2 
A higher basal and induced expression of the composite promoters might be a feature that 
could overcome the challenges in achieving therapeutic effects in vivo. This is particularly 
relevant to the principles of targeted IL-1 and TNFα therapies, which require high IL-1Ra and 
mTNFRII-Fc expression before and during inflammation. Using the knowledge obtained from 
the experiments in Chapter 3 (sections 3.3.5 and 3.3.7), the TFBSs can be positioned closer 
together or positioned closer to the TATA box within the composite promoters to achieve 
higher basal and higher induced gene expression levels than demonstrated by promoter     LV-
2. Functional characterisation of the promoters will be required to confirm multi-
responsiveness and synergistic induction of gene expression.  
 
• Identify the methylation status of the promoters  
Promoters are often silenced by DNA methylation, therefore it would be interesting to perform 
DNA methylation analysis studies to detect the methylation status of the promoters used in 
vivo to determine whether they are prone to silencing.  
 
• Quantify the changes in luciferase mRNA expression in response to the changes in 
miR-23b expression, during inflammation 
Perfect complementarity between miRNAs and the target sites in the mRNA 3’UTR results in 
mRNA cleavage (Bartel, 2004). Therefore, it is feasible to assume that the luciferase mRNA 
(containing perfectly complementary miR-23b target sites) was degraded following miR-23b 
binding, as indicated by the downregulation in luciferase protein expression. However, it would 
be useful to quantify the changes in luciferase mRNA in response to the changes in miR-23b 
expression during inflammation using Real-time qPCR, to determine the threshold luciferase 
mRNA levels for efficient regulation by miR-23b.  
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Potential future work of interest would be to re-design the composite promoters to incorporate 
additional regulatory components which could improve the efficacy and safety of the gene 
therapy. For example;  
 
• Incorporate drug-inducible components into the composite promoter to achieve 
pharmacological- and disease-regulated gene expression 
A general limitation of inflammation-inducible synthetic promoters is that they respond 
indiscriminately to any inflammatory environment and can therefore induce gene expression 
in response to inflammation which is not associated with the disease. By combining drug-
inducible and inflammation-inducible regulatory elements in the same construct, gene 
expression can be magnified and more importantly, completely switched off in the case of RA-
unrelated inflammation. This strategy was demonstrated by Gould’s lab who constructed a 
novel hybrid hypoxia-responsive and Dox-regulated transcriptional system (Subang et al., 
(2012) which can be applied to the composite promoters and miRNA-regulated constructs 
described in this thesis to generate stringently regulated gene therapy cassettes.  
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Chapter 10: Appendices 
 
Appendix 1. Table of sequencing primers  
The selected constructs were sequenced using one of the sequencing primers listed in 
Appendix Table 1.  
Primer (5’-3’) Sequencing direction Binding location 
 
 
 
GL2 primer 
 
 
5’-CTTTATGTTTTTGGCGTCTTCCA-3’ 
 
Reverse 
(towards promoter) 
Binds to 5’-portion of luciferase, 
downstream of promoter 
 
 
 
Forward pCpG primer 
 
 
5’-TGGTTTGTCCAAACTCATCAA-3’ 
 
Forward 
(towards promoter) 
Binds to pCpG vector,  
upstream of promoter 
 
 
 
 
Forward Lenti primer 
 
 
5’-TAGTAGACATAATAGCAACAGAC-3’ 
 
Forward 
(towards promoter) 
Binds to lentivector,  
upstream of promoter 
 
 
 
End of Luc+ primer 
 
 
5’-GGAAAACTCGACGCAAGAAA-3’ 
 
Forward 
(towards miRNA-target)
Binds to 3’-portion of luciferase, 
upstream of miRNA-target sites 
 
 
Appendix 2. Sequencing data of the pGL3mCMV construct  
The pGL3mCMV construct was sequenced using the GL2 reverse primer. The TATAA box is 
highlighted in bold and the XhoI (5’-TCGAG) and HindIII (5’-AGCT) overhangs are underlined 
and represent the start and end of the mCMV promoter.  
   1 GAGCTGATTT AACAAAAATT TAACGCGAAT TTTAACAAAA TATTAACGCT 
  51 TACAATTTGC CATTCGCCAT TCAGGCTGCG CAACYGTTGG GAAGGGCGAT 
 101 CGGTGCGGGC CTCTTCGCTA TTACGCCAGC CCAAGCTACC ATGATAAGTA 
 151 AGTAATATTA AGGTACGGGA GGTACTTGGA GCGGCCGCAA TAAAATATCT 
 201 TTATTTTCAT TACATCTGTG TGTTGGTTTT TTGTGTGAAT CGATAGTACT 
 251 AACATACGCT CTCCATCAAA ACAAAACGAA ACAAAACAAA CTAGCAAAAT 
 301 AGGCTGTCCC CAGTGCAAGT GCAGGTGCCA GAACATTTCT CTATCGATAG 
 351 GTACCGAGCT CTTACGCGTG CTAGCCCGGG CTCGAGGCCT GTAGGCGTGT 
 401 ACGGTGGGAG GCTTATATAA GCAGAGCTCA AGCTGGCATC CGTACKTGAG 
 451 CACTGT 
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Appendix 3. Sequencing data of selected pGL3-4bp-composite synthetic promoters 
with 4 bp space between TFBSs 
The pGL3-4bp-composite promoters were sequenced using the GL2 reverse primer. The 
TFBSs are indicated by a box with an arrow to show the TFBS orientation. The NheI overhang 
(5’-CTAG) and XhoI site (5’-CTCGAG) is underlined and represents the start and end of the 
region containing multimerised TFBSs, respectively. The TATAA box is highlighted in bold. 
Unfortunately, some promoter sequences are incomplete (for unknown reasons). Partial or 
complete sequences are schematically represented for each construct. 
 
Appendix 3.1. Promoter 24 - pGL3-4bp-composite promoter (complete) 
   1 GTGAATCGAT AGTACTAACA TACGCTCTCC ATCAAAACAA AACGAAACAA 
  51 AACAAACTAG CAAAATAGGC TGTCCCCAGT GCAAGTGCAG GTGCCAGAAC 
 101 ATTTCTCTAT CGATAGGTAC CGAGCTCTTA CGCGTGCTAG ACGTGGCTAG 
 151 ACGTGGCTAG CCACGTCTAG GGAATTTCCT AGTGAGTCAC TAGGGAACTT 
 201 CCGGCTAGTG AGTCACTAGC CACGTCTAGC CCGGGCTCGA GGCCTGTAGG 
 251 CGTGTACGGT GGGAGGCTTA TATAAGCAGA GCTCAAGCTG GCATCCGTAC 
 
 
 
Appendix 3.2. Promoter 14 - pGL3-4bp-composite promoter (incomplete) 
   1 CTAGTGGCCA CTGTATATGC GGCTCCGGAC TTACRCASAW TGCCCAATCT 
  51 AGCCCCGTRT ACATTGCGCA ATCTAGCCAC GTCTAGCCAC GTCTAGTGAC 
 101 TCACTAGACG TGGCTAGGGA ATTTCCTAGG AAATTCCCTA GCCCGGGCTC 
 151 GAGGCCTGTA GGCGTGTACG GTGGGAGGCT TATATAAGCA GAGCTCAAGC 
 201 TGGCATCCGT ACKTTGAGCC MCC 
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Appendix 3.3. Promoter 40 - pGL3-4bp-composite promoter (complete) 
   1 GATAGTACTA ACATACGCTC TCCATCAAAA CAAAACGAAA CAAAACAAAC 
  51 TAGCAAAATA GGCTGTCCCC AGTGCAAGTG CAGGTGCCAG AACATTTCTC 
 101 TATCGATAGG TACCGAGCTC TTACGCGTGC TAGACGTGGC TAGTTGCGTG 
 151 GGCGTCTAGT GACTCACTAG CCCGGGCTCG AGGCCTGTAG GCGTGTACGG 
 201 TGGGAGGCTT ATATAAGCAG AGCTCAAGCT GGCATCCGGT ACKTGAGCCA 
 
 
Appendix 3.4. Promoter 134 - pGL3-4bp-composite promoter (incomplete) 
   1 TTAGGAAATC CCCTTKGACT CAWTAGASTT GGGGACTGAC TCACTAGACG 
  51 TGGCTAGATT GCGCAATCTA GCCGGAAGTT CCCTAGCCAC GTCTAGTGAG 
 101 TCACTAGACG CCCACGCAAC TAGTGACTCA CTAGACGTGG CTAGTGACTC 
 151 ACTAGACGTG GCTAGTGACT CACTAGCCGG AAGTTCCCTA GACGCCCACG 
 201 CAACTAGCCC GGGCTCGAGG CCTGTAGGCG TGTACGGTGG GAGGCTTATA 
 251 TAAGCAGAGC TCAAGCTGGC ATCCGGTACT GTKAGCCMMC CC 
 
 
 
Appendix 3.5. Promoter 148 - pGL3-4bp-composite promoter (incomplete) 
   1 CTAAGTAAAC CGTGTTGGAG TTTGAGAAGG AGCGAGGTCY GARAATTTCT 
  51 AGACCCATGG GTAKKCRTGT ATYGCSGGAG GATAYYTAGC AGTGATRGGG 
 101 AATTTCCTAG CCCGGGCTCG AGGCCTGTAG GCGTGTACGG TGGGAGGCTT 
 151 ATATAAGCAG AGCTCAAGCT GGCATCCGGT ACKTGAGRCA ACCC
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Appendix 3.6. Promoter 150 - pGL3-4bp-composite promoter (incomplete) 
   1 YTTTYTTTTT TTGGCGTCTT CCATGGTGGC TTTACCAACA GTACCGGAAT 
  51 GCCAAGCTTG AGCTCTGCTT ATATAAGCCT CCCACCGTAC ACGCCTACAG 
 101 GCCTCGAGCC CGGGCTAGTG ACTCAMTTRG GAACTTCCGG CTAGYCACGC 
 151 ATAAGTGAGT CTCTGAAATT SSCTAGATTG CGCAATCTAG CCACGTCTAG 
 201 ATTGCGCAAT CTAGCCACGT CTAGTGACTC ACTAGTGAGT CACTAGCCGG 
 251 AAGTTCCCTA GTGAGTCACT AGCCCGGGCT CGAGGCCTGT AGGCGTGTAC 
 301 GGTGGGAGGC TTATATAAGC AGAGCTCAAG CTGGCATCCG TACGTKAGCC 
 
 
Appendix 3.7. Promoter 127 - pGL3-4bp-composite promoter (incomplete) 
   1 GCGTGGGCGT CTAGTYSCGT GGGCGTCTAG ACGTGGCTAG TGAGTCACTA 
  51 GTGAGTCACT AGGGAATTTC CTAGCCACGT CTAGTGACTC ACTAGATTGC 
 101 GCAATCTAGG GAATTTCCTA GTGACTCACT AGGGAACTTC CGGCTAGTTG 
 151 CGTGGGCGTC TAGCCACGTC TAGTGACTCA CTAGACGTGG CTAGACGTGG 
 201 CTAGTGACTC ACTAGCCCGG GCTCGAGGCC TGTAGGCGTG TACGGTGGGA 
 251 GGCTTATATA AGCAGAGCTC AAGCTGGCAT CCGGTACKTG AGCCMCC 
 
 
 
Appendix 3.8. Promoter 96 - pGL3-4bp-composite promoter (incomplete) 
   1 CCTAGCCACG TCTAGGGAAC TTCCGGCTAG TGAGTCACTA GACGTGGCTA 
  51 GCCACGTCTA GACGCCCACG CAACTAGGAA ATTCCCTAGT GACTCACTAG 
 101 CCCGGGCTCG AGGCCTGTAG GCGTGTACGG TGGGAGGCTT ATATAAGCAG 
 151 AGCTCAAGCT GGCATCCGTA CKTGAGCACG C 
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Appendix 3.9. Promoter 78 - pGL3-4bp-composite promoter (complete) 
   1 AGTACTAACA TACGCTCTCC ATCAAAACAA AACGAAACAA AACAAACTAG 
  51 CAAAATAGGC TGTCCCCAGT GCAAGTGCAG GTGCCAGAAC ATTTCTCTAT 
 101 CGATAGGTAC CGAGCTCTTA CGCGTGCTAG ACGTGGCTAG GAAATTCCCT 
 151 AGGAAATTCC CTAGCCGGAA GTTCCCTAGC CACGTCTAGG GAATTTCCTA 
 201 GCCCGGGCTC GAGGCCTGTA GGCGTGTACG GTGGGAGGCT TATATAAGCA 
 251 GAGCTCAAGC KGGCWYTCKS GGWMGMTMMT GGGWCACCG 
 
 
Appendix 3.10. Promoter 173 - pGL3-4bp-composite promoter (incomplete) 
   1 CTAGWCACGG CTAAWTACGT CTAGCCACGT MTAGACGTGG CTAGGWAATT 
  51 CCMTAGGGAA TTTCCTARGA AATTCCCTAG GAAATTCCCT AGACGTGGCT 
 101 AGGAATTTCC TAGGAAATTC CCTAGTGAGT CACTAGATTS CGCAATMTAG 
 151 TGACTCACTA GTTGCGTGGG CGTCTAGGGA ATTTCCTARA CGYGGCTAGA 
 201 CGTGGCTAGC CACGTCTAGA CGCCCACGCA ACTAGCCCGG GCTCGAGGCC 
 251 TGTAGGCGTG TACGGTGGGA GGCTTATATA AGCAGAGCTC AAGCTGGCAT 
 
  
 
Appendix 3.11. Promoter 186 - pGL3-4bp-composite promoter (incomplete) 
   1 TTTTTGTGTG AATCGATAGT ACTAACATAC GCTCTCCATC AAAACAAAAC 
  51 GAAACAAAAC AAACTAGCAA AATAGGCTGT CCCCAGTGCA AGTGCAGGYG 
 101 CCAGAACAAC TAGCCACGTC TAGCCMCGTS TWGATTGSGC AATCTAGKGA 
 151 GTCACTAGAT TGCGCAATCT AGGAAATTCC CTAGTGACTC ACTAGCCCGG 
 201 GCTCGAGGCC TGTAGGCGTG TACGGTGGGA GGCTTATATA AGCAGAGCTC 
 251 AAGCTGGCAT CCGTACGTGA GCAMCCC 
 
359 
 
Appendix 3.12. Promoter 176 - pGL3-4bp-composite promoter (complete) 
   1 CAAACTAGCA AAATAGGCTG TCCCCAGTGC AAGTGCAGGT GCCAGAACAT 
  51 TTCTCTATCG ATAGGTACCG AGCTCTTACG CGTGCTAGGA AATTCCMTAG 
 101 TGACTCACTA GACGTGSCTA GCCACGTCTA GACGTGGCTA GATTGCGCAT 
 151 CTAGTGACTC AYTAGTGAGT CACTAGACGT GGCTAGCCAC GTCTAGGGAA 
 201 TTTCCTAGTG ACTCACTAGA CGTGGCTAGG AAATTCCCTA GCCCGGGCTC 
 251 GAGGCCTGTA GGCGTGTACG GTGGGAGGCT TATATAAGCA GAGCTCAAGC 
 301 TGGCATCCGG TACKTGARCA CTC 
 
 
Appendix 3.13. Promoter 41- pGL3-4bp-composite promoter (complete) 
   1 ATAGGCTGTC CCCAGTGCAA GTGCAGGTGC CAGAACATTT CTCTATCGAT 
  51 AGGTACCGAG CTCTTACGCG TGCTAGACGT GGCTAGGGAA CTTCCGGCTA 
 101 GTGAGTCACT AGTGACTCAC TAGATTGCGC AATCTAGCCA CGTCTAGTGA 
 151 GTCACTAGCC CGGGCTCGAG GCCTGTAGGC GTGTACGGTG GGAGGCTTAT 
 201 ATAAGCAGAG CTCAAGCTGG CATCCGTACK TTAAGCCMCC TC 
 
 
Appendix 3.14. Promoter 19 - pGL3-4bp-composite promoter (complete) 
   1 CTGTCCCCAG TGCAAGTGCA GGTGCCAGAA CATTTCTCTA TCGATAGGTA 
  51 CCGAGCTCTT ACGCGTGCTA GGAAATTCCC TAGGGAATTT CCTAGACGTG 
 101 GCTAGTGACT CACTAGACGT GGCTAGCCGG AAGTTCCCTA GCCGGAAGTT 
 151 CCCTAGTGAC TCACTAGACG CCCACGCAAC TAGTGAGTCA CTAGCCGGAA 
 201 GTTCCCTAGC CACGTCTAGT GACTCACTAG TGACTCACTA GTGAGTCACT 
 251 AGTGAGTCAC TAGGAAATTC CCTAGTGACT CACTAGCCCG GGCTCGAGGC 
 301 CTGTAGGCGT GTACGGTGGG AGGCTTATAT AAGCAGAGCT CAAGCTGGCA  
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Appendix 3.15. Promoter 125 - pGL3-4bp-composite promoter (incomplete) 
   1 AACATTTCTC TATCGATAGG TACCGAGYTM TTCCGCGTCC TAGCWCGCGC 
  51 AATCTACCCA MGTCCTAGTG AGTCACTAGG AAATTCCCTA GCCCGGTCTA 
 101 KSCMYSWCTA GATTGCGCAA TCTAGTGAGT CACTAGACGC CCACGCAACT 
 151 AGTGAGTCAC TAGCCCGGGC TCGAGGCCTG TAGGCGTGTA CGGTGGGAGG 
 201 CTTATATAAG CAGAGCTCAA GCTGGCATCC GTACKTRATC CAT 
 
 
Appendix 3.16. Promoter 118 - pGL3-4bp-composite promoter (incomplete) 
   1 GAGCGCGKTG CAATTAATGG GGGYAGCATC CCTCWTCCGG CAAAACAGRA 
  51 GTTACCAAAK CRGGGTAGTT CCCTAGTGAC TCACTAGACG TGGCTAGATT 
 101 GCGCAATCTA GTGAGTCACT AGTGACTCAC TAGCCGGAAG TTCCCTAGTG 
 151 ACTCACTAGC CCGGGCTCGA GGCCTGTAGG CGTGTACGGT GGGAGGCTTA 
 201 TATAAGCAGA GCTCAAGCTG GCATCCGTAC GTGAGCCMCG C 
 
 
 
Appendix 3.17. Promoter 4 - pGL3-4bp-composite promoter (complete) 
   1 AACAAAACGA AACAAAACAA ACTAGCAAAA TAGGCTGTCC CCAGTGCAAG 
  51 TGCAGGTGCC AGAACATTTC TCTATCGATA GGTACCGAGC TCTTACGCGT 
 101 GCTAGGGAAT TTCCTAGGGA ATTTCCTAGC CGGAAGTTCC CTAGCCCGGG 
 151 CTCGAGGCCT GTAGGCGTGT ACGGTGGGAG GCTTATATAA GCAGAGCTCA 
 201 AGCTGGCATC CGGTACKTGA GCACC 
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Appendix 3.18. Promoter 13 - pGL3-4bp-composite promoter (complete) 
   1 TCCCCAGTGC AAGTGCAGGT GCCAGAACAT TTCTCTATCG ATAGGTACCG 
  51 AGCTCTTACG CGTGCTAGTT GCGCAATCTA GCCGGAAGTT CCCTAGCCCG 
 101 GGCTCGAGGC CTGTAGGCGT GTACGGTGGG AGGCTTATAT AAGCAGAGCT 
 151 CAAGCTGGCA TCCGTACKTG AGCMCCC 
 
 
Appendix 3.19. Promoter 17 - pGL3-4bp-composite promoter (incomplete) 
   1 CGGAAGTTCC CTAGTTGCGT GGGCGTCTAG GAAATTCCCT AGGGAATTTC 
  51 CTAGGGAACT TCCGGCTAGT GACTCACTAG GGAATTTCCT AGACGTGGCT 
 101 AGGAAATTCC CTAGCCCGGG CTCGAGGCCT GTAGGCGTGT ACGGTGGGAG 
 151 GCTTATATAA GCAGAGCTCA AGCTTGGCAT CCGTACTGTG AGCCACCG 
 
 
Appendix 3.20. Promoter 21 - pGL3-4bp-composite promoter (complete) 
   1 CAAACTAGCA AAATAGGCTG TCCCCAGTGC AAGTGCAGGT GCCAGAACAT 
  51 TTCTCTATCG ATAGGTACCG AGCTCTTACG CGTGCTAGAT TGCGCAATCT 
 101 AGCCGGAAGT TCCCTAGTGA CTCACTAGAC GTGGCTAGCC ACGTCTAGCC 
 151 ACGTCTAGTG ACTCACTAGC CCGGGCTCGA GGCCTGTAGG CGTGTACGGT 
 201 GGGAGGCTTA TATAAGCAGA GCTCAAGCTK GCATCCCSGG ACCKKGCCCC 
 
 
Appendix 3.21. Promoter 22 - pGL3-4bp-composite promoter (complete) 
   1 AAACAAAACG AAACAAAACA AACTAGCAAA ATAGGCTGTC CCCAGTGCAA 
  51 GTGCAGGTGC CAGAACATTT CTCTATCGAT AGGTACCGAG CTCTTACGCG 
 101 TGCTAGGGAA TTTCCTAGCC CGGGCTCGAG GCCTGTAGGC GTGTACGGTG 
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 151 GGAGGCTTAT ATAAGCAGAG CTCAAGCTGG CATCCGGTAC GTGAGCAACT 
Appendix 3.22. Promoter 204 - pGL3-4bp-composite 
promoter (complete) 
   1 ATTTCTCTAT CGATAGGTAC CGAGCTCTTA CGCGTGCTAGACGTGCTAGC 
  51 CCGGGCTCGA GGCCTGTAGG CGTGTACGGT GGGAGGCTTA TATAAGCAGA 
 101 GCTCAAGCTG GCATCCGGTA CKTKGAGGCC MMCCC 
 
 
 Appendix 3.23. Promoter 207 - pGL3-4bp-composite promoter (complete) 
   1 GGTACCGAGC TCTTACGCGT GCTAGACGTG GCTAGCCCGG GCTCGAGGCC 
  51 TGTASGCGTG TACGGTGGGA GGCTTATATA AGCAGAGCTC AAGCTTGGCA 
 101 TTCCGGTACT GTTGGTAAAG CCACCATGGA AGACGCCAAA AACATAAAGA 
  
  
Appendix 3.24. Promoter 225 - pGL3-4bp-composite promoter (complete) 
   1 AAACGAAACA AAACAAACTA GCAAAATAGG CTGTCCCCAG TGCAAGTGCA 
  51 GGTGCCAGAA CATTTCTCTA TCGATAGGTA CCGAGCTCTT ACGCGTGCTA 
 101 GGGAATTTCC TAGTGAGTCA CTAGGGAATT TCCTAGCCGG AAGTTCCCTA 
 151 GATTGCGCAA TCTAGTGACT CACTAGATTG CGCAATCTAG ACGCCCACGC 
 201 AACTAGCCAC GTCTAGCCAC GTCTAGGGAA TTTCCTAGAT TGCGCAATCT 
 251 AGCCACGTCT AGCCACGTCT AGCCACGTCT AGTGAGTCAC TAGACGTGGC 
 301 TAGGAAATTC CCTAGTTGCG TGGGCGT CCG GAAGTTCCCT AGCCACGTCT 
 351 AGCCCGGGCT CGAGGCCTGT AGGCGTGTAC GGTGGGAGGC TTATATAAGC 
 401 AGAGCTCAAG CNGCANCCGN NNGNNNNNNN NNNN 
 
 
Appendix 3.25. Promoter 245 - pGL3-4bp-composite promoter (complete) 
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   1 ATCGATAGTA CTAACATACG CTCTCCATCA AAACAAAACG AAACAAAACA 
  51 AACTAGCAAA ATAGGCTGTC CCCAGTGCAA GTGCAGGTGC CAGAACATTT 
 101 CTCTATCGAT AGGTACCGAG CTCTTACGCG TGCTAGACGT GGCTAGACGT 
 151 GGCTAGGAAA TTCCCTAGGG AATTTCCTAG CCCGGGCTCG AGGCCTGTAG 
 201 GCGTGTACGG TGGGAGGCTT ATATAAGCAG AGCTCAAGCT GCATCCGNNN 
 
 
Appendix 4. Sequencing data of the pCpGmCMV-Luc+ construct 
The pCpGmCMV-Luc+ construct was sequenced using the GL2 reverse primer. The NheI 
restriction site (5’- GCTAGC; underlined) indicates the end of the pCpGmSEAP fragment 
(position 1 bp- 387 bp) and start of the pGL3mCMV fragment (position 387 bp – 473 bp).    
   1 TGRTTTGWTM TAAATYTTGA TATTTAGTGG AACATTYTTT CSCATTTTST 
  51 TMTACAAGAA TATTKWTGTT RTYGTCTTTT GGGCTTCTAT ATACATTTTA 
 101 GAATGAGGTT GGCAAGTTAA CAAACAGYTT TTWTGGGGTG AACATATTGA 
 151 CTGAATTCCA TACCACATTT GTAGAGGTTT TACTTGCTTT AAAAAACCTC 
 201 CCACACCTCC CCCTGAACCT GAAACATAAA ATGAATGCAA TTGTTGTTGT 
 251 TAACTTGTTT ATTGCAGCTT ATAATGGTTA CAAATAAAGC AATAGCATCA 
 301 CAAATTTCAC AAATAAAGCA TTTTTTTCAC TGCATTCTAG TTGTGGTTTG 
 351 TCCAAACTCA TCAATGTATC TTATCATGTC TGGCCAGCTA GCCCGGGCTC 
 401 GAGGCCTGTA GGCGTGTACG GTGGGAGGCT TATATAAGCA GAGCTCAAGC 
 451 TGGCATCCGT ACGTAGACMC YGC 
 
 
Appendix 5. Sequencing data of the pCpG-variable-6b-NFκB and pCpG-variable-
10NFκB constructs  
Two pCpG-variable NFκB constructs were sequenced using the GL2 reverse primer. The 
variable NFκB motifs are indicated by a box and those similar to the fixed NFκB sequence 
(GGGACTTTCC) are indicated by an asterisk (*).The NheI (5’-GCTAGC) and XhoI (5’-
CTCGAG) sites are underlined and represent the start and end of the region containing the 
multimerised variable NFκB motifs, respectively, and the TATAA box is highlighted in bold.  
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Appendix 5.1. pCpG-variable-6b-NFκB 
   1 TAGCATCACA AATTTCACAA ATAAAGCATT TTWTTCAMTG CATTCTAGTT 
  51 GTGGTTTGTC CAAACTCATC AATGTATCTT ATCATGTCTG GCCAGCTAGC 
 101 GTGCCTCTTA TGATCTGGAT CATGTGGGGT CTCCCACAAG ATCTCTGCGA 
 151 TGAACCTCAC CATGTGGGAG GTCCCACAAG GTGCCTCTTA TGATCTGGAT 
 201 CATGTGGGAA CTTCC*ACAAG ATCTCTGCGA TGAACCTCAC CATGTGGGAT 
 251 TTTCC*ACAAG GTGCCTCTTA TGATCTGGAT CATGTGGGAG GTCCCACAAG 
 301 ATCTCTGCGA TGAACCTCAC CATGTGGGAA TTCC*ACAAGG TGCCTCTTAT 
 351 GATCTGGATC TCGAGGCCTG TAGGCGTGTA CGGTGGGAGG CTTATATAAG 
 401 CAGAGCTCAA GCTTGGCATT CCGGTACKKT RAARRMMMMC CT 
 
 
Appendix 5.2. pCpG-variable-10NFκB constructs  
   1 GTATCTTATC ATGTCTGGCC AGCTAGCGTG CCTCTTATGA TCTGGATCAT 
  51 GTGGGATATT CCACAAGATC TCTGCGATGA ACCTCACCAT TGGAGGTCCC 
 101 ACAAGGTGCC TCTTATGATC TGGATCATGT GGGGCTCTCC ACAAGATCTC 
 151 TGCGATGAAC CTCACCATGT GGGATACTCC ACAAGGTGCC TCTTATGATC 
 201 TGGATCATGT GGGGCTTTCC*ACAAGATCTC TGCGATGAAC CTCACCATGT 
 251 GGGGAGTTCC*CACAAGGTGC CTCTTATGAC CTGGATCATG TGGGAATTCC 
 301 C*ACAAGATCT CTGCGATGAA CCTCACCATG TGGGATTTCC C*ACAAGGTGC 
 351 CTCTTATGAT CTGGATCATG TGGGGGCCTC CACAAGATCT CTGCGATGAA 
 401 CCTCACCATG TGGGGAGCTC CACAAGGTGC CTCTTATGAT CTGGATCTCG 
 451 AGGCCTGTAG GCGTGTACGG TGGGAGGCTT ATATAAGCAG AGCTCAAGCT 
 501 KGCATCCGGT ACTKTWAAGS MMMMMCCT 
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Appendix 6. Sequencing data of selected pCpG-NFκB and pCpG-AP-1-responsive 
promoters with various spacing between TFBSs  
The pCpG-NFκB and AP-1-responsive promoters were sequenced using the GL2 reverse 
primer. The TFBSs are positioned in the forward orientation and are indicated by a box. The 
NheI (5’-GCTAGC) and XhoI (5’-CTCGAG) sites are underlined and represent the start and 
end of the region containing multimerised TFBSs, respectively. The TATAA box is highlighted 
in bold.  
 
Appendix 6.1. Promoter 2 - 15 bp space between 8NFκB motifs  
   1 AACCTCCCAC ACCTCCCCCT GAACCTGAAA CATAAAATGA ATGCAATTGT 
  51 TGTTGTTAAC TTGTTTATTG CAGCTTATAA TGGTTACAAA TAAAGCAATA 
 101 GCATCACAAA TTTCACAAAT AAAGCATTTT TTTCACTGCA TTCTAGTTGT 
 151 GGTTTGTCCA AACTCATCAA TGTATCTTAT CATGTCTGGC CAGCTAGCGT 
 201 GCCTCTTATG ATCGGGACTT TCCTGCGATG AACCTCACGG GACTTTCCGT 
 251 GCCTCTTATG ATCGGGACTT TCCTGCGATG AACCTCACGG GACTTTCCGT 
 301 GCCTCTTATG ATCGGGACTT TCCTGCGATG AACCTCACGG GACTTTCCGT 
 351 GCCTCTTATG ATCGGGACTT TCCTGCGATG AACCTCACGG GACTTTCCGT 
 401 GCCTCTTATG ATCCTCGAGC CATGTCTGGT CGAGGCCTGT AGGCGTGTAC 
 451 GGTGGGAGGC TTATATAAGC AGAGCTCAAG CTGGCATCCG GTACKTKAAG 
 
 Appendix 6.2. Promoter 1 – 20 bp space between 6NFκB motifs  
   1 CCCCMWGAAC CTGAAACATA AAATGAATGC AATTGTTGTT GTTAACTTGT 
  51 TTATTGCAGC TTATAATGGT TACAAATAAA GCAATAGCAT CRCAAATTTC 
 101 ACAAATAAAG CATTTTTTTC ACTGCATTCT AGTTGTGGTT TGTCCAAACT 
 151 CATCAATGTA TCTTATCATG TCTGGCCAGC TAGCGTGCCT CTTATGATCT 
 201 GGATGGGACT TTCCATCTCT GCGATGAACC TCACGGGACT TTCCGTGCCT 
 251 CTTATGATCT GGATGGGACT TTCCATCTCT GCGATGAACC TCACGGGACT 
 301 TTCCGTGCCT CTTATGATCT GGATGGGACT TTCCATCTCT GCGATGAACC 
 351 TCACGGGACT TTCCGTGCCT CTTATGATCT GGATCTCGAG CCATGGTCGA 
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 401 GGCCTGTAGG CGTGTACGGT GGGAGGCTTA TATAAGCAGA GCTCAAGCTG 
 451 GCATCCGGTA CTKTTAGACC AWWCC 
Appendix 6.3. Promoter 5 – 30 bp space between 8NFκB motifs  
   1 AAATTCCCCC CRAGATTTCC AAAAAATAAA RCCTTTTTTT CMCGCCATYM 
  51 ARGTGGTGGT TKGYCCAAAC TTCATCAATG TATYTTAYCA TKTCKGGCCA 
 101 GCTAGCGTGC CTCTTATGAT CTGGATCATG TGGGACTTTC CACAAGATCT 
 151 CTGCGATGAA CCTCACCATG TGGGACTTTC CACAAGGTGC CTCTTATGAT 
 201 CTGGATCATG TGGGACTTTC CACAAGATCT CTGCGATGAA CCTCACCATG 
 251 TGGGACTTTC CACAAGGTGC CTCTTATGAT CTGGATCATG TGGGACTTTC 
 301 CACAAGATCT CTGCGATGAA CCTCACCATG TGGGGACTTT CCACAAGGTG 
 351 CCTCTTATGA TCTGGATCAT GTGGGACTTT CCACAAGATC TCTGCGATGA 
 401 ACCTCACCAT GTGGGACTTT CCACAAGGTG CCTCTTATGA TCTGGATCTC 
 451 GAGTCGAGGC CTGTAGGCGT GTACGGTGGG AGGCTTATAT AAGCAGAGCT 
 501 CAAGCTGGCA TCCGGTACTK TGAAGGCMMA CCTG 
 
Appendix 6.4. Promoter 4 – 35 bp space between 5NFκB motifs  
   1 TRAAACCTGA AAACATAAAA TGAATGCAAT TGTTGTTGTT AACTTGTTTA 
  51 TTGCAGCTTA TAATGGTTAC AAATAAAGCA ATAGCATCAC AAATTTCACA 
 101 AATAAAGCAT TTTTTTCACT GCATTCTAGT TGTGGTTTGT CCAAACTCAT 
 151 CAATGTATCT TATCATGTCT GGCCAGCTAG CGTGCCTCTT ATGATCCCAT 
 201 GTGCGATGAA CCTCACGGGA CTTTCCGTGC CTCTTATGAT CCCATGTGCG 
 251 ATGAACCTCA CGGGACTTTC CGTGCCTCTT ATGATCCCAT GTGCGATGAA 
 301 CCTCACGGGA CTTTCCGTGC CTCTTATGAT CCCATGTGCG ATGAACCTCA 
 351 CGGGACTTTC CGTGCCTCTT ATGATCCCAT GTGCGATGAA CCTCACGGGA 
 401 CTTTCCGTGC CTCTTATGAT CCTCGAGCCA TGTCTGGTCG AGGCCTGTAG 
 451 GCGTGTACGG TGGGAGGCTT ATATAAGCAG AGCTCAAGCT GGCATTCCCG 
 
Appendix 6.5. Promoter 2 – 40 bp space between 6NFκB motifs  
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   1 AAACCTCCCA CACCTCCCCC TGAACCTGAA ACATAAAATG AATGCAATTG 
  51 TTGTTGTTAA CTTGTTTATT GCAGCTTATA ATGGTTACAA ATAAAGCAAT 
 101 AGCATCACAA ATTTCACAAA TAAAGCATTT TTTTCACTGC ATTCTAGTTG 
 151 TGGTTTGTCC AAACTCATCA ATGTATCTTA TCATGTCTGG CCAGCTAGCG 
 201 TGCCTCTTAT GATCCCATGT CTGTTGCGAT GAACCTCACG GGACTTTCCG 
 251 TGCCTCTTAT GATCCCATGT CTGTTGCGAT GAACCTCACG GGACTTTCCG 
 301 TGCCTCTTAT GATCCCATGT CTGTTGCGAT GAACCTCACG GGACTTTCCG 
 351 TGCCTCTTAT GATCCCATGT CTGTTGCGAT GAACCTCACG GGACTTTCCG 
 401 TGCCTCTTAT GATCCCATGT CTGTTGCGAT GAACCTCACG GGACTTTCCG 
 451 TGCCTCTTAT GATCCCATGT CTGTTGCGAT GAACCTCACG GGACTTTCCG 
 501 TGCCTCTTAT GATCCTCGAG CCATGTCTGG TCGAGGCCTG TAGGCGTGTA 
 551 CGGTGGGAGG CTTATATAAG CAGAGCTCAA GCTGGCATCC GGTACTGTTA 
 601 GRCMMCCCT 
 
 
Appendix 6.6. Promoter 1 – 45 bp space between 7NFκB motifs  
   1 CCMTCMCACA CCTCCCCCTG AACCTGAAAC ATAAAATGAA TGCAATTGTT 
  51 GTTGTTTAAC TTGTTTATTG CAGCTTATAA TGGTTACAAA TAAAGCAATA 
 101 GCATCACAAA TTTCACAAAT AAAGCATTTT TTTCACTGCA TTCTAGTTGT 
 151 GGTTTGTCCA AACTCATCAA TGTATCTTAT CATGTCTGGC CAGCTAGCGT 
 201 GCCTCTTATG ATCTGGATCC ATGATCTCTG CGATGAACCT CACGGGACTT 
 251 TCCGTGCCTC TTATGATCTG GATCCATGAT CTCTGCGATG AACCTCACGG 
 301 GACTTTCCGT GCCTCTTATG ATCTGGATCC ATGATCTCTG CGATGAACCT 
 351 CACGGGACTT TCCGTGCCTC TTATGATCTG GATCCATGAT CTCTGCGATG 
 401 AACCTCACGG GACTTTCCGT GCCTCTTATG ATCTGGATCC ATGATCTCTG 
 451 CGATGAACCT CACGGGACTT TCCGTGCCTC TTATGATCTG GATCCATGAT 
 501 CTCTGCGATG AACCTCACGG GACTTTCCGT GCCTCTTATG ATCTGGATCC 
 551 ATGATCTCTG CGATGAACCT CACGGGACTT TCCGTGCCTC TTATGATCTG 
 601 GATCTCGAGC CATGGTCGAG GCCTGTAGGC GTGTACGGTG GGAGGCTTAT 
 651 ATAAGCAGAG CTCAAGCTGG CATCCGGTWC KGTGAGGAAM CCG 
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Appendix 6.7. Promoter 5 – 60 bp space between 4NFκB motifs  
   1 AAACCTCCCA CACCTCCCCC TGAACCTGAA ACATAAAATG AATGCAATTG 
  51 TTGTTGTTAA CTTGTTTATT GCAGCTTATA ATGGTTACAA ATAAAGCAAT 
 101 AGCATCACAA ATTTCACAAA TAAAGCATTT TTTTCACTGC ATTCTAGTTG 
 151 TGGTTTGTCC AAACTCATCA ATGTATCTTA TCATGTCTGG CCAGCTAGCG 
 201 TGCCTCTTAT GATCTGGATC CATGTCTGTA TCTCTGCGAT GAACCTCACC 
 251 ATGTGGGACT TTCCACAAGG TGCCTCTTAT GATCTGGATC CATGTCTGTA 
 301 TCTCTGCGAT GAACCTCACC ATGTGGGACT TTCCACAAGG TGCCTCTTAT 
 351 GATCTGGATC CATGTCTGTA TCTCTGCGAT GAACCTCACC ATGTGGGACT 
 401 TTCCACAAGG TGCCTCTTAT GATCTGGATC CATGTCTGTA TCTCTGCGAT 
 451 GAACCTCACC ATGTGGGACT TTCCACAAGG TGCCTCTTAT ATCTGGATCT 
 501 CGAGTCGAGG CCTGTAGGCG TGTACGGTGG GAGGCTTATA TAAGCAGAGC 
 551 TCAAGCTGGC ATTCCGGTAC TKTKARRCCM CCC 
 
Appendix 6.8. Promoter 4 - 15 bp space between 10AP-1 motifs  
   1 WRRCMTCCCA CACCTCCCCM TGAACCTGAA ACATAAAATG AATGCAATTG 
  51 TTGTTGTTAA CTTGTTTATT GCAGCTTATA ATGGTTACAA ATAAAGCAAT 
 101 AGCATCACAA ATTTCACAAA TAAAGCATTT TTTTCACTGC ATTCTAGTTG 
 151 TGGTTTGTCC AAACTCATCA ATGTATCTTA TCATGTCTGG CCAGCTAGCG 
 201 TGCCTCTTAT GATCTGAGTC ATGCGATGAA CCTCACTGAG TCAGTGCCTC 
 251 TTATGATCTG AGTCATGCGA TGAACCTCAC TGAGTCAGTG CCTCTTATGA 
 301 TCTGAGTCAT GCGATGAACC TCACTGAGTC AGTGCCTCTT ATGATCTGAG 
 351 TCATGCGATG AACCTCACTG AGTCAGTGCC TCTTATGATC TGAGTCATGC 
 401 GATGAACCTC ACTGAGTCAG TGCCTCTTAT GATCCTCGAG CCATGTCTGG 
 451 TCGAGGCCTG TAGGCGTGTA CGGTGGGAGG CTTATATAAG CAGAGCTCAA 
 501 GCTTGGCATC CGGTACTKTG AGCCCCCC 
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Appendix 6.9. Promoter 1 – 20 bp space between 8AP-1 motifs  
   1 AACCTCCCAC ACCTCCCCCT GAACCTGAAA CATAAAATGA ATGCAATTGT 
  51 TGTTGTTAAC TTGTTTATTG CAGCTTATAA TGGTTACAAA TAAAGCAATA 
 101 GCATCACAAA TTTCACAAAT AAAGCATTTT TTTCACTGCA TTCTAGTTGT 
 151 GGTTTGTCCA AACTCATCAA TGTATCTTAT CATGTCTGGC CAGCTAGCGT 
 201 GCCTCTTATG ATCTGGATTG AGTCAATCTC TGCGATGAAC CTCACTGAGT 
 251 CAGTGCCTCT TATGATCTGG ATTGAGTCAA TCTCTGCGAT GAACCTCACT 
 301 GAGTCAGTGC CTCTTATGAT CTGGATTGAG TCAATCTCTG CGATGAACCT 
 351 CACTGAGTCA GTGCCTCTTA TGATCTGGAT TGAGTCAATC TCTGCGATGA 
 401 ACCTCACTGA GTCAGTGCCT CTTATGATCT GGATCTCGAG CCATGGTSGA 
 451 GGCCTGTAGG CGTGTACGGT GGGAGGCTTA TATAAGCAGA GCTCAAGCTG 
 501 GCATCCGGTA CKTGAGCCCC C 
 
Appendix 6.10. Promoter 3 - 35 bp space between 7AP-1 motifs  
   1 AARCSTCCCA CACCTCCCCC TGAACCTGAA ACATAAAATG AATGCAATTG 
  51 TTGTTGTTAA CTTGTTTATT GCAGCTTATA ATGGTTACAA ATAAAGCAAT 
 101 AGCATCACAA ATTTCACAAA TAAAGCATTT TTTTCACTGC ATTCTAGTTG 
 151 TGGTTTGTCC AAACTCATCA ATGTATCTTA TCATGTCTGG CCAGCTAGCG 
 201 TGCCTCTTAT GATCCCATGT GCGATGAACC TCACTGAGTC AGTGCCTCTT 
 251 ATGATCCCAT GTGCGATGAA CCTCACTGAG TCAGTGCCTC TTATGATCCC 
 301 ATGTGCGATG AACCTCACTG AGTCAGTGCC TCTTATGATC CCATGTGCGA 
 351 TGAACCTCAC TGAGTCAGTG CCTCTTATGA TCCCATGTGC GATGAACCTC 
 401 ACTGAGTCAG TGCCTCTTAT GATCCCATGT GCGATGAACC TCACTGAGTC 
 451 AGTGCCTCTT ATGATCCCAT GTGCGATGAA CCTCACTGAG TCAGTGCCTC 
 501 TTATGATCCT CGAGCCATGT CTGGTCGAGG CCTGTAGGCG TGTACGGTGG 
 551 GAGGCTTATA TAAGCAGAGC TCAAGCTTGG CATCCGGTAC TGTGAGMCAM 
  
Appendix 6.11. Promoter 3 – 40 bp space between 5AP-1 motifs  
   1 AAMCSTCCCA CACCTCCCCC TGAACCTGAA ACATAAAATG AATGCAATTG 
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  51 TTGTTGTTAA CTTGTTTATT GCAGCTTATA ATGGTTACAA ATAAAGMAAT 
 101 AGCATCACAA ATTTCACAAA TAAAGCATTT TTTTCACTGC ATTCTAGTTG 
 151 TGGTTTGTCC AAACTCATCA ATGTATCTTA TCATGTCTGG CCAGCTAGCG 
 201 TGCCTCTTAT GATCCCATGT CTGTTGCGAT GAACCTCACT GAGTAAGTGC 
 251 CTCTTATGAT CCCATGTCTG TTGCGATGAA CCTCACTGAG TCAGTGCCTC 
 301 TTATGATCCC ATGTCTGTTG CGATGAACCT CACTGAGTCA GTGCCTCTTA 
 351 TGATCCCATG TCTGTTGCGA TGAACCTCAC TGAGTCAGTG CCTCTTATGA 
 401 TCCCATGTCT GTTGCGATGA ACCTCACTGA GTCAGTGCCT CTTATGATCC 
 451 TCGAGCCATG TYTGGKCGAG GCCTGTAGGC GTGTACGGTG GGAGGCTTAT 
 501 ATAAGCAGAG CTCAAGCTGG CATCCGGTAC TTKRAGCCMC CT 
 
Appendix 6.12. Promoter 5 – 45 bp space between 8AP-1 motifs  
   1 TGTTGWTGTT AACTTGTTTA TTGCAGCTTA TAATGGTTAC AAATAAAGCA 
  51 ATAGCATCRC AAATTTCACA AATAAAGCAT TTTTTTCACT GCATTCTAGT 
 101 TGYGGTTTGT CCAAACTCAT CAATGTATCT TATCATGTCT GGCCAGCTAG 
 151 CGTGCCTCTT ATGATCTGGA TCCATGATCT CTGCGATGAA CCTCACTGAG 
 201 TCAGTGCCTC TTATGATCTG GATCCATGAT CTCTGCGATG AACCTCACTG 
 251 AGTCAGTGCC TCTTATGATC TGGATCCATG ATCTCTGCGA TGAACCTCAC 
 301 TGAGTCAGTG CCTCTTATGA TCTGGATCCA TGATCTCTGC GATGAACCTC 
 351 ACTGAGTCAG TGCCTCTTAT GATCTGGATC CATGATCTCT GCGATGAACC 
 401 TCACTGAGTC AGTGCCTCTT ATGATCTGGA TCCATGATCT CTGCGATGAA 
 451 CCTCACTGAG TCAGTGCCTC TTATGATCTG GATCCATGAT CTCTGCGATG 
 501 AACCTCACTG AGTCAGTGCC TCTTATGATC TGGATCCATG ATCTCTGCGA 
 551 TGAACCTCAC TGAGTCAGTG CCTCTTATGA TCTGGATCTC GAGCCATGGT 
 601 SGRGGCCTGT AGGCGTGTAC GGTGGGAGGC TTATATAAGC AGAGCTCAAG 
 651 CTTGGCATCC GGTACKTKAG MCACCGG 
 
Appendix 6.13. Promoter 1 – 50 bp space between 4AP-1 motifs  
   1 CCTCCCACAC CTCCCCCTGA ACCTGAAACA TAAAATGAAT GCAATTGTTG 
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  51 TTGTTAACTT GTTTATTGCA GCTTATAATG GTTACAAATA AAGCAATAGC 
 101 ATCACAAATT TCACAAATAA AGCATTTTTT TCACTGCATT CTAGTTGTGG 
 151 TTTGTCCAAA CTCATCAATG TATCTTATCA TGTCTGGCCA GCTAGCGTGC 
 201 CTCTTATGAT CTGGATCCAT GTCTGTATCT CTGCGATGAA CCTCACTGAG 
 251 TCAGTGCCTC TTATGATCTG GATCCATGTC TGTATCTCTG CGATGAACCT 
 301 CACTGAGTCA GTGCCTCTTA TGATCTGGAT CCATGTCTGT ATCTCTGCGA 
 351 TGAACCTCAC TGAGTCAGTG CCTCTTATGA TCTGGATCCA TGTCTGTATC 
 401 TCTGCGATGA ACCTCACTGA GTCAGTGCCT CTTATGATCT GGATCTCGAG 
 451 CCATGGTCGA GGCCTGTAGG CGTGTACGGT GGGAGGCTTA TATAAGCAGA 
 501 GCTCAAGCTG GCATCCGTAC KTGARCCMCC T 
 
Appendix 6.14. Promoter 2 – 55 bp space between 7AP-1 motifs  
   1 CCCCCTTKAW CYTGAAAACA TAAAATGAAK GCAATTGTTG TTGTTAAAYT 
  51 TGTTTATTGC AGCTTATAAT GGTTACAAAT AAAGCAATAG CATCACAAAT 
 101 TTCACAAATA AAGCATTTTT TTCACTGCMT TCTAGTTGTG GKTWGTCCAA 
 151 AYTCATCAAT GTATCTTATC ATGTCTGGCC AGCTAGCGTG CCTCTTATGA 
 201 TCTGGATCCA TGATCTCTGC GATGAACCTC ACCATGTTGA GTCAACAAGG 
 251 TGCCTCTTAT GATCTGGATC CATGATCTCT GCGATGAACC TCACCATGTT 
 301 GAGTCAACAA GGTGCCTCTT ATGATCTGGA TCCATGATCT CTGCGATGAA 
 351 CCTCACCATG TTGAGTCAAC AAGGTGCCTC TTATGATCTG GATCCATGAT 
 401 CTCTGCGATG AACCTCACCA TGTTGAGTCA ACAAGGTGCC TCTTATGATC 
 451 TGGATCCATG ATCTCTGCGA TGAACCTCAC CATGTTGAGT CAACAAGGTG 
 501 CCTCTTATGA TCTGGATCCA TGATCTCTGC GATGAACCTC ACCATGTTGA 
 551 GTCAACAAGG TGCCTCTTAT GATCTGGATC CATGATCTCT GCGATGAACC 
 601 TCACCATGTT GAGTCAACAA GGTGCCTCTT ATGATCTGGA TCTCGAGTCG 
 651 AGGCCTGTAG GCGTGTACGG TGGGAGGCTT ATATAAGCAG AGCTCAAGCT 
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Appendix 7. Sequencing data of the pCpG-HRE constructs used to create the pCpG-
spacer vectors for increased spacing between the proximal TFBS and TATA box 
The pCpG-HRE-constructs were sequenced using the GL2 reverse primer and were 
eventually used to create the cloning vectors with various spacings between the proximal 
TFBS and the TATA box. The HRE motifs are indicated by a box and have a 60bp, 66bp, 70bp 
and 74bp space between the proximal HRE and the TATA box. The TATAA box is highlighted 
in bold. The NheI (5’-GCTAGC) and XhoI (5’-CTCGAG) sites are underlined and represent 
the start and end of the region containing 4HRE, respectively (in forward and reverse 
orientations).  
Appendix 7.1.  pCpG-4HRE-0bp-Sal (60 bp from TATA box) 
   1 TATCTTATCA TGTCTGGCCA GCTAGCGTGC CTCTTATGAT CTGGATTGCA 
  51 CCATCTCTGC GATGAACCTC ACACGTGGGT GCCTCTTATG ATCTGGATTG 
 101 CACCATSTCT GCGATGAACC TCACACGTGG GTGCCTCTTA TGATCTGGAT 
 151 CTCGAGWCGR GGCCTGTAGG CGTGTACGGT GGGAGGCTTA TATAAGCAGA 
 201 GCTCAAGCTK GCATTCCGGG TWSTKTGTTK KTTTCCTCT 
 
Appendix 7.2.  pCpG-4HRE-5bp-Sal (66 bp from TATA box) 
   1 RTATCTTATC ATGTCTGGCC AGCTAGCGTG CCTCTTATGA TCTGGATTGC 
  51 ACCATCTCTG CGATGAACCT CACACGTGGG TGCCTCTTAT GATCTGGATT 
 101 GCACCATCTC TGSGATGAAC CTCACACGTG GGTGCCTCTT ATGATCTGGA 
 151 TCTCGAGCCA TGRTSGRGGC CTGTAGGCGT GTACGGTGGG AGGCTTATAT 
 201 AAGCAGAGCT CAAGCTKGCA TCCGKTACTG TGGATWAKKC TTTGCT 
 
Appendix 7.3.  pCpG-4HRE-9bp-Sal (70 bp from TATA box) 
   1 TATCTTATCA TGTCTGGCCA GCTAGCGTGC CTCTTATGAT CTGGATTGCA 
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  51 CCATCTCTGC GATGAACCTC ACACGTGGGT GCCTCTTATG ATCTGGATTG 
 101 CACCATCTCT GCGATGAACC TCACACGTGG GTGCCTCTTA TGATCTGGAT 
 151 CTCGAGCCAT GTCTGGTCGA GGCCTGTAGG CGTGTACGGT GGGAGGCTTA 
 201 TATAAGCAGA GCTCAAGCTT GGCATCCGTA CKTGTGAACT TTTATACGG 
Appendix 7.4.  pCpG-4HRE-14bp-Sal (74 bp from TATA box) 
   1 CAATAGCATC ACAAATTTCA CAAATAAAGC ATTTTTTTCA MTGCATTCTA 
  51 GTTGWGGTTT GTCCAAACTC ATCAATGTAT CTTATCATGT CTGGCCAGCT 
 101 AGCGTGCCTC TTATGATCTG GATTGCACCA TCTCTGCGAT GAACCTCACA 
 151 CGTGGGTGCC TCTTATGATC TGGATTGCAC CATCTCTGCG ATGAACCTCA 
 201 CACGTGGGTG CCTCTTATGA TCTGGATCTC GAGCCATGTC TGTATCCGTC 
 251 GAGGCCTGTA GGCGTGTACG GTGGGAGGCT TATATAAGCA GAGCTCAAGC 
 301 TGGCATCCGG TACKKTGAGC CCCCWTTT 
 
Appendix 8. Sequencing data of the pCpG-NFκB and AP-1-responsive promoters with 
various spacing between the proximal TFBS and TATA box 
The 6NFκB and 8AP-1 motifs were cloned into the different spacer vectors (above; Appendix 
7) to allow a 55 bp, 66 bp, 70 bp and 74 bp space between the proximal TFBS and the TATA 
box. The selected constructs were sequenced using the GL2 reverse primer. The TFBSs are 
indicated by a box and the TATAA box is highlighted in bold. The NheI site (5’-GCTAGC) and 
the XhoI overhang (5’-TCGAG) are underlined and represent the start and end of the region 
containing multimerised TFBS, respectively.  
Appendix 8.1.  pCpG-8AP-1 (55 bp from TATA box) 
   1 TGCCTCTTAT GATCTGGATT GAGTCAATCT CTGCGATGAA CCTCACTGAG 
  51 TCAGTGCCTC TTATGATCTG GATTGAGTCA ATCTMTGCGA TGAACCTCAC 
 101 TGAGTCAGTG CCTCTTATGA TCTGGATTGA GTCAATCTCT GCGATGAACC 
 151 TCACTGAGTC AGTGCCTCTT ATGATCTGGA TTGAGTCAAT YTGTGCGATG 
 201 AACCTCACTG AGTCAGTGCC TCTTATGATT TGGATCTCGAG GCCTGTAGGC 
 251 GTGTACGGTG GGAGGCTTAT ATAAGCAGAG CTCAAGCTGG CATCCGTACK 
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Appendix 8.2.  pCpG-6NFκB-X-0bp-Sal (60 bp from TATA box) 
   1 CAAACTCATC AATGTATCTT ATCATGTCTG GCCAGCTAGC GTGCCTCTTA 
  51 TGATCTGGAT GGGACTTTCC ATCTCTGCGA TGAACCTCAC GGGACTTTCC 
 101 GTGCCTCTTA TGATCTGGAT GGGACTTTCC ATCTCTGCGA TGAACCTCAC 
 151 GGGACTTTCC GTGCCTCTTA TGATCTGGAT GGGACTTTCC ATCTCTGCGA 
 201 TGAACCTCAC GGGACTTTCC GTGCCTCTTA TGATCTGGAT CTCGTGTCGA 
 251 GGCCTGTAGG CGTGTACGGT GGGARGCTTA TATAAGCAGA GCTCAAGCTT 
 301 GGCATCCGGT ACKTGAGMCM CCTAG 
 
Appendix 8.3.  pCpG-6NFκB-X-5bp-Sal (66 bp from TATA box) 
   1 AYTCACAATG TATCTTATCA TGTCTGGCCA GCTAGCGTGC CTCTTATGAT 
  51 CTGGAKGGGA CTTTCCATCT CTGCGATGAA CCTCACGGGA CTTTCCGTGC 
 101 CTCTTATGAT CTGGATGYKC CTTAACGACT CTGCGATGAA CCTCACGGGA 
 151 CTTTCCGTGC CTCTTATGAT CTGGATGGGA CTTTCCATCT CTGCGAGATC 
 201 GCACTTTCCG TGCCTCTTAT GATCYSGATC TGGAAGACTC TCCCCTGTAG 
 251 RCGTTACGGY YKKTTTCTYA TATAAGCAGA GCTAMAAGCT TGCATWCCGG 
  
Appendix 8.4.  pCpG-8AP-1-X-9bp-Sal (70 bp from TATA box) 
   1 GTATCTTATC ATGTCTGGCC AGCTAGCGTG CCTCTTATGA TCTGGATTGA 
  51 GTCAATCTCT GCGATGAACC TCACTGAGTC AGTGCCTCTT ATGATCTGGA 
 101 TTGAGTCAAT CTCTGCGATG AACCTCACTG AGTCAGTGCC TCTTATGATC 
 151 TGGATTGAGT CAATCTCTGC GATGAACCTC ACTGAGTCAG TGCCTCTTAT 
 201 GATCTGGATT GAGTCAATCT CTGCGATGAA CCTCACTGAG TCAGTGCCTC 
 251 TTATGATCTG GATCTCGAGC CATGTCTGTA TCCTCAGGCC TGTAGGCGTG 
 301 TACGGGGGAG GCTTATATAAG CAGAGCTCAA GCTGGCATCC GTACKTAGCA 
 351 TGGGGGGGGA TAACC 
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Appendix 9. Sequencing data of selected pCpG-4bp-composite promoters with a 4 bp 
space between TFBSs and a 66 bp space between the proximal TFBS and TATA box 
The pCpG-4bp-composite promoters were sequenced using the GL2 reverse primer. The 
TFBSs are indicated by a box and the arrows show the TFBS orientation. The NheI overhang 
(5’-CTAG) and XhoI site (5’-CTCGAG) is underlined and represents the start and end of the 
region containing multimerised TFBSs, respectively. The TATAA box is highlighted in bold. All 
sequences are complete and schematically represented for each construct. 
 
 
Appendix 9.1. Promoter 4- pCpG-4bp-composite promoter  
   1 GCGRAAAAAA AAAACAGATA AAAGTAARTC AAACATATAT CCTGCWACWC 
  51 GCGCGKATGT CGGTCATCRT GTSYCGCCCM RKGTMCGYST SCWGTRCSTC 
 101 CCTAGTGACT CACTAGGGGA CTTTCCCTAG GCACGTCTAG GCACGTCTAG 
 151 TGAGTCACTA GGCACGTCTA GCTCGCGATC TTATGATCTG GATCCATGCT 
 201 CGAGGCCTGT AGGCGTGTAC GGTGGGAGGC TTATATAAGC AGAGCTCAAG 
 251 CTGGCATCCG TACKTGAGCC AT 
      
 
Appendix 9.2. Promoter 6- pCpG-4bp-composite promoter  
   1 GCATCACAAA TTTCACAAAT AAAGCATTTT TTTCACTGCA TTCTAGTTGT 
  51 GGTTTGTCCA AACTCATCAA TGTATCTTAT CATGTCTGGC CAGCTAGACG 
 101 CGTGCTAGGG AAAGTCCCCT AGACGTGC GG AAAGTCCCCT AGGCACGTCT 
 151 AGTGAGTCAC TAGGGGACTT TCCCTAGTGA CTCACTAGTG ACTCACTAGC 
 201 TCGCGATCTT ATGATCTGGA TCCATGCTCG AGGCCTGTAG GCGTGTACGG 
251 TGGGAGGCTT ATATAAGCAG AGCTCAAGCT GGCATCCGGT ACKKGRAGCC 
 
376 
 
 
 
Appendix 9.3. Promoter 7- pCpG-4bp-composite promoter  
   1 TTATAATGGT TACAAATAAA GCAATAGCAT CACAAATTTC ACAAATAAAG 
  51 CATTTTTTTC ACTGCATTCT AGTTGTGGTT TGTCCAAACT CATCAATGTA 
 101 TCTTATCATG TCTGGCCAGC TAGACGCGTG CTAGGGAAAG TCCCCTAGAC 
 151 GTGCCTAGGC ACGTCTAGTG AGTCACTAGA CGTGCCTAGA CGTGCCTAGA 
 201 CGTGCCTAGC TCGCGATCTT ATGATCTGGA TCCATGCTCG AGGCCTGTAG 
 251 GCGTGTACGG TGGGAGGCTT ATATAAGCAG AGCTCAAGCT TGGCATCCGG 
 
  
 Appendix 9.4. Promoter 11- pCpG-4bp-composite promoter  
   1 TTTCACAAAT AAAGCATTTT TTTCACTGCA TTCTAGTTGT GGTTTGTCCA 
  51 AACTCATCAA TGTATCTTAT CATGTCTGGC CAGCTAGACG CGTGCTAGGG 
 101 GACTTTCCCT AGGCACGTCT AGTGACTCAC TAGGGGACTT TCCCTAGACG 
 151 TGCCTAGTGA GTCACTAGCT CGCGATCTTA TGATCTGGAT CCATGCTCGA 
 201 GGCCTGTAGG CGTGTACGGT GGGAGGCTTA TATAAGCAGA GCTCAAGCTT 
 251 GGCATCCGGT ACKTKKAGCC ACTA 
 
 
Appendix 9.5. Promoter 15- pCpG-4bp-composite promoter       
   1 AAACCTCCCA CACCTCCCCC TGAACCTGAA ACATAAAATG AATGCAATTG 
  51 TTGTTGTTAA CTTGTTTATT GCAGCTTATA ATGGTTACAA ATAAAGCAAT 
 101 AGCATCACAA ATTTCACAAA TAAAGCATTT TTTTCACTGC ATTCTAGTTG 
 151 TGGTTTGTCC AAACTCATCA ATGTATCTTA TCATGTCTGG CCAGCTAGAC 
 201 GCGTGCTAGG CACGTCTAGT GAGTCACTAG GGGACTTTCC CTAGCTCGCG 
 251 ATCTTATGAT CTGGATCCAT GCTCGRGGCC TGTAGGCGTG TACGGTGGGA 
377 
 
 301 GGCTTATATA AGCAGAGCTC AAGCTGGCAT CCGGTACKTG AGCCACCC 
      
Appendix 9.6. Promoter 17- pCpG-4bp-composite promoter       
   1 AAATAAAGCA ATAGCATCAC AAATTTCACA AATAAAGCAT TTTTTTCACT 
  51 GCATTCTAGT TGTGGTTTGT CCAAACTCAT CAATGTATCT TATCATGTCT 
 101 GGCCAGCTAG ACGCGTGCTA GGGGACTTTC CCTAGGCACG TCTAGTGACT 
 151 CACTAGGGGA CTTTCCCTAG ACGTGCCTAG TGAGTCACTA GCTCGCGATC 
 201 TTATGATCTG GATCCATGCT CGAGGCCTGT AGGCGTGTAC GGTGGGAGGC 
 251 TTATATAAGC AGAGCTCAAG CTTGGCATCC GGTACKTKWA SCCMCCCC 
 
 
 
 
Appendix 10. Sequencing data of the selected pCpG-20bp-composite promoters with a 
20bp space between TFBS and a 66bp between the proximal TFBS and TATA box  
The selected pCpG-20bp-composite promoters were sequenced using the GL2 reverse 
primer. The TFBSs are positioned in the forward orientation and are indicated by a box. The 
NheI (5’-GCTAGC) and XhoI (5’-CTCGAG) sites are underlined and represent the start and 
end of the region containing multimerised TFBSs, respectively. The TATAA box is highlighted 
in bold. All sequences are complete and the schematic diagrams are presented for each 
construct. 
 
 
Appendix 10.1.  Promoter 2 (pCpG-20bp-composite promoter)  
   1 CAGCTTATAA TGGTTACAAA TAAAGCAATA GCATCACAAA TTTCACAAAT 
  51 AAAGCATTTT TTTCACTGCA TTCTAGTTGT GGTTTGTCCA AACTCATCAA 
 101 TGTATCTTAT CATGTCTGGC CAGCTAGCGT GCCTCTTATG ATCTGGATTG 
 151 AGTCAATCTC TGCGATGAAC CTCACTGAGT CAGTGCCTCT TATGATCTGG 
 201 ATACGTGCAT CTCTGCCGAT GAACCTCACT GAGTCAGTGC CTCTTATGAT 
 251 CTGGATACGT GCATCTCTGC GATGAACCTC ACTGAGTCAG TGCCTCTTAT 
378 
 
 301 GATCTGGATT GAGTCAATCT CTGCGATGAA CCTCACTGAG TCAGTGCCTC 
 351 TTATGATCTG GATTGAGTCA ATCTCTGCGA TGAACCTCAC ACGTGCGTGC 
 401 CTCTTATGAT CTGGATGGGA CTTTCCATCT CTGCGATGAA CCTCACGGGA 
 451 CTTTCCGTGC CTCTTATGAT CTGGATGGGA CTTTCCATCT CTGCGATGAA 
 501 CCTCACTGAG TCAGTGCCTC TTATGATCTG GATCTCGAGC CATGGTCGAG 
 551 GCCTGTAGGC GTGTACGGTG GGAGGCTTAT ATAAGCAGAG CTCAAGCTTG 
601 GCATCCGGTA CKKGAGCCMM CC 
 
 
Appendix 10.2.  Promoter 9 (pCpG-20bp-composite promoter)  
   1 TTCTAGTTGT GGTTTGTCCA AACTCATCAA TGTATCTTAT CATGTCTGGC 
  51 CAGCTAGCGT GCCTCTTATG ATCTGGATTG AGTCAATCTC TGCGATGAAC 
 101 CTCACACGTG CGTGCCTCTT ATGATCTGGA TGGGACTTTC CACCTCTGCG 
 151 ATGAACCTCA CACGTGCGTG CCTCTTATGA TCTGGATGGG ACTTTCCATC 
 201 TCTGCGATGA ACCTCACTGA GTCAGTGCCT CTTATGATCT GGATTGAGTC 
 251 AATCTCTGCG ATGAACCTCA CGGGACTTTC CGTGCCTCTT ATGATCTGGA 
 301 TACGTGCATC TCTGCGATGA ACCTCACTGA GTCAGTGCCT CTTATGATCT 
 351 GGATGGGACT TTCCATCTCT GCGATGAACC TCACACGTGC GTGCCTCTTA 
 401 TGATCTGGAT TGAGTCAATC TCTGCGATGA ACCTCACACG TGCGTGCCTC 
 451 TTATGATCTG GATCTCGAGC CATGGTCGAG GCCTGTAGGC GTGTACGGTG 
 501 GGAGGCTTAT ATAAGCAGAG CTCAAGCTGG CATCCGGTAC KTGAGMCMCC 
 
Appendix 10.3.  Promoter 4 (pCpG-20bp-composite promoter)  
   1 CATTCTAGTT GTGGTTTGTC CAAACTCATC AATGTATCTT ATCATGTCTG 
  51 GCCAGCTAGC GTGCCTCTTA TGATCTGGAT TGAGTCAATC TCTGCGATGA 
 101 ACCTCACTGA GTCAGTGCCT CTTATGATCT GGATACGTGC ATCTCTGCGA 
379 
 
 151 TGAACCTCAC ACGTGCGTGC CTCTTATGAT CTGGATGGGA CTTTCCATCT 
 201 CTGCGATGAA CCTCACACGT GCGTGCCTCT TATGATCTGG ATGGGACTTT 
 251 CCATCTCTGC GATGAACCTC ACGGGACTTT CCGTGCCTCT TATGATCTGG 
 301 ATGGGACTTT CCATCTCTGC GATGAACCTC ACTGAGTCAG TGCCTCTTAT 
 351 GATCTGGATG GGACTTTCCA TCTCTGCGAT GAACCTCACG GGACTTTCCG 
 401 TGCCTCTTAT GATCTGGATA CGTGCATCTC TGCGATGAAC CTCACTGAGT 
 451 CAGTGCCTCT TATGATCTGG ATACGTGCAT CTCTGCGATG AACCTCACTG 
 501 AGTCAGTGCC TCTTATGATC TGGATCTCGA GCCATGGTCG AGGCCTGTAG 
 551 GCGTGTACGG TGGGAGGCTT ATATAAGCAG AGCTCAAGCT TGGCATCCGG 
 
 
Appendix 10.4.  Promoter 6 (pCpG-20bp-composite promoter)  
   1 AAACTCATCA ATGTATCTTA TCATGTCTGG CCAGCTAGCG TGCCTMTTAT 
  51 RATCTGGAKT GAGTCAATCT CTGCGATGAA CCTCACACGT GCGTGCCTCT 
 101 TATGATCTGG ATACGTGCAT CTTTGCGATG AACCTCACGG GACTTTCCGT 
 151 GCCTCTTATG ATCTGGATAC GTGCATCTCT GCGATGAACC TCACACGTGC 
 201 GTGCCTCTTA TGATCTGGAT GGGACTTTCC ATCTCTGCGA TGAACCTCAC 
 251 ACGTGCGTGC CTCTTATGAT CTGGATGGGA CTTTCCATCT CTGCGATGAA 
 301 CCTCACACGT GCGTGCCTCT TATGATCTGG ATTGAGTCAA TCTCTGCGAT 
 351 GARCSTCACA CGTGCGTGCC TCTTATGATC TGGATCTCGA GCCATGGTSG 
 401 AGGCCTGTAG GCGTGTACGG TGGGAGGCTT ATATAAGCAG AGCTCAAGCT 
 451 GGCATTCCGG TAYKKGKYRR CCKCCTTYTG 
 
 
Appendix 10.5.  Promoter 20 (pCpG-20bp-composite promoter)  
   1 GTATCTTATC ATGTCTGGCC AGCTAGCGTG CCTCTTATGA TCTGGATTGA 
  51 GTCAATCTCT GCGATGAACC TCACTGAGTC AGTGCCTCTT ATGATCTGGA 
380 
 
 101 TGGGACTTTC CATCTCTGCG ATGAACCTCA CACGTGCGTG CCTCTTATGA 
 151 TCTGGATACG TGCATCTCTG CGATGAACCT CACTGAGTCA GTGCCTCTTA 
 201 TGATCTGGAT CTCGAGCCAW GRTSGAGGCC TGTAGGCGTG TACGGTGGGA 
 251 RGCTTATATA AGCAGAGCTC AAGCTTKGCW TTCCGKAAYC TRYSGTTKKA 
  
 
Appendix 10.6.  Promoter 11 (pCpG-20bp-composite promoter)  
   1 GGTTTGTCCA AACTCATCAA TGTATCTTAT CATGTCTGGC CAGCTAGCGT 
  51 GCCTCTTATG ATCTGGATGG GACTTTCCAT CTCTGCGATG AACCTCACTG 
 101 AGTCAGTGCC TCTTATGATC TGGATTGAGT CAATCTCTGC GATGAACCTC 
 151 ACACGTGCGT GCCTCTTATG ATCTGGATAC GTGCATCTCT GCGATGAACC 
 201 TCACGGGACT TTCCGTGCCT CTTATGATCT GGATGGGACT TTCCATCTCT 
 251 GCGATGAACC TCACTGAGTC AGTGCCTCTT ATGATCTGGA TCTCGAGCCA 
 301 TGGTCGAGGC CTGTAGGCGT GTACGGTGGG AGGCTTATAT AAGCAGAGCT 
351 CAAGCTGGCA TCCGGTACKK RAGRCCCC
 
  
Appendix 10.7.  Promoter 12 (pCpG-20bp-composite promoter)  
  51 CCAGCTAGCG TGCCTCTTAT GATCTGGATT GAGTCAATCT CTGCGATGAA 
 101 CCTCAGGGGA CTTTCCGTGC CTCTTATGAT CTGGATGGGA CTTTCCATCT 
 151 CTGCGATGAA CCTCACTGAG TCAGTGCCTC TTATGATCTG GATTGAGTCA 
 201 ATCTCTGCGA TGAACCTCAC GGGACTTTCC GTGCCTCTTA TGATCTGGAT 
 251 ACGTGCATCT CTGCGATGAA CCTCACGGGA CTTTCCGTGC CTCTTATGAT 
 301 CTGGATCTCG AGCCATGGTC GAGGCCTGTA GGCGTGTACG GTGGGAGGCT 
351 TATATAAGCA GAGCTCAAGC TGGCATCCGG TACKTGAGAC MCCCTC 
 
 
381 
 
 
 
 
Appendix 10.8.  Promoter 14 (pCpG-20bp-composite promoter) 
   1 AAACTCATCA ATGTATCTTA TCATGTCTGG CCAGCTAGCG TGCCTCTTAT 
  51 GATCTGGATG GGACTTTCCA TCTCTGCGAT GAACCTCACG GGACTTTCCG 
 101 TGCCTCTTAT GATCTGGATT GAGTCAATCT CTGCGATGAA CCTCACGGGA 
 151 CTTTCCGTGC CTCTTATGAT CTGGATACGT GCATCTCTGC GATGAACCTC 
 201 ACACGTGCGT GCCTCTTATG ATCTGGATGG GACTTTCCAT CTCTGCGATG 
 251 AACCTCACAC GTGCGTGCCT CTTATGATCT GGATCTCGAG CCATGGTCGA 
 301 GGCCTGTAGG CGTGTACGGT GGGAGGCTTA TATAAGCAGA GCTCAAGCTG 
 351 GCATCCGGTA CKTKRAARCC CMCCC 
 
 
Appendix 10.9.  Promoter 3 (pCpG-20bp-composite promoter) 
   1 CATGTCTGGC CAGCTAGCGT GCCTCTTATG ATCTGGATAC GTGCATCTCT 
  51 GCGATGAACC TCACGGGACT TTCCGTGCCT CTTATGATCT GGATACGTGC 
 101 ATCTCTGCGA TGAACCTCAC ACGTGCGTGC CTCTTATGAT CTGGATTGAG 
 151 TCAATCTCTG CGATGAACCT CACGGGACTT TCCGTGCCTC TTATGATCTG 
 201 GATACGTGCA TCTCTGCGAT GAACCTCACT GAGTCAGTGC CTCTTATGAT 
 251 CTGGATACGT GCATCTCTGC GATGAACCTC ACACGTGCGT GCCTCTTATG 
 301 ATCTGGATCT CGAGCCATGG TCGAGGCCTG TAGGCGTGTA CGGTGGGAGG 
 351 CTTATATAAG CAGAGCTCAA GCTGGCATCC GGTACKTGAG CACTTT 
 
 
Appendix 10.10.  Promoter 5 (pCpG-20bp-composite promoter) 
   1 GCAATAGCGT CACAAATTTC ACAAATAAAG CATTTTTTTC ACTKCRTTST 
  51 AGTTGWGGTT TGTCCAAACT CATCAATGTA TCTTATCATG TCTGGCCAGC 
382 
 
 101 TAGCGTGCCT CTTATGATCT GGATACGTGC ATCTCTGCGA TGAACCTCAC 
 151 ACGTGCGTGC CTCTTATGAT CTGGATACGT GCATCTCTGC GATGAACCTC 
 201 ACTGAGTCAG TGCCTCTTAT GATCTGGATC TCGAGCCAWG GKSGAGGCCT 
 251 GTAGGCGTGT ACGGTGGGAG GCTTATATAA GCAGAGCTCA AGCTTGGCAT 
 301 CCGGTACTGT GARCCWYCTT 
 
 
Appendix 10.11.  Promoter 15 (pCpG-20bp-composite promoter) 
   1 ATTTCACAAA TAAAGCATTT TTTTCACTGC ATTCTAGTTG TGGTTTGTCC 
  51 AAACTCATCA ATGTATCTTA TCATGTCTGG CCAGCTAGCG TGCCTCTTAT 
 101 GATCTGGATG GGACTTTCCA TCTCTGCGAT GAACCTCACG GGACTTTCCG 
 151 TGCCTCTTAT GATCTGGATC TCGAGCCATG GKCGAGGCCT GTAGGCGTGT 
 201 ACGGTGGGAG GCTTATATAA GCAGAGCTCA AGCTGGCATC CGGTACTKTG 
  
 
Appendix 10.12.  Promoter 18 (pCpG-20bp-composite promoter) 
   1 TGTATCTTAT CATGTCTGGC CAGSTAGCGT GCCTCTTATG ATCTGGATGG 
  51 GACTTTCCAT CTCTGCGATG AACCTCACAC GTGCGTGCCT CTTATGATCT 
 101 GGATGGGACT TTCCATCTCT GCGATGAACC TCACGGGACT TTCCGTGCCT 
 151 CTTATGATCT GGATTGAGTC AATCTCTGCG ATGAACCTCA CGGGACTTTC 
 201 CGTGCCTCTT ATGATCTGGA TGGGACTTTC CATCTCTGCG ATGAACCTCA 
 251 CACGTGCGTG CCTCTTATGA TCTGGATCTC GAGCCATGGT CGAGGCCTGT 
 301 AGGCGTGTAC GGTGGGAGGC TTATATAAGC AGAGCTCAAG CTGGCATCCG 
 351 GTACKTTAGC ACTGGCA 
 
 
Appendix 10.13.  Promoter 19 (pCpG-20bp-composite promoter) 
383 
 
   1 TGTCCAAACT CATCAATGTA TCTTATCATG TCTGGCCAGC TAGCGTGCCT 
  51 CTTATGATCT GGATTGAGTC AATCTCTGCG ATGAACCTCA CGGGACTTTC 
 101 CGTGCCTCTT ATGATCTGGA TACGTGCATC TCTGCGATGA ACCTCACTGA 
 151 GTCAGTGCCT CTTATGATCT GGATGGGACT TTCCATCTCT GCGATGAACC 
 201 TCACTGAGTC AGTGCCTCTT ATGATCTGGA TGGGACTTTC CATCTCTGCG 
 251 ATGAACCTCA CACGTGCGTG CCTCTTATGA TCTGGATGGG ACTTTCCATC 
 301 TCTGCGATGA ACCTCACTGA GTCAGTGCCT CTTATGATCT GGATACGTGC 
 351 ATCTCTGCGA TGAACCTCAC ACGTGCGTGC CTCTTATGAT CTGGATCTCG 
 401 AGCCATGGTC GAGGCCTGTA GGCGTGTACG GTGGGAGGCT TATATAAGCA 
 451 GAGCTCAAGC TGGCATCCGG TACKTGAGCA CTTG 
 
 
 
Appendix 11. Sequencing data of selected pCpG-clustered-composite promoters  
The selected pCpG-cluster-composite promoters were sequenced using the Forward pCpG 
primer. The TFBSs are indicated by a box and the arrows show the orientation of the TFBS 
cluster. The NheI (5’-GCTAGC) and XhoI (5’-CTCGAG) sites are underlined and represent 
the start and end of the region containing clustered TFBSs, respectively. The TATAA box is 
highlighted in bold. Schematic diagrams are presented for each construct. 
 
Appendix 11.1. Promoter 4 (pCpG-cluster-proximal 6NFκB)  
241   TTTCACAAAT AAAGCATTTN TTTCACTGCA TTCTAGTTGT  
281   GGTTTGTCCA AACTCATCAA TGTATCTTAT CATGTCTGGC  
321   CAGCTAGCGT GCCTCTTATG ATCTGGATTG AGTCAATCTC  
361   TGCGATGAAC CTCACTGAGT CAGTGCCTCT TATGATCTGG  
401   ATTGAGTCAA TCTCTGCGAT GAACCTCACT GAGTCAGTGC  
441   CTCTTATGAT CTGGATTGAG TCAATCTCTG CGATGAACCT  
481   CACTGAGTCA GTGCCTCTTA TGATCTGGAT TGAGTCAATC  
384 
 
521   TCTGCGATGA ACCTCACTGA GTCAGTGCCT CTTATGATCT  
561   GGATCTCGAG ATCCAGATCA TAAGAGGCAC GCACGTGTGA  
601   GGTTCATCGC AGAGATGCAC GTATCCAGAT CATAAGAGGC  
641   ACGCACGTGT GAGGTTCATC GCAGAGATGC ACGTATCCAG  
681   ATCATAAGAG GCACGCACGT GTGAGGTTCA TCGCAGAGAT  
721   GCACGTATCC AGATCATAAG AGGCACGCTA GCGTGCCTCT  
761   TATGATCTGG ATGGGACTTT CCATCTCTGC GATGAACCTC  
801   ACGGGACTTT CCGTGCCTCT TATGATCTGG ATGGGACTTT  
841   CCATCTCTGC GATGAACCTC ACGGGACTTT CCGTGCCTCT  
881   TATGATCTGG ATGGGACTTT CCATCTCTGC GATGAACCTC  
921   ACGGGACTTT CCGTGCCTCT TATGATCTGG ATCTCGAGCC  
961   ATGGTCGAGG CCTGTAGGCG TGTACGGTGG GAGGCTTATA  
1001  TAAAGCAGAG CTCAAGCTGC ATCCCNGTAC  
 
 
Appendix 11.2. Promoter 5 (pCpG-cluster-proximal 6NFκB)  
1     CTTATAATGG TTACAAATAA AGCAATAGCA TCACAAATTT  
41    CACAAATAAA GCATTTTTTT CACTGCATTC TAGTTGTGGT  
81    TTGTCCAAAC TCATCAATGT ATCTTATCAT GTCTGGCCAG  
121   CTAGCGTGCC TCTTATGATC TGGATACGTG CATCTCTGCG  
161   ATGAACCTCA CACGTGCGTG CCTCTTATGA TCTGGATACG  
201   TGCATCTCTG CGATGAACCT CACACGTGCG TGCCTCTTAT  
241   GATCTGGATA CGTGCATCTC TGCGATGAAC CTCACACGTG  
281   CGTGCCTCTT ATGATCTGGA TCTCGAGATC CAGATCATAA  
321   GAGGCACTGA CTCAGTGAGG TTCATCGCAG AGATTGACTC  
6HRE mCMV Promoter 48AP‐1 6NFκB
385 
 
361   AATCCAGATC ATAAGAGGCA CTGACTCAGT GAGGTTCATC  
401   GCAGAGATTG ACTCAATCCA GATCATAAGA GGCACTGACT  
441   CAGTGAGGTT CATCGCAGAG ATTGACTCAA TCCAGATCAT  
481   AAGAGGCACT GACTCAGTGA GGTTCATCGC AGAGATTGAC  
521   TCAATCCAGA TCATAAGAGG CACGCTAGCG TGCCTCTTAT  
561   GATCTGGATG GGACTTTCCA TCTCTGCGAT GAACCTCACG  
601   GGACTTTCCG TGCCTCTTAT GATCTGGATG GGACTTTCCA  
641   TCTCTGCGAT GAACCTCACG GGACTTTCCG TGCCTCTTAT  
681   GATCTGGATG GGACTTTCCA TCTCTGCGAT GAACCTCACG  
721   GGACTTTCCG TGCCTCTTAT GATCTGGATC TCGAGCCATG  
761   GTCGAGGCCT GTAGGCGTGT ACGGTGGGAG GCTTATATAA  
801   AGCAGAGCTC AAGCTGCATC CGTACCT 
 
Appendix 11.3. Promoter 11 (pCpG-cluster-proximal 8AP-1)  
1     GCATCACAAA TNTCACAAAT AAAGCATTTN TTTCACTGCA  
41    TTCTAGTTGT GGTTTGTCCA AACTCATCAA TGTATCTTAT  
81    CATGTCTGGC CAGCTAGCGT GCCTCTTATG ATCTGGATGG  
121   GACTTTCCAT CTCTGCGATG AACCTCACGG GACTTTCCGT  
161   GCCTCTTATG ATCTGGATGG GACTTTCCAT CTCTGCGATG  
201   AACCTCACGG GACTTTCCGT GCCTCTTATG ATCTGGATGG  
241   GACTTTCCAT CTCTGCGATG AACCTCACGG GACTTTCCGT  
281   GCCTCTTATG ATCTGGATCT CGAGATCCAG ATCATAAGAG  
321   GCACGCACGT GTGAGGTTCA TCGCAGAGAT GCACGTATCC  
361   AGATCATAAG AGGCACGCAC GTGTGAGGTT CATCGCAGAG  
401   ATGCACGTAT CCAGATCATA AGAGGCACGC ACGTGTGAGG  
441   TTCATCGCAG AGATGCACGT ATCCAGATCA TAAGAGGCAC  
481   GCTAGCGTGC CTCTTATGAT CTGGATTGAG TCAATCTCTG  
521   CGATGAACCT CACTGAGTCA GTGCCTCTTA TGATCTGGAT  
6HRE mCMV Promoter 58AP‐1 6NFκB
386 
 
561   TGAGTCAATC TCTGCGATGA ACCTCACTGA GTCAGTGCCT  
601   CTTATGATCT GGATTGAGTC AATCTCTGCG ATGAACCTCA  
641   CTGAGTCAGT GCCTCTTATG ATCTGGATTG AGTCAATCTC  
681   TGCGATGAAC CTCACTGAGT CAGTGCCTCT TATGATCTGG  
721   ATCTCGAGCC ATGGTCGAGG CCTGTAGGCG TGTACGGTGG  
761   GAGGCTTATA TAAAGCAGAG CTCAAGCTGC ATNCCCCGTA  
 
 
Appendix 11.4. Promoter 15 (pCpG-cluster-proximal 8AP-1)  
1     CACAAATAAA GCATTTTTTT CACTGCATTC TAGTTGTGGT  
41    TTGTCCAAAC TCATCAATGT ATCTTATCAT GTCTGGCCAG  
81    CTAGCGTGCC TCTTATGATC TGGATACGTG CATCTCTGCG  
121   ATGAACCTCA CACGTNNGTG CCTCTTATGA TCTGGATACG  
161   TGCATCTCTG CGATGAACCT CACACGTGCG TGCCTCTTAT  
201   GATCTGGATA CNNGCATCTC TGCGATGAAC CTCACACGTG  
241   CGTGCCTCTT ATGATCTGGA TCTCGAGATC CAGATCATAA  
281   GAGGCACGGA AAGTCCCGTG AGGTTCATCG CAGAGATGGA  
321   AAGTCCCATC CAGATCATAA GAGGCACGGA AAGTCCCGTG  
361   AGGTTCATCG CAGAGATGGA AAGTCCCATC CAGATCATAA  
401   GAGGCACGGA AAGTCCCGTG AGGTTCATCG CAGAGATGGA  
441   AAGTCCCATC CAGATCATAA GAGGCACGCT AGCGTGCCTC  
481   TTATGATCTG GATTGAGTCA ATCTCTGCGA TGAACCTCAC  
521   TGAGTCAGTG CCTCTTATGA TCTGGATTGA GTCAATCTCT  
561   GCGATGAACC TCACTGAGTC AGTGCCTCTT ATGATCTGGA  
601   TTGAGTCAAT CTCTGCGATG AACCTCACTG AGTCAGTGCC  
641   TCTTATGATC TGGATTGAGT CAATCTCTGC GATGAACCTC  
681   ACTGAGTCAG TGCCTCTTAT GATCTGGATC TCGAGCCATG  
6HRE mCMV Promoter 118AP‐16NFκB
387 
 
721   GTCGAGGCCT GTAGGCGTGT ACGGTGGGAG GCTTATATAA  
761   AGCAGAGCTC AAAGCTGCAT CCGTACC 
 
 
Appendix 11.5. Promoter 5 (pCpG-cluster-proximal 6HRE)  
1     GTCCAAACTC ATCAATGTAT CTTATCATGT CTGGCCAGCT  
41    AGCGTGCCTC TTATGATCTG GATGGGACTT TCCATCTCTG  
81    CGATGAACCT CACGGGACTT TCCGTGCCTC TTATGATCTG  
121   GATGGGACTT TCCATCTCTG CGATGAACCT CACGGGACTT  
161   TCCGTGCCTC TTATGATCTG GATGGGACTT TCCATCTCTG  
201   CGATGAACCT CACGGGACTT TCCGTGCCTC TTATGATCTG  
241   GATCTCGAGA TCCAGATCAT AAGAGGCACT GACTCAGTGA  
281   GGTTCATCGC AGAGATTGAC TCAATCCAGA TCATAAGAGG  
321   CACTGACTCA GTGAGGTTCA TCGCAGAGAT TGACTCAATC  
361   CAGATCATAA GAGGCACTGA CTCAGTGAGG TTCATCGCAG  
401   AGATTGACTC AATCCAGATC ATAAGAGGCA CTGACTCAGT  
441   GAGGTTCATC GCAGAGATTG ACTCAATCCA GATCATAAGA  
481   GGCACGCTAG CGTGCCTCTT ATGATCTGGA TACGTGCATC  
521   TCTGCGATGA ACCTCACACG TGCGTGCCTC TTATGATCTG  
561   GATACGTGCA TCTCTGCGAT GAACCTCACA CGTGCGTGCC  
601   TCTTATGATC TGGATACGTG CATCTCTGCG ATGAACCTCA  
641   CACGTGCGTG CCTCTTATGA TCTGGATCTC GAGCCATGGT  
681   CGAGGCCTGT AGGCGTGTAC GGTGGGAGGC TTATATAAAG  
721   CAGAGCTCAA GCTGCATCCG TACC 
 
6HRE mCMV Promoter 158AP‐16NFκB
6HRE mCMV Promoter 58AP‐16NFκB
388 
 
 
Appendix 11.6. Promoter 4 (pCpG-cluster-proximal 6HRE)  
1     CATTTTNTTC ACTGCATTCT AGTTGTGGTT TGTCCAAACT  
41    CATCAATGTA TCTTATCATG TCTGGCCAGC TAGCGTGCCT  
81    CTTATGATCT GGATTGAGTC AATCTCTGCG ATGAACCTCA  
121   CTGAGTCAGT GCCTCTTATG ATCTGGATTG AGTCAATCTC  
161   TGCGATGAAC CTCACTGAGT CAGTGCCTCT TATGATCTGG  
201   ATTGAGTCAA TCTCTGCGAT GAACCTCACT GAGTCAGTGC  
241   CTCTTATGAT CTGGATTGAG TCAATCTCTG CGATGAACCT  
281   CACTGAGTCA GTGCCTCTTA TGATCTGGAT CTCGAGATCC  
321   AGATCATAAG AGGCACGGAA AGTCCCGTGA GGTTCATCGC  
361   AGAGATGGAA AGTCCCATCC AGATCATAAG AGGCACGGAA  
401   AGTCCCGTGA GGTTCATCGC AGAGATGGAA AGTCCCATCC  
441   AGATCATAAG AGGCACGGAA AGTCCCGTGA GGTTCATCGC  
481   AGAGATGGAA AGTCCCATCC AGATCATAAG AGGCACGCTA  
521   GCGTGCCTCT TATGATCTGG ATACGTGCAT CTCTGCGATG  
561   AACCTCACAC GTGCGTGCCT CTTATGATCT GGATACGTGC  
601   ATCTCTGCGA TGAACCTCAC ACGTGCGTGC CTCTTATGAT  
641   CTGGATACGT GCATCTCTGC GATGAACCTC ACACGTGCGT  
681   GCCTCTTATG ATCTGGATCT CGAGCCATGG TCGAGGCCTG  
721   TAGGCGTGTA CGGTGGGAGG CTTATATAAG CAGAGCTCAA  
761   GCTGGCATTC CGTA 
 
 
Appendix 12. Sequencing data of plasmid-miR-23b and lentiviral-miR-23b-target 
constructs 
The plasmid-miR-23b and lentiviral-miR-23b-target constructs were sequenced using the End 
of Luc+ forward sequencing primer. For the pcLuc+-miR-23b-target constructs, the XbaI 
6HRE mCMV Promoter 48AP‐1 6NFκB
389 
 
overhang (5’-TCTAG) and the ApaI site (5’-GGGCCC) is underlined and represents the start 
and end of the miR-23b target sequences, respectively. The internal XbaI restriction site (5’-
TCTAGA) is also underlined and the miR-23b target sequences (5’-
GGTAATCCCTGGCAATGTGAT-3’) are indicated by boxes.  
 
Appendix 12.1. pcLuc+-miR-23b-2T        
  801 AAAGAGATCG TGGATTACGT CGCCAGTCAA GTAACAACCG CGAAAAAGTT 
  851 GCGCGGAGGA GTTGTGTTTG TGGACGAAGT ACCGAAAGGT CTTACCGGAA 
  901 AACTCGACGC AAGAAAAATC AGAGAGATCC TCATAAAGGC CAAGAAGGGC 
 
  951 GGAAAGATCG CCGTGTAATT CTAGGGTAAT CCCTGGCAAT GTGATCGATG 
 
 1001 GTAATCCCTG GCAATGTGAT TCTAGAATTC GGGCCCTATT CTATAGTGTC 
 1051 ACCTAAATGC TAGAGCTCGC TGATCAGCCT CGACTGTGCC TTCTAGTTGC 
 1101 CAGCCATCTG TTGTTTGCCC CTCCCCCGTG CCTTCCTTGA CCCTGGAAGG 
 1151 TGCCACTCCC ACTGTCCTTC CTAATAAACK AGTTTSCT 
 
 
 
 
Appendix 12.2. pcLuc+-miR-23b-4T       
  751 AACTTCCCGC CGCCGTTGTT GTTTTGGAGC ACGGAAAGAC GATGACGGAA 
  801 AAAGAGATCG TGGATTACGT CGCCAGTCAA GTAACAACCG CGAAAAAGTT 
  851 GCGCGGAGGA GTTGTGTTTG TGGACGAAGT ACCGAAAGGT CTTACCGGAA 
  901 AACTCGACGC AAGAAAAATC AGAGAGATCC TCATAAAGGC CAAGAAGGGC 
 
  951 GGAAAGATCG CCGTGTAATT CTAGGGTAAT CCCTGGCAAT GTGATCGATG 
 
 1001 GTAATCCCTG GCAATGTGAT TCTAGGGTAA TCCCTGGCAA TGTGATCGAT 
 
 1051 GGTAATCCCT GGCAATGTGA TTCTAGAATT CGGGCCCTAT TCTATAGTGT 
 1101 CACCTAAATG CTAGAGCTCG CTGATCAGCC TCGACTGTGC CTTCTAGTTG 
miR-23b target
XbaI miR-23b target
miR-23b target XbaI ApaI
XbaI miR-23b target
XbaI ApaI
miR-23b target
miR-23b target
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 1151 CCAGCCATCT GTTGTTTGCC CCTCCCCCGT GCCTTCCTTG ACCCTGGAAG 
 1201 GTGCCACTCC CACTGTCCTT CCTAATAAAC KAGTTTSCT 
 
 
For the lentiviral-miR-23b target constructs, the MfeI overhang (5’-AATTG) and the KpnI site      
(5’-GGTACC) is underlined and represents the start and end of the miR-23b target sequences, 
respectively. The miR-23b target sequences (5’-GGTAATCCCTGGCAATGTGAT-3’) are 
indicated by boxes. 
 
Appendix 12.3. LV-SFFV-miR-23b-2T     
  451 GCTGACGTCC TTTCCATGGC TGCTCGCCTG TGTTGCCACC TGGATTCTGC 
  501 GCGGGACGTC CTTCTGCTAC GTCCCTTCGG CCCTCAATCC AGCGGACCTT 
  551 CCTTCCCGCG GCCTGCTGCC GGCTCTGCGG CCTCTTCCGC GTCTTCGCCT 
 
  601 TCGCCCTCAG ACGAGTCGGA TCTCCCTTTG GGCCGCCTCC CCGCCTGGAA 
 
  651 TTGGTAATTC TAGGGTAATC CTGGCAATGT GATCGATGGT AATCCCTGGC 
 
  701 AATGTGATTC TAGAATTCGG GCCCTATTCG GTACCTTTAA GACCAATGAC 
  751 TTACAAGGCA GCTGTAGATC TTAGCCACTT TTTAAAAGAA AAGGGGGGAC 
  801 TGGAAGGGCT AATTCACTCC CAACGAAGAC AAGATGTGAT CCTCCTAGAG 
  851 GGACAGCCCC CCCCCAAAGC CCCCAGGGAT GTAATTACGT CCCTCCYCCG 
 
Appendix 12.4. LV-SFFV-miR-23b-4T   
  501 CGCGGGACGT CCTTCTGCTA CGTCCCTTCG GCCCTCAATC CAGCGGACCT 
  551 TCCTTCCCGC GGCCTGCTGC CGGCTCTGCG GCCTCTTCCG CGTCTTCGCC 
  601 TTCGCCCTCA GACGAGTCGG ATCTCCCTTT GGGCCGCCTC CCCGCCTGGA 
 
  651 ATTGGTAATT CTAGGGTAAT CCTGGCAATG TGATCGATGG TAATCCCTGG 
 
  701 CAATGTGATT CTAGGGTAAT CCCTGGCAAT GTGATCGATG GTAATCCCTG 
 
  751 GCAATGTGAT TCTAGAATTC GGGCCCTATT CGGTACCTTT AAGACCAATG 
  801 ACTTACAAGG CAGCTGTAGA TCTTAGCCAC TTTTTAAAAG AAAAGGGGGG 
  851 ACTGGAAGGG CTAATTCACT CCCACGAAGA CAAGATGTGA TCCTCCTAGA 
  901 GGGACAGCCC CCCCCCAAAG CCCCCAGGGA TGTAATTACC TCCCTCCCCC 
MfeI
miR-23b target miR-23b target
KpnI
MfeI miR-23b targetmiR-23b target
KpnI
miR-23b target miR-23b target
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For the 6NFκB-miR-23b-target construct, the XbaI overhang (5’-TCTAG) and the FseI site (5’-
GGCCGGCC) is underlined and represents the start and end of the miR-23b target sequence, 
respectively. The internal XbaI restriction site (5’-TCTAGA) is also underlined and the miR-
23b target sequences (5’-GGTAATCCCTGGCAATGTGAT-3’) are indicated by boxes. 
Appendix 12.5. 6NFkB-miR-23b-2T  
 
   1 CRRAAAWYYT CMWAAAAGCC AAGAAGGGCG GAAAGATCGC CGTGTAATTC 
 
  51 TAGGGTAATC CTGGCAATGT GATCGATGGT AATCCCTGGC AATGTGATTC 
 
 101 TAGAATTCGG GCCGGCCGCT TCGAGCAGAC ATGATAAGAT ACATTGATGA 
 151 GTTTGGACAA ACCACAACTA GAATGCAGTG AAAAAAATGC TTTATTTGTG 
 201 AAATTTGTGA TGCTATTGCT TTATTTGTAA CCATTATAAG CTGCAATAAA 
 
 
  
XbaI
miR-23b target miR-23b target
XbaI FseI
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Appendix 13. Sequencing data of lentiviral synthetic promoters expressing the 
luciferase gene  
Appendix 13.1. LV-CMV-Luc+ 
The cloning vector LV-CMV-Luc+ was sequenced using the GL2 reverse primer (Appendix 
13.1.1) and the End of Luc+ forward primer (Appendix 13.1.2). A BLAST search was performed 
to compare the sequence of the LV-CMV-Luc+ to that of the backbone lentiviral plasmid 
pLV.CMVenh.gp91.eGFP.cHS4 (Addgene plasmid 30471), using NCBI BLAST 
http://blast.ncbi.nlm.nih.gov/Blast.cgi.   
 
Appendix 13.1.1. LV-CMV-Luc+ (sequenced using the GL2 reverse primer) 
   1 ATATCAACCA TTMCAATTGT TAATACTTTT MTCAGCAAGG CTATGAATGM 
  51 TGTTCCAGCS TGTCAAAATC ACACCTGTTT AATGTGTTTT ACCCAGCACG 
 101 AAGTCATGTS TAGTTGAGTG GSTTAAAAAT TGTGATCAAA TAGSTGGTTA 
 151 GTTAAAAAGT TATTTCACTG TGTAAAATAC ATCCCTTAAA ATGCACTGTT 
 201 ATTWATCTCT TAGTTGTAGA AATTGGTTTC ATTTTCCACT ATGTTTAATT 
 251 GTGACTGGAT CATTATAGAC CCTTTTTTTG TAGTTGTTGA GGTTTAAAGA 
 301 TTTAAGTTTG TTATGGATGC AAGCTTTTCA GTTGACCAAT GATTATTAGC 
 351 CAATTTSTGA TAAAAGAAAA GGAAACCGAT TGCCCCAGGG CTGCTRWTKK 
 401 CATTTCCTCA TTGGAAGAAG AAGCATAGTA TAGAAGAAAA GGCAAACACA 
 451 ACACATCAAC YTYYKGCCMC CCCSWMMRAW YYYCA 
 
 
 
 
Appendix 13.1.1. BLAST output displaying 97% sequence homology between the LV-
CMV-Luc+ and the backbone pLV.CMVenh.gp91.eGFP.cHS4 plasmid. The LV-CMV-Luc+ 
sequence (subject) aligns at position 3457bp of the pLV.CMVenh.gp91.eGFP.cHS4 (query), 
which corresponds to the region upstream of the eGFP reporter gene in the latter plasmid.  
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Appendix 13.1.2. LV-CMV-Luc+ (sequenced using the End of Luc+ forward primer) 
   1 TMSKKKKKTC YYMWWWAARG CCMAGAAAGG GCGGAAGATC GCCGTGTAAT 
  51 TCTAGAGTCG ACAATCAACC TCTGGATTAC AAAATTTGTG AAAGATTGAC 
 101 TGGTATTCTT AACTATGTTG CTCCTTTTAC GCTATGTGGA TACGCTGCTT 
 151 TAATGCCTTT GTATCATGCT ATTGCTTCCC GTATGGCTTT CATTTTCTCC 
 201 TCCTTGTATA AATCCTGGTT GCTGTCTCTT TATGAGGAGT TGTGGCCCGT 
 251 TGTCAGGCAA CGTGGCGTGG TGTGCACTGT GTTTGCTGAC GCAACCCCCA 
 301 CTGGTTGGGG CATTGCCACC ACCTGTCAGC TCCTTTCCGG GACTTTCGCT 
 351 TTCCCCCTCC CTATTGCCAC GGCGGAACTC ATCGCCGCCT GCCTTGCCCG 
 401 CTGCTGGACA GGGGCTCGGC TGTTGGGCAC TGACAAT TCC GTGGTGTTGT 
 451 CGGGGAAGCT GACGTCCTTT CCATGGCTGC TCGCCTGTGT TGCCACCTGG 
 501 ATTCTGCGCG GGACGTCCTT CTGCTACGTC CCTTCGGCCC TCAATCCAGC 
 551 GGACCTTCCT TCCCGCGGCC TGCTGCCGGC TCTGCGGCCT CTTCCGCGTC 
 601 TTCGCCTTCG CCCTCAGACG AGTCGGATCY CCCTTTGGGC CGCCTCCCCG 
 
 
Appendix 13.1.2. BLAST output displaying 99% sequence homology between the LV-
CMV-Luc+ and the backbone pLV.CMVenh.gp91.eGFP.cHS4 plasmid. The LV-CMV-Luc+ 
sequence (subject) aligns at position 4677 bp of the pLV.CMVenh.gp91.eGFP.cHS4 (query), 
which corresponds to the region immediately downstream of the eGFP gene in the latter 
plasmid.  
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Lentiviral-synthetic promoter- luciferase constructs 
Unless stated otherwise, all lentiviral-synthetic promoter-luciferase constructs were 
sequenced using the GL2 reverse primer. TFBS are positioned in the forward orientation and 
are indicated by a box. The NheI (5’-GCTAGC) and XhoI (5’-CTCGAG) sites are underlined 
and represent the start and end of the region containing multimerised TFBSs, respectively. 
The TATAA box is highlighted in bold. Schematic diagrams of complete DNA sequences are 
presented for each construct 
 
 
Appendix 13.2. LV-2-Luc+  
 201 TGCAGGGGAA AGAATAGTAG ACATAATAGC AACAGACATA CAAACTAAAG 
 251 AATTACAAAA ACAAATTACA AAAATTCAAA ATTTTATCGA TCACGAGACT 
 301 AGCTCGAGAA GCTTGATGAT CCGTTTCGAT GGCCAGCTAG CGTGCCTCTT 
 351 ATGATCTGGA TTGAGTCAAT CTCTGCGATG AACCTCACTG AGTCAGTGCC 
 401 TCTTATGATC TGGATACGTG CATCTCTGCC GATGAACCTC ACTGAGTCAG 
 451 TGCCTCTTAT GATCTGGATA CGTGCATCTC TGCGATGAAC CTCACTGAGT 
 501 CAGTGCCTCT TATGATCTGG ATTGAGTCAA TCTCTGCGAT GAACCTCACT 
 551 GAGTCAGTGC CTCTTATGAT CTGGATTGAG TCAATCTCTG CGATGAACCT 
 601 CACACGGCGT GCCTCTTATG ATCTGGATGG GACTTTCCAT CTCTGCGATG 
 651 AACCTCACGG GACTTTCCGT GCCTCTTATG ATCTGGATGG GACTTTCCAT 
 701 CTCTGCGATG AACCTCACTG AGTCAGTGCC TCTTATGATC TGGATCTCGA 
 751 SCCATRGTSG RGGCCTGTAG GCGTGTACGG TGGGAGGCTT ATATAAGCAG 
 801 AGCTCAAGCT GGCATCCGTA CKTGAGAMAA YTT 
 
 
Appendix 13.3. LV-9-Luc+  
351 AAGAATAGTA GACATAATAG CAACAGACAT ACAAACTAAA GAATTACAAA 
 401 AACAAATTAC AAAAATTCAA AATTTTATCG ATCACGAGAC TAGCTCGAGA 
 451 AGCTTGATGA TCCGTTTCGA TGGCCAGCTA GCGTGCCTCT TATGATCTGG 
 501 ATTGAGTCAA TCTCTGCGAT GAACCTCACA CGTGCGTGCC TCTTATGATC 
 551 TGGATGGGAC TTTCCACCTC TGCGATGAAC CTCACACGTG CGTGCCTCTT 
 601 ATGATCTGGA TGGGACTTTC CATCTCTGCG ATGAACCTCA CTGAGTCAGT 
 651 GCCTCTTATG ATCTGGATTG AGTCAATCTC TGCGATGAAC CTCACGGGAC 
 701 TTTCCGTGCC TCTTATGATC TGGATACGTG CATCTCTGCG ATGAACCTCA 
 751 CTGAGTCAGT GCCTCTTATG ATCTGGATGG GACTTTCCAT CTCTGCGATG 
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 801 AACCTCACAC GTGCGTGCCT CTTATGATCT GGATTGAGTC AATCTCTGCG 
 851 ATGAACCTCA CACGTGCGTG CCTCTTATGA TCTGGATCTC GAGCCATGGT 
 901 SGAGGCCTGT AGGCGTGTAC GGTGGGAGGC TTATATAAGC AGAGCTCAAG 
 
 
Appendix 13.4. LV-11-Luc+  
  751 GGGGATTGGG GGGTACAGTG CAGGGGAAAG AATAGTAGAC ATAATAGCAA 
  801 CAGACATACA AACTAAAGAA TTACAAAAAC AAATTACAAA AATTCAAAAT 
  851 TTTATCGATC ACGAGACTAG CTCGAGAAGC TTGATGATCC GTTTCGATGG 
  901 CCAGCTAGCG TGCCTCTTAT GATCTGGATG GGACTTTCCA TCTCTGCGAT 
  951 GAACCTCACT GAGTCAGTGC CTCTTATGAT CTGGATTGAG TCAATCTCTG 
 1001 CGATGAACCT CACACGTGCG TGCCTCTTAT GATCTGGATA CGTGCATCTC 
 1051 TGCGATGAAC CTCACGGGAC TTTCCGTGCC TCTTATGATC TGGATGGGAC 
 1101 TTTCCATCTC TGCGATGAAC CTCACTGAGT CAGTGCCTCT TATGATCTGG 
 1151 ATCTCGAGCC ATGGTCGAGG CCTGTAGGCG TGTACGGTGG GAGGCTTATA 
 1201 TAAGCAGAGC TCAAGCTGGC ATCCGGTACK TKRAAGSCCM CCCC 
 
 
Appendix 13.5. LV-12-Luc+  
  751 GGGAAAGAAT AGTAGACATA ATAGCAACAG ACATACAAAC TAAAGAATTA 
  801 CAAAAACAAA TTACAAAAAT TCAAAATTTT ATCGATCACG AGACTAGCTC 
  851 GAGAAGCTTG ATGATCCGTT TCGATGGCCA GCTAGCGTGC CTCTTATGAT 
  901 CTGGATTGAG TCAATCTCTG CGATGAACCT CAGGGGACTT TCCGTGCCTC 
  951 TTATGATCTG GATGGGACTT TCCATCTCTG CGATGAACCT CACTGAGTCA 
 1001 GTGCCTCTTA TGATCTGGAT TGAGTCAATC TCTGCGATGA ACCTCACGGG 
 1051 ACTTTCCGTG CCTCTTATGA TCTGGATACG TGCATCTCTG CGATGAACCT 
 1101 CACGGGACTT TCCGTGCCTC TTATGATCTG GATCTCGAGC CATGGTCGAG 
 1151 GCCTGTAGGC GTGTACGGTG GGAGGCTTAT ATAAGCAGAG CTCAAGCTTG 
 1201 GCATCCGTAC KTRAAGRMCM MCC 
 
 
Appendix 13.6. LV-14-Luc+  
  151 TACAAAAACA AATTACAAAA ATTCAAAATT TTATCGATCA CGAGACTAGC 
 201 TCGAGAAGCT TGATGATCCG TTTCGATGGC CAGCTAGCGT GCCTCTTATG 
 251 ATCTGGATGG GACTTTCCAT CTCTGCGATG AACCTCACGG GACTTTCCGT 
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 301 GCCTCTTATG ATCTGGATTG AGTCAATCTC TGCGATGAAC CTCACGGGAC 
 351 TTTCCGTGCC TCTTATGATC TGGATACGTG CATCTCTGCG ATGAACCTCA 
 401 CACGTGCGTG CCTCTTATGA TCTGGATGGG ACTTTCCATC TCTGCGATGA 
 451 ACCTCACACG TGCGTGCCTC TTATGATCTG GATCTCGAGC CATGGTCGAG 
 501 GCCTGTAGGC GTGTACGGTG GGAGGCTTAT ATAAGCAGAG CTCAAGCTGG 
 551 CATCCGGTAC KTTKAAGCCC C 
 
 
Appendix 13.7. LV-6-Luc+ (Incomplete) 
   1 TTCTATWMTT TTGGCTCTTC CATGGTGGGT TTAMCAACAG TAMCCGGAAK 
  51 GCCAAGCTKG AGCMCCGCYK AWATTAGCCT CWACCTTTAC GCSTMCKGCA 
 101 GTGACCATWG TGGWGATTTA GATCATGGAR GAAAGAACGT GTGAGGTYCG 
 151 TCGCRGWGAT GRACGTGRCC MGTTATAWGA GGTTCGTACC TGAGMWGRAA 
 201 TCGCCCATAC AGATCATACC AGGCACGGAA AGTCCCGTGA GGTTCATCGC 
 251 AGAGAKGGAA AGTCCCATCC AGATCATAAG AGGCACGCTA GCGTGCCTCT 
 301 TATGATCTGG ATACGTGCAT CTCTGCGATG AACCTCACAC GTGCGTGCCT 
 351 CTTATGATCT GGATACGTGC ATCTCTGCGA TGAACCTCAC ACGTGCGTGC 
 401 CTCTTATGAT CTGGATACGT GCATCTCTGC GATGAACCTC ACACGTGCGT 
 451 GCCTCTTATG ATCTGGATCT CGAGCCATGG TCGAGGCCTG TAGGCGTGTA 
 501 CGGTGGGAGG CTTATATAAG CAGAGCTCAA GCTGGCATCC GGTACYKTKR 
 551 AGRMCAMCCC 
 
Based on the cloning strategy, this construct should have a 6NFκB cluster in the reverse 
orientation, another cluster (either 6NFκB or 8AP-1) and a proximal 6HRE cluster, which was 
not successfully sequenced.  
 
 
Appendix 13.8. LV-245-Luc+  
 551 AGGGGGGATT GGGGGGTACA GTGCAGGGGA AAGAATAGTA GACATAATAG 
 601 CAACAGACAT ACAAACTAAA GAATTACAAA AACAAATTAC AAAAATTCAA 
 651 AATTTTATCG ATCACGAGAC TAGCTCGAGA AGCTTGATGA TCCGTTTCGA 
 701 TCGCGTGCTA GACGTGGCTA GACGTGGCTA GGAAATTCCC TAGGGAATTT 
 751 CCTAGCCCGG GCTCGAGGCC TGTAGGCGTG TACGGTGGGA GGCTTATATA 
 801 AGCAGAGCTC AAGCTGGCAT CCGGTACKGT KWAASMCMMC 
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Appendix 13.9. LV-4NFκB-Luc+  
  651 ACATAATAGC AACAGACATA CAAACTAAAG AATTACAAAA ACAAATTACA 
  701 AAAATTCAAA ATTTTATCGA TCACGAGACT AGCTCGAGAA GCTTGATGAT 
  751 CCGTTTCGAT GGCCAGCTAG CGTGCCTCTT ATGATCTGGA TGGGACTTTC 
  801 CATCTCTGCG ATGAACCTCA CGGGACTTTC CGTGCCTCTT ATGATCTGGA 
  851 TGGGACTTTC CATCTCTGCG ATGAACCTCA CGGGACTTTC CGTGCCTCTT 
  901 ATGATCTGGA TCTCGAGCCA TGGTCGAGGC CTGTAGGCGT GTACGGTGGG 
  951 AGGCTTATAT AAGCAGAGCT CAAGCTGGCA TCCGGTACGT GAGCACCTAT 
 
 
 
Appendix 13.10. LV-mCMV-Luc+  
The start and end of the mCMV promoter is indicated by XhoI (5’-TCGA) and HindIII (5’-
AGCT), overhangs respectively (underlined). The TATAA box is highlighted in bold. The start 
of the luciferase gene is indicated by the NcoI restriction site 5’-CCATGG (underlined). 
 
    1 AMCAGGTTRC TCAAARACMR TTACRAAAAT TCARAATTTT ATCGATCACG 
   51 AGACTAGCTC GAGAAGCTTG ATGATCCGTT TCGATGCGTG CTAGCCCGGG 
  101 CTCGAGGCCT GTAGGCGTGT ACGGTGGGAG GCTTATATAA GCAGAGCTCA 
  151 AGCTTGGCAT TCCGGTACTG TTGGTAAAGC CACCATGGAA GACGCCAAAA 
  201 ACATAAAGAA AGGCCCGGCG CCATTCTATC CGCTGGAAGA TGGAACCGCT 
  251 GGAGAGCAAC TGCATAAGGC TATGAAGAGA TACGCCCTGG TTCCTGGAAC 
           
 
Appendix 13.11. LV-SFFV-Luc+ (sequenced using the Forward Lenti primer) 
The start of the SFFV promoter is indicated by an EcoRI overhang 5’-AATTC (underlined). 
The start of the luciferase gene is indicated by the NcoI restriction site 5’-CCATGG 
(underlined).  
 
    1 CWWRGGATTA MAAAACAAAT TACAAAAATT CAAAATTTTA TCGATCACGA 
   51 GACTAGCTCG AGAAGCTTGA TGATCCGTTT AATTCCTGCA GCCCCGATAA 
  101 AATAAAAGAT TTTATTTAGT CTCCAGAAAA AGGGGGGAAT GAAAGACCCC 
  151 ACCTGTAGGT TTGGCAAGCT AGCTGCAGTA ACGCCATTTT GCAAGGCATG 
  201 GAAAAATACC AAACCAAGAA TAGAGAAGTT CAGATCAAGG GCGGGTACAT 
  251 GAAAATAGCT AACGTTGGGC CAAACAGGAT ATCTGCGGTG AGCAGTTTCG 
  301 GCCCCGGCCC GGGGCCAAGA ACAGATGGTC ACCGCAGTTT CGGCCCCGGC 
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  351 CCGAGGCCAA GAACAGATGG TCCCCAGATA TGGCCCAACC CTCAGCAGTT 
  401 TCTTAAGACC CATCAGATGT TTCCAGGCTC CCCCAAGGAC CTGAAATGAC 
  451 CCTGCGCCTT ATTTGAATTA ACCAATCAGC CTGCTTCTCG CTTCTGTTCG 
  501 CGCGCTTCTG CTTCCCGAGC TCTATAAAAG AGCTCACAAC CCCTCACTCG 
  551 GCGCGCCAGT CCTCCGACAG ACTGAGTCGC CCGGGGGGGA TCTGCGATCT 
  601 AAGTAAGCTT GGCATTCCGG TACTGTTGGT AAAGCCACCA TGGAAGACGC 
  651 CAAAAACATA AAGAAAGGCC CGGCGCCATT CTATCCGCTG GAAGATGGAA 
  701 CCGCTGGAGA GCAACTGCAT AAGGCTATGA AGAGATACGC CCTGGTTCCT 
  751 GGAACAATTG CTTTTACAGA TGCACATATC GAGGTGGACA TCACTTACGC 
  801 TGAGTACTTC GAAATGTCCG TTCGGTTGGC AGAAGCTATG AAACGATATG 
  851 GGCTGAATAC AAATCACAGA ATCGTCGTAT GCAGTGAAAA CTCTCTTCAA 
  901 TTCTTTATGC CGGTGTTGGG CGCGTTATTT ATCGGAGTTG CAGTTGCGCC 
  951 SCGAAACGAC WTTTATAATG AACGTGAATT GCTCAACAGT ATGGGCATTT 
  
 
           
Appendix 14. Sequencing data of lentiviral synthetic promoters expressing the 
therapeutic mTNFRII-Fc or hIL-1Ra gene 
Unless stated otherwise, the lentiviral-synthetic promoter-IL-1Ra and mTNFRII-Fc constructs 
were sequenced using the Forward Lenti primer which binds upstream of the synthetic 
promoter. The TFBSs are positioned in the forward orientation and are indicated by a box. 
The NheI (5’-GCTAGC) and XhoI (5’-CTCGAG) sites are underlined and represent the start 
and end of the region containing multimerised TFBSs, respectively. The TATAA box is 
highlighted in bold. The start of the therapeutic genes mTNFRII-Fc or hIL-1Ra is indicated by 
the underlined BamHI restriction site (5’-GGATCC). Schematic diagrams are presented with 
the sequencing data for each construct 
 
Appendix 14.1. LV-2-mTNFRII-Fc 
    1 ATWAGATTAC AAAAACAAAT TACAAAAATT CAAAATTTTA TCGATCACGA 
   51 GACTAGCTCG AGAAGCTTGA TGATCCGTTT TAGGCCAGCT AGCGTGCCTC 
  101 TTATGATCTG GATTGAGTCA ATCTCTGCGA TGAACCTCAC TGAGTCAGTG 
  151 CCTCTTATGA TCTGGATACG TGCATCTCTG CCGATGAACC TCACTGAGTC 
  201 AGTGCCTCTT ATGATCTGGA TACGTGCATC TCTGCGATGA ACCTCACTGA 
  251 GTCAGTGCCT CTTATGATCT GGATTGAGTC AATCTCTGCG ATGAACCTCA 
  301 CTGAGTCAGT GCCTCTTATG ATCTGGATTG AGTCAATCTC TGCGATGAAC 
  351 CTCACACGGC GTGCCTCTTA TGATCTGGAT GGGACTTTCC ATCTCTGCGA 
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  401 TGAACCTCAC GGGACTTTCC GTGCCTCTTA TGATCTGGAT GGGACTTTCC 
  451 ATCTCTGCGA TGAACCTCAC TGAGTCAGTG CCTCTTATGA TCTGGATCTC 
  501 GAGCCATGGT CGAGGCCTGT AGGCGTGTAC GGTGGGAGGC TTATATAAGC 
  551 AGAGCTCAGG ATCCATGTAC AGGATGCAAC TCCTGTCTTG CATTGCACTA 
  601 AGTCTTGCAC TTGTCACGAA TTCCACCATG GCGCCCGCCG CCCTCTGGGT 
  651 CGCGCTGGTC TTCGAACTGC AGCTGTGGGC CACCGGGCAC ACAGTGCCCG 
  701 CCCAGGTTGT CTTGACACCC TACAAACCGG AACCTGGGTA CGAGTGCCAG 
  751 ATCTCACAGG AATACTATGA CAGGAAGGCT CAGATGTGCT GTGCTAAGTG 
  801 TCCTCCTGGC CAATATGTGA AACATTTCTG CAACAAGACC TCAGACACCG 
 
 
Appendix 14.2. LV-2-hIL-1-Ra  
    1 GAWAGATTAC AAAAACAAAT TACAAAAATT CAAAATTTTA TCGATCACGA 
   51 GACTAGCTCG AGAAGCTTGA TGATCCGTTT GTAGGCCAGC TAGCGTGCCT 
  101 CTTATGATCT GGATTGAGTC AATCTCTGCG ATGAACCTCA CTGAGTCAGT 
  151 GCCTCTTATG ATCTGGATAC GTGCATCTCT GCCGATGAAC CTCACTGAGT 
  201 CAGTGCCTCT TATGATCTGG ATACGTGCAT CTCTGCGATG AACCTCACTG 
  251 AGTCAGTGCC TCTTATGATC TGGATTGAGT CAATCTCTGC GATGAACCTC 
  301 ACTGAGTCAG TGCCTCTTAT GATCTGGATT GAGTCAATCT CTGCGATGAA 
  351 CCTCACACGG CGTGCCTCTT ATGATCTGGA TGGGACTTTC CATCTCTGCG 
  401 ATGAACCTCA CGGGACTTTC CGTGCCTCTT ATGATCTGGA TGGGACTTTC 
  451 CATCTCTGCG ATGAACCTCA CTGAGTCAGT GCCTCTTATG ATCTGGATCT 
  501 CGAGCCATGG TCGAGGCCTG TAGGCGTGTA CGGTGGGAGG CTTATATAAG 
  551 CAGAGCTCAG GATCCATGGA AATCTGCAGA GGCCTCCGCA GTCACCTAAT 
  601 CACTCTCCTC CTCTTCCTGT TCCATTCAGA GACGATCTGC CGACCCTCTG 
  651 GGAGAAAATC CAGCAAGATG CAAGCCTTCA GAATCTGGGA TGTTAACCAG 
  701 AAGACCTTCT ATCTGAGGAA CAACCAACTA GTTGCTGGAT ACTTGCAAGG 
  751 ACCAAATGTC AATTTAGAAG AAAAGATAGA TGTGGTACCC ATTGAGCCTC 
 
 
Appendix 14.3. LV-9-mTNFRII-Fc 
    1 ACWTAAGAAT ACAAAAACAA TTACAAAAAT TCAAAATTTT ATCGATCACG 
   51 AGACTAGCTC GAGAAGCTTG ATGATCCGTT TGTAGGCCAG CTAGCGTGCC 
  101 TCTTATGATC TGGATTGAGT CAATCTCTGC GATGAACCTC ACACGTGCGT 
  151 GCCTCTTATG ATCTGGATGG GACTTTCCAC CTCTGCGATG AACCTCACAC 
  201 GTGCGTGCCT CTTATGATCT GGATGGGACT TTCCATCTCT GCGATGAACC 
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  251 TCACTGAGTC AGTGCCTCTT ATGATCTGGA TTGAGTCAAT CTCTGCGATG 
  301 AACCTCACGG GACTTTCCGT GCCTCTTATG ATCTGGATAC GTGCATCTCT 
  351 GCGATGAACC TCACTGAGTC AGTGCCTCTT ATGATCTGGA TGGGACTTTC 
  401 CATCTCTGCG ATGAACCTCA CACGTGCGTG CCTCTTATGA TCTGGATTGA 
  451 GTCAATCTCT GCGATGAACC TCACACGTGC GTGCCTCTTA TGATCTGGAT 
  501 CTCGAGCCAT GGTCGAGGCC TGTAGGCGTG TACGGTGGGA GGCTTATATA 
  551 AGCAGAGCTC AGGATCCATG TACAGGATGC AACTCCTGTC TTGCATTGCA 
  601 CTAAGTCTTG CACTTGTCAC GAATTCCACC ATGGCGCCCG CCGCCCTCTG 
  651 GGTCGCGCTG GTCTTCGAAC TGCAGCTGTG GGCCACCGGG CACACAGTGC 
  701 CCGCCCAGGT TGTCTTGACA CCCTACAAAC CGGAACCTGG GTACGAGTGC 
  751 CAGATCTCAC AGGAATACTA TGACAGGAAG GCTCAGATGT GCTGTGCTAA 
  801 GTGTCCTCCT GGCCAATATG TGAAACATTT CTGCAACAAG ACCTCAGACA 
 
 
 
Appendix 14.4. LV-9-hIL-1-Ra  
    1 CCWAAGGAAT TAMAAAAACA AATTACAAAA ATTCAAAATT TTATCGATCA 
   51 CGAGACTAGC TCGAGAAGCT TGATGATCCG TTTTAGGCCA GCTAGCGTGC 
  101 CTCTTATGAT CTGGATTGAG TCAATCTCTG CGATGAACCT CACACGTGCG 
  151 TGCCTCTTAT GATCTGGATG GGACTTTCCA CCTCTGCGAT GAACCTCACA 
  201 CGTGCGTGCC TCTTATGATC TGGATGGGAC TTTCCATCTC TGCGATGAAC 
  251 CTCACTGAGT CAGTGCCTCT TATGATCTGG ATTGAGTCAA TCTCTGCGAT 
  301 GAACCTCACG GGACTTTCCG TGCCTCTTAT GATCTGGATA CGTGCATCTC 
  351 TGCGATGAAC CTCACTGAGT CAGTGCCTCT TATGATCTGG ATGGGACTTT 
  401 CCATCTCTGC GATGAACCTC ACACGTGCGT GCCTCTTATG ATCTGGATTG 
  451 AGTCAATCTC TGCGATGAAC CTCACACGTG CGTGCCTCTT ATGATCTGGA 
  501 TCTCGAGCCA TGGTCGAGGC CTGTAGGCGT GTACGGTGGG AGGCTTATAT 
  551 AAGCAGAGCT CAGGATCCAT GGAAATCTGC AGAGGCCTCC GCAGTCACCT 
  601 AATCACTCTC CTCCTCTTCC TGTTCCATTC AGAGACGATC TGCCGACCCT 
  651 CTGGGAGAAA ATCCAGCAAG ATGCAAGCCT TCAGAATCTG GGATGTTAAC 
  701 CAGAAGACCT TCTATCTGAG GAACAACCAA CTAGTTGCTG GATACTTGCA 
  751 AGGACCAAAT GTCAATTTAG AAGAAAAGAT AGATGTGGTA CCCATTGAGC 
  801 CTCATGCTCT GTTCTTGGGA ATCCATGGAG GGAAGATGTG CCTGTCCTGT 
 
 
 
401 
 
Appendix 14.5. LV-mCMV-mTNFRII-Fc  
The start of the mCMV promoter is indicated by the SnabI overhang 5’-GTA (underlined). The 
start of mTNFRII-Fc gene is indicated by the BamHI restriction site 5’- GGATCC (underlined). 
The TATAA box is highlighted in bold. 
 
   1 AAMMMWWARG RWTTWCAAAA AMAAATTACA AAAAATTCAA AATTTTATCG 
  51 ATCACGAKAC TAGCTCGAGA AGCTTGATGA TCCGTTTGTA GCCTGTAGGC 
 101 GTGTACGGTG GGAGGCTTAT ATAACWTAGC TCGGATCCAT GTACAGGATG 
 151 CAACTCCTGT CTTGCATTGC ACTAAGTCTT GCACTTGTCA CGAATTCCAC 
 201 CATGGCGMCC GCCGYCCTCT GGGTCGCGCT GGTCTTCRAA CTGCAGCTGT 
 251 GGGCCACCGG GCACACAGTG CCCGCCCAGG TTGTCTTGAC ACCCT 
              
  
Appendix 14.6. LV-mCMV-hIL-1Ra  
The start of the mCMV promoter is indicated by the SnabI overhang 5’-GTA (underlined). The 
start of hIL-1Ra gene is indicated by the BamHI restriction site 5’- GGATCC (underlined). The 
TATAA box is highlighted in bold. 
 
   1 TWMYYWWRGR AWTTCCAAAA AACAAATTAC AAAAAATTCA AAATTTTATC 
  51 GATCACGAKA CTAGCTCGAG AAGCTTGATG ATCCCGTTTG TAGCCTGTAG 
 101 GCGTGTACGG TGGGAGGCTT ATATAACCMT AGCTCGGATC CATGGAAATC 
 151 TGCAGAGGCC TCCGCAGCCY C 
             
 
Appendix 14.7. LV-SFFV-mTNFRII-Fc  
The start of the SFFV promoter is indicated by the SnabI overhang 5’-GTA (underlined). The 
start of mTNFRII-Fc gene is indicated by the BamHI restriction site 5’- GGATCC (underlined).  
 
   1 AYWWKRGGRA TTAMAAAAAM AAATTACAAA AATTCAAAAT TTTATCGATC 
  51 ACGAGACTAG CTCGAGAAGC TTGATGATCC GTTTGTAAAT TCCTGCAGCC 
 101 CCGATAAAAT AAAAGATTTT ATTTAGTCTC CAGAAAAAGG GGGGAATGAA 
 151 AGACCCCACC TGTAGGTTTG GCAAGCTAGC TGCAGTAACG CCATTTTGCA 
 201 AGGCATGGAA AAATACCAAA CCAAGAATAG AGAAGTTCAG ATCAAGGGCG 
 251 GGTACATGAA AATAGCTAAC GTTGGGCCAA ACAGGATATC TGCGGTGAGC 
 301 AGTTTCGGCC CCGGCCCGGG GCCAAGAACA GATGGTCACC GCAGTTTCGG 
 351 CCCCGGCCCG AGGCCAAGAA CAGATGGTCC CCAGATATGG CCCAACCCTC 
402 
 
 401 AGCAGTTTCT TAAGACCCAT CAGATGTTTC CAGGCTCCCC CAAGGACCTG 
 451 AAATGACCCT GCGCCTTATT TGAATTAACC AATCAGCCTG CTTCTCGCTT 
 501 CTGTTCGCGC GCTTCTGCTT CCCGAGCTCT ATAAAAGAGC TCACAACCCC 
 551 TCACTCGGCG CGCCAGTCCT CCGACAGACT GAGTCGCCCG GGGGGGATCT 
 601 GCGATCTAAG TAAGCTTGGC ATTCCGGTAC TGTTGGTAAA GCCACCGGAT 
 651 CCATGTACAG GATGCAACTC CTGTCTTGCA TTGCACTAAA GTCTTGCACT 
 701 TGTCACSAAT TCCACCATGG CR 
          
 
Appendix 14.8. LV-SFFV-hIL-1Ra 
The start of the SFFV promoter is indicated by the SnabI overhang 5’-GTA (underlined). The 
start of hIL1-Ra gene is indicated by the BamHI restriction site 5’- GGATCC (underlined).  
 
    1 AWYCTWAAAG YATTRCAAAA CAAATTACAA AAATTCAAAA TTTTATCGAT 
   51 CACGAGACTA GCTCGAGAAG CTTGATGATC CGTTTGTAAA TTCCTGCAGC 
  101 CCCGATAAAA TAAAAGATTT TATTTWKTCT CCAGAAAAAG GGGGGAATGA 
  151 AAGACCCCAC CTGTAGGTTT GGCAAGCTAG CTGCAGTAAC GCCATTTTGC 
  201 AAGGCATGGA AAAATACCAA ACCAAGAATA GAGAAGTTCA GATCAAGGGC 
  251 GGGTACATGA AAATAGCTAA CGTTGGGCCA AACAGGATAT CTGCGGTGAG 
  301 CAGTTTCGGC CCCGGCCCGG GGCCAAGAAC AGATGGTCAC CGCAGTTTCG 
  351 GCCCCGGCCC GAGGCCAAGA ACAGATGGTC CCCAGATATG GCCCAACCCT 
  401 CAGCAGTTTC TTAAGACCCA TCAGATGTTT CCAGGCTCCC CCAAGGACCT 
  451 GAAATGACCC TGCGCCTTAT TTGAATTAAC CAATCAGCCT GCTTCTCGCT 
  501 TCTGTTCGCG CGCTTCTGCT TCCCGAGCTC TATAAAAGAG CTCACAACCC 
  551 CTCACTCGGC GCGCCAGTCC TCCGACAGAC TGAGTCGCCC GGGGGGGATC 
  601 TGCGATCTAA GTAAGCTTGG CATTCCGGTA CTGTTGGTAA AGCCACCGGA 
  651 TCCATGGAAA TCTGCAGAGG CCTCCGCAGT CACCTAATCA CTCTCCTCCT 
  701 CTTCCTGTTC CATTCAGAGA CGATCTGCCG ACCCTCTGGG AGAAAATCCA 
  751 GCAAGATGCA AGCCTTCAGA ATCTGGGATG TTAACCAGAA GACCTTTCTA 
  801 TCTGAGGAAC AACCAACTAG TTGCTGGATA CTTGCAAGGA CCAAATGTCA 
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miR-23b  
  
Appendix 15. Absolute Real-Time qPCR standard curve plot, amplification plot and dissociation curve of miR-23b 
and control miRNAs (miR-16, U6, miR-17-5p, miR-103, miR-191). All standard curve plots show very good R2 values of 
0.98- 1.0 (two decimal places). Amplification plots show that miRNA PCR products (within samples) are within the standards. 
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miR-103 control  
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miR-16 control  
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miR-17-5p control  
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miR-191 control  
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U6 control  
 
  
409 
 
Scientific Communications 
Poster presentations: 
1. Hodan H.A. Mohamed, Yuti Chernajovsky and David J. Gould. ‘Generation and 
Characterisation of Synthetic Inflammation-Responsive Promoters’. William Harvey 
Day, Queen Mary University of London, UK, 2011.  
 
2. Hodan H.A. Mohamed, Yuti Chernajovsky and David J. Gould. ‘Generation and 
Characterisation of Synthetic Inflammation-Responsive Promoters’. 6th Meeting of 
Gene Therapy of Arthritis and Related Disorders, Queen Mary University of London, 
UK, 2011. 
 
3. Hodan H.A. Mohamed, Yuti Chernajovsky and David J. Gould. ‘Development of Novel 
Transcriptionally Responsive Promoters for Therapeutic Gene Expression in Direct 
Response to Disease Activity’. William Harvey Annual Review Day, Queen Mary 
University of London, UK, 2012. 
 
4. Hodan H.A. Mohamed, Yuti Chernajovsky and David J. Gould. ‘Development of Novel 
Transcriptionally Responsive Promoters for Therapeutic Gene Expression during 
Disease Activity’. BSGCT Conference, Royal Holloway University of London, UK, 
2013. 
 
5. Hodan H.A. Mohamed, Yuti Chernajovsky and David J. Gould. ‘Development of Novel 
Transcriptionally Responsive Promoters for Therapeutic Gene Expression during 
Disease Activity’. BSGCT Conference, Institute of Child Health, UCL, London, UK, 
2014. 
 
410 
 
Oral presentations: 
1. Hodan H.A. Mohamed, Yuti Chernajovsky and David J. Gould. ‘Development of Novel 
Transcriptionally Responsive Synthetic Promoters for Therapeutic Gene Expression 
during Disease Activity’. William Harvey Annual Review Day, Queen Mary University 
of London, UK, July 2013. 
 
Nominated for Young Investigator Award. Oral presentation at the William Harvey Annual 
Review Day, January 2014: 
2. Hodan H.A. Mohamed, Yuti Chernajovsky and David J. Gould. ‘Development of Novel 
Transcriptionally Responsive Synthetic Promoters for Therapeutic Gene Expression 
during Disease Activity’. William Harvey Annual Review Day, Queen Mary University 
of London, UK, January 2014. 
 
Publication: 
Mohamed HHA, Chernajovsky Y & Gould DJ. Compact multi-responsive synthetic promoters 
built by an optimised assembly PCR approach display synergistic activation and are suited to 
gene therapy application. Submitted for publication July 2014.  
 
 
 
